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Abstract 
The literature has long contained statements that certain flavonoid-containing drinks 
are able to enhance, improve or mimic the effects of vitamin C. To investigate this, a 
bioavailability study was undertaken to determine whether 200 mg of ascorbic acid (AA) 
would be more readily available to human volunteers when presented in 500 ml water, 
orange juice (OJ) or a blackcurrant drink (BCD). In a random crossover trial, each of 
twelve non-smoking, free-living male volunteers was asked to avoid vitamin C- 
containing foods and drinks for three periods of 31 days (their mean residual intake was 
calculated as 4.1 ing per day), over which their mononuclear and polymorphonuclear 
leukocyte AA (tong term stores) were monitored. The procedure to isolate the two 
fractions of white cells was developed by the author for this study. The first 21 days 
successfully depleted the levels of AA in the subject. From days 22 to 31 each subject 
was given one of the three drinks and the effects on the white blood cell AA levels 
examined. On the first day of supplementation, each subject had his plasma AA (short 
term stores) monitored from before taking vitamin C in each of these vehicles and up to 
7 hours after. Using an original high performance liquid chromatography (HPLQ 
method for AA quantification developed prior to and specilrically for this volunteer 
study, it was found that the rate of absorption over the initial 65 and 90 minutes was 
significantly lower from the blackeurrant drink compared with the orange juice 
(p=0.0009 and 0.0423) and the water (p=0.0001 and 0.0083). There was no significant 
difference between the rates of absorption when presented in water or orange juice. 
However, any initial differences in absorption rate were no longer apparent after seven 
hours, nor were there any differences in the levels achieved in either type of leukocyte. 
HPLC and Nuclear Magnetic Resonance (NMR) profiling of urines showed that there 
were no significant differences in hippuric acid, anthocyanins or aromatic 
(polyphenolic) protons excreted whichever vehicle was used. It can be concluded that 
under the conditions employed in this volunteer study there are no nutritionally 
significant differences between water, orange juice or a blackcurrant drink as vehicles to 
supply vitamin C. 
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1. Introduction. 
The term anthocyanin (from the Greek anthos=flower and kyanos--blue) was originally 
used by Marquat in 1835 (Markakis 1982), to describe the blue colour of the Cornflower (Centaurea cyanus) (Strack and Wray 1989). This term has come to be used for a group of water- 
soluble pigments responsible for a whole range of colours from blue, violet and purple through infinite shades of red to orange and pink in the flowers, fruits, leaves and storage organs of plants (Harborne and Grayer 1988). Anthocyanins are a class of naturally occurring ubiquitous plant 
polyphenolic compounds collectively known as the flavonoids of which some 5000 structures are known (Harborne 1994), a figure which will certainly rise. 
The importance of anthocyanins in our perception of the beauty of a flower, the ripeness of 
an apple or the preconceived quality of a red wine is well. established. Colour is a vital part of food 
quality; indeed the red radish and the red cabbage appear to be grown primarily for their colour 
(Timberlake 1993). Grape pomace has long been used as a colouring agent in foods; and 
anthocyanins are being actively investigated to replace the azo (coal tar-derived) food dyes. 
The possible properties and uses of anthocyanins beyond natural colouring agents have 
only been considered relatively recently. These include their purported 'vitamin P' activity, their 
interactions with vitamin C and their antioxidant nature characteristic of many flavonoids. One 
great advantage is their apparent lack of toxicity, borne out over millennia by the feeding habits of 
humans. Timberlake (1988) points out that early man would have been attracted to the vivid red 
and purple colours and the fruits' inherent sweetness, and he argues that we may have become 
deficient in anthocyanins. Even if they do not have an essential role like a vitamin, it may be that 
our diets are deficient in the foods containing anthocyanins (and other flavonoids). Consumption 
of foods such as fruit and vegetables (and grains) has beneficial epidemiological associations with 
certain cancers which has led to the recommendation of eating five servings of fruit or vegetables a 
day. 
The literature concermng anthocyanins is spread across a range of disciplines from botany 
through phytochemistry to the thrust -of 
this review: nutrition and pharmacology. Apart from the 
devoted chapter in the periodical updates of current flavonoid knowledge by Jeffrey Harborne and 
that by Clifford (1996), few authoritative and objective reviews of the anthocyanins exist. 
Published and reliable knowledge of the absorption, metabolism and disposition of the 
anthocyanins is conspicuous by its absence, especially in view of their ubiquitous presence in the 
diet and in comparison with the wealth of research into many of the other flavonoids over the last 
twenty-five years. 
1.1.1 Definition of terms. 
The terminology of phenols, polyphenols, flavonoids and tannins in the literature is 
confusing so some definitions are needed. Phenol is simply a benzene ring 
bearing a hydroxyl 
group, sometimes referred to as a monophenol. More hydroxyl groups on the same single 
benzene 
ring can then be defined as di, tri- and poly-hydroxy-phenol. 
Polyphenol then describes 
compounds containing two or more hydroxylated aromatic rings and their 
derivatives, which 
includes flavonoids and tannins. Flavonoid refers to compounds based on the 
flavan skeleton 
which consists of two phenolic nuclei connected 
by a three carbon element which gives rise to the 
C6---C3-C6 description. Tannins are naturally occurring, structurally complex, water-soluble 
secondary metabolites having molecular masses 
from 500-4000 and possess 12-16 phenolic 
I 
hydroxyls and 5-7 aromatic rings per 1000 relative molecular mass. (All definitions from Clifford 
1996) 
1.1.2 Synthesis, occurrence and role of anthocyanins in plants. 
The flavonoid biosynthesis enzymes are bound to the cytoplasm and endoplasmic reticulum 
(Gross 1987) in plant cells. Anthocyanins are synthesized ftom malonyl-CoA and p-coumaryl-CoA 
precursors through chalcone and flavanone intermediates to the anthocyanidin, which may then be 
glycosylated and acylated (Grisebach 1982, Gross 1987, Mazza and Miniati 1993). They are 
transported into the cell vacuole where they accumulate in membrane-bound bodies called 
anthocyanoplasts (Middleton and Kandaswarni 1993). 
In some fruits the anthocyanins are located mainly in the skins as in apples, plums and 
pears. In berries and currants they are distributed throughout the whole ffilit. The amount of 
anthocyanins in a fi-uit varies depending on stage of ripening and the inherent genetic character of 
the plant (Gross 1987), though colour intensity is not a good indicator of anthocyanin quantity per 
se (see later). Anthocyanins are found in the Ericaceae (blueberry and cranberry), Rosaceae 
(including apple, pear, apricot, cherry, plum, peach, strawberry), Rubus (blackberry and raspberry) 
and Vitaceae (grape), as well as the Solanaceae family (potato and aubergine) (Timberlake 1993). 
This review centres on the Saxifragaceae family; namely the blackcurrant (Ribes nigrum L. ). 
The survey of anthocyanin distribution in food plants by Timberlake and Bridle (1982) 
demonstrates that some fruits (and flowers) are rich sources of particular anthocyanins while 
having lower quantities of others. Despite there being some 270 anthocyanins, only about 50 are 
present in common fruits. 55% of these are cyanidins, 12% peonidins and delphinidins, 8% 
pelargonidins and malvidins and 6% petunidins. Most fruits contain a mixture through different 
glycosylation and acylation patterns of one anthocyanidin. For example, strawberries are rich in 
pelargonidin, redcurrants and apples in cyanidin. Others such as grapes and lowbush berries have 
five of the six common anthocyanidins, pelargonidin being absent. In blackcurrants four types of 
anthocyanidin glycosides dominate (Table 1.1.3a). The reader is directed to Herrmann (1997), 
Timberlake and Bridle (1980,1982), Mazza and Miniati (1993) and the ongoing series of 
Harborne for details of individual foods and beverages and their anthocyanin contents. It is 
important to bear in mind that inter-laboratory comparisons of quantitative anthocyanin data can 
be unreliable (Clifford 1996). 
Specific anthocyanin patterns characterise different species and cultivars. For example the 
wine made from a European Vitis vinifera can be distinguished from an American species by the 
absence of anthocyanidin 3,5-diglucosides (Gross 1987). This 'fingerprinting' can be used to 
detect adulteration or false labelling of fruit juices and wines. It has also been demonstrated in 
flowers (Asen 1984), and Vaccinium spp. (Ballington et al. 1987). 
The reasons for the existence of many of the plant phenolic compounds is unclear 
(Harbome 1994). They may have a ftmetion. in plant growth, in protecting the plant from UV 
radiation damage, overgrazing, microbial infection or as insect antifeedants. The anthocyanins 
presence in fruit skin and flower petals give a clue to two of their roles as visual attraction to 
pollinators in petals and seed dispersal animals that eat the fruit. However the role of the pigments 
in the flesh of some fruits (if any) is unknown. 
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1.1.3 Blackcurrants. 
The blackcurrant; Ribes nigrum L. of the family Saxifragaceae, grows wild in Northern 
Europe and North America (Mazza and Miniati 1993), and is used primarily in the juice processing 
industry. According to Barney (1996), herbalists since the 15" century have collected Ribes fruit 
for medicinal uses, such as an infusion of blackcurrant leaves for the treatment of rheumatic 
disease (Tits et aL 1992a). Blackcurrant anthocyanins were first investigated by Robinson and 
Robinson (1931) who suggested the presence of a cyanidin-3 -bio side confirmed by German 
workers in the late 1950s (Morton 1968). 
Blackcurrants have been found to contain approximately 130-400 mg/100 g (wet weight) 
of anthocyanins (Kuhnau, 1976, Eder 1996a). Anthocyanins in an unspecified blackeurrant juice 
have been estimated at 76 mg/100 ml (Gleisberg and Aumann 1958 cited in Morton 1968), 75- 
100 mg/100 ml (Kuhnau 1976), 145 mg/ 100 ml (Morton 1968). However, the levels of 
anthocyanins, are strongly dependent on the growing conditions, the maturity of the fruit and the 
measurement methodology. 
It has always been thought, as Table 1.1.3a shows, that cyanidin and delphinidin glucosides 
and rutinosides predominate in blackcurrants, though the exact proportions and types will again 
vary with blackcurrant variety. Some pelargonidin is regularly found but recently for the first time 
so have two methylated anthocyanins by Andersen's group in Bergen, Norway (Fossen et aL 
1998). Table 1.1.3a gives four summaries of blackcurrant anthocyanins. As with all natural tissues, 
precise composition will vary with environmental factors and plant variety. Tables 1.1.3b and 
1.1.3c show the approximate macro- and micronutrient composition of blackcurrants 
Table 1.1.3a. Anthocvanin content of blackcurrants (exDressed as aDercent of total). 
Literature Source and 
blackcurrant variety 
Anthocyanin. 
Koeppen and 
Herrmann (1977) 
Silvergieters 
Schwarze 
Eder(1996a) 
Schwarze 
Langtraubige Typ 
Falch 
Lelous et al. 
(1975)in 
Herrmann (1997) 
No named variety 
Morton (1968) 
No named variety 
Cyanidin 3-rutinosidea 36 28.3 35 22.8 
Delphinidin 3-rutinoside 34 44.2 30 14.9 
Cyanidin 3-glucoside 15 5.9 17 8.3 
Delphinidin 3-glucoside 15 21.6 13 42.6 
Pelargonidin 3-rutinoside - 0.1 3 0.0 
Cyanidin 3-sophoroside - - 0.0 
Delphinidin 3-sophoroside - 0.0 
Anthocyanidins (CyDel) - 0.0 
b 11.7 
Denotes also known as keracyanin). 'benotes probably an artefact of the extraction method. 
Table 1.1.3b. Typical Macronutrient ition of blackcurrants (from HoRand et al. 1992). 
Component % 
Energy (100 g) 121 U (28 kcal) 
Water 77.4 
Fibre (total) 7.8 
Carbohydrate (all sugars) 6.6 
Protein 0.9 
Fat Trace 
The raw blackcurrant as a whole EuitMth stalks removed has a 98% edible portion. 
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Table 1.1.3c. Tyvical Nficronutrient ComDosition of blackcurrants (from Holland et aL 1992). 
Vitamins /100g Minerals /1010g 
Retinol N. D. Sodium 3.0 mg 
Carotene 100 ýtg Potassium 370 mg 
D N. D. Calcium 60 mg 
E 1.0 mg Magnesium 17 mg 
Thiamin 0.03 mg Phosphorous 43 mg 
Riboflavin 0.06 mg Iron 1.3 mg 
Niacin 0.3 mg Copper 0.14 mg 
B6 0.08 mg Zinc 0.3 mg 
B12 N. D. Sulphur 33 mg 
Folate Chlorine 15 mg 
Pantothenate 0.4 mg Manganese 0.3 nig 
Biotin 2.4 [tg Selenium 
C 150-230 ma Iodine 
* The nutrient is present in significant quantities (gg levels), but there is no reliable information on the amount. 
N. D. not detected. (Tabulated in the original table as 0.0 ýLg) 
Blackcurrants contain high amounts of organic acids (of which ascorbic acid is one). 
Estimates are 2.9 g /100 g edible portion of citric acid and 0.4 g malic acid (Holland et aL 1992), 
and 50-150 mg/100 g quinic acid (Romero Rodriguez et aL 1992). Morton (1968) found the 
phenolic substances of blackcurrants, exclusive of anthocyanins, to be approximately 69 mg/100 g, 
of which 24 mg were flavonols. Herrniann (1976) tabulates up to 10 mg/kg kaempferol, 33-68 
mg/kg quercetin and 41-95 mg/kg myricetin as glycosides, the variation caused by ripeness and 
variety. Probably the best, most authoritative and recent paper is Herrmann (1997) which brings 
together data sources concerning the constituents of blackcurrants (and redcurrants) covering 
most sources quoted here. One must remember that there is great natural variation in the 
blackcurrant and its cultivars, but the figures of tables 1.1.3b and 1.1.3c taken from the McCance 
and Widdowson series agree well with other studies (Heiberg et aL 1992). 
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1.2 Anthocyanin Chemistry. 
Anthocyanins are glycosides of anthocyanidins. Anthocyanidins have a C6-C3--C6 
structure of two aromatic rings joined by a three carbon unit (the 2-phenylbenzopyryUium or 
flavylium salt). WiRstqtter named the six major types of anthocyanidin at the beginning of the 
century after the flower sources from which they were first isolated (Gross 1987): cyanidin, 
delphinidin, pelargonidin, peonidin, petunidin and nialvidin. Further variation arises from three 
attributes of each individual anthocyanin. Firstly the degree and position of hydroxylation and 
methylation of the two aromatic rings. This gives rise to the seventeen anthocyanidins so far 
known (Harborne and Grayer 1988) (Table 1.2a). Secondly, the type, position and number of 
sugar residues attached to the skeleton. Thirdly, the type, position and number of acyl residues 
attached to the glycoside units. 
Despite this variation, most anthocyanins share similar characteristics. For example, the 
hydroxyl at positions 5 and 7 are not glycosylated while that at position 3 is. Also position 4' is 
rarely methylated. 
Figure 1.2a. The basic flavylium aglycone structure. 
(The anthocyanin is glycosylated at position 3) 
80 +1 
7)" 
A 
54 
Figure 1.2b. The 6 commonest anthocyanidins. 
H 
-OH 
Pelargonidin 
OH 
OH 
0+ 
0 
Ilý OH 
H 
Delphinidin 
OH Malvidin 
5 
OH A W-ILUUIUJLRI 
Table 1.2a. NaturaRy Occurring Anthocyanidins. 
Those in bold are shown in Fiaure 1.2b. 
Substitution pattern. 
_ __ __ Name 3 5 6 7 3' _ 4' 5' Colour"- 
Apigenidin (Ap) H OH H OH H OH H Orange 
Aurantinidin (Au) OH OH OH OH H OH H Orange 
Capensinidin (Cp) OH Ome H OH OMe OH OMe Bluish-red 
Cyanidin (Cy) (535 nm) OH OH H OH OH OH H Orange-red 
Delphinidin (Dp) (546 nm) OH OH H OH OH OH OH Bluish-red 
Europinidin (Eu) OH OMe H OH OMe OH OH Bluish-red 
Hirsutinidin (Hs) OH OH H OMe OMe OH OMe Bluish-red 
6-Hydroxycyanidin(6-OHCy) OH OH OH OH OH H Red 
Luteolinidin (Lt) H OH H OH OH OH H Orange 
Malvidin (Mv) (542 nm) OH OH H OH OMe OH 
b OMe Bluish-red 
5-Methylcyanidin (5-Mcy) OH OMe H OH OH H Orange-red 
Pelargonidin (Pg) (520 nm) OH OH %;: 11,1, ýH OH 
H OH H Orange 
Peonidin (Pn) (532 nm) OH OH iH OH OMe OH H Orange-red 
'Petunidin (Pt) (543 nm) OH OH H OH OMe OH OH Bluish-red 
Pulchellidin (PI) OH OMe :. H OH OH OH OH Bluish-red, 
Rosinidin (Rs) OH OH ::: H ý; !;: OMe OMe OH H Red 
Tricetinidin (Tr) H OH -H OH OH OH OH Red - (Mazza and Miniati 1993, ?,,. from Timberlake 1980). 
values are dependent on many factors and are not useful in isolat ion as an absolute value. 
b Mazza and Miniati (1993) tabulate the 4' as having an OMe group that I am sure is am istake and have amended 
it so. 
C Despite the well-respected Brouillard (19 82), putting the OMe at the 5', Others including Harborne and Grayer 
(1988), Mazza and Miniati (1993) and Strack and Wray (1994) all put it at the 3 '. 
d at low pH 
Anthocyanins are found most usually as 3 -monoglyco sides or 3,5-diglyco sides but also as 
triosides (Eskin 1979, Wong 1989). The sugar acts to stabilize the anthocyanin moiety and 
increase its solubility. The commonest glycosylating sugars are glucose, arabinose, xylose, 
galactose and rhamnose, a list that varies from worker to worker and as new anthocyanins are 
discovered (after Wong 1989, Strack and Wray 1989, Mazza and Miniati 1993, Clifford 1996). 
Diglycosides involve gentiobiose, sophorose (both glucosylglucoses), sambubiose (xylosylglucose) 
and rutinose (rhamnosylglucose) (Gross 1987, Clifford 1996). With few exceptions there is always 
a sugar at C-3; diglycosides can be glycosylated additionally at any of the other hydroxyls 
(Brouillard 1988) but most usually at the 5-position. 
Where acylation occurs it is usually by one of the four cinnamic acids, p-coumaric, caffeic, 
ferulic or sinapic acid, or by aliphatic dicarboxylic acids such as malic, malonic, oxalic or succinic, 
acids. This can render the cationic flavylium ion a zwitterion (Harborne and Grayer 1988). Thus, it 
is the variation in glycosylation and acylation that IS responsible for the large number of 
anthocyanins presently known. 
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1.2.1 Structural Transformations of the Anthocyanins. 
In aqueous media an anthocyanin acts as a pH indicator: a weak di-acid, changing from red 
at low pH to blue/purple and colourless at higher pH. The work of Brouillard has elucidated the 
structural transformations each pigment undergoes as a result of pH change (Brouillard and 
Delaporte 1977). These isornerisation, tautomerisation and proton transfer reactions are outlined 
well by Brouillard (1988) (see figure 1.2.1 a). 
Figure 1.2.1a. 
1 
The structural transformations of anthocyanins in water. (From Brouillard 1988) 
(see text for explanation). 
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In mildly acidic or neutral media, anthocyanins exist as four structures in equilibrium: as 
the flavyliurn cation (AH), the quinoidal base (A), the carbinol pseudobase (B) and the chalcone 
(C) (see figure 1.2.1 a above). At pH values below 2, the red flavylium cation predominates. As 
the pH is raised, protons are lost yielding neutral red-blue quinoidal bases (e. g. A7) with pY-., a 
values of 3.50-4.85. A finiher proton can be lost from any of the hydroxyl groups to form the 
anionic quinoidal base (e. g. A: 75)which gives rise to large bathochromic and hypsochromic shifts. 
In aqueous media, the flavylium structure becomes hydrated to give the colourless carbinol 
pseudobase (B2and B4) at pH 3-6, where water addition takes place at the C2 and more rarely C4 
position through nucleophilic attack. This hydration is less efficient in aglycones and carbinol 
pseudobases only form at pH values >4-5. In turn, the B2 structure equilibrates to the colourless 
chalcone pseudobase (CE) and the chalcone (Cz) forms. 
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An appreciation of these changes will demonstrate that the relative amounts of each 
tautorner in a given solution will vary with pH and anthocyanin type. This is demonstrated by 
figure 1.2.1 b, which shows the relative concentrations of a typical anthocyanin at different pH. 
Figure 1.2.1b. The generalised effect of pH Value on Anthocyanin Equilibria. 
100- 
ed Flavylium Cation [AH'I 
Human Blood pH approx. 7 
Small Intestine pH 7.5-&0 
Colourless Pseudobase [B] 
80- 
>4 Q 
60- 
/ 
HManýtomach 
-5 pH range 2 
(post-prandial) 
F. -O ý40 
20- 
Colourless Chalcone [C] 
ye Quinoidal Bases [A, A 
-T- 
0 2 3456 
pH value 
(After Clifford 1996) 
The existence of several structural forms of anthocyanins and the resultant transience of 
colour must be understood and considered in analysis for anthocyanins in, for example, biological 
tissues. Their colour will probably not be seen (i. e. pH of blood/plasma: -7.4, small intestine: -7.5- 
8.0, urine: -variable), which can lead to incorrect qualitative and quantitative estimates of 
anthocyanin content. Conversely, their colour not being seen is not proof of absence. Other 
phenomena such as deviation from the Beer-Lambert Law and co-pigmentation can add to 
imprecise reporting of anthocyanin presence in biological tissues and is discussed later. 
1.2.2 Anthocyanin colour and stability. 
Colour is produced by the reflection or transmission of a certain wavelength of visible light 
and the absorption of all others. Compounds that absorb visible light are called pigments, with 
anthocyanins being the most important and widespread plant pigments (Harborne and Grayer 
1988). Anthocyanins are very unstable and degrade easily upon processing. The colour of 
anthocyanin solutions will also be affected by Maillard browning reactions and reactants if heated. 
The colour of anthocyanin solutions depends on structure and concentration of the 
pigment, pH, temperature, presence of copigment (and concentration), metaffic ions, enzymes, 
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oxygen, ascorbic acid, sugars and sulphur dioxide. Mazza and Miniati (1993) discuss these factors 
well. 
Structure. A hydroxyl group supplies non-bonded electrons to the flavyliurn system and 
can both destabilise (e. g. OH at C3) or stabilise the anthocyanin (OH at C5,7 or 4'). For example 
in 0.01% HCl-MeOH solutions the ý,. of pelargonidin (tetrahydroxyflavyhum) is orange (520 
nm), cyanidin (pentahydroxyflavylium) is orange-red (535 nm) and delphinidin 
(hexahydroxyflavylium) is bluish-red (545 nm) (Mazza and Miniati 1993), an example of 
bathochromatism. (shift to higher, bluer wavelengths). However, methylation of positions 5,4' or 
7 is hypsochromic (Mazza and Brouillard 1987) and decreases stability. 
Glycosylation of the anthocyanidin stabilises the flavylium. ion, and 3-glycosides are more 
intensely coloured at a given wavelength than 3,5- or 5-glucosides. Glycosylation at C-3 produces 
a hypsochromic shift (to lower wavelengths) of about 15 nm relative to the corresponding 
aglycone and a shoulder at 440 nm on the absorption curve (Gross 1987). Diglycosylation (usually 
at the 5-position) results in a further bathochromic shift (Jackman et al. 1987a). 
Acylation also improves colour stability, as 1) acylated pigments are to begin with more 
intensely coloured at a given pH (Bridle and Timberlake 1997) and 2) the intramolecular 
hydrophobic interaction between the anthocyanidin ring and the aromatic acyl groups causes a 
physical hindrance to the nucleophilic attack of OIT at C2 (Brouillard 1981), thus protecting the 
flavyliurn ion from hydration and stabilising the red colour. 
Concentration. Anthocyanins do not follow the Beer-Lambert law but deviate positively 
from it (see later). The colour change is due to increasing concentration, decreasing pH and 
possibly enhanced colour stability through intermolecular and intramolecular copigmentation and 
self association (Mazza and Miniati 1993). The total amount of anthocyanin present therefore is a 
very important factor. 
Copigmentation. Plant tissues have pH values around 3.5-5.5. At pH 3.5 the 
concentration of the red species All' is around 10% diminishing to nothing at around pH 4.5. 
Consequently the contribution of the colourless pseudobases rises from 65% to 85% in this pH 
range (see figure 1.2.1 b) - The question arises as to how the plant still manages to retain such vivid 
coloration. Two phenomena; co-pigmentation and self-association do this (termed tertiary 
structures by Brouillard and Cheminat 1988). 
Copigmentation is the hydrophobic association of an anthocyanin chromophore, i. e. the 
flavyliurn cation or a quinoidal base, with the planar electronically unsaturated part of a copigment 
(Brouillard and Dangles 1994), either internally (intramolecular) or externally with 
(intermolecular) the anthocyanin moiety. The association of the hydrophobic aromatic ring of the 
anthocyanin and (usually) that of the copigment displaces several water molecules and protects the 
flavyliurn chromophore from nucleoPhilic attack (Brouillard 1982, Brouillard et al 1989). The 
association of the copigment with the Ali' means more AW molecules are reformed from the B 
and CE forms (Brouillard et al. 1989, Cai et al. 1990) (see figure 1.2.1a, p1l). Thus 
copigmentation produces hyperchromatic and bathochron-& effects (Asen et al. 1971,1972,1977, 
Osawa 1982, Mazza and Brouillard 1990), imparting a bluer hue and protecting against pigment 
degradation. It is thought that the co-pigments interleave with the flavylium. cations to form an 
alternating stack (Brouillard 1988, Wong 1989), see Figure 1.2.2a. The effect is maximal in the 
range pH 3-5 in aqueous solution though is reduced by adding methanol or by applying heat 
(Brouillard et al. 1989). Co-pigmentation is not limited to the anthocyanin's natural plant 
environment but occurs in fruit and vegetable products such as wine. Brouillard's group has 
recently produced evidence that copigmentation may be followed by a covalent coupling of the 
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anthocyanin and copigment thus leading to the complex polymerisation processes observed in old 
red wines (Escibano-Baflon et al. 1996) 
Intermolecular copigmentation. This author finds that the most compeffing and clear 
evidence for this phenomenon is put forward by Asen and colleagues with work on a Red Wing 
azalea (Rhododendron cultivar) (Asen et al. 1971). Their work demonstrated that while the 
anthocyanin type and content in red and orange petals was the same, there were six (colourless) 
flavonol glycosides in the red flower that they hypothesised caused the colour difference (all other 
contents and conditions in the leaves being the same). 
Anthocyanins can associate with other molecules which can be other flavonoids, 
polyphenols, alkaloids, amino acids, organic acids and the anthocyanins themselves (Robinson and 
Robinson 193 1, Osawa 1982, Mazza and Miniati 1993). The intensity of the copigmentation. effect 
is dependent upon several factors (Robinson and Robinson 193 1, Asen et al. 1972, Timberlake 
and Bridle 1975, Osawa 1982), but is increased with greater methoxylation, glycosylation and 
acylation (Mazza and Brouillard 1987,1990, Dangles et al. 1993b). Increasing temperature 
reduces the hypsochromic effect, though this is reversible upon cooling (Baranac et al. 1996). 
Different copigments exert maximal effects at different molar ratio concentrations. For example 
chlorogenic acid has its maximal effect when 150+ times the concentration of anthocyanin 
(Brouillard et al. 1989), while rutin has its greatest effect at a 1: 1 molar ratio. pH and metal ions 
also affect intermolecular copigmentation. (Osawa 1982). 
Intramolecular copigmentation. This phenomenon occurs in anthocyanins containing 
two or more aromatic acyl groups (Mazza and Miniati 1993). The anthocyanin molecule is 
thought to be stabilised by sandwich-type packing of the aromatic moiety with the pyrylium. ring of 
the flavylium cation, which decreases hydration of the flavylium ion and so improves stability 
(Brouillard 1982,1988), again see Figure 1.2.2a. The aglycone structure, nature, number and 
position of the acyl groups all affect the final copigmentation. effect (Brouillard 1982,19883, 
Dangles et al. 1993b). Evidence has recently been found to support this existence of 
intramolecular hydrophobic interactions (Figueiredo et al. 1996). 
Figure 1.2.2a. Diagrammatic representation of (i) intramolecular co-pigmentation, 
(ii) Inten-nolecular co-pigmentation and (iii) self-association. (From Goto et aL 1984). 
Key: sugar 
aromatic acid 
(i) GO 
anthocyanin 
flavonol (co-pigment) 
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Self-association. The increase in colour intensity with concentration in acidic and neutral 
conditions does not follow the Beer-Lambert law and it was first suggested that this was due to 
self-association (Asen et aL 1972). The nature of the anthocyanin complex is thought to be a 
vertical stack of the anthocyanin quinoidal bases, held through the hydrophobic attraction and/or 
hydrogen bonding between the flavylium nuclei (Wong 1989, Hoshino 1991,1992), see Figure 
1.2.2a. Similar to co-pigmentation, this tends to shelter the chromophore within the sugar residues 
and protect it from nucleophilic attack and so loss of colour (Wong 1989, Mazza 1995). 
Anti-copigmentation. This can be defined as the colour loss of an anthocyanin solution 
upon the addition of P-cyclodextrin, an encapsulating polysaccharide- due to the encapsulation 
of the copigment within the P-cyclodextrin cavity (Dangles et aL 1992b). 
Meta I-com plexing. Work outlined by Osawa (1982) has shown that metallo-anthocyanin 
complexes exist. Anthocyanins containing ortho-dihydroxy groups react with AIC13at pH 2-4 to 
form blue chelates whose visible absorption maxima are 25-35 mn higher than the corresponding 
anthocyanin (a bathochromic shift). This metal chelating behaviour is used diagnostically in the 
characterisation of anthocyanins. Such chelatogenic activity is thought to explain some of the 
antioxidant nature of the anthocyanins---e. g. in chelation of Cuý'. (Figure 1.2.2b). Much larger 
complexes have been characterised and are outlined by Harborne (198 8). 
Figure 1.2.2b. Examples of Metallo-anthocyanin complexation 
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Cyanidin and (i) copper (ii) aluminium ion complex 
pH. The effect of pH has been discussed above and is essentially mediated through the 
structural tautornerism. of anthocyanins. At pH<2 anthocyanins are mostly red; between 4-6 are 
colourless; and above this give purple and blue colours which may change to yellow upon heating 
(Mazza and Miniati 1993). Acidification reverses the colour change, with acylated anthocyanins 
more resistant to colour loss. 
Other Factors. Temperature, light, oxygen and hydrogen peroxide are all severely 
detrimental to anthocyanin stability and colour. Acetaldehyde is involved in some condensation 
reactions (see below) to form condensed anthocyanins. Sulphur dioxide adds to the 4- position of 
the anthocyanffi to form a bisulphite compound (Wong 1989), though does not affect the 
condensed anthocyanins in matured wines (see below). Different sugars have different effects on 
anthocyanin stability (Eskin 1979). Generally the breakdown products of sugars- flirfural-type 
compounds- are much more effective in accelerating anthocyanin breakdown (Debicki-Pospisil 
et aL 1983, Jackman et aL 1987a). The influence of ascorbic acid is discussed later. 
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1.3 Determination of Anthocyanins. 
The analysis of anthocyanins is covered more thoroughly by Harborne (1984), Gross 
(1987), Jackman et al. (I 987b), Strack and Wray (1989) and most recently Lee and Hong (1992), 
and for further information and references the reader is directed there. The tendency of 
anthocyanins to structurally transform and form complex moieties complicates anthocyanin 
analysis and isolation. Comparison against pure standards is difficult as they are not easily 
available and can be prohibitively expensive. However throughout the last 20 years many workers 
have synthesised the basic flavylium. skeleton. Several approaches are outlined well in lacobucei 
and Sweeny (1983). 
Whatever extraction medium is employed it will undoubtedly differ from the natural 
medium, which may well alter the in vivo structure of the pigment. Tertiary structures will be lost 
and there will be increases in the proportion of pseudobases and the initiation of chemical and 
enzymic transformations (Clifford 1997 unpublished). Anthocyanidins may also be formed by acid 
catalysed depolymerisation from colourless polymeric tannins. 
Extraction. As anthocyanins are unstable in neutral or alkaline solution, anthocyanin 
pigments are commonly extracted from plant tissues by hornogenising or macerating the sample 
with a 1% HCI methanol solution and storing in a dark refrigerator. Recently Bronnurn-Hansen 
and Flink (1986) have worked to optimise extraction procedures and suggest extensive crushing as 
opposed to maceration in a blender with OAM HCI alone rather than acidified ethanol, and use a 
solvent to pomace ratio of 2.5: 1 with 4 extractions steps. The use of enzyme addition to improve 
the anthocyanin extraction by cell wall destruction was found to be unnecessary and possibly 
counterproductive if the sample was crushed prior to extraction. Vacuum evaporation can be used 
to rapidly concentrate anthocyanin extracts without loss of the anthocyanin component. 
Sample clean up. Mazza and Miniati (1993) suggest following crude extraction with 
concentration under vacuum, purification and separation of the pigments for qualitative analysis. 
Commonly solid phase extraction with insoluble adsorbents such as polyvinylpyrolidone (PVP) 
(Barritt and Torre 1973, Wilkinson et al. 1977), C18 silica (Oszmianski and Sapis 1988, Kim et 
al. 1989, Hong and Wrolstrad 1990) and Sephadex. (Kim et al. 1989) are used. The crude extracts 
are applied to a column or cartridge of the adsorbent followed by sequential elution with 
appropriate solvents, usually with an increasing proportion of acidified methanol solution. Most 
recently, Kraemer-Schafhalter et aL (1998) compared 16 solid-phase extraction materials and 
found Amberlite XAD-7 from Sigma and RP silica gel 100, C-18 from Fluka to be the most 
suitable, scaling up the former to a 36 litre operation. This paper outlines well the specifications 
required of a solid-phase extraction material for anthocyanin clean-up and the drawbacks of many, 
including PVP and Sephadexes that are commonly used. However the paper has little information 
about exactly how it was done or what exactly was separated from what. Bloor et al. (1998) using 
a polyamide eluted the anthocyanins as a band using 0.1% aqueous trifluoroacetic acid (TFA) and 
gradually increasing the proportion of methanol. Froyflog et al. (1998) partition the blackcurrant 
juice with ethyl acetate prior to application to XAD-7 and, elution with TFA acidified methanol. 
Separation. High performance liquid chromatography (HPLQ has the advantages of 
sensitivity, rapidity and easy quantification (Harborne and Grayer 1988) and the method of choice 
is usually C18 silica columns of 3-10 [tra using a gradient of aqueous and organic phases 
(methanol or acetonitrile). Thin layer chromatography (TLC) is still employed as a convenient and 
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effective separation step in anthocyanin analysis. However, the separation of anthocyanins for use 
as 4pure' preparations is very difficult and time consuming. Droplet counter-current 
chromatography (Hostettmann et al. 1986) has been seen to be 'satisfactory' for blackcurrant 
anthocyanins (Francis and Andersen 1984), but requires extensive apparatus. However, 
Andersen's group have developed traditional HPLC further by using a combination of column 
chromatographic methods and achieve excellent separation using two stages of extraction with 
ethyl acetate then XAD-7 and two of purification using Toyopearl material (Froytlog et al. 1998). 
Despite the anthocyanins being ionic in nature, only recently has significant success been 
had in separating them by electrophoresis (Tsuda and Fukuba 1989 in Lee and Hong 1992). Some 
commercial companies market anthocyanins, notably Apin chemicals, Oxon, UK, Extrasynthese, 
Lyon, France, and most recently Polyphenols AS, Bergen, Norway, but these preparations are 
very expensive and can ýco st over f2000 per 100 mg. 
Absorption Characteristics. Quantitative determination of the anthocyanins by 
absorption spectrophotometry is difficult since anthocyanins deviate from the Beer-Lambert law 
(Asen et al. 1972). Many workers use a published, generalised extinction coefficient to estimate 
concentration, though the magnitude of the molar absorption coefficients depends very much on 
the individual compound and media in which they are measured. 
Coupled with separation by HPLC, UV-visible spectrophotometry or diode array 
detection have been used to great effect as each pigment has characteristic absorption spectra and 
two absorption maxima, one in the visible region between 465 and 550 nrn, the other in the 
ultraviolet between 270 and 280 nm. Both vary slightly with the nature of the solvýnts, 
measurements being standardised using 0.01% HCI in methanol. The eight double bonds of the 
anthocyanidin backboneand (7-electrons of the heterocyclic oxygen of the cation give a highly 
coloured chromophore in acidic media, and for good resolution it is important to use low pH 
values (<1.5) to ensure the coloured flavylium. form is predominant. Artefacts can be produced 
when formic or acetic acids are used, so should be avoided (Bakker and Timberlake 1985ab). 
Many workers including the author prefer perchloric acid, though this is non-volatile. 
Physical Spectroscopy. The first NMR (nuclear magnetic resonance) spectra of 
anthocyanins were reported in the seventies by Goto and co-workers. Such techniques have 
continued to develop and can now be used to elucidate complex anthocyanin stereo structures. 
Fast Atom Bombardment (FAB) Mass spectrometry gives fragmentation patterns of anthocyanins 
producing further structural information such as the identity of the aglycone. However because 
they are based on molecular mass they do not distinguish between fi-agments of the same mass, 
such as glucosyl and caffeoyl residues (Brouillard 1988). NMR techniques such as proton, 13c 
NMR and 1H-'H correlated spectroscopy (COSY) are becoming increasingly routine. These 
techniques are detailed filrther in Brouillard (19 8 8) and Strack. and Wray (19 8 9,1994). 
Chemical characteristics. The anthocyanin can be hydrolysed in acidified boiling water 
for 30 minutes to yield the aglycone and sugar, which can be identified separately, such as by 
paper chromatography (Chandler and Harper 1962) or the more modem HPLC. The acylating 
groups can be removed by mild alkaline hydrolysis (Strack and Wray 1989). 
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1.4 Anthocyanin Transformations. 
Anthocyanin transformation is directly associated with colour loss. The nature of 
transformation is determined by a number of factors including pH, temperature, ascorbic acid, 
sugars, oxygen, metallic ions and other molecules present such as flavonoids and amino acids. 
Raising pH causes the conversion of the stable flavylium. ion to labile pseudobases that transform 
and degrade to a brown precipitate. Metallic ions can be complexed by anthocyanins with o- 
dihydroxy groupings causing a hypsochromic shift. Anthocyanins undergo six main types of 
reaction: 
1. Hydrolysis to the anthocyanidin followed by fragmentation 
2. Condensation (direct and acetaldehyde-mediated) 
3. Oxidation 
4. Sulphur dioxide decoloration 
5. Enzymic degradation 
6. Cycloaddition 
1. Hydrolysis and _Fragmentation. 
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anthocyanidin; a moiety with a free hydroxyl group that can enolise and thus destabilises since the 
resultant chalcone is an unstable (x-diketone (Clifford 1997 unpublished). This is readily 
hydrolysed to give 2,4,6-trihydroxyphenylacetaldehyde and a benzoic acid (Figure 1.4a). 
2. Condensation. Anthocyanins, are open to electrophilic attack by virtue of the extensive 
electron delocalisation over the aromatic ring structure. The progressive loss of anthocyanins by 
condensation is seen in the maturation of wine. These condensed pigments are less sensitive to pH 
changes and are resistant to S02 (as the 4-position is blocked to bisulphite addition). They 
condense in two ways to form condensed dimers, also termed condensed tannins. 
Direct Condensation. Anthocyanins condense at position 4 with other flavonoids such as 
flavanols (catechins) via electrophilic substitution, to give dimers and polymers (Somers 1971, 
Wong 1989) (Figure 1.4b). 
Fijzure 1.4b. The direct condensation of anthocyanins with other flavonoids (from Wong, 1989) 
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Acetaldehyde-Mediated Condensation. Condensation also occurs with acetaldehyde 
forming 'bridges' between the anthocyanin and co-condensing phenolic compound. This was first 
seen by Saucier et aL (1997ab) who claimed to have found the first unambiguous evidence for 
such products in red wine. The acetaldehyde attacks electrophilically at the 8-position of a flavanol 
or anthocyanin producing a moiety which then reacts with the anthocyanin or flavanol to form the 
condensed dimer (Figure 1.4c). These reactions also cause bathochromic and considerable 
hyperchromic shifts (Timberlake and Bridle 1977,1980, Dallas et al. 1996ab). Such reactions are 
prevalent in media such as wine that by its fermentative nature has a significant level of 
acetaldehyde and protons present and it has been shown that acetaldehyde formed in situ from 
ethanol plays an important role in polymerisation of water-soluble anthocyanins, (Tanaka et al. 
1994). 
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Figure 1.4c. The Acetaldehyde-mediated condensation of anthocyanins (from Wong 1989). 
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3. Oxidation. Anthocyanidin 3-glycosides can be peroxidized by hydrogen peroxide 
(H202) to benzoyloxyphenylacetic acid esters known as rnalvones. The reaction is a Bayer- 
Villager type of oxidation; the H202attacks nucleophilically at C2, the hydrogen atom migrates to 
the adjacent oxygen and the C2--C3 bond cleaves. King et aL (1979) found evidence that the 
*OH generated from H202by the Haber-Weiss reaction (catalysed by Fe++ salts) cause the lossof 
anthocyanins, not the H202 itself. Whichever, the resultant ester is readily oxidisable to various 
breakdown products (Wong 1989) (figure 1.4d). H202 iSproduced when ascorbic acid is oxidised 
and may contribute to the co-degradation of ascorbic acid and anthocyanins in model and real 
solutions (see 'ex vivo interactions of anthocyanins with vitamin C'). 
4. Sulphur dioxide decoloration. Sulphur dioxide (S02) is commonly added to fruit 
drinks as a reducing agent, and it can add to the 4-position of the anthocyanin to form a bisulphite 
compound (Figure 1.4e). Anthocyanins with the 4-position blocked with a methyl or phenyl group 
are unaffected by S02, and also show increased stability to light. Interestingly, mature wine 
pigments are stable toS02- 
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Fiaure 1.4d. Oxidation product of anthocyanins by the attack of hydrogen peroxide (Wong 1989). 
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5. Enzymic Degradation. Peng and Markakis (1963) studied the effect of (mushroom) phenolase 
on the red chen-y anthocyanins cyanidin-3-gentiobioside and rhamnoglucoside and showed that 
they were poor substrates for this enzyme. However in the presence of catechol the colour was 
Figure 1.4f. Indirect enzymic degradation of anthocyanins. (Peng and Markakis 1963) 
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lost rapidly. As catechol is a substrate for this phenolase, they proposed an indirect mechanism in 
which the enzymically oxidised catechol could non-enzymatically degrade the anthocyanin (Figure 
1.4fl. 
Sakarnura et al. (1966) demonstrated a polyphenol oxidase (PPO) preparation isolated 
from aubergine oxidised the major anthocyanin from that fruit, delphinidin-3-0- 
coumaroylrutinoside-5-glucoside. Pifferi and Cultrera (1974) found that the extent of degradation 
of cyanidin-3 -gluco side by polyphenol oxidases from two cherry varieties in the presence of 
chlorogenic acid, catechin and pyrocatechol coincided with the order of affinity of the phenolases 
with each phenol; namely chlorogenic acid > catechin > pyrocatechol. However the maximal effect 
of each phenol on colour degradation occurred at a pH significantly higher than one of the 
phenolases' optima at pH 3.9 and lower than the other at around pH 7.0-7.5. The anthocyanin 
destruction paralleled the oxidation of chlorogenic acid and the workers concurred with Peng and 
Markakis (1963) and Sakamura, et aL (1966). Similar results with caftaric acid were found along 
with the confirmation of anthocyanin-caftaric acid adducts (Sarni-Manchado et al. 1996ab, 
Fulcrand 1996ab, below). Wesche-Ebeling and Montgomery (1990) found little PPO activity 
could be detected using anthocyanin as a substrate in a strawberry juice model systen-4 but the 
inclusion of D-catechin [sic] caused 50-60% pigment loss after 24 hours. Raynal and Moutounet 
(1989) found similar results, as did Kader et al. (1998) who found cyanidin-3 -gluco side was only 
degraded by polyphenol oxidase in the presence of chlorogenic acid; with the quinone of the latter 
being involved. Sarni et aL (1995) and Kontek et al. (1996) have taken this a step finther and 
found evidence that indicates the o-diphenol anthocyanins (such as cyanidin) follow Peng and 
Markakis' pathway, while non-o-diphenol anthocyanins (such as malvidin) form an adduct with 
the reacting quinone. Plus the reaction of the o-diphenol occurs at a faster rate and can partly 
protect malvidin-like anthocyanins if in the same solution. All pigments formed were eventually 
degraded to colourless compounds. 
Anthocyanases have been isolated and found to decolourise anthocyanins. These enzymes 
are glucosidases that catalyse the hydrolysis of the anthocyanin to the sugar moiety and 
corresponding aglycone. The aglycone is extremely labile and is rapidly degraded to colourless 
products (Eskin 1979); as shown in figure 1.4a. 
6. Cycloaddition. Fulcrand et al. (1996ab) isolated and analysed two unidentified wine 
pigments using mass spectrometry and NMR spectroscopy, and tentatively attributed the 
additional signals to a 4-vinylphenol twice linked to the anthocyanidin moiety. The mechanism 
leading to the formation of the new pigments is a cycloaddition of the C4 and C5 hydroxyls of the 
malvidin molecule and the double bond ofa 4-vinyl phenol. The next step is an oxidative re- 
aromatisation process regenerating the flavylium. cation. This allows two benzopyrylium moieties 
to coexist in the new structure. Interestingly, this new molecule showed greater stability to 
temperature, pH and sulphite consistent with the blocking of positions C4 and C5 (Sarni- 
Manchado et al. 1996ab) (Figure 1.4g). 
Bakker and Timberlake (1997) found four new anthocyanin pigments (two plus their 
acylates) in red wines and established their structures by FAB-MS and NMR. They indicate the 
formation of stable quinoidal bases, expressing more colour up to pH 7 than malvidin 3-glucoside 
and resisting to sulphite bleaching. These have been termed vitisins and become the dominant 
monomeric anthocyanins in matured red wines as they cannot polymerise through position 4 
(figure 1.4h). Also, Francia-Aricha et al. (. 1997) have proposed a similar C4-C5 cyclic structure 
containing two flavylium mesomeric forms for a new pigment detected in model wine solutions 
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that showed stability to increased pH andS02. Most recently Fulcrand et aL (1998) identified 
pyruvic acid adducts of malvidin 3-monoglucoside that underwent such a cycloaddition and having 
similar colour stability. 
Figure 1.4g. Newly identified cycloaddition compounds (Fulcrand et aL 1996a). 
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1.5 Chemical Interactions of Anthocyanins with Vitamin C. 
1.5.1 Ascorbic acid stability in blackcurrants. 
Blackcurrant juice is an aqueous solution of anthocyanins, organic acids (citric, malic, 
ascorbic), flavonol aglycones and glycosides and iron and copper at 1-10 pprn (Morton 1968, 
Herrmann 1976, Holland et al. 1992). Its complexity and natural variability mean that model 
systems are often used for in vitro investigations to ascertain the chemistry that occurs within it. 
While ascorbic acid has been seen to significantly increase the stability of four green tea 
catechins in a dose dependent manner independently of pH (Chen et al. 1998), the presence of 
anthocyanins and ascorbic acid in a model solution appears to cause or at least accelerate their 
mutual degradation (Sondheirner and Kertesz 1952,1953, Meschter et al. 1954, Pratt et al. 1954, 
Timberlake 1960ab, Starr and Francis 1968, Harper ýet al. 1969, Shriklmde and Francis 1974, 
Calvi and Francis 1978, Poei-Langston and Wrolstad 1981, Santos-Buelga et al. 1996). The 
ascorbic acid in blackcurrant juice is said to be remarkably stable (Sills 1939, Hooper and Ayres 
19505 Clegg and Morton 1968). While the latter two report experimental data for this, the Sills 
(1939) paper-often quoted-in fact contains NO evidence to support the statement that ascorbic 
acid is more stable in blackcurrant juice. 
One explanation for the experimentally observed mutual degradation of anthocyanins and 
ascorbic acid is that the electron deficient anthocyanin molecule is susceptible to the nucleophilic 
attack of degradation compounds of ascorbic acid, such as hydrogen peroxide (Sondheimer and 
Kertesz 1953) who outlined two pathways, both involving direct hydroperoxidation at C2, one 
catalysed by iron and a slower pathway not iron-catalysed (see Anthocyanin 
transformations ... number 4). Also, Shrikhande and Francis 
(1974) proposed that anthocyanins 
(like copper ions) act as possible initiators in ascorbic acid degradation therefore being able to 
greatly increase the destruction of pigment seen by workers such as Meschter (1954) in strawberry 
juice (though not by Clegg and Morton 1968). Timberlake (1960ab) found anthocyanins 
increased the metal-catalysed oxidation of ascorbic acid in a model system. He postulated that in 
blackcurrant juice, the oxidation of ascorbic acid would proceed largely by a non-enzymic 
mechanism catalysed by the natural copper and enhanced by the natural iron and anthocyanins 
present: thus pasteurisation was shown not to decrease ascorbic acid oxidation. He tentatively 
ascribed any increased stability of ascorbic acid in blackcurrant juice to its low natural copper 
content and high citrate content, which lessens the catalytic effects of copper and iron by chelati 
them and disallowing their prooxidative activity. 
1.5.2 Protection of ascorbic acid by other substances in blackeurrant juice. 
Protection may be afforded by other phenolic substances, which are present at less than 
half the concentration of the characteristic anthocyanin pigments (Morton 1968). As early as 1936 
Damodaran and Ramakrishnan (193 6) found evidence of a tannin consisting of glucose, gallic acid 
and ellagic acid having a definite retarding influence on the oxidation of ascorbic acid in a solution 
of pressed juice compared with a solution of ascorbic acid of similar concentration with the same 
pH. The work of Parrot (Parrot and Coter, eau 1946, Pdrrot and Gazave 1951ab, Parrot et aL 
1953) continued to show such a possiblity (see 'vitaminC2' in Anthocyanins and Health). In model 
systems flavonol aglycones protect the ascorbic acid and anthocyanins (Hooper and Ayres 1950, 
Clegg and Morton 1968, Harper et aL 1969, Shrikhande and Francis 1974). Rutin and quercitrine 
[sic] have been seen to slow the copper-catalysed oxidation of ascorbic acid (Davidek 1960). 
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Clemetson and Andersen (1966) suggested that part of the mechanism for this activity is likely to 
be due to those polyphenols that possess the chelatogenic 3'4'-dihydroxy group or the 3-hydroxyl- 
4-carbonyl couplet of the C-ring. However antioxidant activity of polyphenols in fruit juices such 
as blackcurrant juice cannot be attributed to their ability to sequester trace metal catalysts as no 
chelation could be demonstrated, and especially since known potent sequestrants like mahc and 
citric acids are present (Harper 1969). Also, Harper et al. (1969) found dihydroquercetin (which 
has no metal chelating ability) to be as efficient as other aglycones in protecting ascorbic acid. 
Harper et al. (1969) concluded that the stabilising factor in blackcurrant juice is not the 
anthocyanins but other flavonoids associated with them; whose antioxidant activity appears to 
reside in their ability to act as free radical acceptors, especially in view of the presence of the high 
levels of sequestering natural acids. (Supported later by Thompson et al. 1976). 
Miller and Rice-Evans (1997 and Miller 1998) compared the calculated cumulative total 
antioxidant activity (TAA) of an apple, orange and a blackcurrant juice drink (Ribena R from 
SmithKline Beecham) using the relative molar antioxidant activities or Trolox Equivalent 
Antioxidant Capacity (TEAC) of the juice components with the engrimental TAA [TEAC is 
defined as the miffimolar concentration of a Trolox (water-soluble vitamin E analogue) solution 
having the antioxidant capacity equivalent to a 1.0 mM solution of the substance under 
investigation (Miller 1998)]. The authors (Miller and Rice-Evans, 1997, Miller 1998) concluded 
that the results suggest the presence of a significant, unidentified antioxidant that would account 
for the 23.8% shortfall in calculated TAA. This work should be ignored as 1) the metal ion 
concentration of the drinks were not found which may have been significant considering the role 
copper appears to play in anthocyanin-ascorbic acid chemistry, 2) no reference is made to the 
contribution that other flavonoids may make to the measured TAA, such as quercetin, kaempferol, 
myricetin as well as other organic acids such as citric, quinic, malic acids, 3) the method used, 
estimating dehydroascorbic acid fluoresence with ortho-phenylenediamine after conversion of all 
the vitamin C to dehydroascorbic acid by iodine relies on a non-specific chemical reaction and so 
is far from ideal for fiuk juice vitamin C determination and reduces the reliability of the results, 
and 4) the standard deviation of the means of the concentrations of actively antioxidant 
constituents (with an n of only three) ranges up to 71% of the mean for the Ribena anthocyanins. 
However, probably most significantly, no mention is made of anyS02in the drinks. S02 is not 
only used as a food additive to retard oxidation (so may significantly affect the measured TAA), 
but it also reacts with polyphenols such as anthocyanins in blackcurrants. S02may well prevent 
anthocyanins and ascorbic acid from causing their mutual degradation as outlined above so 
retarding ascorbic acid disappearance in Ribena in the storage study of Miller and Rice-Evans 
(1997). 
1.5.3 Mechanism of mutual degradation of anthocyanins and ascorbic acid. 
Jackman and Smith (1992) and earlier Sondheimer and Kertesz (1953) attributed the 
degradation of anthocyanins by vitamin C to the formation of hydrogen peroxide in the presence 
of metals. Sondheimer and Kertesz (1952,1953) noted the importance of the presence Of 02 
(headspace) in the mutual degradation of anthocyanins and ascorbic acid, reaffirmed later by King 
et aL (1979). Poei-Langston and Wrolstad (1981) inferred that degradation of anthocyanins and 
ascorbic acid occurs through a direct condensation mechanism since the colour decreased more 
rapidly when oxygen was NOT present, though they did not provide unequivocal proof of such an 
interaction. However, lacobucci and Sweeny (1983) suggested the degradation was through 
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oxidative cleavage of the pyriliwn ring. Also, support for Iacobucci and Sweeny comes from 
Garcia-Viguera and Bridle (1999) who found the condensation reaction is unlikely to take place 
as 1) the colour loss is slow, 2) no new UV absorbing compounds were found and the X. did not 
change and 3) ascorbic acid has a degradation effect on flavylium salts even when the 4-position- 
the centre for nucleophile attack-is substituted. Also, the helical manner in which anthocyanins 
stack would possibly sterically hinder any condensation reaction. It may well hinder ascorbic acid 
also, so the degradation of anthocyanins may be mediated through a free radical species, or 
perhaps the hydrogen peroxide produced from ascorbic acid in the presence of metals. 
Apart from oxidation by hydrogen peroxide (and the free radicals produced when H202 is 
hornolytically split), the mutual loss of anthocyanins and ascorbic acid in model systems may also 
be due to a condensation of ascorbic acid with anthocyanins. Jurd (1972) postulated that ascorbic 
acid may condense with the flavylium salt at position 4 forming an adduct (Figure 1.5.3a). Jurd's 
foundations for this are (1) that the P-diketone dimedone readily has such a reaction with the 
flavylium. salt and that ascorbic acid has a similar structure; and (2) the sodium salt of ascorbic 
acid reacts with the benzyl carbonium ion to form a C-benzyl product. Markakis (1982) comments 
that such a condensation product would be unstable and degrade to colourless, compounds. [The 
structure shown here is that from Jurd's original paper, but the author believes the double bond 
(#) is a mistake/misprint. It would create two pentavalent carbons, and the structure would be 
extremely unstable. Some reviewers (Simpson et aL 1979) have copied this original without 
comment. ] 
Figure 1.5.3a. Proposed anthocyanin-ascorbic acid condensation product. 
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More recently, Sarma et al. (1997) found experimental evidence that anthocyanins may 
protect ascorbic acid from oxidation in the presence of ions such as copper by forming a stable 
coordinate complex of all three (figure 1.5.3b). Sarma et al (1997) observed hypochromic and 
bathochromic shifts in a model solution of anthocyanin-AIC13-ascorbic acid than in anthocyanin- 
AIC13 alone. It would require an ortho-diphenol. group (such as in cyanidin or delphinidin) to 
initially chelate the metal). This could explain (but not prove) the mutual disappearance of ascorbic 
acid, of anthocyanins (and therefore colour) and why the anthocyanins are antioxidative to 
ascorbic acid in the presence of copper ions. However, the presence of citric acid (ubiquitous in 
fi-uit juices) would chelate any metal ions and prevent any anthocyanin-metal complex. 
Figure 1.5.3b 
From Sarma et al. (1997) see text 
1.5.4 Other ascorbic acid stabilising possibilities. 
Samorodova-Bianki (1965) (in Charley 1966) using model systems generated results that 
indicated: (1) certain flavonoids such as quercetin and morin are effective inhibitors of ascorbic 
acid oxidation and (2) fruits with a high flavonoid, content usually show a low ascorbic acid 
oxidase activity. Early work found that an active substance that inhibits enzymic ascorbic acid 
oxidation was of two main fractions; one associated with the anthocyanins and one associated with 
the yellow material, possibly a flavanone (Hooper and Ayres 1950). Some workers have observed 
that the presence of ascorbic acid protects the indirect enzymic oxidation of anthocyanins by 
favourably reacting with the phenolic quinone (Pifferi and Cuhrera 1974) or by inhibiting 
polyphenol oxidase that creates them (Lozano et aL 1994). However both mechanisms would 
cease as soon as all of the ascorbic acid has been oxidised. 
The interactions of ascorbic acid with anthocyanins, flavonols, metal ions, oxidative 
enzymic systems, sequestrants and their relative concentrations, as Well as the pro and 
antioxidative nature of ascorbic acid and its breakdown products creates a complex picture of 
ascorbic acid stability in blackcurrant juice, serving to demonstrate that investigations in 'model' 
systems have serious shortcomings and make extrapolations to behaviour in the natural juice very 
difficult. While factors such as hydrogen peroxide, oxygen-, metal ions, indirect enzymic oxidation 
and possibly anthocyanins encourage the depletion of ascorbic acid; metal ions, flavonols, 
chelatogenic organic acids and the inhibition of direct and indirect enzymic oxidation will stabilise 
the ascorbic acid in blackcurrant juice. 
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1.6 Absorption and Metabolism of Anthocyanins. 
Despite their ubiquitous presence in the diet, there is very little evidence for absorption of 
anthocyanins and very little knowledge of their metabolism Proof of absorption is fundamental to 
any hypothesis that anthocyanins have in vivo biological effects. In investigations earRer this 
century workers did not consider the tautomerism of the anthocyanins, and the fact that they are 
coloured only at low pH. Therefore, with body fluids at pH values well above 1.5, the 
anthocyanins would not be detectable visually and so false conclusions may have been drawn. 
1.6.1 Animal studies. 
Horwitt (1933) administered subcutaneously to rats 50 mg of anthocyanidin chloride 
prepared from grapes and found it largely unchanged in the urine. When starved rats were gavaged 
with 100 mg of anthocyanidin chloride no pigment was found in the urine over 4 days. No 
absorption was observed when a dog was dosed through a gastric fistula, but after intravenous 
injection of anthocyanidin chloride, it appeared in the bile and urine in 20 minutes and the lymph in 
50 minutes. In rabbits fed anthocyanidin chloride, 1-2% of dose was found in the urine and faeces, 
which showed 1-2% of the pigment was excreted through the kidney. Horwitt concluded 
4 ... anthocyanins are not easily absorbedftom the intestine... '. Certainly his work shows this to be 
true,, however detection techniques at this time were relatively insensitive, and the anthocyanidin is 
well known to be highly unstable, certainly at physiological pH. 
Metabolites of delphinidin and pelargonidin-digluco sides, including ring fission products 
such as hydroxy-phenyl-lactic acids, were found in the urine of rats and after in vitro incubation 
with rat intestinal microflora (Griffiths and Smith 1972ab) but not of cyanidin. Griffiths (1973) 
also found unknown phenolic metabolites after nialvidin-diglucoside was administered in a similar 
way, and concluded that flavonoids containing the flavylium. structure have a different degradative 
pathway to the other flavonoids. This study also confirmed work by Scheline (1968) that 
cyanidin-the most ubiquitous anthocyanin was found to be resistant to such catabolism by 
intestinal bacteria. 
The work carried out by Lietti and Forni (1976) and Morazzoni et al. (1991) with 
Vaccinium m). Ttillus (bilberry) anthocyanins (VMA) administered to rats uses a very poorly 
defined method for quantification and identification of the anthocyanins appearing to be based 
simply upon coloritnetric determination at 530 nm. No more information is given, the 
methodology cannot be critically reviewed and so the data and the conclusions gained from it 
cannot be accepted. 
1.6.2 Human studies. 
No human studies exist on the absorption and metabolism of anthocyanidins up to 1996 
(Dragsted et al. (1996). More recently though Rice-Evans' group have found possible evidence of 
anthocyanins in human plasma (Paganga and Rice-Evans 1997), and in urine in subjects with a 
high intake of fruit (Bourne and Rice-Evans 1998). Also Lapidot et al. (1998) after feeding six 
volunteers red wine at approximately 3.5 mg anthocyanins/kg body weight detected red wine 
anthocyanins and possibly modified anthocyanin compounds in the urine at 1.5-5.1 % of oral dose 
though it seems about 95% of dose is still unaccounted for. Lapidot's team prepared their samples 
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more suitably for anthocyanin analysis than Paganga and Rice-Evans (1997), where the latter 
workers' non-acidified extraction conditions suggest that the anthocyanin detected is unlikely to 
be native, but is more likely to be a transformation product like those suggested by Carneira-Dos- 
Santos et aL (1996) (Clifford, personal communication). 
There are many important questions still to be answered, such as what role do intestinal 
flora play in the metabolism of ingested anthocyanins. Also, where and how are the anthocyanins 
absorbed and do they exist as one of the equilibrium forms or are they hydrolysed and/or 
fragmented. Generally, the number of in vivo studies on the absorption of anthocyanins precludes 
any real conclusions. Hopefully soon the availability of radiolabelled anthocyanin studies will help 
in understanding the pharmacokinetics of anthocyanins in the body. 
1.6.3 Anthocyanins in the Diet. 
Anthocyanins occur in 27 different plant families (Bridle and Timberlake 1997), being 
especially associated with fruits. The greatest source worldwide is probably black grapes that may 
give an annual consumption of 10 000 tons (Timberlake 1980), since concentrations in red wines 
of 200 mg/L are not exceptional (Timberlake 1988). Red wines vary considerably in their pigment 
contents according to cultivar, fermentation process and age. 
There have been large differences in the estimates of anthocyanin intake. Kuhnau (1976) 
estimated the average daily consumption of anthocyanins in the USA in 1971 at 215 mg in the 
summer and 180 mg in the winter, with about 50% from fruits and fruit juices. However, this 
would rise rapidly in an individual or other country where red wine is consumed such as in France 
or Italy; or in under-developed countries where wild fruits and berries are more significant in the 
diet (Timberlake 1988). Dragsted et al. (1996) estimated a daily anthocyanin intake of 6-60 
mg/day, and pointed out this figure is much higher for individuals with high intakes of berry or 
grape juices and red wine. A recent paper cited by Bridle and Timberlake (1997 (Alberti-Fidanza 
et al. 1996)) of >500 Italian subjects found a daily intake of anthocyanins, of 25-215 mg/day with 
the greatest intake from red wine. Also too, while red wine consumption would contribute 
significant levels of monomeric anthocyanins to the diet, it would also contribute a large amount 
of polymeric proanthocyanidins that may be fragmented to yet more anthocyanins upon digestion. 
Another recent study using the German National Food Survey found 2.7 mg/day (Linseisen et al. 
1997). 
The picture then is unclear. However, one can say that: 1) dietary variation between and 
within any population group would make any figure for flavonoid intake an average of all but 
representative of few; 2) the original estimates from Kuhnau seem not to be too large and 3) even 
at the lowest estimated intakes the anthocyanins (and other flavonoids) may still be absorbed at 
pharmacologically active doses. 
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1.7 Anthocyanins and Health. 
Man is well acclimatised to ingesting anthocyanins, as they have been a part of the human 
diet since man began to eat the fruits and berries of flowering plants (Timberlake 1988). Plant 
extracts rich in anthocyanins are also used in folk medicine (Kyerematen and Sandberg 1986, 
Borissova et aL 1994), though scientific interest in the biological and beneficial properties of 
anthocyanins originates from the work by Szent-Gy6rgyi and his group in the 1930s, with 
investigations into the antiscorbutic properties of flavonoid extracts. 
Anthocyanins are believed to have pharmacological properties and are used by man for 
therapeutic purposes (Mazza and Miniati 1993). They have been claimed to reduce capillary 
fragility (vitamin P activity), be anti-inflammatory, antioxidative, have anti-ulcer and antibacterial 
properties, as well as being of use in ophthalmology, diabetes, cardiovascular disease and possibly 
cancer. They have also been implicated in the 'French Paradox'. There are a number of 
pharmaceutical preparations on the European market that are or contain anthocyanin-rich extracts. 
These are usually from Vaccinium spp., notably V myrtillus (the bilberry, blueberry or 
whortleberry) and are known as VMA (V myrtillus anthocyano, sides). 
VMA is rich (generally 25-36% w/w) in a whole range of anthocyanidin 3- and 5- 
glycosides and may be regarded as representative of anthocyanins as a whole (Timberlake and 
Henry 1988). Also, anthocyanins of berries and grapes are of particular interest since they are the 
dominant sources of anthocyanins in the diet. However, two important points must be made: 1) 
that much of the research carried out into the health properties of anthocyanins have only used 
VMA extracts and extrapolation of any effects to other anthocyanin (containing) 
foods/preparations would be incorrect; and 2) VMA is not a pure anthocyanin preparation, and 
simply ascribing 0 of these effects directly to the presence of the anthocyanins would be naYve at 
best. 
With the importance of the interactions of anthocyanins and vitamin C in this review, it is 
noteworthy that VMA has a very low vitamin C content, at 0.9-1.0 mg/100 g fresh weight 
(Romero Rodriguez et aL 1992). It is equally noteworthy that interactions may occur in vivo with 
endogenous ascorbic acid. 
1.7.1 Vitamin P and vitaminC2- 
The areas most pertinent to this literature review are the suggested vitamin P and vitamin 
C2 activity of anthocyanins. Although these are not mainstream terms, they do best describe two 
possible aspects of the benefits of anthocyanins. 
1.7.2 Vitamin P. 
The original work by Rusznyak and Szent-Gy6rgyi (1936) proposed the term vitamin P for 
the substances responsible for acting on vascular permeability, hence 'P'. They suggested that the 
symptoms of ascorbic acid deficiency (scurvy) masked the deficiencies of a second substance that 
could reduce capillary permeability (the flow of fluid across the capillary wall and its pathogenic 
consequence, oedema) and fragility (the passage of erythrocytes across a ruptured capillary wall, 
with the consequential purpurea) and was found in extracts of Hungarian red pepper and lemon 
juice. (n. b. the idea that the 'P' stood for paprika is unlikely when the original paper is referred 
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to). Szent-Gy6rgyi and his group found the active substance was practically pure hesperidin and 
its demethylated glycoside (Bruckner and Szent-Gybrgyi 1936) and had the same permeability 
effect in man at 40 mg per day as that in giunea pigs. Later the team suggested scurvy was a 
deficiency disease caused by the combined lack of vitamins C and P (Benthsath et al. 1936), 
though pure P avitaminosis had no clinical symptoms (Benthsath et al. 1937). However, this team 
(Scarborough 1945 , Zilva 1937) and teams cited by King (1939ý-said to be Szent-Gy6rgyi's 
arch rival (Carpenter 1988)-were unable to repeat the original work and vitamin P was shown 
ultimately not to fulfil the definition of a vitamin; and the suggested role for vitamin P as a 
rnodif3dng factor in sc11M was then abandoned (Crarnpton and Lloyd 1950). However, at the end 
of the 1940s, flavonoids were considered to be physiologically significant, though possibly only 
influencing capillary resistance, and that their activity was probably independent of ascorbic acid 
(Hughes and Jones 1977). The term vitamin P is still used, especially by Russian researchers and 
has become a term more for a pharmacological effect (on vascular permeability) rather than as a 
substance per se. 
Most of the work of the 1970s on the pharmacological (largely vitamin P) effects of 
anthocyanins was carried out by Inverna della Beffa (A commercial pharmaceutical company) who 
have sponsored Italian workers. Their work, noteably Lietti et aL (1976), Morazzoni and 
Magistretti (1986), Bertuglia et al. (1990,1995), Colantuoni et al. (1991) and Conti et aL (1990, 
1992), has been critically assessed but has been found to make use of experimental models that do 
not necessarily best reflect the effect being studied. An example of this is the hamster cheek pouch 
capillary perfusion model for vitamin P activity. Also, their models are extremely subject to 
worker to worker variation and have very subjective endpoints. Interesting work has not been 
repeated by them or any other group. A final observation is their patenting of anthocyanins with 
brand names which can only be for future commercial exploitatiom Therefore this work is not 
discussed ftirther. 
1.7.3 Anthocyanins and the action of vitamin P. 
Theoretical mechanisms for any physiological effects of anthocyanins far outweigh any 
hard experimental evidence. However, the author directs the interested reader to the following 
papers that propose mechanisms: Niebes (1972) in Kuhnau (1976), Suohnna et al (1975), 
Fewtrell and Gornperts (1976), Mian et aL (1977), Wutrich and Scharzmann (1980), Morazzoni 
and Magistretti (1986), Cristoni and Magistretti (1987), Nfiddleton and Kandaswami (1993), Saija 
(1994), van Acker et al. (1995). 
1.7.4 VitaminC2- 
The term vitaminC2 has been used to describe the observation that certain flavonoids 
appear to 'spare', 'enhance' or 'enconomise' vitamin C in guinea pig feeding studies (see table 
1.7.4 below). In these studies, animals fed vitamin C associated with certain flavonoids appeared 
to have more vitamin C detected in their tissues compared with those animals fed vitamin C 
without the flavonoids. The termC2' derives from work by Bezssonoff in France in the '20s 
(Bezssonoff 1926,1927), who proposed that there were two forms of vitamin C in milk, one more 
stable than the other. This work has nothing to do with the conceptOf C2 as described in the first 
sentence of this paragraph, but it was Cotereau et al. (1948) who suggested the use of the term 
C2- 
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This ascorbic acid-enhancing effect is separate from vitamin P and since Cotereau, theC2 
banner was firmly taken up by a team of French researchers led by J-M. Gazave and J-L Parrot 
throughout and beyond the 1950's. Many workers have observed evidence for an interaction in 
feeding studies with guinea pigs, with the general outcome that some flavonoids are observed to 
exert a sparing or potentiating action on ascorbic acid (Table 1.7.4a). 
Table 1.7.4a. In vivo studies on the role of flavonoids as vitamin C 'enhancers' or 'economisers' 
in P-uineaDiIZS. 
Authors Design Effect 
Todhunter et aL AA fed to guinea pigs in The two groups made similar gains in 
1940 aqueous solution and in lemon weight, but less scorbutic lesions seen in 
juice lemon juice group 
Cotereau et aL Dietary supplementation of Increased ascorbic acid levels in the Ever, 
1948 (+)-catechin to guinea pigs spleen and kidneys. 
Papageorge and Oral rutin fed to guinea pigs Rutin supplemented group had increase of 
1ýfitchefl 1949 receiving suboptimal AA AA in adrenals only, not liver or blood 
Crampton and Oral rutin fed with 'synthetic' Rutin significantly increased the biological 
Lloyd 1950 and 'natural' AA to guinea value of ascorbic acid from both synthetic 
pigs and natural sources (by. over 50%). 
Douglass and Oral rutin fed to guinea pigs Rutin supplemented group had greater 
Kamp 1959 receiving suboptimal AA AA in adrenals, not liver. 
Blanc and Von der Oral rutin with AA fed to Greater AA in the liver and adrenals 
MuhU 1967 thermally stressed guinea pigs 
Sturua et al. 1971 Purified anthocyanin complex Increased accumulation of AA in adrenals, 
given orally to guinea pigs and liver. 
Hughes and Jones AA with blackeurrant juice, Blackeurrant juice group had greatest 
1971 with acerola cherry juice and growth rate and significantly greater AA 
alone fed to guinea pigs on levels in the spleen and adrenals 
AA-free diet 
Zloch 1973 Oral rutin or (-)-epicatechin Greater AA found in adrenals, liver and 
fed with AA to guinea pigs spleen when with rutin and especially 
receiving scorbutogenic diet epicatechin. 
Kerr Wilson et aL AA fed to guinea pigs in Greater AA found in adrenals, spleen and 
1976 flavonoid-rich orange peel leukocytes but not brain or liver 
extract 
Vinson and Bose AA in citrus fi-uit media given Greater absorption (by 48%) of AA when 
1983 to ascorbate-deficient guinea administered with citrus fruit media 
pigs compared with AA alone. 
(AA= ascorbic acid) 
Thus these flavonoids may become an indispensable factor for hypovitamin C organisms, 
and would protect trace amounts of ascorbic acid in Szent-Gyorgi's original extracts explaining 
their original findings. In these animal studies it is always the tissues-the long term stores that 
show greater ascorbic acid accumulation. In fact Papageorge and Mitchell (1949) did not find 
increased levels in the blood. 
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Studies in humans have shown greater (Elmby and Warburg 1937, Vinson and Bose 1987, 
1988), equal (Todhunter and Fatzer 1940, Nelson et aL 1975, Mangels et aL 1993, Johnston and 
Luo, 1994) and less (Pelletier and Keith 1974) bioavailability of ascorbic acid in its natural source; 
i. e. with flavonoids compared with 'synthetic' or 'crystaffine' ascorbic acid. [Synthetic ascorbic 
acid is chemically identical to natural ascorbic acid, the differences being in the substances of the 
media in question]. 
However, all human studies (above paragraph) and animal studies (in table 1.7.4a) used 
Qld, non-sMcific quantitation techniques for ascorbic acid such as DCPIP* titration or colorimetry 
(F, hnby and Warburg 1937 and Todhunter and Fatzer 1940), or fluorimetry/DNPH* (Vinson and 
Bose 1987,1988, Nelson et al. 1975, Mangels et al. 1993, Johnston and Luo 1994) (seepage 37 
for details of these methods). None used highly specific and sensitive HPLC, and so the 
differences in ascorbic acid found could very well be due to non-specific reduction of the DCPIP 
or derivatisation of the DNPH by other compounds. The qualitative data obtained, and hence the 
inferences drawn, are then of questionable validity, since also there were no specific ascorbic acid 
assays in the 1940s and 1950s. . In addition they are all slightly different 
in design in some way or 
other and employ various levels of vitamin C supplementation leaving critical comparison almost 
impossible. Also, all of the human studies in these paragraphs used plasma as their choice of 
medium. Plasma levels do not give a complete picture and can rather give a nusleading one as they 
reflect only short term ascorbic acid status. Pelletier and Keith (1974) whose one human study 
found flavonoids hindered a plasma ascorbic acid increase looked also at leukocytes, but their 
method did not isolate the different types of leukocyte, and besides no difference in leukocyte 
ascorbic acid levels with different drinks was seen, possibly because they used subjects that were 
ascorbic acid replete and used a low level of vitamin C supplementation. 
1.7.5 Possible mechanisms for Flavonoid augmentation of Vitamin C absorption. 
The poor, non-specific assays and non-comparable methodology as discussed above weaken the 
efficacy of these vitamin C2 studies. However, as is typical, many theoretically possible 
explanations for the 'observed' improvement in the delivery of vitamin C when associated with 
flavonoids have been suggested, though usually with no evidence to support them It was 
originally accounted for by the protection (sparing) of ascorbic acid from oxidation, first proposed 
by Sornogyi (1945) and demonstrated with (+)-catechin by Parrot and Cotereau (1946), confirmed 
by Gero, (1947ab) and concluded also by Crampton and Lloyd (1950). Other explanations put 
forward can be identified as either effects on processes in the lumen of the intestine (luminal) or 
effects occurring in vivo. The former include the idea of complexation of catalytic metal ions such 
as copper by (a) flavonoids (Clemetson and Andersen 1966) or (b) organic acids (Thompson et aL 
1976) thus reducing metal ion-catalysed oxidation. However, Mangels found the presence of iron 
has no influence on ascorbic acid absorption or stability in the lumen (Mangels et aL 1993). Kerr 
Wilson et aL (1976) suggested the low pH in the intestine created by the large amounts of organic 
acids in fruit juices acts to protect the ascorbic acid, but in this study the fiuit extract was not only 
acid-free but was administered separately from the ascorýic acid. Other hypotheses by Clemetson 
and Andersen (1966), Mayersohn (1992) and Blanchard et aL (1997) all lack hard evidence. The 
proposed effects in vivo are even more lacking in evidence and so are only listed here: a) by 
potentiating the reduction system that converts dehydroascorbic acid back to ascorbic acid by 
glutathione (Parrot and Gazave 1951ab, Parrot et aL 1953, Parrot and Cotereau 1957), b) by 
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increasing the adrenal secretion of cortisone Clemetson and Andersen (1966), c) by taking over 
some of its biological functions reducing the metabolic demand (Kerr Wilson ef aL 1976), d) by 
forming an oxidation resistant 4ascorbigen' (Kuhnau 1976 after Kiss and Neukom 1966,1968, 
Jurd 1972) and e) because ascorbic acid penetrates cell membranes only as a complex bound to a 
polyphenol (Chamrai 1969). 
Even if the vitaminC2 effectcould be explained by one or several of the above, it does not 
help explain why only some tissues increase in ascorbic acid content. This author believes there is 
no strong evidence for any lurnenal or in vivo effect, since the studies (in table 1.7.4a) would be 
greatly influenced by dosage and inter-individual variation; that reduces the efficacy of their 
conclusions as would their poor choice of assay. Also, any ascorbic acid enhancing effect is 
generally only seen in animals that are suboptimal for ascorbic acid. 
Gazave et al. (1973,1974) found and continued to put forward (1981) the structure ofC2 
to be L-epi-3', 4', 5', 5,7 pentahydroxyflavan-3-ol, the archaic name for what is now called (-)- 
epigallocatechin. The concept of C2 today is of a factor secondary to ascorbic acid that is 
polyphenolic in its chemistry, that in some way protects or economises the ascorbate or enhances 
its absorption, or even its activity and storage once in the body; possibly taking over some 
ascorbate roles. In fact Cotereau et al. (1948) went on to state that: 'it seems impossible to study 
any action of vitamin C without having determined previously the amount of the 'sparing factors' 
of ascorbic acid present in the diet'. 
1.7.6 VitaminC2 and anthocyanins. 
An abstract translated from Russian (Sturua et al. 197 1) observed that a 'purified 
anthocyanin complex isolatedftom red grape skin and given orally to guinea pigs had a strong 
vitamin P-like activity and increased the accumulation of vitamin C in the adrenals and liver'. 
Hughes and Jones (197 1) studied the tissue deposition of ascorbic acid and the growth response in 
guinea pigs using two natural sources of vitamin C: blackcurrant juice and acerola cherry juice 
(virtually flavonoid free), as well as synthetic ascorbic acid in water. They found the ascorbic acid 
concentration in both the spleen and the adrenal glands was significantly higher in the blackcurrant 
group than the acerola group, and both higher again than the synthetic ascorbic acid group. The 
same order was seen for the animals growth rates. Jones and Hughes (1984) repeated this, feeding 
5 human subjects 500 mg ascorbic acid in blackcurrant juice or in water and measuring their 
urinary ascorbate. Upon finding more ascorbate excreted when drunk as blackcurrant juice, the 
authors implied this meant better gastrointestinal absorption. These workers therefore attribute the 
differences in part to the bioflavonoids in the blackcurrant juice, where they may increase the time 
available for absorption of ascorbic acid in the stomach and intestine and/or improve the stability 
of the ascorbic acid in the tissues. 
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1.8 Other Health Aspects of Anthocyanins. 
1.8.1 Antioxidant activity. 
The implication of anthocyanins, showing in vivo antioxidant activity is their possible 
involvement in the amelioration of a range of diseases linked with oxidative stress, such as 
cardiovascular disease (CVD), cancer, rheumatoid arthritis, cataracts and even ageing. Much of 
this interest comes from the epidemiological observation known as the 'French Paradox' (see 
below). Many of the biological properties of anthocyanins have been correlated with their ability 
to scavenge oxygen-generated free radicals by proton donation and to inhibit lipid peroxidation 
(Saija 1994). 
The antioxidant activites of compounds is commonly measured by a simple in vitro assay 
such as the TEAC, (Trolox Equivalent Antioxidant Capacity), ORAC (oxygen radical absorbance 
capacity) or TBARS assay (thiobarbituric acid-reactive substances) that produces a convenient 
value that can be useful in comparing and thus screening different compounds for antioxidant 
activity. However, the limitations of these kind of assays are often at best misunderstood and at 
worst conveniently overlooked. They are often critised by workers using a different assay in a 
different laboratory. They all have severe shortcomings in design, show only one aspect of a 
compound's antioxidant activity and are usually incorrectly used as the basis for extrapolating to 
the benefits of such compounds to human health. Therefore while the list of publications about the 
in vitro antioxidant activity of flavylium. compounds grows (Morazzoni and Malandrino, 1988, 
Tsuda et aL 1994, Tamura and Yamagami 1994, Rice Evans et al. 1995, Vinson et al. 1995, 
Itakura et al. 1996, Kanner 1996, Kanner et aL 1997, Merillon et aL 1996, Teissedre et aL 1996, 
Baldi et al. 1996, Satue-Gracia et aL 1997, Wang et al. 1997, Ghiselli et aL 1998, Rice-Evans and 
Miller 1998) the data from these assays do not contribute to the body of evidence that suggests 
these compounds are nutritionally significant. 
It is important also to keep in mind the range and potency of endogenous antioxidant 
systems in the human body. Human plasma is endowed with an array of antioxidant mechanisms 
including ascorbate, urate, cc-tocopherol, albumin-bound bilirubin and albumin itselý plus 
transferrin and ceruloplasmin, extracellular superoxide dismutase and glutathione peroxidase (Frei 
et aL 1988). It would require a large amount of convincing evidence to begin to believe that 
relatively small levels of dietary antioxidants have any significant part in the antioxidant defence of 
the body tissues and from there a role in the prevention and/or amelioration of any oxidative 
damage-linked disease 
1.8.2 Flavonoids and The French Paradox. 
The potent antioxidant activity of phenolic substances in red wine has been proposed as an 
explanation for the French Paradox-the apparent incompatibility of a high fat diet with a low 
incidence of coronary heart disease. Epidemiological studies have consistently shown that the 
consumption of red wine correlates with reduced CHD mortality (Renaud and De Lorgeril 1992, 
Gronbxk et aL 1995). Similarly, the Dutch group led by Hertog have shown that the intake of five 
flavonol aglycones was inversely associated with mortality from coronary heart disease and the 
incidence of myocardial infarction (Hertog et aL 1993b, 1995). However, flavonol intake was not 
inversely associated with coronary heart disease in the Caerphilly study in Wales (Hertog et al. 
1997),, which the authors suggest is due to the Welsh having milk with their tea and preventing 
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absorption of flavonols whereas the Dutch do not add milk to their tea. However, current data 
suggest that milk being added to tea does not influence plasma levels (Clifford, personal 
communication) 
Similar to the previous section, there is no lack of evidence for the in vitro antioxidant 
properties of red-wine constituents (including anthocyanins) or their ability to protect LDL against 
oxidation (Mangiopane et al. 1992, Frankel et aL 1993ab, 1995,1998, Tamura and Yamagami 
1994, Fuhrman et aL 1995, Rice-Evans et aL 1995, Vinson et aL 1995, Itakura et aL 1996, 
Lehtonen et aL 1996, Heinonen et aL 1998, Vinson and Hontz 1995, Day et aL 1997, Carbonneau 
et aL 1998, Ghiselli et aL 1998, Meyer et aL 1998a, Nigdikar et aL 1998). None of these studies 
provide proof for a role in vivo. Furthermore, it is far from established whether red wi4e drinking 
results in an increase in polyphenol concentration in the serum that would be great enough to 
explain this rise in serum antioxidant capacity. 
The only in vitro ex vivo evidence is from Maxwell et aL (1994) and Whitehead et aL 
(1995) who demonstrated that the ingestion of red wine increased the antioxidant activity of serum 
assessed by the TRAP assay (Total Reactive Antioxidant Potential). (The TRAP assay allows for 
any synergism between antioxidant molecules to be accounted for rather than just their single 
concentrations (Baldi et aL 1996)). 
Day and Stansbie (1995) have suggested from in vitro ex vivo that the effect of red wine 
may be mediated through serum urate, which contributes up to 65% of total plasma peroxyl 
radical scavenging activity and is also important in recycling ascorbate (Sevanian et aL 1991). Day 
and Stansbie found upon ingesting port wine, serum urate increased by 23% (ethanol was 
insignificant) and serum total antioxidant capacity increased by 24% within 30 minutes; and go on 
to say that 73% of the acute increase in serum total antioxidant capacity after the ingestion of port 
wine may be attributable to an increase in urate concentration. Day and Stansbie believe the 
acuteness of the effect suggests an increase in urate production by purine breakdown, rather than 
an inhibition of renal urate excretiorL 
The platelet anti-aggregation activity of red wine constituents may also contribute to the 
French Paradox, and anthocyanins have been shown to be very effective in this regard in vitro, at 
pH 7-similar to physiological pH (Baldi et aL 1996). Anti-aggregation is discussed further in the 
cardiovascular disease section, below. 
1.8.3 Cardiovascular disease and Thrombotic Tendency. 
Three recent epidemiological studies have suggested a role for selected flavonoids in the 
prevention of heart disease (Hertog et aL 1993b (The Zutphen Study), Hertog et al. 1995 (The 
Seven Countries Study), Knekt et al. 1996). However, there are no studies involving anthocyanins 
specifically. Also, with low intakes of vitamin C being correlated with increased heart disease and 
the possibility of flavonoids having the 'sparing' (vitaminC2) effect, any epidemiological studies 
may be seriously confounded. Evidence for a possible role for anthocyanins in preventing or 
ameliorating heart disease comes only from in vitro studies showing red wine (Maalej et al. 1997), 
VMA (Pifferi et al. 1992, Timberlake 1993, Baldi et al. 1996), grape juice (Demrow et al. 1995, 
Maalej et al. 1997) and isolated anthocyanins (Morazzoni and Magistretti 1990) to inhibit blood 
platelet aggregation and improve blood filtrability (Millet et al. 1984) thereby reducing thrombotic 
tendency. This is thought to be mediated through prostaglandins, which inhibit platelet aggregation 
and whose local synthesis has been shown to be stimulated by anthocyanins in vitro (Bettini et al. 
1984 ab, 1985). 
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1.8.4 Cancer. 
Based on consistent and strong evidence (from over 170 epidemiological studies), it has 
been proposed that a large number of cancer-related deaths could be prevented by increased 
consumption of fruit and vegetables (Block 1991b). However, Hertog et al. (1995) concluded the 
average intake of five 'marker' aglycones was not an important determinant of cancer mortality. 
Only one cohort study on anthocyanins and cancer has been found in the literature, a three month 
anthocyanin treatment of fibrocystic mastopathy in Italian women by Leonardi (1993) that was 
found to be 'beneficial', though the anthocyanin source, study design and patient controls are 
unknown. There is no epidemiological or in vivo evidence to suggest any role for anthocyanins in 
cancer prevention or amelioration. There are many in vitro studies that give anthocyanins a 
mechanism for an anti-cancer role (Kano and Nfiyakoshi 1976, Minkova et al. 1990, Karnei et aL 
1995, Bomser et al. 1996, Rechkernmer and Pool-Zobel 1996, Kamei et al. 1998, Madhavi et al. 
1998, Nagase et aL 1998). 
At this stage, if the anthocyanins were to have anticarcino genic activity, then it would most 
likely be through their demonstrated antioxidant abilities. One possibility is that their intake could 
be used as a dietary marker for a fruit and vegetable rich, 'healthy' diet and so encouraged in the 
general population; just as a high cholesterol intake is discouraged as it is a marker for a diet high 
in saturated fat. 
1.8.5 Other effects 
Ophthalmology. There are unsubstantiated reports of anthocyanins (taken orally) 
enhancing sight acuity (Lietti et al. 1976). Only two studies were found in this area. Pourrat 
(1977) gave anthocyanin preparations from red wine grapes to 8000 subjects for 15 years at 600 
mg/day, finding a 73-97% improvement in vascular conditions of the bioflavonoid-responsive type 
as well as significant improvements in night vision and myopia retinopathy. He also cites work 
demonstrating the use of anthocyanins, for better night vision and quicker dark adaptation in pilots. 
However, simple arithmetic (8000 people x 15 years x 365 days x 600 mg per day) demonstrate 
that he would have required a massive 26 tons of 'anthocyanin preparation' for the study. Also, 
imagine the logistics of such a huge study! Plus the precise measurement of these endpoints is very 
Micult. Reference to the original paper sheds no light on the planning and execution and so such 
data should be considered merely suggestive. However, Scharrer and Ober (1981) found in 31 
patients with various types of retinopathy that anthocyanins had a positive influence on the 
tendency to haemorrhage and permeability of, retinal vessels, especially those with diabetic 
retinopathy, and concluded any effect is probably mediated through a vitamin P effect. 
Anti-ulcer activity. A pattern of evidence from rat models (Cristoni and Magistretti 1987, 
Cristoni et al. 1988, Saija 1994) and human studies (Barzaghi et al. 1988,1991, Mertz-Nielsen et 
aL 1988, Warrington et al. 1988) support the possibility of anthocyanins as efficacious anti-ulcer 
treatment. 
Anti-inflammatory While there are studies showing VMA having anti-inflarnmatory 
activity (Lietti et al. 1976, Gabor and Razga 1991, Borissova 1994), the models used such as 
carragenan-induced rat paw-oedema are very subjective and interlaboratory comparisons are not 
possible. 
Anti-bacterial effects. Anthocyanins have been reported to be anti-bacterial to 
Escherichia coli and Salmonella typhosa possibly through enzyme inhibition, but have no effect 
on Staphylococcus aureus (Carpenter et al. 1967). Sarni-Manchado et al. (1998) found grape 
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seed tannins inhibited the growth of Streptococcus mutans, an oral Gram-positive micro-organism 
and major aetiological agent in human dental caries. The workers observed a decrease in colony 
forming units (CFU) and changes in the morphology of the bacteria under scanning electron 
microscopy. Cranberry juice, high in cyanidins and pelargonidins, has long been used as a folk 
remedy for urinary tract infections, though the mechanism of action is unknown (Fleet 1994). 
Anthocyanins have been reported to have antifimgal activities against Aspergillus sp., Bottytis 
cinerea and Penicillium notatum (Rizvanov and Karadýnecheva 1973) and delphinidin 3- 
glucoside has been reported to inhibit the growth of Lactobacillus acidophilus, (Pratt 1960 cited 
in Leung and Foster 1996). 
Other effects. There are studies suggesting anthocyanins have anti-diarrhoeal activity 
(Kyerematen and Sandberg 1986), the ability to reduce blood-brain barrier permeability (Robert et 
aL 1977) and to be hepatoprotective (Mitcheva et aL 1993, Gibb et al. 1987), though there is too 
little data for conclusions to be drawn. 
1.9 Toxicity. 
JECFA, (Joint FAO/WHO Expert Committee on Food Additives 1982), observe that man 
is naturally exposed to anthocyanins through the ingestion of fruit and vegetables, and that 
'extractsfrom a variety offruits ... are of a very low order of toxicity' * They accept a daffy intake for man of 0-2.5 mg/kg body weight of a grape skin preparation at 3% anthocyanins, which 
translates to 150-175 mg/day for a 60-70 kg adult. Becci et aL (1983b) fed beagle dogs a 
colorant containing 40% of the naturally occurring grape-colour extract in a malto-dextrin carrier 
at 0,7.5 and 15% (w/w) of total intake for 13 weeks. They found a significantly decreased body- 
weight gain at the higher dose in males and females but no other treatment-related effects were 
seen, and concluded no toxic effect or pathological change was caused by the preparation. Earlier, 
Becci et aL (1983a) came to the same conclusion in a 13 week, two generation feeding study in 
rats of the same colorant at the same dietary level. They also concluded that the lower body- 
weight gain was due to a lower calorific content of the diet, and that no adverse effects on the 
reproductive performance were found. 
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1.10 Vitamin C-Introduction., 
Vitamin C, ascorbate or ascorbic acid are tenns used interchangeably for all compounds 
exhibiting the biological activity of ascorbic acid, namely L-ascorbic acid, dehydroascorbic acid 
and semi/monodehydroascorbic acid (or ascorbyl free radical). It is a water-soluble vitamin 
synthesised from glucuronic acid, originally named hexuronic acid by Szent-Gyorgyi. Humans, 
flying mammals and most significantly the guinea pig (which continues to be used for in vivo 
investigations) have lost the metabolic ability to produce vitamin C; making itan essential dietary 
component. Fortunately, it is ubiquitous in plant foods. D-ascorbic acid (isoascorbic acid) shows 
only 5% of the biological activity of its isomer (Bui-Nguyen 1985). 
There is a huge literature concerning vitamin C intake, function and health and over the 70 
years since its discovery, evidence for various functions has accumulated. This continues to grow 
as apart from established functions in collagen formation, iron absorption, folic acid metabolism 
and in scurvy prevention, the research in latter years into the antioxidant theory of common 
chronic diseases has given vitamin Ca key role through its function as an important physiological 
antioxidant. Most workers would agree that our knowledge concerning vitamin C is far from 
exhaustive. 
Ascorbate is added to foods as E300, E301 or E302 to prevent oxidation, increase acidity 
or to enhance the vitamin C content for nutritional reasons (fortification or supplementation). 
Vitamin C is ubiquitous in plants thus fruit and vegetables are our main source, though 
despite recent findings. (Wheeler et aL 1998), the precise pathway for its biosynthesis is still 
unknown. The only notable animal sources are milk (1-5 mg per 100 g) and organ meats (offid) 
such as liver and kidney. In the U. Y, diet we obtain most of our vitamin C from tomatoes, citrus 
fi-uit and juices, peppers, leafy vegetables and potatoes. Most fi-uits are good sources of vitamin C, 
some are richer than others. The richest fi-uit sources are the acerola cherry, guavas (300 mg per 
100 g) and blackcurrants (150-230 mg per 100 g) (Holland et aL 1992). The exact content 
depends on many factors such as species, variety and ripeness (Romero Rodriguez et aL 1992); 
see Table 1.1 Oa. 
Table 1.10a. The vitamin C content of some blackcurrant varieties. 
Variety Vitamin C content, 
mg/100g fresh weight. 
Black Down 213-215 
Noir Bourgogne 150-153 
Royal Naples 165 
Tifon 155 
Troll 157 
Tsema 160-162 
(Romero Rodriguez et al. 1992). 
The quantity of the vitamin in the food 'when it reaches the table' varies with the extent of 
processing it undergoes, notably in the domestic kitchen and also the conditions of storage. As 
well as heat, leaching and chemical oxidation, vitamin C is lost enzymatically to ascorbic acid 
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oxidase and phenolases as soon as the cell structure of the food is disrupted (for example by 
chopping or slicing). The enzyme functions with oxygen and is catalysed by copper (11) and other 
transition metal ions. Short heat processing such as blanching can protect vitamin C by destroying 
the ascorbate oxidase enzymes. 
1.10.1 Chemistry 
I ISc 18 ular gh Ac orbic acid is an a-keto lactone with molecular formulaC61 06; molec wei t 
176.13. Ascorbic acid is reversibly oxidised to dehydroascorbic acid and then irreversibly to 2,3- 
diketogulonic acid (Figure 1.10.1a). The rate of oxidation is enhanced by factors such as alkaliý 
heat, copper and light. 
Figure 1.10. la. The chemistry of ascorbic acid (from Basu and Schorah 1982) 
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Because both enolic hydroxyl groups can dissociate, it acts as a dibasic acid with pK,, 
values of 4.18 for the hydroxyl at C-2 and 11.8 for C-3 at 37'C. The ene-diol structure creates a 
complex chemical behaviour. The three forms ascorbic acid, semi-dehydroascorbic acid and 
dehydroascorbic acid are a reversible redox system which gives it its unique place in biochemistry 
and enables it to have such a diverse and oxymoronic nature. Ascorbic acid is a strong reducing 
agent. 
1.10.2 Ascorbate Analysis 
The continuing interest in ascorbic acid and its role in human health and nutrition has 
required the development of ever more sensitive and reliable methods for its quantitation. Ideally, 
the best measurement of ascorbic acid content of biological samples would be through its 
biological activity at the site of action. However, an exact, definite and specific role for ascorbic 
acid has yet to be determined and so the most suitable method is the measurement of ascorbic acid 
concentration. Assays for ascorbic acid have been available for over 60 years and are mostly based 
on its reducing character, creating a lack of specificity due to interfering substances that also have 
reducing characteristics. These methods also tend to be time consuming, cumbersome, lacking 
precision and accuracy and usually involve some derivatisation to produce a chromophore. 
Common methods include derivatisation with 2,4-dinitrophenylhydrazine (DNPH) by Roe and 
Kuether (1943), or the reduction of the chromophore 2,6-dichlorophenolindophenol (DCPIP) to 
a colourless derivative described originally in Owen and Iggo (1956), but more clearly in 
Omaye et al. 1979 and Kirk (199 1). 
Another popular method is to oxidise the ascorbic acid to dehydroascorbic acid and react 
with o-phenylenediamine to form a fluorescent quinoxaline derivative (0maye et al. 1979 , Kirk 
1991, Deutsch and Weeks 1965). Also, potentiometry is popular for its speed and simplicity. 
However, these analyses yield biased results relative to chromatographic methods and are not 
suitable for the accurate clinical investigation of ascorbic acid. 
The advent of high-performance liquid chromatography (HPLQ has allowed the 
development of more specific and sensitive quantitative methodologies. Ascorbic acid can be 
analysed with an ion-exchange column or with a 'reverse phase' (non-polar stationary phase) 
column under the right conditions, usually a C18 reverse phase column (Rizzolo et al. 1984, 
Vandeýagt et al. 1986, Behrens and Madere 1987, Kutnink et al. 1987, Finglas et al. 1993, Liau 
et al. 1993, Harapanhalli et al. 1993, Baija and Hernanz 1994, Manoharan and Schwille 1994, 
Ross 1994). It is well known that for the reverse phase HPLC analysis of ascorbic acid, the mobile 
phase must be acidic to protect the ascorbate from oxidation to dehydroascorbic acid and 2,3- 
diketo-L-gulonic acid. This has been achieved by the additioti of an acid (oxalic, trichloroacetic, 
citric, metaphosphoric or perchloric) to maintain a low pH (Lumley 1993), at which hydrolysis of 
the lactone ring is prevented. Reverse phase HPLC analysis of ascorbate is done under two 
distinct conditions. 
The first approach has used a mobile phase of pH 4.6-6.0 and an ion-pair agent (Rizzolo et 
al. 1984, Vandedagt et al. 1986, Behrens and Madere 1987, Kutnink et al. 1987, Finglas et al. 
1993, Baija and Hernanz 1994, Ross 1994). Ascorbic acid has a pK, of 4.18, so in aqueous 
solutions around pH 5.5, the ascorbate ion [All] predominates, which necessitates the use of the 
ion-pairing reagent. The ion-pair formed then behaves like a very polar organic molecule and so 
has less affinity for the non-polar stationary phase than the mobile phase. However, ion-pair 
reagents are often 'unfriendly' compounds to deal with, have a surfactant nature causing them to 
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froth and bubble, and reduce chromatographic reproducibility. Reproducibility can be a major 
problem through variable retention times and inadequate equilibration of the column with solvent 
which occurs when ion-pairs are used. 
The second approach has been to use a more acidic mobile phase, i. e. 1-2 PH units below 
the pYi; at PH 2.34 (Manoharan and Schwille 1994), at PH 3.1 (Harapanhalli et aL 1993) or at PH 
2.95 (Liau et aL 1993). Chromatography at this lower PH dispenses with the need for an ion-pair. 
However, this methodology invariably employs a phosphate buffered mobile phase to maintain PH 
which, without extreme care, can precipitate out within the I-1PLC system (in the presence of 
organic solvents) with damage to the HPLC hardware and significant losses in reproducibility. 
Modem chromatographic columns are stable at much lower PH than ever before. Therefore a 
better approach is to lower the PH further to 1.5 so that neither phosphate buffer nor ion-pair is 
used. Not only does this simplify the methodology greatly but it is also quick, reproducible, 
reliable, sensitive and specific, as well as being cost-effective. This approach and methodology has 
been used successfiffly to determine ascorbic acid in fi-uit juices, plasma and leukocytes (Edmed 
and Clifford, unpublished) 
Chromatographic methods such as 11PLC are ideal as they have excellent sensitivity and 
specificity, higher resolution and are less prone to interference. Ascorbic acid can be quantified 
directly by absorbance at its X. around 254 nm; depending on the medium in which it is measured 
(Lumley 1993). In complex matrices such as foods or biological tissues there are usually 
substances that interfere with the analysis of ascorbic acid since they absorb UV light at similar 
wavelengths. In this situation, the choice of absorption wavelength depends more on reducing 
these factors to obtain a good resolution of the ascorbic acid peak rather than simply a pursuit for 
the largest ascorbic acid peak. 
Dehydroascorbic acid has a low response with most detection methods, but must be 
quantified as it is biologically active and its presence may be physiologically significant. It can be 
calculated by the difference between the ascorbic acid assay and a similar assay with a reducing 
agent added such as dithiothreitol or homocysteine. The difference, in theory, is the result of 
conversion of any dehydroascorbic acid to ascorbic acid. 
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1.11 Absorption and Transport of Vitamin C. 
I va A scorbic acid is rapidly absorbed via the buccal mucosa (Odumasu and Wilson 197 1) and 
stomach (Penney and Zilva 1946), but quantitatively the absorption by a sodium dependent 
process in the ileum (Nicholson and Chornock 1942, Stevenson and Brush 1969, Kubler and 
Gehler 1970, Mayersohn 1972, Stevenson 1974) is the most important. Later workers have added 
that it may be pH dependent and rely on the presence of a carrier to take it across the gut wall 
(Ehnadfa and Koenig 1996). Certainly, at intestinal pH it is very soluble (Rose 1987). The work of 
Rose et al. has done most to pursue this process and the reader is directed to his work for more 
detail. 
The process of absorption is similar to but distinct from the sodium gradient mechanism 
for sugars and amino acids found in the ileum (Rose 1981). Ascorbic acid is taken up across the 
brush border membrane against a concentration gradient coupled with Na' diffusion down an 
electrochemical potential gradient (Rose 1996). Ascorbic acid leaves the cell by a carrier-mediated 
process at the basolateral membrane. Dehydroascorbic acid also enters the cell from either the 
lumen or interstitium. by facilitated diffusion and is enzymatically reduced (Rose 1996). 
More efficient absorption is achieved through small multiple doses (Yung et al. 1981, 
Singh and Gaby 1991) such as a 98% efficiency in doses of 4-64 mg found by ingesti 
radiolabelled ascorbic acid and measuring the radioactivity in the faeces to be <2% of dose (Baker 
et al. 1969,1971). Further, 90 and 180 mg/day is absorbed at 80-90% (Kallner et al. 1977), 75% 
at Ig 44% at 2 g, 39% at 3 g, 28% at 4 g, 20% at 5g (Hornig et al. 1980), 50% at 1.5 g, 26% at 
6g and to 16% at 12 g Kubler and Gehler 1970). Ascorbic acid absorption is increased when 
given soon after food possibly due to delayed and prolonged absorption (Yung et al. 1981) 
through increased presentation time to the active absorptive mechanisms and promoting passive 
diffusion. Stevenson (1974) found equirnolar concentrations of glucose-enhanced absorption by 
41%, suggesting, a) that ascorbic acid does not use the same transport route as glucose, and b) 
that the glucose may serve as an energy substrate. Pectin and zinc may impair absorption 
(Sauberlich 1990). Also, there may be up to a 20-fold interindividual variation in the physiological 
handling of ascorbic acid in guinea pigs (Williams and Deason 1967) and humans (Yung et al. 
1982), the latter finding 'good' and 'poor' absorbers of ascorbic acid. 
Cowley et al. (1987) found ascorbic acid malabsorption potentiated by citrate, but their 
study was poorer in design and conclusion than that by Mangels et al. (1992), who found a 
nutritionally insignificant antagonistic effect. The process is inhibitable by aspirin (loannides et al. 
1982). 
Vitamin C is transported predominately as the reduced form in the plasma as a free 
monovalent anion (Olson and Hodges 1987), possibly in association with the protein albumin 
(Combs 1992), though other workers disagree with the significance of protein-bound ascorbic acid 
and report no detectable protein bound ascorbic acid (Schorah 1992, Wang et al. 1992, Dhariwal 
et al. 1991). Dehydroascorbic acid may not be present in plasma and serum of normal humans 
except where assay conditions permit ascorbic acid oxidation (Dhariwal et al. 1991), which 
in this 
authors view is virtually always the case even when the best attempts are made to prevent 
it. 
Whichever, it is certain that at physiological pH of 7.4 it exists as the monoanion, which hinders its 
passage across the hydrophobic cell membrane. But ascorbic acid at some sites-such as 
in the 
chrornaffin vesicles of the adrenal medulla-and in some cells--such as the white cells--must 
be 
present at a concentration higher than the surrounding tissue and interstitia for 
it to function. 
Human leukocytes accumulate ascorbic acid in the cytosol up to a concentration 80 times that in 
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plasma (Evans et aL 1982) (10-fold again in activated neutrophils (Washko, et aL 1993)) and is found to be at least 94% unbound and only in the reduced form (Washko et aL 1991). This and 
similar observations of the higher concentration of ascorbic acid in certain cells compared with its 
surroundings plus its polarity in aqueous fluids are indicative of an active uptake mechanism 
1.11.1 Transport into the cell. 
Any material which cannot be synthesised within the cell would need to be transported 
across cell membranes and through biological fluids. The study of the transport of vitamin C 
across cell membranes has been taken up by many workers, not least by Mark Levine and again 
Richard Rose. It is to these two researchers that the reader is directed for further detail. The 
recent review of Rumsey and Levine (1998) conveniently brings most aspects together though not 
uncontentiously. 
The proposed mechanism is that ascorbic acid is extracellularly oxidised to 
dehydroascorbic acid and then preferentially translocated across the membrane where it is quickly 
reduced back. Such a mechanism would create a concentration gradient down which the ascorbic 
acid could get into the cell (Washko et al. 1993). When a neutrophil is activated, its increased 
oxidative capacity provides the oxidants that transform extracellular ascorbic acid to 
dehydroascorbic acid, which is then transported (independent of sodium) into the cell- 
Extracellular discrimination of the D- and L- isomers of dehydroascorbic acid has been 
demonstrated (Combs 1992). 
Once it is across the membrane and inside the cell, dehydroascorbic acid is reduced back to 
ascorbic acid independently of the transport process but in a sodium-dependent manner (Vera et 
aL 1995, Bode 1997). The exact mechanism is unknown but it may be non-enzymatic (Winkler et 
aL 1994), or enzymatic (Bigley et aL 1981, Rose and Bode 1995, Bode 1997). This would allow 
ascorbic acid to be concentrated well above physiological levels. Whichever, it appears important 
to convert the dehydroascorbic acid back to ascorbic acid not only from the point of view of 
maintaining high levels of ascorbic acid, but also because dehydroascorbic acid may have potential 
toxic effects on biological systems mediated through intracellular enzymes, cell membranes, 
transport proteins or receptors (Rose et aL 1992). 
1.11.2 Role of glucose in vitamin C transport 
With the structural similarity between glucose and vitamin C some cross affinity of their 
respective transporters can be expected (Goldenberg and Schweinzer 1994). A study by Johnston 
and Yen (1994) found cellular uptake of ascorbic acid and glucose use a common transport 
system, and that elevated plasma ascorbic acid alters insulin response to a glucose challenge in 
normoglycaernic adults, perhaps by competitive inhibition of glucose uptake by pancreatic P cells 
which Bergsten et al. (1994) found to be in a dose-dependent and completely reversible manner. 
Some evidence suggests that in some tissues dehydroascorbic acid may also be transported 
by a glucose transporter, setting up competition and inhibition for the transport site. Of the seven 
glucose transporter isoforms GLUTI and GLUT3 but not GLUT2, GLUT5 or SGLTI transport 
DHAA (Vera et al. 1993, Rumsey et aL 1997). Glucose-has been found to compete with ascorbic 
acid for the ascorbic acid transporters in various cells (Moser and Weber 1983, Kapeghian and 
Verlangieri (1984) cited in Washko et aL 1991, Padh et aL 1985, Moser 1987, Washko et aL 
1991), and that ascorbic acid uptake was sodium-dependent while dehydroascorbic acid was not. 
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The competition for the glucose and ascorbate transporters therefore lead to diabetic patients 
having abnormally high plasma levels of dehydroascorbic acid. 
1.11.3 Tissue Distribution 
Typical of a water-soluble vitamin, no particular organ acts as a store for the vitamin, 
though some tissues are able to accrue high amounts of it. However only a certain amount is 
absorbed at any meal and excess is either not absorbed or is excreted rapidly. Tissue levels are 
decreased by normal metabolism but also by physical and physiological stress and injury. 
Although there is a large inter-individual variation, approximate figures for vitamin C 
status have been published by various workers. At saturation, the total body pool is about 1.5-5 g 
(Omaye et al. 1979, Basu and Schorah 1982, Elmadfa and Koenig 1996), or 22 mg/kg body 
weight or 32 to 34 mg/kg fat free weight (Basu and Schorah 1982) of a total body pool of 1.5 g.. 
This equates very approximately to 0.8-1.5 mg/100 ml plasma, 1.0-1.5 mg/100 ml whole blood 
and 25-35 mg 100 ml buffy-coat (leukocytes and platelets) (Omaye et al. 1979). Normal 
leukocyte ascorbate is 20-53 ýIg/ 108 white blood cells. 
Table 1.11.3a. The distribution of ascorbic acid in the human body. 
Ascorbic Acid % of total body 
Tissue (mg/100 g wet tissue) pool 
Pituitary glands 40-50 0.17 
Leukocytes 35 3.5 
(granulocytes) 21 
(monocytes) 65 
Adrenal glands 30-40 0.01 
Eyelens 25-31 
Aqueous humour 18.6 
Brain 13-15 10.3 
Liver 10-16 8.8 
Pancreas 10-15 
Spleen 10-15 0.9 
Lungs 7 2.9 
Heart muscle 5-15 0.9 
Kidneys 5-15 0.8 
Skeletal muscle 3-4 66.6 
Testes 3 0.06 
Thyroid 2 0.03 
Plasma 0.4-1 5.2 
Erythrocytes 0.3-1 
Saliva 0.07-0.09 
Ascorbic acid is distributed throughout the bodý (table 1.1 1.3a) and the levels found in a 
particular tissue or organ are likely to reflect a specialised role. However it is important to point 
out that though the data in table 1.1 1-3a came from 1990s references, these references quote 
papers published in the 1980s; then those in the 1980s quote those in the 1970s and so on, with 
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Kirk 1962 the first to bring original studies together. The original works cited in Kirk (1962) are: Brain: Yavorsky et al. (1934), Giroud (1938), Schaus (1957), Plaut and Btilow (1934), (1935), 
Plaut et al. (1935). Pituitary gland: Schaus (1957). Lens: Nordmann and Wien (1934), Bietti 
(1935) Euler and MaImberg (1936). Adrenal glands: Yavorsky et al. (1934), Giroud (1938), 
Ingals (1939). Pancreas: Yavorsky et al. (1934). Liver: Yavorsky et al. (1934), Ingals (1939). 
Kidney: Yavorsky et al. (1934), Giroud (1938). Heart and skeletal muscle: Yavorsky et aL 
(1934), Schaus (1957). 
The concentration of ascorbic acid in the adrenal is very high; approximately 1/3 of the 
vitamin is found at the site of catecholamine formation in that organ, which releases newly 
synthesised corticosteroids in response to stress. Similarly, the greatest concentrations in the brain 
are found in regions that are also rich in catecholamines. The concentration in the plasma, the 
transportation mediun-4 depends on nutriture, plasma -. tissue movement and renal excretion. The 
ascorbic acid : dehydroascorbic acid ratio in plasma is probably kept constant (Margolis et al. 
1991). The eye contains a relatively large amount of ascorbic acid where it is thought to protect 
lens and retinal proteins from oxidation. Erythrocytes also contain ascorbic acid, and it is thought 
theT contribute more to the antioxidant reserve of blood than is evident from plasma 
concentrations alone, as they can effectively scavenge dehydroascorbic acid released in the 
vascular bed in areas of oxidant stress and recycle the dehydroascorbic acid to ascorbic acid (May 
et aL 1995). 
1.11.4 Vitamin C status markers. 
Table 1.11.4a. Reference ranges for the interpretation of Vitamin C status. (From Jacob 
1994) 
Status Plasnia Body pool (mg) Mixed leukocytes Mononuclear 
(Mg/ 100 mi) (ýig/108 cells) leukocytes 
(ýtg/10' cells) 
normal 0.4-1.5 500-1500 20-53 25-44 
Adequate >0.4 >600 >20 >25 
Low 0.2-0.4 300-600 1 G-20 20-25 
Deficient <0.2 <300 <10 <20 
mg/100 ml x 56.8 -= gmol/L ** ýLg/108 cells x 56.8 =- nmol/10't cells 
The concentrations of both plasma and leukocytes are used to monitor ascorbic acid status; 
the former to reflect the intakes over the previous few hours, the latter to represent tissue levels 
affected by longer-tenn dietary intake and physiological usage over days and weeks. It is 
important to bear in mind that when mononuclear leukocytes are isolated for vitamin C analysis 
the white cell suspension will also contain platelets. The contribution of platelets to the white cell 
vitamin C titre is unknown and unmeasured in most cases. 
A plasma concentration of 0.4-1.4 mg/100 ml reflects a daily ascorbate intake of 40 
(Omaye et aL 1979) to 60 (Basu and Schorah 1982) mg/day, An adequate status of 0.4 mg/100 
ml can be maintained at 29 mg intake per day (corresponding to an RDI of 41 mg/day). However, 
because of individual variation the range of serum levels of ascorbic acid associated with a given 
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intake is broad. Smokers require a higher ascorbic acid intake to maintain a level comparable with 
a non-smoker. 
Sex may (Dodds 1969) or may not (Benzie and Strain 1997) affect ascorbic acid levels. 
Blanchard (1991ab) found few gender-related differences and that some of them may simply be 
explained by body composition differences. VanderJagt et al. (1989) found elderly women had 
significantly higher ascorbic acid concentrations in mononuclear cells than men for similar intakes. 
The best data available probably come from the NHANES III study (Third National Health and 
Nutrition Examination Survey) that found feniales had significantly higher levels (by 8-21%) than 
males (Schleider et al. 1998). Blanchard and colleagues found no age-related differences in 
vitamin C disposition between young and old males (Blanchard et aL 1990a) or females 
(Blanchard et al. 1989). 
Oral contraceptives may decrease tissue ascorbate levels (Rivers 1975). There also appears 
to be a circadian rhythm in leukocyte ascorbic acid concentration (Loh and Wilson 1973), and a 
periodic rhythm related to ovulation in females (Loh and Wilson 197 1). 
1.11.5 Metabolism and Excretion of Vitamin C. 
A c! o 
. Asc rbic acid is oxidised in vivo by two successive losses of single electrons as outlined in 
section 1.10.1. Hydrolysis to 2,3-diketo-L-gulonic acid (DKG) is irreversible, and results in the 
loss of biological activity. DKG is further degraded toC02 and 5-C ftagments (xylose, xylonic 
acid) or oxidised to oxalic acid and 4-C fragments (threonic acid) (see figure 1.10.1 a). A portion, 
usually less than 2% of vitamin C is excreted asC02by respiration (60-70% in guinea pigs), many 
workers not finding it at all in exhaled breath. The body pool is estimated to lose 2-4% per day, 
approximately 0.2 mg/kg/day fat-free weight in non-smokers (Baker et al. 1969, Basu and 
Dickerson 1 ý996). Both Kallner et al. (1979) and Blanchard (199 1) have found strong evidence 
that a conservation effect may be operative at low plasma vitamin C concentrations; Le. there 
exists an inverse relationship between the half-life of vitamin C and its plasma concentration. 
Up to a threshold concentration in the plasma of 0.88-1.8 mg/100 ml, ascorbic acid is 
mainly reabsorbed in the renal tubules by a sodium-dependent transport mechanism (Rose 19,86, 
Bowers-Komro and McCormick 1991, Elmadfa and Koenig 1996). Humans excrete the vitamin in 
the urine as various metabolites; approximately 20-25% ascorbic acid, 20% DKG and 40-45% 
oxalate (Combs 1992). The excretion of ascorbic acid does not consistently correlate with intake, 
and in fact has a sigrnoidal. relationship (Melethil et al. 1986). To this reviewer, statements such as 
"the urinary excretion of ascorbic acid is nearly equivalent to the absorption and can, therefore, 
be taken as a measure for ascorbic acid absorption" found in Elmadfa and Keonig (1996) are 
grossly misleading. Besides which, a "nearly equivalent" relationship is not good efficacy. Above 
1-3 g per day, ascorbic acid is excreted unchanged in the faeces, and may well be metabolised by 
intestinal flora. 
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1.12 Functions of Vitamin C. 
Vitamin C is arguably the most well known and controversial vitamin. Its role in the 
prevention and cure of scurvy through ancient civilisations; of sailors and explorers eating fiuits, 
vegetables, germinating seeds and even pine needles has been well documented, probably best and 
most exhaustively by Carpenter (1988). It is generally accepted that the clinical experiments 
(today called clinical trials) carried out by Lind in the l8thcentury gave the first strong evidence of 
the anti-scorbutic properties of citrus fruits where previous evidence was in the main anecdotal. 
The exact functions of vitamin C are still far from completely understood despite the vast 
amounts of research since its discovery and in vitro synthesis by Szent-Gyorgy nearly 70 years 
ago. It is possible to characterise the known roles of vitamin C as oxidations, reductions and redox 
reactions. Although it cannot directly promote oxidations (it is a reducing agent), it occurs in cells 
in different forms with various pairings. These are capable of both oxidations and reductions of 
other redox couples, depending on their relative redox potentials. Vitamin C also acts as a classic 
enzyme co-factor (for hydroxylating enzymes), as a protective agent (against hydroxylases in 
coflagen synthesis) and as ascorbyl radical in reactions with transition metal ions. The symptoms of 
vitamin C deficiency give suggestions to some of its specific roles. 
1.12.1 Vitamin C deficiency. 
The clinical manifestation of vitamin C deficiency is scurvy, characterised by haernorrhagic 
tissues due to capillaries leaking, bleeding gums, loose teeth, anaernia and general weakness. The 
first signs of scurvy are not seen until the vitamin C reserve is depleted to 300 mg (Hodges et al. 
1969,1971 Baker 1971)-about 84-97 days of no vitamin C-depending on individual subject 
variation and which symptom of scurvy is used. Mild deficiency results in pre-scorbutic symptoms 
including fatigue, anorexia and increased susceptibility to infection. The reader is directed to the 
excellent studies by Hodges and Baker reported in Hodges et aL (1969,1971) and Baker et aL 
(1969,1971), as well as the outline in structural changes in vitamin C deficiency by Bourne 
(1953). 
Recent research and epidemiological studies have suggested that low vitamin C. status is 
associated with cancer, coronary heart disease and cataract formation. Vitamin C deficiency is 
now widely recognised as common among the chronically sick, the institutionalised elderly, men 
living alone, those avoiding acidic foods because of various digestive problems, chronic alcoholics 
and smokers (who coincidentally have poor diets), patients on haemo- or peritoneal dialysis and 
infants fed unsupplernented cow's milk. The extent of vitamin C deficiency in the general 
population is open to the debate of what is a 'suitable' day intake. 
Ascorbic acid deficiency in infants (Moeller-Barlow disease) is characterised by decreased 
bone formation, with myelofibrosis and enlargements at the epiphyses of long tubular bones being 
seen as well as the more common symptoms of deficieny seen in adults (Elmadfa and Koenig 
1996). 
1.12.2 Oxidation and Hydroxylation. 
(i) Collagen formation. Probably the most established role for vitamin C is the post- 
translational hydroxylation of proline and lysine to hydroxyproline and hydroxylysine in the 
formation of collagen, the main fibrous connective tissue in animals (Combs 1992). Collagen is the 
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wound healing protein, formed at wound sites to 'shore up' tissue lesions against infection and 
further damage as well as acting as the template for bone formation. The prolyl and lysyl 
hydroxylases (EC 1.14.11.1 and 2) require ascorbic acid to maintain the iron in the Fe 2+ state 
(Combs 1992): a classic co-factor role. 
(ii) Neurotransmitter Formation. Ascorbic acid serves as the electron donor for 
dopamine-p-monooxygenase (EC 1.14.17.1), a Cu-enzyme located in the (ascorbate-rich) 
chrornaffin vesicles of the adrenal medulla and in adrenergic synapses that hydroxylate dopamine 
to form the neurotransmitter noradrenaline (Stryer 1988, Combs 1992). When noradrenaline is 
converted to adrenaline, adrenaline tends to be oxidised but ascorbic acid prevents this, allowing it 
to potentiate adenyl cyclase which in turn activates the formation of cAMP from ATP (Basu and 
Dickerson 1996). Ascorbic acid also reduces the breakdown of cAMP to 5'-AMP by inhibiting the 
phosphodiesterase enzyme (Basu and Dickerson 1996). 
Tryptophan is hydroxylated and decarboxylated by two ascorbate-dependent enzymes to 
form the vasoconstrictor and neurotransmitter 5-hydroxytryptamine (serotonin). Ascorbate may 
also have a role in protecting neurotransmitters such as NO (see later). There already exists 
considerable evidence linking ascorbate with nerve function; and high extra- and intracellular 
levels (200-400 pM) are strictly regulated (Lilley and Gibson 1997). Plus in periods of vitamin C 
deficiency such levels are maintained in the brain for much longer than other tissues (Pelletier 
1969). 
The enzyme peptidyl glycine alpha-amidating monooxygenase (PAM) (EC 1.14.17.3) 
requires ascorbic acid to cc-amidate neuro-endocrinal hormones such as gastrin and bombesin 
(Eipper and Mains 1991); and so is essential for their biological activity, and is found mainly in 
soluble form in the pituitary gland and membranes in the auricle of the heart. 
(iii) Drug and Steroid Metabolism. Ascorbic acid affects the metabolism of xenobiotic 
compounds. Animal studies have shown correlations between ascorbic acid status, hepatic activity 
of cytochrome P450 (a mixed function oxidase) and drug metabolism (Zannoni and Sato 1975, 
Combs 1992). 
Ascorbic acid may well be involved in microsomal hydroxylation reactions coupled to the 
electron transport chain. For example, vitamin C-deficient guinea pigs have a diminished 
cholesterol 7cc-hydroxylase activity that is stimulated by later supplementation of vitamin C. In 
humans, studies have detected significant positive correlations of ascorbic acid and HDL- 
cholesterol in the plasma/serurn (Combs 1992), which has beneficial implications for 
cardiovascular diseases such as coronary heart disease. 
(iv) Fatty Acid Metabolism. Lysine and methionine are converted into carnitine by two 
ascorbate-dependent oxidases (gamma-butyrobetaine, 2-oxoglutarate 4-dioxygenase (EC 
1.14.11.1) and trimethyllysine-2-oxoglutarate dioxygenase (EC 1.14.11-8) that act at two points in 
a chain reaction. Carnitine is essential for the transport of long chain fatty acids from the 
cytoplasm to the rrAtochondria for cellular energy production (Rebouche 1991). The symptoms of 
fatigue and lassitude in scurvy has been blamed on its absence (Nelson et al. 198 1). 
(v) Biomembrane energetics. Morre et aL (1987) found evidence for a role of ascorbate 
free radical as an electron acceptor in a redox system involving the NADH-free radical reductase 
that is found in cellular membranes, being part of a mechanism to drive membrane translocations 
and for an involvement as an energy-producing enzyme. - 
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1.12.3 Reduction 
(i) Metal Ion Metabolism. Ascorbic acid interacts with several nutritionally significant 
metallic elements, most usually as a co-factor for, e. g. Cu-mediated enzymes. Some dietary 
elements that are toxic in excess are poorly absorbed or more rapidly excreted in their reduced 
form; e. g. Ni, Pb, V and Cd (Ehnadfa and Keonig 1996) and as a reductant, ascorbic acid thereby 
reduces toxicity. Selenium is the exception; ascorbic acid increases the apparent bioavailability of 
many forms of Se (Combs 1992). 
In plant foods iron is present in its ferric (non-h(xm) state (Fe) and in animal tissue 
foods as ferrous (Lcte)vj) (Fe++) iron. The latter is considerably better absorbed, but unaffected by 
ascorbic acid intake. However, it has been known for decades that vitamin C enhances non-hcqn, 
iron absorption when it is present in the same meal (Siegenberg et aL 1991, Gershoff 1993). 
Hallberg et aL (1987) recommended that 25-50 mg of ascorbic acid should be present in the main 
meal, especially if the meal is high in phytates and tannins (iron absorption inhibitors). Ascorbic 
acid increases the bioavailability of iron in foods by reducing ferric iron (Fe+") to ferrous iron 
(Fe'), and then forming a soluble, stable chelate that is quite well absorbed. In some diets it may 
be considered an essential physiological factor for iron absorption. 
Vitamin C can also act as a prooxidant in the presence of metal ions. This demonstrates the 
oxymoronic nature of vitamin C. By reducing the redox state of the metal ion it allows the ion to 
react with02 tOform oxygen radicals02' and OH* (Combs 1992). 
(ii) Antioxidant/Proomidant functions. In a concise review by Rose and Bode (1993), 
ascorbic acid easily f4fills their seven attributes to be an effective antioxidant, attributes that 
should be used to question any substance purported to be an antioxidant. Ascorbic acid represents 
one of the first and most important lines of defence against circulating and intracellular oxidation 
contributing up to 24% of plasma antioxidant activity (Wayner et al. 1987), and is believed to 
reduce agents capable of forming free radicals which damage DNA leading to neoplasm formation 
(Margolis 1994 list). While Frei et aL (1989) demonstrated ascorbate to be the most effective 
aqueous-phase antioxidant in human blood plasma, its contribution as a whole may well be very 
different. For example, Wayner et aL (1987) found ascorbate contributes only 0-2% of the total 
radical-trapping content of plasma from fasted humans. Ascorbate (AH-) reacts with toxic forms 
of oxygen: superoxide anion (02*-), hydroxyl radical (OM, peroxyl radical and singlet oxygen 
(Basu and Dickerson 1996) as well as alkyl radicals (R*) and hydrogen peroxide. The unpaired 
electron nature is delocalised over the whole ascorbate molecule and is comparatively unreactive 
(equations 1-4). 
Equation I + AN + 02* H202+A* 
Equation 2 AH + Ofr -v"', H20+ A` 
Equation 3 Afr + R' RH + A' 
Equation 4 AN + H202 + 2H20+ A 
Ax. scorbate itself is then regenerated from the radical form (A') by other reducing agents noteably 
glutathi, one (GSH) and NADH: 
Equation 5 2A*- + 2GSH GSSG + 2AFF 
Equation 6 2A7- + NADH+W NAD+ + 2AH 
(adapted from Basu and Dickerson 1996) 
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By inhibiting lipid peroxidation initiated by a peroxyl radical, ascorbic acid can protect 
against biomembrane oxidative damage. In hydrophobic regions such as the cellular membranes, 
ascorbic acid appears able to regenerate the hpid soluble antioxidant vitamin E. Ascorbate appears 
to mediate superoxide dismutase, which traps the superoxide radical to give H202 at a diffusion 
controlled rate (Niki 1991) (Equation 1, above). This partnership of ascorbate with other 
endogenous antioxidants is thought to prevent cataract formation caused by LTV light damage to 
the lens, andimprove sperm quality in smokers (Dawson et al. 1992). 
Ascorbic acid may also be important for the provision of the correct redox environment to 
allow NO to fulfill its proposed neurotransmitter role (Lifley and Gibson 1997). Scorza et al. 
(1997) found ascorbate (and protein thiols) in the plasma induced a slow decomposition and 
scavenging of S-nitrosothiols which confers on them long range regulatory functions such as 
vasorelaxation and antiplatelet aggregation. Dudgeon et al. (1998) found ascorbate has the ability 
to protect NO from destruction by superoxide thereby suggesting that ascorbate may have an 
indirect effect on the vasculature via NO. 
(iii) Interaction with Folic acid. Folic acid (or folate) is an essential co-factor in various 
one-carbon transfers. To be functional, folic acid must be in its most reduced tetrahydrofolate 
form, which is maintained or brought about by the oxidant nature of ascorbic acid in two reduction 
steps by NADPH-dependent reductase enzymes from folic acid (F) through dihydrofolate (FH2) to 
its active form, tetrahydrofolate (171-L) (Basu and Dickerson 1996). 
1.12.4 Other Functions. 
(i) Metabolism. Clernetson found that when plasma ascorbic acid levels drop below I 
mg/100 m]ý histamine levels increase exponentially; oral administration of ascorbic acid reduces 
the histamine levels in humans in every instance (Clemetson 1966). Ascorbic acid is involved in 
histamine metabolism acting with copper to inhibit its release and enhance its degradation. 
Ascorbic acid may also enhance the synthesis of the prostaglandin E series over the F series 
further reducing histamine sensitivity. Histamine-linked pregnancy complications such as pre- 
eclampsia., abruption and prematurity may be relieved by Vitamin C therapy (Combs 1992). 
Lewin ((1976), in Basu and Dickerson 1996)) found evidence that vitamin C can relieve 
asthma by increasing cANT levels (through its role in the protection of adrenaline) which leads to 
a decreased histamine release. Cohen et aL (1997) found vitamin C may have a protective effect 
on airway hyperreactivity in some patients with exercise-induced asthma. 
Morris et aL (1998) found evidence that vitamin C supplements may lower the risk of 
Alzheimer disease in persons 65 or older 
(ii) Immunomodulation. In white blood cells (leukocytes) such as neutrophils, ascorbic 
acid is thought to protect the cell from its own bacteriocidal oxidative burst (Washko et aL 1993). 
The oxidants can also diffuse into the cytosol and cause oxidative damage to cell macromolecules 
and structures. Ascorbic acid also affects the immune function by stimulating chemotactic and 
proliferative responses of neutrophils, interferon production, stimulation of IgG and IgM 
antibodies and at >10 g/day enhancement of some hypersensitivity responses in humans (Combs 
1992). Also vitamin C appears to stimulate macrophages to adhere to their substrate-the first 
step in phagocytosis, (Del Rio et aL 1998). Interestingly, yitamin C has been found to decrease the 
adherence of E. coli to human endothelial cells which may have a role in disease prevention 
(Szkaradkiewicz et aL 1998). 
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The involvement of ascorbic acid in histamine metabolism and as an immunomodulator has 
acted to fuel the speculation that ascorbic acid has a significant role in the amelioration of the 
common cold (see below). 
(iii) Anti-carcinogenic. Ascorbic acid has also been found to reduce/delay tumour 
formation, reduce the binding of polycyclic aromatic carcinogens to DNA and is a potent inhibitor 
of nitrosamine-induced carcinogenesis by reducing nitrite (N02-) tOnitrogen oxide (NO). These 
cancer preventative roles are supported by epidemiological evidence that vitamin C is protective 
for cancers of the oesophagus, larynx, oral cavity, pancreas, stomach and breast. The prevention 
of cancer is positively associated with fruit and vegetable intake, both good sources of vitamin C. 
However protective effects have also been detected in studies in which the intake of fruit but not 
vitamin C was assessed (Combs 1992). 
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1.13 Diseases associated with ascorbic acid. 
1.13.1 Cardiovascular Disease. 
Epidemiological data indicate significant associations of low plasma ascorbic acid 
concentration with increased risk to ischaemic heart disease (Riemersma et al. 1992, Gey et al. 
1987,1993; Bendich and Langseth 1995, Matilainen et al. 1996, Nyyssonen et al. 1997, Delport 
et al. 1998), positive correlations between plasma or dietary ascorbic acid and the cardioprotective 
HDL (high density lipoprotiens) (Jacques 1992; Jacques et al. 1994, Ness et al. 1996), a negative 
correlation with plasma total cholesterol (Jacques et al. 1994) and LDL (low-density lipoprotein) 
levels (Jacques et a 1994). 
The oxidative modification of LDL and VLDL (very LDL) to a form unrecognisable by the 
body is believed to be an initial step in the development of the atherosclerotic plaque (Steinberg et 
al. 1989). Briefly, oxidised LDL is taken up by macrophages which become cholesterol-laden 
foarn cells which lead to the development of the fatty streak. Physiological and dietary antioxidants 
such as vitamin C are thought to prevent this by 'mopping up' harmful reactive oxygen species 
and preventing any oxidation in the hydrophilic regions of the blood (Jialal and Grundy 1992). 
Vitamin C has other antioxidant capabilities (see p 49). 
These theories are not held by all. Samman et al. (1997) found ascorbic acid 
supplementation at I g/day for two weeks over a baseline intake of 40 mg/day did not alter plasma 
lipids, or LDL oxidisability in male smokers. Also, Herbert publishes many papers warning against 
the use of excess amounts of. vitamin C (Herbert 1992, Herbert et al. 1994,1996, Shaw et al. 
1994) 
There are many other hypotheses for the role vitamin C plays in cardiovascular health, 
including a) increasing circulating HDL (high-density lipoprotein), b) lowering serum cholesterol 
(Bordia 1980), c) protecting against atherogenic lipoproteins (Siow et al. 1998), d) dimnus g 
the independent risk factor of Lipoprotein(a), e) chelating transition metal ions keeping them in a 
reduced state, D increasing prostacyclin (vasodilator) and decreasing thromboxane (prostacyclin 
antagonist), g) improving mitogenic response of T-cells, h) reducing prostaglandin production and 
lipoxygenase activity and i) improving the chemotactic response and migration of 
monocytes/macrophages (Gey 1995). 
Hypertension is a major risk factor for cardiovascular disease and is inversely related to 
vitamin C intake (Jacques 1992, Bates et al. 1998) even after adjustment for age, body mass, 
physical activity, and plasma cholesterol (Block and Mangels 1998) as well as sex, smoking and 
alcohol intake (Ness et al. 1996). Supplementation with ascorbic acid was seen to reduce blood 
pressure in a well-designed study of borderline hypertensives (Trout 1991). However this 
relationship is confounded by foods rich in vitamin C-fruit and vegetables-which have high 
potassium to sodium ratios that would also reduce hypertension. Plasma vitamin C levels may 
simply be a marker of other factors. 
The clotting of blood is mediated through prostaglandins such as thromboxane, which 
signal the platelets to aggregate. Also, prostacyclins protect vessel walls from platelet 
accumulation. This aggregation and adhesion to vessel walls following injury may be a critical step 
in the second stage of heart disease (Singh and Gaby 1991). Vitamin C may reduce these 
factors 
as well as reducing platelet activity (Bordia 1980) and increasing fibrinolytic activity (Bordia et al. 
1978, Bordia 1980) at pharmacological dosage of 1-2 g/day. The effects at normal intakes is 
probably masked by more influential factors such as n-6 and n-9 fatty acid intake ratio. 
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1.13.2 Cancer. 
Epidemiological, animal study and cell culture evidence suggests a reasonable rationale for 
a protective role for vitamin C in cancer prevention (Gershoff 1993), with low intakes of dietary 
vitamin C linked with an increased risk of cancer (Bendich and Langseth 1995). This is consistent 
with ascorbate's function as an antioxidant, free radical scavenger and suppresser of the formation 
of carcinogens such as nitrosamines (Tannenbaum and Wishnok 1987, Tannenbaum et al. 1991, 
Schorah et al. 1991) and quinones (Terrar and Matsuskita 1988), enhancing immune system 
response and possible stimulation of liver detoxifying enzymes (Singh and Gaby 1991). Cooke et 
al. (199 8) suggest a non-scavenging antioxidant role for vitamin C in the regulation of DNA repair 
enzymes. 
However, the sources of vitamin C such as fruit and vegetables contain other nutrients that 
may well have similar effects that cannot be ruled out, and may themselves add to the 
anticarcinogenic correlation attributed to vitamin C. (The prolongation of the life of terminally ill 
cancer patients by Pauling by vitamin C supplementation studies is commonly referred to, but was 
poorly controlled and should not be considered as evidence for cancer amelioration). As with 
cardiovascular diseases, it is unclear if low ascorbate status is a cause or an effect of the disease. 
1.13.3 Diabetes. 
The cellular uptake of vitamin C is promoted by insulin and inhibited byhyperglycaemia 
Diabetics have been found to have 50% of the ascorbic acid levels in leukocytes compared with 
non-diabetics (Cunningham et al. 1991) despite adequate Vitamin C intakes (Cunningham 1998). 
Ascorbic acid supplementation in non-insulin dependent diabetes has been seen to improve 
glycaemic control and decrease fasting blood glucose, triglycerides and cholesterol levels (Eriksson 
and'Kohvakka 1995), as well as decreasing the accumulation of sorbitol through reducing aldose 
reductase activity that has been implicated in diabetic complications (Cunningham et al. 1994, 
1998). However, the efficacy of ascorbic acid supplementation in improving diabetic health is not 
fully borne out by all such studies. 
1.13.4 Immunostimulation and the common cold. 
The role of vitamin C in the incidence, length and intensity of the common cold has been 
studied extensively, supported by the observation that white cells concentrate ascorbic acid to 
levels 10-80 times those in plasma, and the plausible theories of the antioxidant and antihistaminic. 
properties of ascorbic acid. .- Vitamin C 
is also thought to enhance neutrophil functiom Since 
Pauling's claims about the positive effects of ascorbic acid on the common cold (Pauling 
1970,1975) there have been many studies and reviews of studies. Pauling went as far as to say that 
adequate ascorbic acid intake could control the common cold. Certainly, Pauling's book 'Vitamin 
C and the Common Cold' makes very compelling reading. However, as outlined by Hemild 
(1997), the level of vitamin C intake has not been shown to affect the incidence of the common 
cold; and that any effect is only quantitatively meaningful in certain groups and is not very large. 
Protocols for nearly all of the studies are open to significant criticism; not least those with free- 
living subjects, self-reporting of symptoms, small sample size, distinguishable placebos and also 
failure to determine the subjects' initial vitamin C status., A definitive conclusion remains elusive. 
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1.13.5 Cataracts. 
Low vitamin C intakes are associated with increased risk of cataracts (Bendich and 
Langseth 1995). The lens is approximately 98% protein, the oxidation of which over time reduces 
translucency and so becomes cataracts. Elderly people are seen to have lower vitamin C nutriture 
but a higher level of cataracts. Evidence suggests that the ascorbic acid prevents the photo- 
oxidation of the lens proteins (Jacques et aL 1997). 
1.13.6 How much vitamin C do we need? 
Since the inception of recommended dietary amounts of nutrients, nutritionists have always 
been concerned with the prevention of the clinical manifestation of the deficiency. disease; in 
essence minimal nutrition rather than optimum nutrition. For example, the U. K Dietary Reference 
Values (DRVs) for vitamin C are based: 
on the amount of vitamin C needed to prevent the signs and clinical symptoms ofscurvy, on 
vitamin C turnover studies and on biochemical indices of vitamin C status in humans". 
While the Reference Nutrient Intake (RNI) for the U. K is currently 40 mg/day for males 
and females over 15 years old, the corresponding European Community level is 60 mg/day. The 
Recommended Daily Allowance (RDA) for vitamin C in the USA is also 60 mg, and goes a step 
ftirther than disease prevention. The US RDA is based on: 
It C the maintenance ofgood nutrition ofpractically all healthy people in the USA " 
According to Levine et al. (1995) this essentially means 1) the prevention of scurvy for I 
month upon cessation of vitamin C intake, 2) urinary excretion threshold, and 3) vitamin C 
catabolism. However the amount of vitamin C that prevents deficiency with a margin of safety 
may not be similar to that needed for optimum health. 
None of these figures are arrived at with great scientific exactness and have a "just in case" 
factor built in, since for example, scurvy has been seen to be prevented by as little as 10 mg per 
day (Hodges et al. 1971). However, there may well be great interindividual variation in ascorbic 
acid needs. With guinea pigs, Williams and Deason (1967) found at least a 20-fold variation in 
vitamin C needs, and suggested that the corresponding variation in humans is probably just as 
great. Indeed some groups such as the pregnant and the lactating require an additional allowance. 
Other groups of the population such as hypertensives, smokers, diabetics and elderly men may also 
have a special need for extra ascorbic acid. 
Levine et al. (1995) recommend the daily amount of vitamin C should be 200 mg (Levine 
et al. 1996), an amount supported by Bendich (1997). 
1.13.7 High-level intakes. 
The promotion of Vitamin C mega-dosing is widespread throughout the Western 
world and controversy exists over its efficacy in human health. Despite tissue saturation of vitamin 
C occurring in humans at 100-150 mg/day, higher intakes can elevate ascorbic acid levels in 
extracellular fluids, where pharmacological action may occur (Stein et al. 1976). 
A 'mega-dose' can be defined as a dose 10 times the RDA. The theory of mega-dosing 
was first Put forward by Stone (1966) based on the human inability to synthesise ascorbic acid. 
He 
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considered it an "inborn error of metabolism7'. Two years later Linus Pauling (1968), arguably the 
most eminent scientist of the time came into the picture and wrote an essay entitled 
'Orthomolecular Psychiatry', suggesting that varying the concentrations of substances in the 
human body may control mental disease; i. e. the provision of the optimum molecular environment 
for the mind. He uses ascorbic acid as an example of where the process of evolution does not 
necessarily result in the normal provision of optimum molecular concentrations. Pauling (1970) 
believed that when our ancestors had a food supply plentiful in ascorbic acid (in mg/2500 kcal), 
the loss of the ascorbic acid producing 'machinery' was advantageous and so was lost in true 
Darwinian style. 
However, the Stone-Pauling hypothesis assumes animals always synthesise metabolites at 
an optimal rate; something Hughes (1981) considers a fundamental flaw. Also, if -vegetarian 
animals such as the gorilla and the rabbit were already obtaining large amounts of ascorbic acid 
from their diet why did they need to synthesise ascorbic acid at such a high rate? And even though 
an animal consumes enough food to satiate his calorific requirements, it does not follow that the 
non-calorific dietary components are consumed at optimal levels; as Jukes in Hughes (1981) 
points out; 'natural' diets contain phytates, fibre, organic acids, etc. but these do not represent a 
nutritionally optimal level. 
For ascorbic acid, tissue saturation meant daily gram doses of vitamin C, to mirror the 
tissue saturation levels of animals that can synthesise ascorbic acid. Pauling (1975) concluded that 
the optimum daily intake of ascorbic acid by humans is between 2.3 and 9g and that the state of 
health of most people would be greatly improved by an increase in intake of this food (sic). He 
himself is said to have taken 40 g/day if he felt a cold coming on. But evidence suggests that both 
saturable gastrointestinal and non-linear renal clearance act additively to produce a ceiling effect in 
plasma, and as a consequence there is no pharmacological justification for the use of mega-doses 
of ascorbic acid (Blanchard et aL 1997). Levine et aL (1996) found doses less than 1000 mg per 
day were safe, and that daily doses above 400 mg have no evident value. 
Gram-size dosing has been advocated for the prophylaxis/treatment of conditions such as 
the common cold, cold sores, immune system support, cardiovascular diseases, 
hypercholesterolaemia, hypertension, hypertriglyceridaemia, diabetes and some forms of cancer 
(Combs 1992). The efficacy of these effects is controversial and the benefits of mega-dosing are 
unclear. When one considers that the total body store of vitamin C is only 1.5-5 g, and that 
intakes above 1.0 g in single doses do not create a response significantly greater than that induced 
by 0.5 g (Benzie and Strain 1997), then it is hard to comprehend what benefit a sustained intake of 
1 g/day-1667% of the current RDA-more than 6666% of that needed to prevent scurvy-can 
possibly have. 
The two schools of thought can be defined as 1) those who support the prevention of 
disease--based on well-established evidence--or 2) those who support the optimisation of 
vitamin C nutriture-where evidence is still wanting. The latter school financially flourishes in the 
fight of ascorbic acid's apparently negligible toxicity and the public's perception that "if a little is 
good for you, a lot more would be better". Today, through the affluence of the industrialised 
world, we see the highest levels of vitamin supplementation ever, fuelled by an industry that 
supplies a massive range of supplementation products to cater for everyone's needs. 
Until the roles of ascorbic acid are better defined, and until the causal role of oxidative 
stress in the aetiology of disease is further resolved, we must continue to have a scientific foot in 
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each schoolý-scrutinise everything but discard nothing. However it is becoming increasingly clear 
that the use of the absence of scurvy as the benchmark for vitamin C nutrition is inadequate. 
1.13.8 Toxicity. 
Its water-soluble nature makes ascorbic acid one of the most non-toxic vitamins, as any 
excess is easily excreted. Possibly the best evidence comes from a meta-analysis by Bendich and 
Langseth (1995) where, in 14 published clinical trials with vitamin C doses up to 10 g/day for 3 
years, no confirmation of previously reported anecdotal adverse effects was found. However, 
some toxic effects have been suggested. The most quoted detrimental effect of megadoses of 
vitamin C is that with oxalate (kidney) stone formation. Evidence suggests that excess ingested 
ascorbic acid is converted to oxalic acid in the gut and is then absorbed, rather than being formed 
in the vascular system (Chalmers et al. 1986,1994). It is becoming more generally accepted that 
while theoretically possible it is unlikely to be significant in most individuals; but it would be 
prudent for someone predisposed to renal calculi to avoid megadoses (Gerster 1997). 
Large intakes have been proposed to enhance the destruction of vitamin B12 in the gut, 
though this anomaly has since been found to be due to an artifact of the method (Marcus et aL 
1980). Moreover, large intakes have also been proposed to cause a harmful rebound effect upon 
cessation of supplementation due to the habituated increased catabolism caused by a prolonged 
high intake, though no actual evidence of this has been found in the literature by this author. 
Extremely high dietary levels of vitamin C (>605 mg/day) have been shown to reduce the 
efficiency of enteric copper absorption. Conversely, increased risk of iron-overload diseases 
through excess vitamin C nutriture has also been suggested, the significance being that excess iron 
may contribute to major killers such as heart disease and cancer. Vitamin C could accelerate this 
by increasing iron absorption and exacerbating iron-induced tissue damage (Lauffer 1991 in 
Herbert et al. 1996). Herbert et al. (1996) found added vitamin C enhanced free radical-induced 
iron-catalysed lipid peroxidation in vitro. The observations of Podmore et aL (1998) are then 
much clearer and not so unexpected. However, in a review of the safety of antioxidants, Meyers et 
aL (1996) not only find no anecdotal evidence for such harmful interactions of vitamin C with iron 
or toxicity to those with iron metabolism disorders, but also cites Bendich and Cohen (1990) who 
in a meta-analysis of 1412 subjects in 24 studies found that ascorbic acid supplements were shown 
not to increase susceptibility to iron overload. While Herbert's arguments are provocative, they 
are largely anecdotal and suffer from a lack of data (Bendich, personal communication). However, 
Herbert's group did find that added vitamin C or DHAA are dangerously prooxidant in the 
presence of storage iron, since the increased DHAA in serum and unbound iron would so disturb 
the redox balance of blood as to prove lethal in individuals with raised iron stores (Shaw et al. 
1994). Overall, as Bendich and Langseth (1995) point out, if ascorbic acid did cause such toxicity 
through iron overload, then surely there would be evidence to show it. 
It is fairly well accepted that the sudden introduction of grain amounts of vitan-fin C into 
the diet would cause some gastrointestinal upset and diarrhoea through the imbalance of the 
intraluminal osmotic potential. Such effects are short-term. Vitamin C can induce false-negative 
results for occult blood in stools (Jaffe et al. 1975). More seriously, individuals with erythrocyte 
glucose-6-phosphate dehydrogenase defiency have been - reported 
to develop haernolysis due to the 
intravenous administration of ascorbic acid in massive (2 x 80g) doses to promote wound healing 
(Campbell et al. 1975). At very high levels ascorbic acid could invalidate studies involving the 
measurement of uric acid and so obscure the diagnosis of gout in some cases (Stein et al. 1976) 
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Overall, I concur with Combs (1992) and Bendich and Langseth (1995) in that such 
concerns of toxicity are very much on the side of caution. The risk of toxicity to a healthy 
individual is so low that concerns are largely outweighed by the possible benefits of ingesting a 
larger amount of vitamin C per day. 
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1.14 Concluding Statement and Formulation of Objectives 
The evidence in the literature for an interaction between anthocyanins and ascorbic acid is 
little more than suggestive. There are very few studies and they commonly suffer from poor 
endpoints and conclusions that have been extrapolated well beyond the strength of the data. Also, 
too often the methodology (especially in ascorbic acid determination) is poorly defined and non- 
specific for the analyte or the effect being measured (such as the hamster cheek model for capillary 
permeability measurements). There is also a wealth of in vitro and lack of in vivo studies. Many 
observations from data in work carried out by Bertuglia, Colantuoni, Contiý Liettiý Magistretti and 
Morazzoni appear to have not been repeated or followed up sufficiently to merit more appropriate 
critical appraisal and so acceptance of the findings. 
However, the suggestive evidence of an interaction of anthocyanins and ascorbic acid is of 
enough professional and commercial interest that ftirther research is merited. There is also a long 
held belief that vitamin C is more stable in blackcurrants compared with other fi-uits, and it is 
encumbent on us to make new discoveries as well as to dispel falsely held scientific 'truths'. 
Furthermore-, there is a huge lack of evidence concerning the absorption and metabolism of 
anthocyanins which are often overlooked in many kinds of studies on flavonoids. 
Therefore, the main objective of this thesis is to look for evidence of an interaction of 
anthocyanins and ascorbic acid specifically in the absorption of the latter imman. Through this 
objective the author hopes to develop original methods for ascorbic acid and anthocyanin analysis 
by high performance liquid chromatography, for human white blood cell isolation and the handling 
of biological samples. The main objective also requires the design of an original feeding study 
involving volunteers. This thesis also hopes to gain more understanding of the disposition of 
anthocyanins after ingestion and to learn more about the compartmentalisation of ascorbic acid or 
indeed add more to our existing evidence. 
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2. Methods and Materials 
2.0 Aims of the Methods 
This chapter details all of the methods employed in this thesis. It is split into sections 
covering (2.1) the Pilot feeding study, (2.2) the Main feeding study, (2.3) supporting methods, 
(2.4) statistical methods and (2.5) the materials and equipment used. 
The overall aim of the Pilot feeding study was to design and test a protocol that if 
successful, was to be used later as the basic design of the much larger Main feeding study. 
The primary aim of the Main feeding study was to investigate whether the same amount of 
vitamin C in three different drinks (water, orange juice and a blackcurrant drink) would cause 
different increases in short-term (plasma) and long-term (white cell) ascorbic acid levels in 
human subjects. Urine samples were also taken for anthocyanin analysis in the Main study. 
Therefore the aim of the supporting methods were to develop original protocols and 
procedures to support the feeding studies. These large feeding trials required the development 
of a suitable ascorbic acid assay for plasma, white cells and fruit juices (by HPLQ as well as 
a white cell isolation procedure. The protocols also required the development of a food diary 
system for each subject, methods to collect and analyse urine samples for anthocyanins, and 
deconjugated anthocyanins, as well as to prepare urine samples for nuclear magnetic 
resonance (NMR). 
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2.1 The Pilot Feeding Study. 
2.1.1 Aim and Design of the Pilot Feeding Study 
As outlined above, the aim of the Pilot study was to test the protocols of study design, 
sample collection and sample analyses that were to be used for the Main study. It was to test 
whether the human subjects would be able to keep to a low (below 10 mg/day) vitamin C diet 
(with the help of a food diary especially designed for this purpose). The pilot study was also 
undertaken to find whether the subjects' plasma and white cell levels would drop to a suitable 
baseline before they were supplemented with vitamin C. The study would also hopefully 
show us whether the designs of the plasma sampling day, white cell collection and isolation 
protocols had an acceptable level of efficacy. It was planned that the data from it would be 
analysed and relevant improvements and changes made to the main study protocols before the 
main study was undertaken. 
2.1.2 What elements were required for such a study 
A feeding study designed to investigate the change in ascorbic acid levels in human 
subjects required certain elements. Firstly, it was necessary to recruit suitable human 
volunteers and screen, motivate and arrange financial remuneration for them to act as 
subjects. These 'free-living' subjects were asked (and helped) to maintain a very low vitamin 
C diet so that their normal intake would not interfere significantly with the vitamin C that was 
given to them as part of the study. Such an investigation also required the repeated and 
minimally invasive sampling of suitable human tissue/media to measure vitamin C status. The 
design also needed to involve a period of time where both short and long term aspects of 
vitamin C nutriture could be assessed. 
2.1.3 Choice of biological media for determining ascorbic acid status 
Ideally, the best measurement of ascorbic acid status would be through its biological 
activity at the site of action. However, a suitable and readily quantifiable role for ascorbic acid 
has yet to be determined, and so a more crude method is the measurement of the concentration 
of the vitamin in an easily available tissue. 
Urine ascorbate is unreliable, as ascorbic acid excretion ceases when the body pool 
falls only slightly below normal since excretion is determined by an individual's renal 
threshold. Also, ascorbate is excreted in many different, degradable and quantitatively 
unpredictable forms. 
Salivary ascorbic acid does not consistently reflect ascorbic acid status. Whole blood 
analysis is not a reliable indicator of vitamin C status, as levels in the erythrocytes (great in 
number in the blood) do not change in ascorbate in response to intake. Early workers looked 
at the 'buffy-layer'ascorbic acid level (white cells and platelets). This is a reliable index per 
se (Omaye et aL 1979), but the ratio of platelets to white cells is not constant (Blanchard et aL 
1989). Platelets may be useful as an indicator of lean tissue ascorbic acid (McCulloch and 
Vandongen (1992), but Omaye et aL (1987) observed that the leukocytes are a better 
reflection of lean tissue than red blood cells as they have a nucleus, mitochondria and all other 
organelles. 
It is widely agreed that plasma ascorbate levels--comparable to serum (Wang et aL 
1992)--reflect the recent short-term intake of ascorbic acid (as plasma is the vehicle in which 
ascorbic acid is transported to the relevant body tissues) while leukocyte ascorbic acid reflects 
the longer term body store status. Plasma levels are not reliable in predicting leukocyte levels 
of ascorbic acid (Blanchard et aL 1989), requiring this study to measure the concentration in 
both. 
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It is also important to consider that the total leukocyte population shows a bimodal 
distribution of ascorbic acid concentrations, since they can be divided into two cell types; 
mononuclear leukocytes and polymorphonuclear leukocytes. The former maintains higher 
levels of ascorbic acid than the polymorphonuclear leukocytes. Therefore for higher quality 
data, the cell types must be isolated and their ascorbic acid levels assessed separately. (This is 
covered in more depth in section 2.1.7.2). 
2.1.4 Pilot study design 
After assessing previous short-term and long-term ascorbic acid feeding studies in the 
literature (Hughes and Jones 1971, Jones and Hughes 1984, Omaye et aL 1986, Vinson and 
Bose 1987, Vinson and Bose 1988), it was decided to assess the absorption of ascorbic acid 
by the rate and extent of repletion of ascorbic acid stores. This required the subjects to be 
depleted of ascorbic acid first by a 'washout' period before they were supplemented with 
ascorbic acid for an 'observation' period. The length of these periods were chosen as 21 days 
for washout followed immediately by 10 days of supplementation, a total of 31 days. The 
subject had to maintain a low vitamin C diet throughout the 31 days. A vitamin C-containing 
drink was taken every day from day 22 to day 3 1. Blood samples were taken at intervals 
throughout the 31 days to assess white cell ascorbic acid levels. On day 22, the first day of 
supplementation, the subjects would be brought to a clinical investigation unit, have a cannula 
fitted and then be given their first supplementation drink. Then, at pre-determined intervals 
over the next seven hours, blood samples would be taken to assess the plasma ascorbic acid 
levels. 
The period lengths were decided on the following criteria. Firstly, in the Main study to 
follow, the subjects would require three x 31 day periods to assess the pre-requisite three 
drinks so each period had to be as short as was feasible. Secondly, the volume of blood that 
could be safely taken was limited for ethical reasons, which shortens the length over which 
sampling can be done. Thirdly, it was neccesary to have a period long enough to deplete and 
then replete the subject's stores sufficiently so that any difference in the drinks could be seen. 
Therefore a compromise of these three factors resulted in the choice of 31 days. 
The supplement chosen was to be as simple as possible. So 200 mg of ascorbic acid 
(Food Grade from Hoffman-La Roche Vitamins Inc. Basel, Switzerland, assayed as 100.1% 
ascorbic acid) in 500 ml water (from SmithKline Beecham, Coleford, Gloucestershire, UK) 
was to be the daily supplementation dose for days 22 to 3 1. This dose was chosen after 
consultation and discussion with the Nutrition Team at SmithKline Beecham, as it was not 
only a level at which active absorption processes were though to be saturated, but was also of 
commercial relevance. 
2.1.5 Implementation of the Pilot Study 
2.1.5.1 Ethical Approval 
The white cell samples were to be taken at the University of Surrey under University 
of Surrey guidelines. The plasma sampling required the facilities of a clinical investigation 
unit (CIU),, and the unit at the Royal Surrey County Hosptial (RSCH) was chosen. Therefore 
the study had to pass the Ethics Committees of both The University of Surrey and the RSCH 
(The South West Surrey Local Research Ethics Committee), to which exhaustive protocols 
were submitted (protocol submission numbers ACE/97/39/SBS and EC129/97 respectively). 
Medical supervision was provided by Professor Gordon Ferns who holds appointments at the 
University of Surrey and the RSCH. The protocols were written after reference to the Ethical 
Guidelines for Teaching and Research published by the Advisory Committee on Ethics, 
University of Surrey, June 1990, as well as with help from Samantha Long, Nutrition 
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D- be un in appendix 6.1 a). Research Group at the University. (the committees' approval can fo d 
The study was undertaken from Tuesday 25hNovember to 23dDecember 1997. (Because of 
the extensive delay gaining ethical approval, the study was shortened by 3 days). 
2.1.5.2 Subject recruitment, screening and consent 
Four healthy male subjects from the University of Surrey were recruited by posters 
and 'word of mouth'. They were screened to ensure that: they were not diabetic, were not 
receiving regular medication, did not have a significant current or previous medical history, 
did not smoke or consume more than 28 units of alcohol per week. They also had blood tests 
to ensure liver function and blood cell counts were normal. Subjects were provided with an 
information sheet, gave written consent to take part in the study and their GP's permission for 
inclusion was gained. The subjects received ; E200 each upon completion of the study as an 
inconvenience allowance. Each subject was also given the opportunity of having aB vitamin 
complex tablet (Tesco's "One-a-day vitamin B complex") to take each day to further ensure 
good nutrition. This supplement was analysed to ensure it was ascorbic acid-free. The full 
content of each tablet is given in appendix 6.5. Subjects were also instructed to avoid 
medication or, if essentiaL to inform me immediately. 
2.1.5.3 Blood sampling 
It was decided that it made practical sense for Stewart Edmed to take the blood 
samples himself Therefore he spent time at the RSCH Phlebotomy unit to learn how. He then 
became registered as a phlebotomist at the University of Surrey after passing a practical 
demonstration for Dr John Wright, who officiates the Register of Phlebotomists at the 
University. 
During the study, blood samples of a maximum of 15 ml were taken to assess the 
levels of vitamin C in white blood cells on days 1,10,18,21,22,25,28,31. For a blood 
samples we asked that subjects came in early in the morning fasting from 12 midnight the 
night before. 
On day 22 (Tuesday 16th December, the first day of the observation period), the 
subjects were requested to stay some eight hours with us at the RSCH CIU. They were 
instructed not to eat after 12 midnight the night before or have any breakfast. They came to 
the Investigation unit at 8.30 am and were fitted with an intravenous cannula (under local 
anaesthetic if requested), and a blood sample taken (at time 'zero') into a Vacutainerg. They 
were then given their first vitamin C-fortified drink of water and gave blood samples at +60, 
+1203, +150ý +180, +210, +240, +270, +300, +330, +360, +390, +420 and +450 minutes 
thereafter. A white cell sample of 15 ml was also taken at +450 minutes. The sampling on this 
day was done by two clinical assistants, Sue Slowe and Hye-Song Park who were trained to 
-take samples from the cannulae that were then passed to me for sample preparation (see 
below). To keep track of when each subject was due to be bled and the exact time this was 
done, a schedule was created on paper for each subject and their clinical assistant (see 
appendix 6.2) 
The subjects had a can of soft drink, tea, coffee or water available after four hours if 
necessary as well as a light lunch of sandwiches at five hours. For days 23-31 they received a 
similar drink daily, but were only required to give blood on days 25,28 and 31. The total 
blood sampling volumes were 8x 15 ml for white cells and 14 x 2.5 ml plasma samples. 
Total maximum volume was then (8 x 15) + (14 x 2.5) 2= 
15 5 ml. 
2.1.5.4 Food diary 
Each subject was given five x seven-day food diaries where they were instructed to 
iternise their complete food intake for the 28 days. This was designed to enable the 
investigators to assess their 'background' vitamin C intake over the 28 day period. It was 
designed to be easy to use and the subjects were asked to give approximate weights and 
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portion sizes. sing McCance and Widdowson's food tables (Holland 1992), the diary also 
contained three lists of what they could eat, could not eat and foods to eat sparingly to 
maintain a low vitamin C diet. The diary also contained an example of a low vitamin C diet 
for a week (the relevant excerpts of the diary are given below), as well as space for them to 
tell me of their health or any problems encountered. (These data were analysed by the process 
in section 2.3.5) 
List 1- Foods that could be eaten ad libitum 
Cereal/cereal products: Flours and grains, soya, custard powder, rice, pasta, bread (French, 
fresh, brown, whole grain), breakfast cereals (except those with vit C (see list 3). biscuits, 
cakes, buns, pastries, eclairs, crumpets. 
Milk and Milk Products: cream, cheese, ice cream, non-fruit desserts, cheesecakes, flans, 
custard, rice puddings and fresh milk up to 568 ml (I pint)/day. 
Eggs and Egg products: any, but not vegetable or ornlettes with tomatoes (cheese, ham or 
plain ornlettes are okay), quiche (but no peppers/tomatoes). 
Fats and Oils: any butter, spread, animal or vegetable fat or oil. 
Meat and Meat Products: bacon, pork, beef, lamb, veal, game, chicken and turkey, burgers, 
sausages (check the label), steaks, meat pies, nut/lentiVrice roasts. 
Fish and Fish Products: any fish, shellfish, fish cakes/fingers/paste, tuna but not fish pie or 
roe. Scampi (but not with lemon juice! ). 
Beans and Lentils: soya, tofu, lentils, chickpeas, tempeh burgers, baked beans, butter beans. 
Nuts: any except unripe walnuts. 
Soups, Sauces and Pickles: chicken/lentil/oxtaiVmushroom/any powdered soup. Sauces: 
gravy, salad cream, mayonnaise, Worcestershire, soy, brown and horseradish sauces. 
Sugar, Preserves and Snacks: honey, sugar, syrup, chocolate!, sweeties, toffees, fudge, 
Turkish delight, mints, Easter eggs, twiglets, corn or maize based crisps (e. g. wheat crunchies, 
Doritos, Frazzles, Skips, Monster Munch, Wotsits, Mini Cheddars, popcorn, tortilla chips), pot 
noodles, Pretzels. 
Beverages: Tea (Not green or instant), coffee, hot chocolate, Coke, beer, cider, wine, spirits 
(but not with fruit mixers). 
Other: Marmite, Bovril, salt, black pepper, vinegar, chocolate/peanut butter spreads, mustard, 
Quorn, stuffing, dried herbs and spices, mushrooms. 
List 2- Foods to avoid/reduce consumption of 
Vegetables: canned sweetcorn and peas, fried and boiled onions. 
Other: dairy sauces (bread, cheese, onion, white), tomato/barbeque sauce, cake icing, garlic, 
nut cutlets, pizzas (but not with peppers or pineappLe). 
Savouries: cauliflower/vegetables in cheese/sauces, vegetable samosas, Bhajis. 
Fish and Fish Products: fish pie. 
Beverages: mulled wine, eggnog. 
Soup, Sauces and Pickles: canned minestrone/tomato/vegetable soups. Sauces: Black 
bean/curry/mint/sour-cream based/cook-in (e. g. bolognese (but not with peppers)/pesto)/1000 
island/any dressings (not oil and lemon)/sweet & sour/tartare/ketchup/piccalilli/pickle/ relishes. 
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List 3- Foods that had to be avoided 
Fruit: absolutely no fruit, fruit juices or anything with fruit in it. 
Vegetables: absolutely no vegetables or anything with vegetables in it. Includes fresh, 
frozen, boiled, microwaved, canned and fried. Includes all potatoes (chips, potato powders 
(Smash), croquettes, waffles and crisps), mustard and cress, peppers, all salads, 
raw/baked/dried onions stir-fry vegetables. 
Beans and Lentils: all except those on list 1. 
Cereal/Cereal Products: Cheerios, Golden Grahams, Special K, Start, Sustain, All-Bran, 
Nestle Fibre, Bran Flakes, muesli, ANY FRUIT CEREAL. 
Biscuits: Jaffa cakes, jam biscuits/tarts. 
Puddings: all fruit puddings, trifles and pies, fruit meringues. 
Milk and Milk Products: Dried, fortified or condensed milks, fruit yoghurts, desserts, 
cheesecakes, banana splits, trifle. 
Meat and Meat Products: offal (heart, kidney, liver), canned ham, pate, chilli con carne, 
meat dishes with vegetables (hot pot, Irish stew, Shepherds pie, ratatouille, risotto, stir fry). 
Fish and Fish Products: fish roe, seaweed. 
Herbs and Spices: any fresh herbs or spices. 
Sugar, Preserves and Snacks: jams and fruit preserves (including marmalade), fruit/jelly 
filled chocolates, potato based crisps (Walkers, Golden Wonder, Discos, Hula-hoops, Quavers 
etc) fruit sweets (e. g. fruit pastilles). 
Beverages: weight-loss/body-building shakes, Complan, fruit juices, fizzy fruit drinks (e. g. 
Tango, Fanta, Lemonade etc), Lucozade, squashes and fruit cordials, Virnto, Dr Pepper, green 
tea, instant tea, spirits with fruit juice mixers. 
Soup, Sauces and Pickles: chilli sauce, guacamole, chutneys, vegetable/tomato puree, 
coleslaw, fresh vegetable soups. 
A week's example of a very low vitamin C diet 
EXAMPLE. - 
DA Y. - Monday DATE. - 241IM7 
TIME LOCATION DESCRIPTION OF FOOD/DRINK 
CONSUMED 
7.15 am Home 1 large bowl of Cornflakes & semi-skimmed 
milk. 1 slice white toast (large loaf, medium cut), 
thinly spread with Flora & Marmite. I cup of 
tea with semi-skimmed milk &1 tspn of sugar. 
10 am University I cup of coffee - white with sugar (from vending 
machine). 1 Danish pastry. 
1.30 pm University Sandwich (bought from restaurant) (2 slices 
brown bread, 2 slices ham, grated cheese, with 
little/some/lots of mayonnaise, thinly spread 
margarine. 1 can of Coke, I packet Skips (30 g, ) 
3.30 pm University 1 coffee - as above 
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pm Home 2 chocolate chip biscuits, cup of tea with semi- 
skimmed milk with 1 sugar 
7.30 pm Home Ready made healthy eating (low fat) Lasagne 
portion (300 g), 2 pieces of garlic bread. 
10 pm Pub 2 pints of beer. I small packet of KP salted 
peanuýs. 
Throughout the day I packet of polo mints. 
2.1.6 Ascorbic acid stabilisation and detection 
The propensity for ascorbic acid to be oxidised required that plasma and leukocyte 
samples were stabilised with an acid and frozen or analysed as soon as possible after 
collection. The lower pH decreased the tendency for hydrolysis of the lactone ring thus 
stabilising the ascorbic acid. It was also necessary to remove the proteins from the biological 
samples to prevent damage to the column. Acidifying the sample followed by centrifugation 
achieved both. Omaye et aL (1979) noted that best results for plasma ascorbic acid are 
obtained if it is quickly stabilised with TCA (trichloroacetic acid) or NTA (metaphosphoric 
acid) and analysed immediately. Lloyd et al. (1987) found no difference in using_ 5 or 10% 
MPA (w/v) and noted that MPA is a late eluting peak and does not interfere with ascorbic acid 
under their conditions. PCA (perchloric acid) has also been used Liau et aL (1993). PCA 
would be preferable as anthocyanins. are analysed with a mobile phase of a PCA solution at 
pH 1.5. Lee et al. (1997) 
-found 
5% PCA (v/v) gave results similar to those obtained with 
MMXci reýb iWothreitol-a reducing agent) --so-nal communication). However, Liau et aL 
(114 Vroýý; t)d. &TA was not as ý, ooJ o, pmt a t'vl deeiat-vy-o nt- o ý- 19tA c4that asooAft acid wot -S 
unstable in PCA. Hence Liau et aL (1993) compromised with 10% PCA (v/v) and 1% NTA 
(w/v) for plasma analysis. 
In this laboratory, ascorbic acid staiwards were diluted into MPA and PCA- and were 
found to behave very similarly, both with a phosphate-buffered or a PCA-acidified IHEPLC 
mobile phase. Therefore it was decided after experimentation that the sample diluent should 
be 10% perchloric acid (v/v), 2% meta-phosphoric acid (w/v) with 10 ing 3,4- 
dihydroxybenzoic acid as an internal standard (see section 2.3.1.7). To ftirther protect the 
-ascorbic acid and facilitate dehydroascorbic acid quantification (by difference), DTT was 
added at 0.1% similar to the methodology of Margolis' group (Margolis et aL 1988,1990, 
1996). The method of detection and quantification was by high performance liquid 
chromatography (HPLQ and the conditions are detailed in section 2.3.1. Section 2.3.1.6 
details how ascorbic acid and dehydroascorbic acid were quantified. 
Due to the large number of samples generated and, -restricted access 
to the HPLC, 
the samples were prepared and then snap frozen and stored at -70'C before thawing for later 
analysis. Work by Margolis and Davies (1988), Motchnik et al. (1994), Margolis et aL (1990) 
and Margo lis and Deuwer (1996) show that ascorbic acid is stable under these conditions. 
Metal ions catalyse ascorbic acid oxidation, so it is preferable to use EDTA as an anti- 
coagulant in the blood tubes rather than heparin, as EDTA will complex any free metal ions. 
However, EDTA was not soluble in aqueous s6lutions at pH 1.5 and was not added to the 
mobile phase. 
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2.1.7 Sample preparation of white cells and plasma 
2.1.7.1 Plasma preparation 
The method for plasma analysis was based on Omaye et al. (1986), VanderJagt et al. 
(1986), Wei et al. (1996), Lee et al. (1997) as well as preliminary investigations in our 
laboratory to optimise the procedure. It comprises blood collection, plasma isolation, sample 
stabilisation, protein denaturation and then sample storage. The samples were diluted with the 
acidic solutions: A=10%PCA,, 2%UTA, 0.2%DTT, 10 mg/100 ml 3,4-dihydroxybenzoic acid 
and B= 10%PCA,, 2%NVA, 10 mg/100 ml 3,4-dihydroxybenzoic acid. The sample 
preparation has two stages; one before and one after frozen storage. See figure 2.1.7.1 a for 
full details. 
Figure 2.1.7.1a Plasma Sample preparation 
Stage 1. 
Collect 2.5 ml whole Centrifuge at 
blood into preservative- 2118 xg 
free EDTA tubes 15 min VC 
Remove 2 
x 750 ýd 
aliquots of 
Add I aliquot to a 1.5 ml. nlasma- 
Eppendorf tube with 750 ýtl ice- 
cold solution A 
Vortex for 5 seconds 
Snap freeze in liquid 
N2. Store at -70'C 
Stage 2. %%I 
Add 1 aliquot to a 1.5 ml 
Eppendorf tube with 750 ýil ice- 
cold solution B 
haw samples at 4'C I Pipette supernatant to 
for 10 minutes and P, septa capped brown 
, ntrifuge at 1509 xg I-IPLC vials in the chilled 
for 10 min at 4'C autosampler 
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2.1.7.2.1 Leukocyte Preparation 
The determination of ascorbic acid in plasma requires only microlitres of sample 
whereas leukocyte analysis requires larger volumes of blood and is a much more difficult 
technique. Early workers either measured 'buffy-coat' ascorbic acid or hetergenous mixtures 
of leukocytes. There are many kinds of white blood cells each designed for certain 
immunological roles and each with different ascorbate contents. These can be divided into 
mononuclear cells (MN) and polyrnorphonuclear cells (PMN). The relative number of each 
cell can vary between individuals and can be ftirther influenced by many other factors such as 
exercise, smoking, stress and infection. It is therefore important to find the cell type that best 
represents ascorbic acid intake and tissue stores. 
The MN cells have 2-3 times the amount of ascorbic acid of PMN (Lee et aL 1982), 
twice that again of the platelets (Evans et al. 1982), ten-fold that of the plasma (Lee et al. 
1982). Omaye et al. (1987) and Jacob et al. (1987) investigated which one of the white cells 
best-reflected vitamin C status. Omaye et al. (1987) found that while the ascorbic acid content 
of PMN correlate positively with plasma concentration, MN did not. However, MN have the 
higher level of ascorbic acid. They also found (in unpublished results) that with some 
subjects, ascorbic acid content of both MN and PMN did correlate positively with plasma 
levels. They concluded that further work is necessary to evaluate which white blood cell is the 
better cellular marker. Blanchard et al. (1989) addressed this question, and found MN are less 
sensitive to changes in dietary vitamin C than PMN, concluding that plasma and PMN are 
more sensitive to changes in vitamin C nutriture. They suggest their data show that MN 
represent a deeper store of ascorbic acid than do the PMN. However, it is unclear from the 
method of Blanchard et aL (1989) whether the MN were separated from contaminating 
platelets. 
In light of this controversy over which cell fraction reflects what status, it was deemed 
prudent to analyse both the MN and PMN for ascorbic acid. 
Isolation of each fraction requires the use of density gradient media to isolate the 
white cells from the other blood components. Essentially whole blood is pipetted onto a 
solution of certain density and osmolality. This is centrifuged and the different cell types will 
pass through the medium to differing extents according to their density, rather like putt' 
different sized stones through a series of sieves with ever decreasing perforations. 
PolymorphprepTm from Nycomed Pharma AS performs this admirably; in contrast to 
Histopaqueg from Sigma Diagnostics. The former solution separates the cells through a 
continuous gradient set up by virtue of the osmolality of the PolymorphprepTm. The procedure 
from Sigma Diagnostics requires two Histopaqueg density media, one layered on top of the 
other to set up a discontinuous gradient. From work done in our laboratory PolymorphprepTM 
was the favoured medium. With a density of 1.113 g/ml erythrocytes are forced to the bottom 
of the Universal container. Plasma and platelets remained on top and within the density 
medium itself in two discreet layers were the MN and PMN fractions. Photographs of the two 
fractions showing the separation of MN and PMN cells were taken and are shown below in 
Figure 2.1.7.2.1 b. The methodology for preparing the cell suspensions and taking photographs 
of them is detailed in section 2.3.6. 
The diluents A and B are used as in plasma sample analysis. The sample preparation 
has two stages; one before and one after frozen storage. See figure 2.1.7.2a for details. Note 
that PBS is phosphate-buffered saline. 
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2.1.7.2.2 Cell counting and viable cell number 
This method used the Neubauer Haernocytorneter. The white cells do not require a dye 
to identify them, but Trypan Blue is added to pick out the non-viable (dead) white cells which 
can be identified as they take up the dye and are stained violet/black. It was important to 
analyse the cells for viability, because uptake of ascorbic acid is an energy-driven process and 
if the cells were not viable they would give falsely low results. The viability method is based 
on that outlined by Dr. Julie Howarth at the University of Surrey (unpublished) and that of 
Sigma Chemicals. (catalogue, 1997). 
The 50 ýtl aliquot of white blood cell suspension (polymorphonuclear or mononuclear 
leukocytes) was added to 50 ýd 0.4% trypan blue and 900 ýd phosphate-buffered saline 
(1: 18: 1). This was allowed to stand for 5-15 minutes at room temperature to allow non-viable 
cells to take up the dye. 
With the cover slip in place, a glass Pasteur pipette was used to transfer a tiny amount 
of trypan blue-cell suspension to both counting chambers of the haemocytometer. Carefully 
the tip of the pipette was touched to the edge of the cover slip and the chamber allowed to fill 
by capillary action. Care was taken not to overfill or underfill the counting chambers. 
Starting with chamber I of the haemocytometer, a the cells in the 1 mm centre square 
and the four I mm comer squares were counted. A separate count of viable and non-viable 
cells was kept. Only those cells that touch the top and left lines of a square were counted not 
those that touch the bottom or the right lines of a square. This was repeated for the second 
chamber, so that finally 10 squares have been counted. If greater than 10% of the cells 
appeared clustered, the entire procedure was repeated with either a greater level of dilution 
and/or more vigorous pipetting to disperse the cells satisfactorily. The aim was to have a 
count of 200-500 cells for the sum of the two chambers (10 squares). The dilution ratio can 
be changed to obtain the required cell numbers. 
2.1.7.2.3 Cell count calculation 
Each square of the haemo cytometer represented 0.1 nimý, or 1x 10 -4 cm3- 
Cells per ml = the average count per square x dilution factor x 
104 (count 10 squares). 
Example: If the average count per square is 45 cells x 20 x 
()4 = 9.0 X 106 cells/ml 
Total cells = cells per ml x the original volume of fluid from which cell sample was removed. 
Example: 9.0 x 106 (cells/ml) x2 ml (original volume) = 1.8 x 107 cells 
Cell viability (%)= total viable cells (unstained) - total cells (stained and unstained) x 100. 
65 
Figure 2.1.7.2.1a Leukocyte sample preparation 
Stage 1. 
Collect 15 rnl fresh whole blood into 
preservative- free EDTA tubes. Invert once. 
Whole blood 
(within2hours) 
(15 ml) 
NYCOMED 
polymorphprepTm 
(13 ml) 
Plasma 
498 xg MN 
35 min PMN 
18-22'C. 
Erythrocytes 
Harvest the monocyte and granulocyte layers 
and put into separate centrifuge tubes 
marked 'MN' and 'PMN' respectively. 
Wash with 5 ml 
PBS solution 
and aspirate 
with Pasteur 
pipette 
-1 
778 xg 
Discard supernatant, 778 xg Discard 
10 min add 900 ýd 
ice-cold 10 * supernatant and 
18-221C distilled water and 18-221C resuspend pellet to vortex for 20 2.0 ml with PBS seconds. Add 5 ml 
solution PBS, aspirate. II 
Add I aliquot to a 1.5 Remove2 
ml Eppendorf tube x 750 ýtl 
with 750 ýtl solution A aliquots of Vortex for 
white 5 seconds Add I aliquot to a 1.5 blood cell 
ml Eppendorf tube 
with 750 ýtl solution B 
suspension 
Pipette 
supernatant to 
fresh Eppendorf 
tubes and smp 
freeze in liquid N2- 
Store at -70'C in 
labelled sample 
bags 
Stage 2. 
Thaw at VC for I hour and 
transfer to septa capped 
brown FIPLC vials in the 
chilled autosampler 
Remove 20 
ýil aliquot for 
cell count 
and viability, 
keep at 30'C 
until additi6n 
at 1: 18: 1 to 
0.4% trypan 
blue: PBS: 
sample 
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Figure 2.1.7.2.1 b 
I. 
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Alb 
2.2 The Main Feeding Study 
2.2.1 Aim and Design of the Main Feeding Study 
As outlined in section 2.0, the Main feeding study formed the backbone of the whole 
Thesis, whose aim was to investigate whether the same amount of vitamin C in three different 
drinks (water, a blackcurrant drink and orange juice), would cause different increases in short- 
term (plasma) and long-term (white cell) ascorbic acid levels in human subjects. To this end, 
the basic design for the Main study was tested out in the Pilot study, and the results and inferences gained from the Pilot study helped shape the Main study. The results and 
inferences are discussed in the Results section. However, overall, the methodology changes 
very little, and those differences are covered in the following sections. 
2.2.2 What elements were required for such a study 
The Pilot study involved 4 subjects with one drink. The Main study required 12 people 
each taking three drinks. However, the basic design of the Pilot study remained the same, but 
it was nine times larger, with 3x 31 day regimes for each subject. Otherwise the elements 
required were the same as in the Pilot study (section 2.1.2). 
2.2.3 Main Study design 
It was decided to continue with the plan of firstly depleting the subjects' ascorbic acid 
stores over 21 days followed by 10 days of supplementation, where the repletion of stores was 
observed and then compared between the three drinks. The study was of a randomised 
crossover design with the subjects acting as their own controls. 
White cell and plasma samples were taken in the same manner, but improvements in 
the white cell isolation protocol meant that less blood (12 ml instead of 15 ml) was needed 
each time. As it was decided to increase the number and change the intervals of the plasma 
samples, the saving of (8 x3 ml) 24 ml was used to enable 22 plasma samples to be taken 
instead of the previous 14, though over the same seven hour period. Plasma sampling was still 
carried out on day 22, though the subjects were not allowed food until the end of the plasma 
sampling period. The lengths of the washout and observation periods were kept the same, but 
each subject had three such periods separated by a five day break (they would finish one 
regime period on a Thursday and start the next regime period the following Tuesday). 
It was decided to use 12 subjects to reduce any effect of the order the drinks were 
taken in. With three drinks there were six possible orders: A-B-C, A-C-B, B-A-C, B-C-A, 
C-A-B, C-B-A. So, for example, subjects one and two had the drinks in the order 
blackcurrant drink--orange juice-water. The next pair had the drinks in the order blackcurrant 
drink-water-orange juice, and so on. Because of logistical constraints, the twelve subjects 
were divided into 3 groups of four. The start dates of these three groups were staggered one 
week apart, as the clinical unit could only handle 4 subjects at a time. 
It was decided to continue to use a level of supplementation of 200 mg ascorbic acid 
in 500 ml of drink. (The drinks are discussed further in section 2.2.4.6). 
To investigate the absorption of anthocyanins by the subjects after drinking the 
blackcurrant drink, 24-hour urine samples were collected by all subjects. They were asked to 
collect their urine for each drink period so that comparisons could be made between when the 
subject was drinking water, orange juice or the blackcurrant drink (see section 2.2.4.4). 
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2.2.4 Implementation of the Main Study 
2.2.4.1 Ethical Approval 
Exactly as the Pilot study, sampling was carried out at the University of Surrey and at 
the RSCH Clinical Investigation Unit. Both University and RSCH Ethical Committee 
approval was required to which exhaustive protocols were submitted (numbers 
ACE/97/40/SBS and EC129/97). Professor Gordon Ferns again provided medical supervision. 
(the approval of these committees can be found in appendix 6.1 b). The study was undertaken 
from Tuesday 20th January 1998 to Thursday 14 th May 1998. 
2.2.4.2 Subject recruitment, screening and consent 
Twelve healthy male subjects from the University of Surrey were recruited by posters 
and 'word of mouth'. They were screened in the same manner as in the Pilot study. They 
underwent blood cell counts and liver function tests and were given information sheets. Their 
consent and that of their GP's was sought and gained. Each sub ect received E750 upon j 
completion of the study as an inconvenience allowance. Each subject was given the 
opportunity of having the B vitamin complex tablet. Subjects were also instructed to avoid 
medication or, if essential, to inform me immediately. 
2.2.4.3 Blood sampling 
Again, Stewart Edmed took all white cell samples under University of Surrey 
regulations. White cell samples were taken on days 1,10,18,21,22,25,28,31, though as 
discussed earlier, only 12 ml was required. For all blood samples subjects were asked to come 
in early in the morning fasting from 12 midnight the night before. 
On day 22 of the observation period, the subjects were again requested to stay some 8 
hours at the RSCH CIU. 'They were instructed to not eat after 12 midnight the night before or 
have any breakfast. They came to the Investigation unit at 8.30 am and were fitted with an 
intravenous cannula (under local anaesthetic if requested), and two blood samples taken (at 
time 'zero'). They were then given their first vitamin C-fortified drink and gave blood 
samples at +40, +65, +90, +105, +120, +135, +150, +165, +180, +195, +210, +225, +240, 
+255, +270, +300, +330, +360, +390, and +420 minutes thereafter. A white cell sample of 12 
ml was also taken at +450 minutes. The sampling was done by helpers that rotated in pairs 
(Sue Slowe, Hye-Song Park, Richard Barnes, Samantha Long and Sarah Oakley), who were 
trained to take samples from the cannulae that were then passed to me for sample preparation 
(see below). 
The subjects were not allowed to eat or drink until after the last sample was taken at 
+420 minutes. For the following days 23-31 they received a similar drink daily, but were only 
required to give blood on days 25,28 and 3 1. The total blood sampling volumes were: 8x 12 
ml for white cells and 22 x 2.5 ml plasma samples. Total maximum volume was then (8 x 12) 
+ (22 x 2.5) = 151 ml. As each subject had three such periods separated by 5 days, the total 
over the 103 days was 453 ml. 
2.2.4.4 Urine sample collection 
It was decided that the subjects collect their own urines for a period of 24 hours for 
each observation period. Therefore a quantitative comparison between the urines of each 
subject could be made when they were being supplemented with water, orange juice or 
blackcurrant drink. The sample was to be taken at the end of the supplementation period from 
after the first urination on day 30, up to and including the first urination on day 31. The 
subjects were provided with the instruction sheet given in appendix 6.3. The subject only 
saved 50 ml (in a 'Falcon' tube) for investigation, taken from the total 24 hour collection 
volurne, but recorded the total 24-hour volume to allow quantitative comparisons. 
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2.2-4.5 Food diary 
The food diary was found to be very successful in the Pilot study and so remained 
unchanged in format and deployment in the Main study. However, a professional dietician 
was employed to carry out the analysis process (section 2.3.2.1). 
2.2.4.6 Choice of drinks used and their ingredients 
Three drinks were used. The first and simplest was water with 200 mg food grade 
ascorbic acid added as in the Pilot study. The ascorbic acid was added at the point of 
consumption, not in advance as the ascorbic acid would oxidise rapidly. Water was used as 
the positive control, a comparison against the more complex orange juice and blackcurrant 
drinks. 
SmithKline Beecham supplied the blackcurrant drink. This contained 208.5 mg per 
500 ml (with 12% blackcurrant juice). To match this level, The orange juice (100% juice) was 
Sainsbury's Economy sweetened concentrated (code numbers W7328 and W8005). This 
brand was chosen not only as an example of a commercial competitor but also because it 
contained the requisite ascorbic acid level AND was available in the quantities required. Code 
W7328 contained 209.5 mg 1500 ml and so 2 ml was removed and replaced with water before 
consumption. Code W8005 required 18 ml to be replaced with water. The drinks were tested 
again towards the end of the Main study, and were found to still have ascorbic acid contents 
of 41 mg/100 ml. 
Other orange juice brands were tried and are listed in appendix 6.4, as well as their 
ascorbic acid content. In every case, the ascorbic acid content on the label underestimated the 
level found after analysis (this is a standard manufacturer's policy to ensure, after opening, 
each serving still contains the advertised ascorbic acid content). The drinks contained minimal 
levels0f S02. The importance of this is discussed in the introduction, section 1.5.2. The fiffl 
analysis of the drinks is given below in table 2.2.4.6a. 
Table 2.2.4.6a Contents of the drinks used in the Main study 
Analyte 
Water 
Drink (per 100 ml) 
Orange juice (mean) Blackcurrant drink 
Ascorbic acid (mg) 40.0 41.7 (after dilution) 41.7 
S02 (Ing) 0 Not detected 1.9 
Sucrose (g) 0 3.8 Not detected 
Glucose (g) 0 2.4 5.9 
Fructose (g) 0 2.7 5.1 
Total sugars (g) 0 8.9 10.9 
2.2.5 Sample preparation of white cells and plasma 
2.2.5.1 Plasma preparation 
The method of plasma sample preparation was unchanged from that in the Pilot study, 
in section 2.1.7.1 . and 
detailed in figure 2.1.7.1 a. 
2.2.5.2.1 Leukocyte preparation 
Although the method used in the Pilot study to isolate the leukocyte fractions was 
perfectly adequate, it was decided that there was still room for improvement. This was driven 
by the results of the Pilot study. Firstly, more plasma samples were required which meant 
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more blood. As there was an ethical limit on the amount of blood that could be taken, any 
extra would have to have been at the expense of the white cell sampling volume. Secondly, 
after carrying out extensive trials on a better isolation protocol it was possible to reduce the 
platelet contamination of the mononuclear leukocytes and improve cell segregation while also 
reducing the volume of blood required to assay the white cells. This was done by layering the 
MN fraction over a diluted OptiprepTm solution. OptiprepTm, with a density (at 18-30'C) of 
1.320 g/mI is designed to be diluted with saline to suit its application. In this case, it is diluted 
at 5 volumes of OptiprepTm to 22 volumes of saline to give a density (again at 18-30'C) of 
1.063 g/ml which allows the mononuclear cells to pass through but not the platelets. This 
improved white cell isolation procedure is detailed below in figure 2.2.5.2. Ia. Solutions A and 
B are as in the Pilot study. 
2.2.5.2.2 Cell counting and viable cell number 
This procedure is identical to that in the Pilot study, section 2.1.7.2.2 
2.2.5.2.3 Cell count calculation 
This procedure is identical to that in the Pilot study, section 2.1.7.2.3 
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Figure 2.2.5.2.1a Leukocyte sample preparation 
Collect 12 ml fresh whole blood into 
preservative- free EDTA tubes. Invert once. 
\4 
498 xg 
35 1 
18-22'C. 
Harvest the monocyte and ganulocyte 
layers and put into separate centrifuge 
tubes marked 'MN' and TMN' 
Add 4 235 xg Discard PMN 
volumes of 15 min supernatant; add 
PBS buffer 18- 900 pI ice-cold -10' Layer the MN 
to MN and 220C distilled water solution over 4 
PMN and vortex for 20 ml OptiprepTm 
fractions seconds. Add 4 solution 
ml PBS. 
Add I aliquot to a 1.5 ml 
Eppendorf tube with 750 ýd 
1509 xg .4 - 
Vortex for solution A 
10 min 5 seconds Add I aliquot to a 1.5 ml 18-22'C 
Eppendorf tube with 750 ýtl I 
solution B 
Pipette 
supernatant to 
fresh 
Eppendorf 
tubes and snap 
freeze in liquid 
N2- Store at 
-70'C in 
labelled sample 
bags. 
Stage 2. 
/ 
/ 
7 
328xg 
15 min, 
18- 
22'C 
-D - Remove 2 
x 750 ýtl 
aliquots of 
white 
blood cell 
suspension 
--------------- 10. 
Thaw at 4'C for I hour and 
transfer to septa capped 
brown BPLC vials in the 
chilled autosampler 
Plasma 
MN 
PMN 
Erythrocytes 
Discard 
supernatant 
and resuspend 
pellet to 2.0 
ml with PBS 
'Remove 20 pI 
aliquot for 
cell count and 
viability, keep 
at 30"C until 
addition to 
1: 16: 1 to 
0.4% trypan 
blue: PBS: 
sample. 
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2.3 Supporting Methods 
2.3.1 HPLC detection method for ascorbic acid 
2.3.1.1 Introduction 
Section 1.10.2 describes why HPLC is the method of choice both here and by 
previous workers. It also outlines the background to the approach used in this thesis in 
developing an original 1HPLC methodology for ascorbic acid analysis. 
2.3.1.2 Sample preparation 
As the studies investigate the absorption of ascorbic acid when drunk in different 
forms, the levels of the vitamin must be known so that accurate comparative data are 
produced. It was therefore desirable to make the ascorbic acid analysis method suitable for the 
drinks as well as the biological tissues. The preparation of the biological samples is detailed in 
the previous sections. Fruit juices were prepared for ascorbic acid analysis by diluting by a 
factor suitable for the standard curve (fruit juices contain 10-200 mg ascorbic acid) with 5% 
perchloric acid solution, centrifuging to remove solid matter, and injecting the supernatant. 
The sample/solution mixtures were pipetted into a glass insert (to minimise headspace 
in the vial as much as possible) inside an amber vial with a fresh air-tight PTFE septum and 
placed in the chilled autosampler at 4'C. 
2.3.1.3 Peak detection 
The ascorbic acid peak was identified by ascorbic acid oxidase (EC 1.10.3.3). The 
method was calibrated using six standard concentrations over the range 0.125 to 1.25 mg/1 00 
ml prepared in solution A. These bracketed the expected concentrations of the samples. The 
level of detection was determined by injecting a set of serially diluted ascorbic acid solutions 
down to I ng/ml. Recovery was determined using six samples of pooled plasma and spiking 
two of them with a known amount of ascorbic acid. Two samples of an orange juice were 
analysed in our laboratory by the method described here and by Reading Scientific Services 
Limited (RSSL), Reading UK who use a phosphate-buffered mobile phase with dithiothreitol 
as reducing agent. 
It was also shown, through the use of uricase (EC 1.7.3.3) that uric acid could be 
detected in the plasma samples. The peak is shown in figure 2.3.1.5b. 
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2.3.1.4 Assay validation 
When ascorbic acid oxidase was added to a suspension of ascorbic acid and mijected 
the peak presumed to be ascorbic acid disappeared. The enzyme did not affect a peak of iso- 
ascorbic acid. Therefore the peak was positively identified as ascorbic acid. The calibration 
curve generated from the peak areas of these standards had little deviation from linearity 
(r 2=0.999) . Ascorbic acid in standard solutions could 
be detected at levels down to 10 ng/ml 
(mean blank response plus three standard deviations), though the method would be less 
sensitive in biological matrices. Recovery was found to be 100.7% (n7=6). The standard 
solutions were stable for at least one year. The analyses of the two orange juices in our 
laboratory and at RSSL were within 1% of each other. 
Figures 2.3.1.4 (a-d) show the peaks of AA produced with this method upon 
analysis of (a) blackeurrant juice, (b) plasma, (c) mononuclear leukocytes and (d) 
polymorph onu clear leukocytes. Figure 2.3.1.4 (b) shows the uric acid peak detected in 
plasma. 
Figure 2.3.1.4(a) 
Blackcurrant juice 
Internal standard 
Ascorbic acid 
I 
dithlothreltol 
I 
IIIIIIIII 
02468 10 12 14 16 
Time (minutes) 
Figure 2.3.1.4(b) 
Human plasma 
Uric acid I 
Time (minutes) 
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Figure 2.3.1.4(c) 
Mononuclear leukocytes 
Ascorbic acid 
I 
Time (minutes) 
Figure 2.3.1.4(d) 
Polymorphonuclear leukocytes 
I 
Time (minutes) 
2.3.1.5 Standard curve 
The ascorbic acid content of the fruit j uce, plasma and white cell preparations could all 
be interpolated on a standard curve of 0.125.0.25,0.5,0.75,1.00 and 1.25 mg/100 ml 
ascorbic acid. The standards for the curve were made up in solution A: 5% PCA ýV/v), 1% 
MPA (w/v) and 0.1% DTT (w/v). The internal standard of 3,4-dihydroxybenzoic acid at 5 
mg/I 00 ml acts to remove any injector error. (Note, the samples are diluted by two within the 
preparation procedure, therefore the standards are toý. 
2.3.1.6 Dehydroascorbic acid and 2,3-diketogu Ionic acid (DKG) analysis 
VAiile diketogulonic acid and other oxidation products of ascorbic acid have no 
biological activity, dehydroascorbic acid does and so must be quantifled to find the effective 
total ascorbic acid concentration. Attempts were made to do this directly and dehydroascorbic 
acid standards were analysed by IIIPLC with a view to creating the requisite dehydroascorbic 
acid standard curve for direct quantitation of ý dehydroascorbic acid in samples. However, 
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dehydroascorbic acid standards absorb UV light so very poorly that it was not possible to 
detect dehydroascorbic acid at the low levels found in biological tissues. Therefore, it was 
found preferable to analyse dehydroascorbic acid by difference, a well-established approach 
(Margolis and Davies 1988, Margolis et al. 1990 and Margolis and Deuwer 1996). This is 
carried out by analysing duplicate samples with and without a reducing agent, dithiothreitol, 
(DYI). DTT reduces all dehydroascorbic acid back to ascorbic acid, thus giving total ascorbic 
acid. The duplicate that does not contain DTT gives ascorbic acid only. The dffference 
between the duplicates gives the dehydroascorbic acid content. The use of a reducing agent 
such as DTT (or homocysteine) also prevents artifactual formation of dehydroascorbic acid in 
the preparation of samples and irreversible hydrolysis to DKG. 
2.3.1.7 Internal Standard 
Before 3,4-dihydroxybenzoic acid was chosen as the internal standard, many others 
were tried: isoascorbic, acid, shikimic acid, quinic acid, vanillic acid, 2,5-dihydroxybenzoic 
acid, aspartic acid, 3-hydroxybenzoic acid, sorbic acid, succinic acid, maleic acid and 
ascorbyl pahnitate. 
2.3.1.8 Instrumental 
The 1HPLC system comprised a pump, combined chilled autosampler (kept at 4'Q and 
column oven (kept at 30'C), detector (254 nm) and computer software (see section 2.5 for 
details). A Luna RP C18 ODS2 column (5 pim, 250 x 4.6 mm I. D. ) was used for the 
chromatographic separation. Two mobile phases were used: A: pH 1.5 perchloric acid 
solution and B: 87.5% phase A/12.5% BPLC grade methanol. The pump profile was 100% 
phase A from 0.0 to 4.0 minutes at 1.4 ml/min and 4.01 to 15 minutes phase B at 1.3 ml/min. 
The methanol allows samples to be analysed quicker. 
2.3.1.9 Detection 
The commonest methods are by ultraviolet absorption or electrochemical detection. 
The resources in our laboratory favour the former. Liau et aL (1993) found a correlation of 
0.99 between EC and UV detection. The method as outlined above requires no pre or post 
derivatisation of the ascorbic acid. The wavelength chosen for detection of ascorbic acid 
under these conditions was 241 nm. 
2.3.1.10 Other conditions 
Brown (or amber) vials with fresh PTFE septa are essential, and decreasing the 
headspace in any vial is encouraged to reduce any oxidation that may occur. A chilled 
autosampler also further minimises any oxidation of the ascorbic acid. Retention time 
fluctuation and other temperature-dependent effects are diminished by keeping the column 
temperature at 30'C -above, and so independent from, room temperature. An 
injector flush 
of 1.0 ml distilled water was felt to be optimal. A 50 ýtl sample was injected. Both mobile 
phase solvents were filtered and degassed with helium. 
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2.3.2.0 HPLC analysis for anthocyanins and other flavonoids 
As part of the Main study urine samples were collected. To prevent microbial growth 
0.1% sodium azide was added before the samples were frozen. These were to be analysed for 
anthocyanins and conjugated anthocyanin metabolites (see section 2.3.2.3). This required a 
]HPLC method to detect them. 
There were two methods used. One was an existing IIPLC method used in the 
laboratory for urine analysis. This used mobile phases of A) 0.5% formic acid and B) 50% 
acetonitrile, 50% phase A. This used a wavelength of 530 nm for anthocyanins. However, 
since the conditions are not below pH 1.5, the method should detect only pH-stable 
anthocyanins at 530 nm. The solvent gradient and further details are given below. 
Formic acid-acetonitrile method 
Pump: P2000 binary gradient 
Injection: 100 ýd 
Column: Sphereclone ODS2 C 18,5 
250 x 4.6 mm analytical from Phenomenex. 
Solvent A: 0.5% formic acid 
Solvent B: 50% acetonitrile, 50% solvent A. 
Flow rate: 1.0 ml/min. 
Detection: 530 m-n 
Gradient: 
Time (min)" IX A%B 
0.0 100 0 
10.0 100 0 
75.0 35 65 
80.0 0 100 
90.0 0 100 
95.0 100 0 
100.0 100 0 
The second method uses a perchloric acid solution as mobile phase A, creating a pH of 
1.5. The samples are prepared by diluting 1: 1 with mobile phase A to ensure the sample is at 
the required low pH for the anthocyanin to be detected at 530 nm Full details are given 
below. 
Perchloric acid-methanol method 
Pump: P2000 binary gradient 
Injection: 100 [d (50% mobile phase A) 
Column: Sphereclone ODS2 C 18,5 ptm 
250 x 4.6 mm analytical from Phenomenex. 
Solvent A: perchloric acid solution pH 1.5 
Solvent B: 95% methanol, 5% solvent A. 
Flow rate: 1.0 ml/min. 
Detection: 530 mn 
Gradient: 
Tiine (min) %A %B 
_ 0.0 95 5 
5.0 95 5 
20.0 65 35 
30.0 65 35 
55.0 0 100 
60.0 0 100 
62.0 95 5 
80.0 95 5 
In this section, all mobile phase ratios are (vlv) 
2.3.2.1 Deconjugation of metabolites in urines 
A major site for the metabolism of absorbed flavonoids (including anthocyanins) is in 
the liver by xenobiotic metabolising enzymes, where they may be conjugated with a sulphate 
or glucuronate residue before excretion. In the case of anthocyanins there is no evidence that 
they are absorbed from the human gut and metabolised in this way. Therefore, as humans 
cannot synthesise flavonoids the presence of conjugates (as well as free flavonoids) in plasma 
or urine is evidence of their absorption. This work should then show whether anthocyanins are 
present in urine and whether they are free or conjugated. Such presence would give the first 
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proof that anthocyanins are absorbed and metabolised (though their absence is not evidence 
that they are not absorbed). 
To analyse the conjugated forms they are first hydrolysed enzymically of their 
sulphate or glucuronate by a sulphatase (type H-1) and a P-glucuronidase (type B-1) 
respectively. After analysing for anthocyanins again the proportion of conjugated forms can be calculated by difference. 
As the sulphatase also shows P-glucuronidase activity, the inhibitor for the 
glucuronidase-D-saccharic acid-I 4-lactone (DSL)-is introduced in the sulphatase reaction 
vessel. This is reported to have >95% activity (Steensma, et aL 1994). 
2.3-2.2 Deconjugation procedure 
1. Dissolve enzymes in 0.2M sodium acetate buffer adjusted to pH 5.0 with acetic acid to 
activity levels of 5000 units/ml for the bovine P-glucuronidase and 250 units/ml 
sulphatase. In the sulphatase solution have DSL at 17 mM. 
2. Mix 500 ýd urine with either an equal volume of glucuronidase solution or sulphatase 
solution. Total reaction volume is 1000 ýtl. 
3. Vortex, put in to a shaking water bath and incubate at 371C overnight. 
4. After incubation add an equal amount of pH 1.5 perchloric acid and centrifuge to remove 
protein. 
5. Freeze and store at -1 8'C until analysis. 
2.3.2.3 The different conditions of analysis 
The urine samples were analysed for anthocyanins, under six different conditions with 
detection at 530 nm. The six conditions are as follows: 
Formic acid - acetonitrile 
method for native and non- 
native anthocyanins 
Not deconjugated 
sulphatase E Deconjugated 
with: 
A 
Perchloric acid - methanol 
method fo r native 
anthocyanins 
B 
P-glucuronidase D F 
Therefore, any anthocyanin peaks found by HPLC in the samples analysed by 
conditions A were unconjugated and non-native; being stable at a pH higher than 1.5. 
Conditions B would find unconjugated but native and non-native anthocyanins. Conditions C 
would find non-native anthocyanins conjugated with a sulphate residue, and conditions D 
would find non-native anthocyanins with a P-glucuronate residue. Conditions E and F would 
find both native and non-native anthocyanins: conjugated with a sulphate and a P-glucuronate 
residue respectively. (Non-native anthocyanins are stable at a higher pH). 
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2.3.3 HPLC analysis of hippuric acid 
In the Food Safety Research Group, previous investigations of human urines have 
created interest in the excretion of hippuric acid-a glycine derivative of benzoic acid and 
major urinary product of dietary phenols-and the ingestion of flavonoids. In this study it was decided to study the content of hippuric acid in the subjects' urines after each 
supplementation period, since their intake of dietary flavonoids from sources other than the 
test beverage would be quite low. Hippuric acid was analysed by HPLC with using mobile 
phases of A) 0.5% formic acid and B) 50% acetonitrile, 50% phase A. The wavelength of 240 
nm was used. 
Pump: P2000 binary gradient 
Injection: 100 ýd 
Column: Sphereclone ODS2 C 18,5 ýLm 
250 x 4.6 mm analytical from Phenomenex. 
Solvent A: 0.5% formic acid 
Solvent B: 50% acetonitrile, 50% solvent A. 
Flow rate: 1.0ml/min. 
Detection: 240 nm 
Gradient: 
Time (nýn), ' %A%B 
0.0 100 0 
10.0 100 0 
50.0 60 40 
55.0 0 100 
65.0 0 100 
70.0 100 0 
75.0 100 0 
In this section, all mobile phase ratios are (v/v) 
2.3.4.0 NMR analysis 
The nuclear magnetic resonance (NMR) analysis of urines for aromatic protons as a 
marker for the excretion of metabolised flavonoids has been pioneered in the Food Safety 
Research Group at the University of Surrey. NMR is a technique that exploits the natural 
spinning of protons in a magnetic field. At room temperature there are slightly more protons 
aligned with the magnetic field than against it (about one in a million). This difference is 
increased at lower temperatures. When individual nuclei are exposed to a specific 
radiofrequency, they jump from a lower energy state (aligned with the field) to a higher 
energy state (aligned against the field). This change can be measured and quantified. Also the 
frequency at which the jump occurs depends on the environment of the nuclei; what local 
bonds they have. Therefore, using a suitable internal standard it is possible to apply a 
radiofrequency to the sample and quantify the amount of aromatic protons. 
All urine samples underwent NMR spectroscopy to investigate the loading of aromatic 
molecules after subjects had drunk blackcurrant drink, orange juice or water. 
2.3.4.1 Sample preparation for NMR analysis 
1.5 ml of urine is centrifuged at 1509 xg for 10 minutes. 
2.2 ml of supernatant is pipetted into a universal tube. 
3. Freeze at -30'C then freeze dry until desiccated. 
4. Reconstitute the dried urine with 2 ml deuterium water (D20)containing 1 mg/mI sodium 
formate as the internal standard. 
5. This is sent to the NMR specialist for analysis. 
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2.3.5 Food diary analysis 
The food diaries from both Pilot and Main feeding studies were entered into the Dietary Analysis package Diet 5 (Aberdeen University). This required that each food has a 
code and a weight, from which Diet 5 is able to assess the nutrient intake per day. A quaffied dietician was employed to input those from the Main study. 
2.3.6 Preparation of white cell fractions for photography 
This method, entitled 'May-GrunwaldIGiemsa Staining Methodfor Blood Films', was 
taken from the histology protocols of Dr Julie Howarth of the University of Surrey. Safety 
precautions must be taken to avoid contact of reagents with the skin and eyes. Solutions are disposed of down the drain with excess cold running water. 
Stock solutions 
1. Sorensen's Phosphate buffer: 0.066M stock solution: 
(A) Na2HP04 9.465g/litre 
(B) KH2PO4 9.07g/litre 
(these solutions can be stored at 4'C) 
To obtain the working solution of pH 6.5 (buffered distilled water): 
Na2BP04solution 30 ml 
KH2P04 solution 70 ml 
Dilute to I litre with distilled water. 
Check the pH and adjust if necessary. 
2. May-Grunwald stock solution 
3. Giemsa stock solution 
Method 
1. Rapidly air-dry blood films and then fix in methanol for 10 minutes. 
2. Transfer slides to May-Grunwald stain, freshly diluted with an equal volume of 
pH 6.5 buffered distilled water for 5 minutes. 
3. After draining, transfer the slides to the Giemsa stain, freshly diluted with 9 
volumes of buffered distilled water for 10 minutes. 
4. Transfer the slides to buffered distilled water and wash rapidly in 2 changes 
aflowing them to differentiate for about 2 minutes in the second change before 
a final quick rinse in a third change. 
5. Stand the slides vertically to drain and dry. Examine using a microscope 
equipped with a camera. 
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2.4 Statistical methods 
Statistical advice was taken and analysis carried out by Peter Williams of the Statistics Department of the University of Surrey. The specific statistical tests carried out on the plasma 
and white cell data are described in the Results section. 
2.5 Materials and Equipment 
2.5.1 Materials 
All chemicals used were from Sigma (Poole, Dorset, UK) except the following. 
Methanol (BPLC grade) from Fisher Chemicals Ltd (Loughborough, Leicestershire, UK). 
Metaphosphoric acid from BDH (Poole, Dorset, UK). 
Dithiothreitol from Aldrich (Poole, Dorset, UK). 
BPLC vials, septa, caps were all from BPLC Technology, (Macclesfield, Cheshire, UK). 
BPLC columns from Phenomenex. (Macclesfield, Cheshire, UK) 
Quinic acid from Koch-Light (Suffolk, UK). 
Syringes and VacutainersO from Becton Dickinson (Drogheda, Ireland). 
Falcon tubes from Bibby Sterilin (Stone, Staffordshire, UK). 
PolymorpbprepTm and OptiprepTm from Nycomed Pharma AS (Oslo, Norway). 
Saline from Phoenix Pharmaceutics, (Gloucestershire, UK). 
Plasters from Johnson and Johnson (Skipton, UK). 
Needles from Terumo (Leuven, Belgium). 
EDTA blood tubes from Teklab (London, UK). 
Tourniquet from Guest Medical (Sevenoaks, Kent, UK). 
Cannulae (Y-CAN 19g) from Wallace (UK). 
2.5.2 Equipment and instrumentation 
The BPLC system comprising pump (model P2000), combined chilled autosampler 
and column oven, (model AS3000), detector (model UV2000) and PCIOOO software were 
from Thermoseparation Products Ltd, (Manchester, UK). The Luna RP C 18 ODS2 analytical 
columns were from Phenomenex, (Macclesfield, Cheshire, UK). 
Centrilugation was carried out in a Hereus 40OR (Brentford, Essex, UK). 
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3.0 Results 
This chapter contains the results of the thesis and it is split into sections. The first part 
(3.1) presents results of the Pilot study. The inferences from it and the subsequent changes 
made to the protocols for use in the Main study are discussed in section 4. The second part 
(3.2) tabulates the results of the Main study, including (3.2.1) the validation of the improved 
mononuclear leukocyte isolation procedure, (3.2.2) ascorbic acid content of white cell and 
(3.2.3) ascorbic acid content of plasma, (3.2.4) dietary analyses and (3.2.5) urine analyses. 
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3.1 The Pilot study 
3.1.1 White cell ascorbic acid levels 
Table 3.1.1 a summarises the white cell ascorbic acid concentrations on days 1,8,15, 
21,22,25 and 28 of the Pilot study. The raw data and the example calculation are shown in 
appendix 6-6a-g. The Pilot study was cut short by three days due to the delay in obtaining 
permission from the Ethics Committees. Therefore there was no sampling on day 3 1. ('PMN' 
are polymorphonuclear cells, 'MN' are mononuclear cells. The values given are Total 
ascorbic acid in ýig / 108 white cells). 
Table 3.1.1a. The white cell ascorbic acid contents during the Pilot study 
gg ascorbic acid /106 PMN cells 
Day 
18 15 21 22 25 28 
IM 19.6 15.9 
NB 10.0 3.0 
RW 14.7 22.4 
DP 13.8 11.6 
13.6 
23.8 
14.0 
22.5 
11.0 
8.0 
9.3 
6.1 
6.5 
64.0 
10.7 
9.0 
23.5 
57.3 
70.4 
21.5 
12.8 
14.6 
84.6 
45.0 
mean 14.5 13.2 18.5 8.6 22.6 43.2 39.3 
ýtg ascorbic acid /108 MN ceUs 
1 8 15 21 22 25 28 
im 65.9 57.0 32.8 28.5 44.5 101.6 60.0 
NB 124.9 41.2 74.8 105.1 74.8 73.2 122.1 
RW 166.0 49.6 77.7 113.7 66.4 137.6 153.9 
DP 96.7 114.1 70.2 99.5 78.5 89.7 149.8 
me-an* 113.4 65.5 63.9 86.7 66.1 100.5 121.5 
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3.1.2 Plasma ascorbic acid levels 
Table 3.1.2a shows the plasma ascorbic acid levels at time zero and at sample intervals 
thereafter. Each subject had been given 200 mg ascorbic acid in water. As this was a Pilot 
study, the samples were not always taken at exactly the time point required. The changes in 
plasma ascorbic acid levels of the subjects are shown also in figure 3.1.2a. to demonstrate the 
effect of the small meal the subjects had at +240 minutes (see discussion). 
Table 3.1.2a The plasma ascorbic acid levels of the four subjects at time points from 
zero to 450 minutes after taking the ascorbic acid drink. 
IM NB RW DP 
sample mg ascorbic sample mg ascorbic sample mg ascorbic sample mg ascorbic 
time acid /100 ml time acid /100 ml time acid/ 100 ml time acid /100 ml 
(min) plasma (min) plasma plasma plasma 
0 0.160 0 0.211 0 0.171 0 0.197 
60 0.318 60 0.351 61 0.259 60 0.373 
120 0.251 120 0.309 121 0.271 122 0.392 
172 0.293 178 0.334 150 0.298 153 0.377 
195 0.332 198 0.358 182 0.331 180 0.389 
220 0.309 223 0.332 211 0.344 213 0.369 
245 0.273 248 0.335 240 0.334 240 0.437 
270 0.210 273 0.249 272 0.250 270 0.326 
300 0.282 300 0.304 300 0.276 300 0.326 
33-0 0.290 330 0.313 330 0.286 330 0.348 
360 0.240 360 0.269 360 0.246 360 0.347 
390 0.275 390 0.286 390 0.262 390 0.337 
420 0.261 420 0.266 420 0.251 420 0.307 
450 0.246 450 0.250 450 0.261 450 0.321 
Graph 3.1.2a Plasma ascorbic acid levels in Pilot study subjects 
0.50- 
0.30 - 
. 00.201 , *C 40 IM 
NB 
Z0.10- RW 
DP 
0.00 - 
0 100 200 300 400 
Time (minutes) 
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3.1.3 Validation of the dietary regime 
The effectiveness of the dietary regime recommended was evaluated by its ability to 
keep the volunteer on a daily intake of less than 10 mg ascorbic acid as judged by the diary 
record of consumption and published food composition data (Diet 5, Aberdeen University). 
The diaries were analysed as detailed in section 2.3.5. The data for the intake of each subject 
over the Pilot study period is given in table 3.1.3a. The study was shortened by 3 days and 
dietary information on day 28 was omitted since the last white cell sample was given on the 
morning of day 28, which effectively finished the study. 
Table 3.1.3a Daily intake of ascorbic acid by each subject during the Pilot study 
day 
Im NB 
subject 
RW DP 
1 1.0 13.2 6.8 21 
2 7.5 6.0 0.5 1.0 
3 4.7 10.4 8.8 19.5 
4 4.7 4.0 0.5 10.0 
5 12.5 0.0 5.0 13.6 
6 2.5 0.0 0.5 10.8 
7 3.0 2.3 2.8 2.5 
8 5.8 5.3 10.3 2.5 
9 2.5 0.3 1.8 0.8 
10 0.5 0.3 7.0 4.4 
11 1.3 2.5 2.5 5.8 
12 3.9 1.6 3.5 12.4 
13 1.0 2.5 1.5 2.5 
14 2.3 4.3 6.0 1.0 
15 1.8 5.5 3.0 1.5 
16 1.1 9.5 3.8 7.3 
17 8.3 0.0 1.8 1.5 
18 5.2 2.8 6.9 6.6 
19 1.9 2.5 0.8 4.3 
20 0.3 0.0 1.5 2.8 
21 3.8 6.9 0.8 1.3 
22 6.4 3.6 0.5 3.0 
23 2.9 9.6 1.0 5.8 
24 1.3 2.0 0.8 2.5 
25 2.0 14.5 1.5 10 
26 10.3 4.0 9.5 6.3 
27 0.3 3.4 0.3 3.3 
Mean daily intake (mg) 6.1 3.7 4.3 3.3 
% of days below 10 mg/day 93 89 96 74 
Overall average: 4.3 mg /day 
% of days below 10 mg/day: 88% 
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3.2 The Main study 
3.2.1 Validation of improved mononuclear leukocyte isolation procedure. 
It was noted from the results of the Pilot study and the behaviour of the mononuclear 
leukocyte fraction that there was contamination from Platelets. As is discussed in section 4.1, 
platelets contain ascorbic acid and add to the titre. They also tend to cause the mononuclear 
cells to clump together which affects the counting process. Therefore to improve the isolation 
of mononuclear leukocytes the density gradient medium OptiprepTm was used. Optiprep was 
diluted as described in section 2.2.5.2.1 and the mononuclear cell suspension layered over it. 
After a second centrifugation stage the cells were resuspended and then prepared for 
photography as described in section 2.3.6. Figure 3.2.1b, below, shows the resultant 
photograph of this new procedure compared with the procedure without the Optiprep stage, 
figure 3.2.1a. There were visibly less platelets in the procedure employing Optiprep, and the 
decrease in the clumping of the mononuclear cells was significant. This method was then used 
for the Main study. 
3.2.2 White cell ascorbic acid levels 
The complete data set of the white cell counts and corresponding ascorbic acid levels 
are given in appendix 6.7. A summary of the data is given below in tables 3.2.2 a, b and c, 
representing the subjects white cell levels during the blackcurrant drink supplementation 
(treatment 1), orange juice (treatment 2) and water (treatment 3) respectively. The data of all 
twelve subjects are given together. There are data points missing (nd = no data), notably from 
subjects RW and PC. These omissions are discussed later. 
Figures 3.2.2a and 3.2.2b show visually the rise in leukocyte ascorbic acid levels in 
mononuclear and polymorphonuclear leukocytes respectively for all subjects for all three 
drinks. These data are presented using the baseline measurement at day 21 as 'zero', with all 
subsequent points as the rise above the baseline. 
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Figure 3.2.1a: May-Grurnwald/Giemsa stain of the mononuclear leukocyte fraction separated 
from whole blood using Nycomed PolymorphprepTM (above). 
Figure 3.2.1b May-Grurnwald/Giemsa stain of the mononuclear leukocyte fraction separated 
from wholeý blood using Nycomed PolymorphprepTM followed by a second stage of layering 
the cell suspension over Nycomed OptiprepTM (below). 
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Table 3.2.2a. White cell ascorbic acid levels for the subjects while undergoing 
supplementation with the blackcurrant drink (from days 22 to 31 inclusivýe) 
Sample day 
Subject Cell Washout period Supplementation period type 
18 15 21 22 25 28 31 
DP 
PMN 8.7 nd 8.6 8.8 9.0 9.2 11.6 12.9 
MN 55.9 31.3 26.9 28.0 35.5 69.0 72.3 73.2 
PMN 12.5 10.6 11.3 12.3 12.8 12.8 16.3 16.1 
NB 
MN 47.3 22.9 22.7 28.0 35.9 53.0 66.4 62.8 
PMN 8.4 6.5 5.1 5.9 7.4 8.1 10.9 11.2 
NP 
MN 39.6 30.7 33.9 32.4 35.5 52.7 55.0 48.0 
PMN 23.1 15.5 9.3 nd 10.3 14.8 17.4 19.0 Py 
MN 46.7 22.3 21.0 nd 18.9 33.7 36.8 36.3 
PMN 17.8 9.8 9.1 7.7 7.9 11.1 11.0 12.2 
HD 
MN 37.5 31.2 23.9 5.5 22.1 20.4 20.9 23.5 
PMN 14.0 14.1 9.9 8.0 10.7 12.6 17.9 15.8 
JT 
MN 37.1 26.0 14.3 18.4 24.4 45.1 48.5 43.4 
PMN 16.7 12.7 9.6 7.6 11.7 13.7 14.4 14.6 
NH 
MN 55.3 45.4 43.2 27.8 27.9 65.3 63.8 64.4 
PNN 23.6 23.5 15.1 10.9 11.0 13.1 19.2 18.5 
RW 
MN 44.4 29.3 22.5 24.0 26.0 40.8 53.6 56.3 
PMN 10.5 8.7 6.2 5.3 5.0 7.0 7.3 8.6 
DN 
MN 33.6 30.2 22.6 11.7 21.4 24.4 25.1 28.5 
PMN 7.6 3.4 3.0 2.4 1.9 2.4 5.9 6.3 
JR 
MN 34.5 22.3 16.0 11.5 16.5 16.3 22.4 29.1 
PMN 14.4 13.6 7.2 6.1 6.6 9.6 9.2 11.6 
PC 
MN 28.4 18.6 14.0 11.6 12.8 19.7 24.8 26.2 
PMN 9.1 7.8 4.5 2.6 3.5 4.9 5.9 7.9 
SD 
MN 29.0 23.3 15.2 13.7 16.3 20.4 26.7 30.5 
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Table 3.2.2b. White cell ascorbic acid levels for the subjects while undergoing 
supplementation with the orange juice (from days 22 to 31 inclusive). 
Sample day 
Cell Subject 
type Washout period 
I Supplementa tion period 
1 8 15 21 22 25 28 31 
PMN 17.8 nd 9.6 8.6 10.2 11.9 13.0 11.5 DP 
MN 64.4 nd 49.7 45.3 60.6 66.8 62.4 61.0 
PMN 8.4 6.6 3.7 3.9 6.5 6.6 6.9 6.4 
NB 
MN 61.0 25.4 22.2 22.7 38.4 35.8 40.5 46.8 
PMN 11.0 nd 5.0 6.0 5.9 10.1 11.4 10.5 NP 
MN 41.5 nd 37.0 43.3 38.1 48.4 51.3 49.1 
PMN 16.4 nd 12.9 9.5 11.1 14.5 18.2 10.3 Py 
MN 39.7 nd 12.6 14.6 23.9 27.5 24.4 28.8 
PNW 16.5 12.5 10.6 6.3 7.2 11.6 12.1 12.2 
HD 
MN 43.6 44.5 31.7 25.7 35.6 51.2 51.2 52.6 
PMN 14.7 11.8 9.8 8.5 8.1 15.4 15.7 15.3 
JT 
MN 42.7 24.3 20.9 14.9 15.0 34.8 34.7 37.8 
PMN nd 10.9 8.9 4.7 5.1 10.0 12.2 11.6 
NH 
MN 46.4 35.0 33.9 35.6 55.8 57.8 63.5 58.5 
PMN 16.5 nd 8.7 4.3 4.8 8.1 13.4 13.6 
RW 
MN 55.6 43.1 38.9 22.6 28.3 37.9 40.3 43.2 
PMN 18.1 14.8 nd 6.6 8.1 10.1 10.0 nd 
DN 
MN 45.1 39.2 17.5 19.6 34.1 37.8 41.3 nd 
PMN 16.7 12.1 7.8 5.2 7.9 9.3 10.3 nd 
JR 
MN 30.3 27.1 18.7 17.1 23.6 26.9 30.8 nd 
PN4N 15.1 11.0 7.7 7.2 7.6 9.5 9.7 nd 
PC 
MN 19.4 19.7 13.2 12.0 15.0 15.7 22.5 nd 
PMN 15.3 9.9 5.5 4.4 5.1 8.1 9.0 nd 
SD 
MN 50.3 38.6 32.7 26.2 26.4 40.1 43.7 nd 
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Table 3.2.2c. White cell ascorbic acid levels for the subjects while undergoing 
supplementation with the water (from days 22 to 31 inclusive). 
Sample day 
Subject Cell 
type Washout period 
I Supplementation period 
1 8 15 21 22 25 28 31 
PNN 7.0 6.1 6.8 6.2 11.1 10.3 11.1 11.9 
DP 
MN 63.6 53.4 14.0 9.4 31.1 31.4 34.5 28.3 
PNW 17.7 11.9 14.2 11.9 12.9 13.0 15.9 15.4 
NB 
Nw 67.5 46.5 37.6 46.9 53.6 62.7 63.9 61.0 
PMN 11.3 4.4 4.3 4.3 6.6 8.3 8.5 9.3 
NP 
MN 44.4 40.6 20.8 24.3 24.9 33.0 38.8 42.4 
PN4N 22.4 nd 7.0 7.9 9.3 13.9 17.4 17.3 Py 
MN 35.6 nd 32.9 23.3 27.2 41.4 46.0 40.8 
PMN nd 13.3 12.9 8.3 8.9 16.6 16.3 19.6 HD 
MN nd 27.2 16.7 18.6 40.3 45.2 43.1 42.7 
PNW 11.7 9.7 5.1 5.8 6.4 13.6 13.1 14.7 
JT 
MN 37.0 31.8 25.8 21.8 37.9 48.8 48.7 47.8 
PNN nd 11.9 10.5 8.0 9.6 9.6 16.9 17.2 NH 
MN nd 45.7 42.3 40.9 59.8 57.6 65.1 62.8 
PNN nd nd nd nd nd nd nd nd RW 
MN nd nd nd nd nd nd nd nd 
PNW 9.5 7.6 5.8 3.4 3.2 5.8 8.6 8.8 
DN 
MN 25.8 18.2 17.0 16.6 19.5 24.3 32.5 27.0 
PNN 9.5 4.3 3.1 2.3 2.5 5.3 6.2 8.4 
JR 
MN 41.3 35.5 26.3 17.9 23.1 24.3 23.4 29.7 
PMN 14.0 12.9 9.1 6.0 7.6 nd nd nd 
PC 
MN 22.9 7.6 12.3 11.4 13.4 nd nd nd 
PNN 14.2 12.0 5.7 4.4 5.6 7.4 9.2 9.7 
SD 
MN 51.8 30.5 15.0 17.5 21.2 34.3 40.4 40.1 
90 
3.2.3 Plasma ascorbic acid levels 
Tables 3.2.3a-I represent the plasma ascorbic acid levels (in units of mg/100 ml 
plasma) of the subjects after taking the three drinks. The data are tabulated by subject. 
Therefore table 3.2.3a shows the three sets of figures for subject DP, 3.2.3b shows those of 
subject NB, and so on. The data are expressed as the increase in plasma ascorbic acid above 
the pre-drink baseline ('time zero'). Two baseline readings were taken for improved efficacy. 
For full triplicate IHEPLC values, standard error and the actual unadjusted plasma levels see 
appendix 6.8. Figure 3.2.3a shows all the data, in tables 3.2.3a to 1, pooled together on one 
graph.. The error bars are ± standard error from the mean. 
Table 3.2.3a. Subject DP 
Blackcurrant drink Orange juice Water 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mgUO ml mg/100 ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
40 0.046 43 0.107 40 0.105 
65 0.098 67 0.234 65 0.204 
90 0.137 92 0.435 90 0.211 
105 0.138 107 0.312 105 0.209 
120 0.166 121 0.275 120 0.200 
135 0.179 136 0.214 135 0.181 
150 0.172 150 0.190 150 0.172 
165 0.161 167 0.207 165 0.182 
180 0.160 182 0.196 180 0.161 
195 0.165 197 0.181 195 0.167 
210 0.163 212 0.253 210 0.158 
225 0.146 227 0.221 225 0.155 
240 0.151 242 0,206 240 0.153 
255 0.136 257 0.184 255 0.144 
270 0.123 272 0.150 270 0.137 
302 0.129 305 0.170 300 0.123 
332 0.136 330 0.168 330 0.131 
360 0.132 362 0.166 360 0.123 
390 0.116 391 0.145 390 0.121 
420 0.107 424 0.139 420 0.125 
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Table 3.2.3b. Subject NB 
Blackcurrant drink I Water I Orange juice 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
40 0.034 41 0.079 40 0.058 
65 0.072 65 0.117 65 0.101 
90 0.094 91 0.081 90 0.110 
105 0.137 105 0.113 105 0.102 
120 0.152 120 0.100 120 0.095 
135 0.143 135 0.101 135 0.092 
150 0.148 150 0.086 150 0.096 
165 0.126 165 0.109 165 0.082 
180 0.148 180 0.078 180 0.087 
195 0.130 201 0.086 195 0.062 
210 0.084 210 0.096 210 0.084 
225 0.078 226 0.075 225 0.090 
240 0.088 241 0.055 240 0.086 
255 0.091 255 0.083 255 0.094 
270 0.095 270 0.070 270 0.082 
300 0.101 300 0.067 300 0.079 
330 0.084 330 0.051 330 0.068 
362 0.098 362 0.050 360 0.072 
390 0.111 391 0.059 390 0.066 
422 0.108 1 420 0.073 420 0.069 
Table 3.2.3c. Subject NP 
Blackcurrant drink Orange juice Water 
time mean rise in ascorbic time mean rise in ascorbic acid time mean rise in ascorbic 
(min) acid above baseline, (min) above baseline, mg/100 (min) acid above baseline, 
mg/100 ml ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
40 0.015 43 0.082 40 0.075 
65 0.016 68 0.118 65 0.141 
90 0.042 93 0.131 90 0.162 
105 0.044 108 0.132 105 0.190 
120 0.050 122 0.136 120 0.211 
135 0.061 138 0.132 135 0.220 
151 0.061 152 0.139 150 0.186 
165 0.077 168 0.133 165 0.199 
180 0.048 183 0.110 180 0.192 
195 0.085 198 0.109 195 0.190 
211 0.072 213 0.115 210 0.198 
225 0.080 227 0.125 225 0.164 
240 0.069 242 0.120 240 0.179 
256 0.073 257 0.106 255 0.183 
273 0.074 272 0.105 270 0.201 
300 0.060 308 0.116 300 0.197 
331 0.078 333 0.121 330 0.171 
358 0.067 361 0.099 360 0.171 
395 0.054 390 0.131 390 0.170 
420 0.054 1) r% 4,25 0.098 420 0.181 
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Table 3.2.3d. Subject PY 
Blackeurrant drink Water Orange juice 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mg/100 MI. 
0 0.000 0 0.000 0 0.000 
40 0.034 40 0.117 40 0.099 
65 0.106 66 0.137 65 0.126 
90 0.124 90 0.158 90 0.152 
105 0.149 105 0.161 105 0.168 
120 0.150 120 0.208 120 0.169 
137 0.128 135 0.265 135 0.170 
150 0.142 150 0.239 150 0.143 
167 0.102 165 0.211 165 0.141 
180 0.118 180 0.164 180 0.118 
195 0.122 195 0.147 195 0.109 
212 0.105 210 0.118 210 0.103 
228 0.092 225 0.107 225 0.101 
245 0.080 240 0.098 240 0.101 
261 0.070 255 0.108 255 0.091 
270 0.109 270 0.100 270 0.084 
300 0.100 300 0.127 300 0.083 
330 0.082 330 0.078 330 0.074 
360 0.080 359 0.049 360 0.077 
390 0.069 389 0.048 390 0.077 
420 0.092 420 0.050 420 0.076 
Table 3.2.3e. Subject HD 
Water Orange juice Blackcurrant drink 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 MI mg/100 ml mg/100 mi 
0 0.000 0 0.000 0 0.000 
40 0.043 41 0.062 40 0.064 
65 0.103 63 0.099 65 0.090 
90 0.103 91 0.150 90 0.109 
105 0.069 105 0.161 105 0.109 
120 0.089 120 0.165 120 0.107 
135 0.072 137 0.153 135 0.099 
150 0.080 150 0.182 150 0.099 
165 0.070 165 0.154 165 0.125 
180 0.075 181 0.156 180 0.108 
195 0.076 195 0.157 195 0.099 
210 0.067 210 0.114 210 0.085 
225 0.070 226 0.116 225 0.100 
240 0.051 240 0.143 240 0.090 
255 0.057 255 0.107 255 0.090 
270 0.063 270 0.117 270 0.087 
300 0.047 300 0.113 300 0.100 
330 0.044 330 0.131 330 0.095 
360 0.041 358 0.148 360 0.089 
390 0.035 390 0.130 390 0.080 
434 0.069 420 0.104 420 0.084 
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Table 3.2.3E Subject JT 
Water Orange juice Blackcurrant drink 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mg/100 MI 
0 0.000 0 0.000 0 0.000 
40 0.083 41 0.078 40 0.045 
67 0.095 65 0.098 65 0.071 
90 0.086 91 0.110 90 0.081 
105 0.097 106 0.090 105 0.079 
120 0.117 120 0.105 120 0.069 
135 0.098 136 0.077 135 0.089 
150 0.097 150 0.090 150 0.087 
165 0.091 165 0.101 165 0.081 
180 0.088 180 0.110 180 0.076 
195 0.091 195 0.068 195 0.073 
210 0.091 210 0.088 210 0.078 
225 0.084 226 0.083 225 0.074 
240 0.065 240 0.074 240 0.076 
255 0.075 255 0.068 255 0.065 
270 0.075 270 0.076 270 0.062 
300 0.048 300 0.058 300 0.062 
330 0.069 330 0.077 330 0.052 
360 0.062 363 0.056 360 0.050 
390 0.067 390 0.052 390 0.047 
420 0.064 419 0.066 420 0.047 
Table 3.2.3g. Subject NH 
Water Blackcurrant drink Orange juice 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mg/100 MI. 
0 0.000 0 0.000 0 0.000 
40 0.103 42 0.041 40 0.087 
65 0.140 65 0.071 65 0.087 
90 0.133 91 0.104 90 0.100 
105 0.122 105 0.108 105 0.122 
120 0.102 120 0.108 120 0.111 
135 0.116 135 0.113 135 0.111 
150 0.076 150 0.094 150 0.087 
165 0.097 165 0.072 165 0.086 
180 0.095 180 0.068 180 0.079 
195 0.070 195 0.058 195 0.086 
210 0.078 210 0.066 210 0.082 
225 0.076 225 0.062 225 0.067 
240 0.072 240 0.060 240 0.074 
255 0.045 255 0.086 255 0.075 
270 0.067 270 0.067 270 0.064 
300 0.068 300 0.076 300 0.064 
330 0.048 330 0.051 330 0.056 
360 0.050 360 0.061 360 0.072 
390 0.038 390 0.054 390 0.060 
420 0.041 420 0.063 1 420 0.065 
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Table 3.2.3h. Subject RW 
Water Blackeurrant drink Orangejuice 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
40 0.110 42 0.044 40 0.070 
67 0.139 65 0.044 65 0.106 
90 0.101 90 0.075 90 0.119 
105 0.120 106 0.083 105 0.150 
120 0.169 120 0.078 120 0.144 
135 0.150 136 0.084 135 0.120 
150 0.117 150 0.102 150 0.121 
165 0.110 165 0.103 165 0.115 
180 0.127 180 0.089 180 0.106 
195 0.127 195 0.088 195 0.094 
210 0.126 210 0.079 210 0.084 
225 0.101 227 0.086 225 0.090 
240 0.130 240 0.076 240 0.105 
255 0.105 255 0.084 255 0.101 
270 0.117 270 0.074 270 0.094 
300 0.096 300 0.074 300 0.091 
330 0.082 330 0.064 330 0.104 
360 0.117 364 0.081 360 0.076 
390 0.121 390 0.056 390 0.072 
420 0.095 420 0.060 420 0.084 
Table 3.2.3L Subject DN 
Orange juice Blackcurrant drink Water 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml meloo ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
40 0.075 40 0.025 40 0.099 
65 0.101 65 0.065 65 0.145 
90 0.143 90 0.080 90 0.141 
105 0.175 105 0.092 105 0.144 
120 0.123 120 0.116 122 0.121 
135 0.151 135 0.126 135 0.135 
150 0.154 150 0.124 150 0.122 
165 0.132 165 0.123 165 0.136 
180 0.152 180 0.110 180 0.132 
195 0.131 195 0.083 195 0.110 
210 0.114 210 0.097 210 0.128 
225 0.103 225 0.082 225 0.105 
240 0.113 240 0.089 240 0.127 
255 0.114 255 0.118 255 0.132 
270 0.098 270 0.119 270 0.134 
302 0.088 300 0.084 300 0.117 
343 0.106 330 0.096 330 0.114 
360 0.086 360 0.093 360 0.113 
390 0.085 390 0.058 390 0.111 
420 0.106 420 0.088 420 0.099 
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Table 3.2.3j. Subject JR 
Orange juice Water Blackeurrant drink 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
. 
mg/100 ml mg/100 ml mgý100 ml 
0 0.000 0 0.000 0 0.000 
42 0.070 40 0.044 40 0.029 
67 0.109 65 0.084 65 0.048 
91 0.138 90 0.119 90 0.073 
106 0.145 105 0.118 105 0.071 
121 0.144 120 0.107 120 0.088 
137 0.134 135 0.099 135 0.070 
152 0.150 150 0.117 150 0.118 
165 0.133 165 0.109 165 0.077 
181 0.150 180 0.097 180 0.076 
195 0.134 195 0.099 195 0.057 
211 0.120 210 0.096 210 0.060 
226 0.127 225 0.123 225 0.072 
241 0.126 240 0.129 240 0.064 
256 0.116 255 0.134 255 0.067 
270 0.101 270 0.102 270 0.053 
303 0.108 300 0.095 300 0.065 
334 0.068 330 0.102 330 0.056 
360 0.093 360 0.095 360 0.089 
392 0.071 390 0.087 390 0.072 
424 0.073 420 0.102 420 0.048 
Table 3.2.3k. Subject PC 
Orange juice Blackcurrant drink Water 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/100 ml mgý100 ml 
0 0.000 0 0.000 0 0.000 
40 0.138 40 0.021 40 0.144 
65 0.126 65 0.037 65 0.126 
90 0.151 90 0.127 90 0.180 
105 0.150 105 0.121 105 0.162 
120 0.181 120 0.177 120 0.137 
135 0.144 135 0.160 135 0.125 
150 0.153 150 0.175 150 0.120 
165 0.117 165 0.194 165 0.163 
180 0.155 180 0.196 180 0.145 
195 0.153 195 0.189 195 0.151 
210 0.156 210 0.148 210 0.131 
225 0.116 225 0.153 225 0.112 
240 0.155 240 0.160 240 0.112 
255 0.117 255 0.178 255 0.117 
270 0.130 270 0.181 270 0.162 
300 0.126 300 0.181 300 0.101 
330 0.120 330 0.166 330 0.132 
360 0.118 360 0.164 360 0.101 
390 0.167 390 0.168 390 0.100 
420 0.144 420 
_ 
0.148 420 0.100 
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Table 3.2.31. Subject SD 
Orange. juice Water Blackurrant drink 
time mean rise in ascorbic time mean rise in ascorbic time mean rise in ascorbic 
(min) acid above baseline, (min) acid above baseline, (min) acid above baseline, 
mg/100 ml mg/ 100 ml mg/100 ml 
0 0.000 0 0.000 0 0.000 
41 0.110 40 0.151 40 0.081 
66 0.121 65 0.204 65 0.122 
90 0.184 90 0.213 90 0.149 
105 0.194 105 0.218 105 0.191 
171 0.173 120 0.189 120 0.195 
136 0.146 135 0.177 135 0.181 
151 0.164 150 0.179 150 0.195 
165 0.133 165 0.164 165 0.197 
180 0.132 190 0.161 180 0.171 
195 0.121 195 0.160 195 0.158 
210 0.108 210 0.135 210 0.177 
226 G. 1 15 225 0.177 225 0.174 
240 0.129 240 0.13-2 240 0.188 
255 0.083 255 0.128 255 0.163 
270 0-111 270 0.107 271 0.157 
303 0.112 300 0.108 300 0.172 
3,40 0.110 330 0.102 330 0.161 
360 0-108 360 0.098 360 0.164 
391 0.098 390 0.110 390 0.150 
420 0.075 420 0.101 421 0.146 
Figure 3.2.3a shows the mean plasma ascorbic acid levels for all four subjects in the 
Pilot study, as increase in total plasma ascorbic acid over baseline in mg per 100 mf 
measured over time (in minutes). 
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3.2.4 Diet Diary Analysis. 
Figure 3.2.4a graphically represents the data in tables 6.9a, b and c that show the daily 
ascorbic acid intake of all of the subjects for periods 1,2 and 3 respectively. Figure 3.2-4a is a 
scatter graph that visually demonstrates the scatter of daily intake values. Figure 3.2.4b shows 
the mean daily intake over the whole period for each sub ect and includes the mean of all j 
subjects for all days (4.1 mg/day). 
Figure 3.2.4a. Scatter graph of all. subjects' daily ascorbic acid intake during the Main 
study 
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The efficacy of the study design could be ascertained by assessing how frequently the subjects 
achieved a target ascorbic acid intake of less than 10 mg/day. Table 3.2.4d shows the 
frequency with which each subject ingested less than 10,15 and 20 mg/day. This allows the 
data to be expressed as the percentage of days each of these target intakes was achieved (10, 
15 and 20 mg/day (Figure 3.2.4c). 
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Figure 3.2.4b The mean daily intake of ascorbic acid by the subjects during the Main 
study. 
Table 3.2.4d frequency of each subject achieving a daily intake of less than 10,15 
and 20 mg during the Main study. 
Less than 10 m g/day Less than 15 m g/day Less than 20 m g/day Subject Total days days % days % days % 
DP 87 72 82.8 84 96.6 87 100 
py 84 76 90.5 84 100 84 100 
NB 88 84 95.5 86 97.7 88 100 
NP 86 83 96.5 86 100 86 100 
HD 90 83 92.2 89 98.9 90 100 
NH 90 84 93.3 90 too 90 too 
JT 84 82 97.6 84 100 84 100 
RW 64 61 95.3 63 98.4 64 too 
PC 28 21 75.0 27 96.4 27 96.4 
JR 89 76 85.4 88 98.9 89 100 
SD 90 85 94.4 90 100 90 100 
DN 90 84 93.3 90 100 90 100 
_ Mean 91.9 99.0 99.7 
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Figure 3.2.4c Graph of table 3.2.4d, showing the frequency (%) with which each subject 
achieved a daily intake of less than 10,15 and 20 mg during the Main study 
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3.2.5 Urine analysis 
3.2.5.1 Hippurie acid 
Hippuric acid was determined by HPLC using the method described in section 2.3.3. The 
mean peak area values given in table 3.2.5.1a have been divided by 100,000 for clarity, and 
need to be multiplied back again for the calculation of hippuric acid concentration given in 
appendix 6.10.1. 
Table 3.2.5.1a. The hippuric acid excreted in subjects' urines in the Main study 
Subject Drink Mean peak area, duplicate Urine volume Hippuric acid mg /24 injections (arbitrary units) over 24 hours hours of urine excreted. 
blackcurrant 136 1680 76 
DP orange juice 313 1360 142 
water 257 1210 104 
blackcurrant 123 1210 50 
NB water 369 1570 193 
orange juice 312 1690 176 
blackcurrant 361 1675 202 
NP orange juice 294 1525 150 
water 445 970 144 
blackcurrant 495 800 132 
Py water 276 880 81 
orange juice 632 1010 213 
water 89 1960 58 
HD orange juice 151 2280 115 
blackcurrant 128 1180 51 
water 376 1640 206 
JT orange juice 707 1860 438 
blackcurrant 245 3750 307 
water nd nd 
NH blackcurrant 165 1850 102 
orange juice 228 1900 144 
water nd nd nd 
RW blackcurrant 534 1940 345 
orange juice 622 1540 319 
orange juice 58 1300 25 
DN blackcurrant 137 1400 64 
water 222 780 58 
orange juice 112 1650 62 
JR water 124 900 37 
blackcuffant 278 885 82 
orange juice 62 1250 26 
PC blackcuffant nd 1150 
water nd nd 
orange ju ice 144 1220 59 
SD water 147 1900 93 
blackcuffant 44 1200 18 
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3.2.5.2 NMR analysis 
The urines were prepared for nuclear magnetic resonance (NMR) analysis as described 
in section 2.3.4. Figure 3.3.5.2 shows an example of the trace produced by NMR. The data in 
tables 3.2.5.2a, b and c show the signal areas of formate (the internal standard) and the region 
of aromatic protons. These values are the areas under the curves from the regions 8.5-8.1 and 
8.1-6.5 ppm. respectively. The formate and aromatic signal areas given in tables 3.2.5.2a, b 
and c have been divided by 100,000 for clarity, and need to be multiplied back again for the 
calculation of aromatic to formate signal area ratio given in appendix 6.10.2. These ratios can 
be used to compare the aromatic proton loading of all of the urine samples. The larger the 
ratio, the greater the number of aromatic protons in the urine /24 hour excretion period. 
Figure 3.2.5.2 showing the NMR spectrum of the urine of subject 
supplemented with blackcurrant drink. (The y-axis (response) is measured 
units and is not shown) 
Formic acid (8.5-8.1 ppm) 
DN while 
in arbitrary 
10 80 
PPM 
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Tables 3.2.5.2a, b and c, showing the NMR signals for aromatic protons in urines for 
each subject after supplementation with a) blackcurrant drink, b) orange juice and c) 
water respectively. 
a) Blackcurrant drink 
Subject formate signal 
area 
aromatic 
signal area 
aromatic area 
formate area 
urine 
volume 
Oitres) 
(aromatic/formate) 
x urine volume 
DP 634 455 0.72 1.680 1.208 
NB 439 42 0.10 1.210 0.116 
NP 1402 43 0.03 1.675 0.051 
py 931 547 0.59 0.800 0.470 
HD 964 433 0.45 1.180 0.530 
JT 804 568 0.71 3.750 2.646 
NH 929 222 0.24 1.850 0.442 
RW 28 49 1.79 1.940 3.468 
DN 965 189 0.20 1.400 0.275 
JR 643 1038 1.61 0.885 1.428 
PC 396 1203 3.04 1.150 3.493 
SD 908 246 0.27 1.200 0.325 
b) Orange juice 
Subject formate signal aromatic aromatic area urine (aromatic/formate) 
area signal area formate area volume x urine volume 
(litres) 
DP 1300 380 0.29 1.360 0.398 
NB 466 967 2.08 1.690 3.512 
NP 641 348 0.54 1.525 0.827 
Py 931 2237 2.40 1.010 2.426 
HD 896 783 0.87 2.280 1.992 
JT 630 1057 1.68 1.860 3.123 
NH 1020 996 0.98 1.900 1.855 
RW 641 287 0.45 1.540 0.690 
DN 515 655 1.27 1.300 1.654 
JR 486 155 0.32 1.650 0.526 
PC 898 402 0.45 1.250 0.560 
SD 901 782 0.87 1.220 1.059 
0 Water 
Subject formate signal 
area 
aromatic 
signal area 
aromatic area 
formate area 
urine 
volume 
(litres) 
(aromatic/formate) 
x urine volume 
DP 631 484 0.77 1.210 0.927 
NB 524 925 1.77 1.570 2.773 
NP 542 1156 2.13 0.970 2.070 
py 736 1214 1.65 0.880 1.451 
HD 862 496 0.58 1.960 1.128 
JT 637 447 0.70 1.640 1.151 
NH nd nd 
RW nd nd 
DN 360 481 1.34 0.780 1.042 
JR 449 617 1.37 0.900 1.236 
PC nd nd 
SD 1259 1170 0.93 1.900 1.767 
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3.2.5.3 HPLC analysis 
The urine samples were analysed for anthocyanins under six different conditions with 
detection at 530 nm, as specified in section 2.3.2.3. To summarise the anthocyanins found by: 
Conditions A are non-native, unconjugated. 
Conditions B are native and non-native, unconjugated,. 
Conditions C are non-native and conjugated with a sulphate residue. 
Conditions D are non-native and conjugated with a P-glucuronate residue. 
Conditions E are native and non-native conjugated with a sulphate residue. 
Conditions F are native and non-native conjugated with a P-glucuronate residue. 
The tables 3.2.5.3a to I tabulate the peaks found by IIPLC of each urine sample 
analysed under the six different conditions. Within subject comparisons were then made to 
investigate the different kinds of anthocyanins (if any) found in the urines after the volunteer 
had consumed the three different drinks. Further, comparisons can be made across the 
subjects to find any pattern in the type and number of anthocyanins in each urine found under 
the different conditions of analysis. All dilution steps and the urine volumes have been 
accounted for when considering the peak sizes. (Rt = retention time (minutes), peak area is 
measured in arbitrary units). 
Table 3.2.5.3a Subject DP 
Analvtical conditions 
A B c D E F Drink Rt Area Rt Area Rt Area Rt Area Area Rt Area Rt 
(min) (min) (min) (min) (min) 
_ 
(min) 
48.8 5373 34.1 66649 85.3 1680 41.6 21141 B'crnt 34 9 4980 85.6 2231 46.8 66058 drink . 54.3 4959 49.6 32054 
43.8 5236 34.6 2633 84.5 838 
45.2 12058 85.3 1262 
Orange 46.4 6563 85.6 2236 
j uice 46.9 1792 
50.2 1792 
53.1 3998 
51.3 17538 33.0 6413 84.4 939 
33.7 3165 84.7 2028 
Water 48.9 3751 
81.7 1437 
83.7 2154 
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Table 3.2.5.3b Subject NB 
Analvtical conditions, 
Drink A B C D E F 
Rt Area Rt Area Rt Area Rt Area Rt Area Rt Area 
(min) 
_ _(min) - 
(min) (min) (min) (min) 
40.1 2420 33.0 8843 83.9 445 _ 
Blcrnt 45.4 3753 33.7 1573 84.6 450 
drink 47.0 3712 48.6 3485 84.9 1476 
53.3 2955 
33.1 4503 84.1 540 
33.7 1922 84.8 1557 
Water 48.4 12089 85.1 2292 
82.3 396 
83.4 2261 
45.0 52498 33.0 15379 37.6 18367 35.7 46928 46.6 27459 
46.1 13591 33.8 6523 47.0 5523 45.9 28798 48.1 37031 
46.7 69898 43.9 9687 80.4 2156 47.5 45765 
48.5 4316 44.5 155 81.7 1366 
49.9 28328 48.4 46069 82.7 22639 
55.6 5719 84.3 764 
Orange 71.8 8396 85.0 6469 
juice 73.4 4779 85.4 4590 
75.4 5070 86.5 28345 
76.6 32313 
80.3 5232 
81.9 41621 
83.0 1366 
83.8 1129 
Table 3.2.5.3c Subject NP 
Analvtical conditions 
Drink A B c D E F 
Rt Area Rt Area Area Rt Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) (min) 
B'crnt 46.7 13464 33.9 1642 84.1 4817 
drink 48.6 5940 84.2 1916 50.2 18381 84.5 2312 
46.1 12789 33.7 5704 84.3 10638 
Orange 47.6 57166 35.1 2324 83.9 763 j nice 84.1 1513 
84.7 775 
22.9 5038 33.9 10177 83.7 551 
46.6 5416 35.1 1653 84.2 372 Water 48.4 2623 49.8 5362 84.6 4179 
50.1 9296 84.2 5102 
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Table 3.2.5.3d Subject PY 
Analytical conditions 
Drink -A 
B C D E F 
Rt Rt Rt Rt Rt Rt Area Area Area Area Area Area (min) (min) (min) (min (min) (min) 
39.3 2803 34.0 4979 34.5 7872 
47.2 5941 35.3 1619 83.8 432 
50.5 5894 49.9 5558 84.4 294 
Blernt 50.7 9314 77.2 2208 84.6 611 
drink 81.8 806 84.8 1376 
82.6 518 
84.3 3379 
84.9 2006 
47.5 9215 34.7 11028 34.5 13147 
50.8 8314 36.0 2295 84 7 426 Water . 52.2 10507 84.9 891 
80.5 4129 85.3 1426 
44.9 3159 34.9 9959 34.6 10860 47.7 19933 47.2 15473 
45.2 2626 36.1 3414 81.5 549 
46.9 28904 52.1 9272 82.3 1972 
Orange 53.1 1481 85.8 4028 83.3 541 
juice 86.1 3369 83.5 622 
88.2 8379 85.1 226 
85.4 1050 
86.0 15865 
Table 3.2.5.3e Subject HD 
Analvtical conditions 
A B c D E D i k r n Rt Area Rt Area Rt Area 
Rt Area Rt Area 
Rt Area 
(min) (min) (min) 
-ýMin) 
(min) 
_Crm 
n) 
49.6 6162 34.2 2595 Water 52.9 4931 
45.3 11327 34.7 7415 86.1 2590 
45.6 3684 47.5 19964 86.2 739 Orange 46.4 7606 53.7 5600 j uice 52.0 4223 82.1 5217 
53.1 3653 85.2 1021 
B'crnt _ 28.2 6141 34.8 982 
drink 82.6 1525 
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Table 3.2.5.3f Subject JT 
Analvtical conditions 
Drink A B C D E F 
Rt Area ki Area Rt Area Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) (min) 
35.0 4107 
Water 36.8 1856 
54.7 2775 
83.2 1647 
Orange 46.0 17718 35.3 10528 
juice 37.2 3616 
55.6 9776 
Blcrnt 48.8 11273 35.7 14070 
drink 
Table 3.2.5.3g Subject NH 
Analvtical conditions 
Drink A - 
B c D E F 
Rt Area Rt Area Rt Area Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) (min) 
Water No data 
B'crnt 50.9 14523 33.3 10700 
drink 34.4 1672 
84.4 1835 
Orange 48.7 5996 33.2 5806 51.1 33653 
juice 1 84.5 1170 
Table 3.2.5.3h Subject RW 
Analytical conditions 
Drink A B c D E F 
Rt Area Rt Area Rt Area Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) in) 
Water No data 
47.2 17561 32.6 13308 50.1 28231 
B'crnt 33.9 8854 
drink 49.7 14418 84.4 3065 
84.8 10173 
19.3 8245 32.0 1454 52.0 3289 
Orange 46.3 10309 33.4 2569 46.9 46200 49.1 2519 j uice 50.2 17390 84.4 1632 
53.1 5639 84.8 5489 
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Table 3.2.5.3i Subject DN 
Analvtical conditions 
A B c D E F D i k - r n Rt Area Rt Area Rt Area Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) (min) 
46.1 24560 31.5 1794 84.7 1529 
Orange 47.2 15041 32.9 1290 84.8 650 
j Uice 47.8 5049 80.6 4467 
49.6 3692 83.2 1700 
44.6 6695 33.1 5337 83.3 750 
B'crnt 46.1 5617 34.5 3427 84.9 2016 
drink 47.7 9974 48.7 9878 
49.6 4494 
45.8 8543 32.7 1710 
Water 47.4 5140 34.0 1133 
48.7 4256 
Table 3.2.5.3j Subject JR 
Analvtical conditions 
A B C D E D k _ rin Area Rt Area Rt Area Rt Area Rt Area Rt Rt Area 
(min) (min) (min) (min) (min) (min) 
46.2 22051 84.2 2911 83.6 726 
Orange 47.3 12557 85.3 3049 
juice 47.8 33446 
51.2 15084 
42.1 3740 33.1 2837 59.1 1706 20.0 27972 
47.8 6979 34.4 1631 84.8 900 47.2 13298 Water 49.6 3116 49.3 5281 85.6 1019 50.7 19303 
83.5 1278 86.4 1504 
28.3 4400 32.9 4149 86.0 1218 
32.2 3349 34.2 2078 86.9 1405 Blcrnt 39.3 5083 49.2 3324 drink 47.3 6400 83.5 1034 
50.7 12486 
Table 3.2.5.3k Subject PC 
Analytical conditions 
Drink 
Rt 
A 
Area Rt 
B 
Area 
I 
Rt Area Rt Area Rt Area Rt Area 
(min) (min) 
-(min) _ 
(mio 
_ 
(inin) (min) 
Orange 84.6 425 84.9 745 
juice 84.8 540 
B'crnt 
49.7 3652 33.0 5962 84.9 741 
drink 
84.2 695 
84.5 1224, 
Water No data 
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Table 3.2.5.31 Subject SD 
Analvtical conditions 
A B c D E F D i k r n Rt Area Rt Area Rt Area Rt Area Rt Area Rt Area 
(min) (min) (min) (min) (min) (min) 
Orange 47.3 25530 84.7 830 85.0 420 
j uice 84.9 1201 
85.3 2845 
86.3 761 
Water 47.9 6832 32.7 6984 85.0 1999 
49.7 5559 84.9 1322 
85.1 935 
85.4 1809 
Blcrnt 27.5 2810 84.9 686 
drink 46.9 4903 85.2 763 
53.1 3938 , 85.5 1080 
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4. Discussion 
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4.1 The dietary regime, subjects' health and well being 
The original target was for the subjects to eat a diet supplying less than 10 mg of 
ascorbic acid per day, i. e. less than 5% of the ascorbic acid in the beverage. The results of the 
Pilot study shown in table 3.1.3a, demonstrate that over the 27 days four subjects averaged a 
daily ascorbic acid intake of just 4.3 mg per day proving that the regime worked very well. 
All subjects achieved an average intake below 10 ing per day. Further, the frequency with 
which the subjects achieved a daily intake of less than 10 mg per day during the Pilot study 
was 88%, with subject RW being the best subject, achieving the target 96% of the time. The 
subjects felt that while the first few days of the regime had been difficult, it became easier and 
the diary was extremely helpful in achieving the aim. They also observed the convenience of 
its small physical size while containing all necessary information clearly and unambiguously. 
The design of the regime and the diet diaries therefore remained unchanged for the Main 
study. 
During the Main study, the average intake for the 12 subjects over their three periods 
of 31 days was 4.1 nig per day, with the worst average being 6.6 mg per day (by DP) and the 
best being NP at only 2.4 mg per day (results section 3.2.4). The greater amount of data 
collected in the main study allowed better evaluation of the regime. By looking at the 
frequency with which the subjects achieved targets of 10,15 and 20 mg per day an assessment 
of the success can be made. In table 3.2.4d (graph 3.2.4c), overall the target of less than 10 
mg ascorbic acid per day was achieved 91.9% of the time, slightly improving on the Pilot 
study. It could then be said that this regime is nearly 92% successful at 10 Mg per day. 
However, when the target was 15 mg per day, achievement was 99.0% and 99.7% at 20 mg 
per day. 
In the literature, only one study (Omaye et aL 1986, though republished in a different 
format a year later (Jacob et aL 1987)) has published and used a dietary regime. This study 
used 11 subjects spending 14 weeks in a metabolic unit who were given all their food as part 
of a 7-day prescripted diet that gave on average 4.9 mg of ascorbic acid per day. Our regime 
allows the subjects to be free living and to achieve an average daffy ascorbic acid intake of 
just 4.1 mg per day. Also, our design is cheaper, simpler and less restrictive, and has been 
proven to be effective for over 90 days (13+ weeks). In addition our subjects were male 
volunteers who had little prior knowledge about foods that contain ascorbic acid or how to 
complete a diet diary. As with all such studies the validity of this regimen is subject to the 
reliability of the reporting of food consumed (nature and quantity) and of the validity of the 
database for the food consumed. Since the desired depletion was achieved by each volunteer 
on each occasion any mis-reporting, for whatever reason, is of no significance with regard to 
the data obtained and their interpretation. 
Another important aspect of the study was the subjects' health and well being. If the 
regime had made them ill or sick or caused significant physical or mental stress then the 
design would have required review. No sickness that required medication or treatment 
by a 
health professional was recorded by any of the subjects. The well-being of the subjects could 
be measured by the observation that three of the four subjects (NB, RW and 
DP) who 
participated in the Pilot study enlisted for the Main study. 
The subjects also reported having had no apprehension or objections 
in the way the 
blood sampling was carried out, or of the overall design of the study. 
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4.2 The Pilot study 
The effectiveness of the study design can be discussed in reference to its aims. These 
can be split into those concerning the dietary regime and subject health and well-being (discussed previously in section 4.1), those related to the white cell sampling (section 4.2.2) 
and those concerning plasma sampling (section 4.2.3). 
4.2.2 Pilot study white cell ascorbic acid levels 
The aims of the white cell sampling were to measure the depletion and repletion of leukocyte ascorbic acid and therein to produce data that would allow the comparison of leukocyte ascorbic acid repletion kinetics after supplementation with ascorbic acid in different beverages. The results are found in section 3.1.1. 
The depletion curves were far from linear, and did not always follow a continuous downward trend ( tables 3.1.1 a and b). Compared with published data, the values found for leukocyte ascorbic acid in the Pilot study were higher than expected. Jacob et aL (1994) give 
4normal' values for mixed leukocytes and mononuclear leukocytes as 20-53 gg and 25-44 gg 
per I 08cells respectively. Earlier work by Omaye et aL (1987) found in six healthy males an 
average of 3.0 and 15.8 ýtg ascorbic acid per 108polymorphonuclear and mononuclear cells 
respectively. The results published in this thesis in table 3.1.1a show that after 7 days 
supplementation the subjects' mononuclear leukocytes have ascorbic acid concentrations of 
60-154 gg per 108 mononuclear leukocytes and 12.8-84.6 gg per 108 polymorphonuclear 
leukocytes. 
Firstly, there appears to be an error in the reference ranges of Jacob et aL (1994). The 
results in this thesis show that mononuclear leukocytes consistently have higher ascorbic acid 
levels than polymorphonuclear leukocytes. Both Omaye et al. (1987) and Jacob et al. (1994) 
observe that mononuclear cells contain some two to threefold higher ascorbic acid than 
polymorphonuclear cells. These observations then raise the question as to why do Jacob et al 
(1994) find higher ascorbic acid levels in mixed leukocytes (mononuclear and 
polymorphonuclear leukocytes) than in mononuclear leukocytes alone? 
This inconsistency aside, the levels and ranges for white cell ascorbic acid are far from 
reliably established and there are reasons in this thesis' methodology that can explain the 
relatively high ascorbic acid levels. The main reason is that a vital step in the white cell 
isolation protocol is to produce a homogenous suspension of white cells from which an 
aliquot is taken for counting while the remainder is acidified for ascorbic acid analysis. If the 
white cells are clumped together and resist being dispersed by vortexing or the action of a 
repeated pipetting then the aliquot taken for counting will probably take less cells per volume 
than is truly representative of the suspension since the clumps will settle to the bottom of the 
tube. Therefore after the calculations were carried out the ascorbic acid titre would be high. 
This was certainly the case in the Pilot study, when techniques were continually being refined. 
The mononuclear leukocyte fraction was found to be especially clumpy, due to platelet 
contamination. This problem was largely solved by improving the mononuclear leukocyte 
isolation procedure to reduce platelet contamination (section 4.3.2). 
The inconsistent fall and rise of white cell ascorbic acid levels seen in the Pilot study 
were thought to be due to variable degrees of clumping of the white cells that was addressed 
and reviewed before the Main study started. From the diet diaries there were no indications 
that these unexpected results were due the subjects mistakenly ingesting large doses of 
ascorbic acid. From the point of view of the Pilot study achieving its aims, all subjects did end 
the washout period at lower levels of ascorbic acid in white cells than at the start of the 
period, and all subjects showed a trend of an increase in white cell ascorbic acid after and 
112 
during supplementation. The washout period appeared to be long enough to deplete the levels 
of ascorbic acid in the white cells and the repletion could be measured and used in 
comparison with other drinks and other subjects. Therefore the aims of the Pilot study for 
white cell sampling were largely achieved. 
4.2.3 Pilot study plasma ascorbic acid levels 
The aim of taking plasma samples in the Pilot study was to develop a sampling 
procedure to obtain data of the absorption kinetics of ascorbic acid that could be used to 
compare the rate and amount of absorption of ascorbic acid from other drinks in the Main 
study. 
Table 3.1.2a shows the plasma ascorbic acid levels of the four subjects for 450 
minutes after their first drink of ascorbic acid in water (plotted in figure 3.1.2a). Firstly, the 
baseline ('time zero') levels of the subjects of 0.160,0.171,0.197 and 0.211 mg per 100 ml 
plasma are, according to literature values (Jacob et al. 1994), borderline deficient. While it is 
accepted that plasma ascorbic acid levels reflect only recent ascorbic acid intake, these low 
values show that the washout period is sufficient to deplete the plasma level as required for 
the study. 
At 270 and 300 minutes the ascorbic acid levels are seen to rise. This is unexpected 
and unwelcome, as only one rise is expected and a 'two step' absorption phase would make 
comparisons more difficult and less reliable. However, it was most probably due to the 
subjects having a meal at 240 minutes after supplementation- This meal, though very low in 
ascorbic acid, would certainly affect the plasma since splanchic and hepatic flow would be 
greatly increased and would interfere with the decline of ascorbic acid as it is transported into 
cells and metabolised by the body. It was decided therefore that during the Main study the 
subjects would have to fast until the end of the day after the last plasma sample had been 
taken. 
It was required that the plasma-sampling period be long enough to see the appearance 
of a homeostatic plateau in plasma ascorbic acid levels and to show in sufficient detail the rate 
and extent of the initial rise over approximately the first two hours. From these results in the 
Pilot study, it was decided in the Main study not to take the last sample at 420 minutes as the 
plateau had already been reached and it meant the subjects would not have to fast quite so 
long. The deletion of this sampling point, in combination with the improved procedure for 
preparing white cells, permitted a reduction in the volume of blood required. This saving was 
utilised to introduce more sampling points during the first two hours post-supplementation 
thus allowing a better monitoring of the early rate of repletion. In examining the data from the 
Pilot study it became clear that the reliability of the baseline value was crucial in achieving a 
sound interpretation of events post-supplementation. Accordingly, it was decided that in the 
Main study two baseline data points should be taken since the baseline is the most important 
sample point and it must be accurate and reliable. 
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4.3 The Main study 
4.3.1 Study methodology and study design 
Of the 12 subjects that started the study 11 completed it. The 12th, subject PC, dropped 
out four days from the end of the last period. Missing data points and subject PC are discussed 
in 4.3.3. There were no major problems during the study, and this demonstrated that one 
person can co-ordinate a 12 person, free-living, long-term ascorbic acid feeding study with 
good planning and good execution. The decision to stagger the three groups so that they 
started one week apart meant that it was possible to host the plasma sampling day at the 
RSCH CIU with four subjects at a time, and that for any given white cell sampling day a 
maximum of eight samples were taken which was approximately the limit for one person to 
do sensibly in one day. The successful completion of the study also demonstrates that long- 
term and relatively inexpensive ascorbic acid feeding studies can be carried out on free-living 
subjects who do not require extensive knowledge about food and nutrition. 
Another important aspect of the study was that it looked at the depletion and repletion 
of both polymorphonuclear and mononuclear leukocytes. All previous studies that looked at 
these phenomena used either a mixed leukocyte population, mononuclear leukocytes only or 
the 'buff-y-layer' (white cells and platelets). None of these are ideal, and it is because the 
isolation of white cell fractions is so time-consuming and difficult that many workers use one 
of these non-ideal indices. This thesis then also describes in detail a procedure to isolate both 
cell types and validate the homogeneity of each fraction (section 3.2.1). 
4.3.2 Validation of the improved mononuclear leukocyte isolation procedure 
The improved method meant that less blood was required for white cell analysis and 
the volume spared could be used to decrease the intervals and increase the sampling rate. 
More importantly, the improved protocol reduced the number-and seemingly the activity- 
of the platelets that contaminate the mononuclear leukocyte fraction. Not only do the platelets 
contain ascorbic acid that was not specifically quantified in this study, but their propensity to 
clump the mononuclear leukocytes caused the ascorbic acid titre to be overestimated by 
underestimating the number of cells in the sample. Figures 3.2.1a and b show how the 
improved method isolated many more mononuclear leukocytes relative to the number of 
platelets in a given volume. 
The range of repleted white cell ascorbic acid levels in the Main study (20.9-73.2 ýtg 
per 108 mononuclear leukocytes and 5.9-19.6 ýtg per 108polymorphonuclear leukocytes from 
days 28 and 31 of tables 3.2.2a, b and c) are quite similar to the most recent published values 
of 20-53 ýtg per 108 mononuclear leukocytes and 25-44 ýIg per 108 polymorphonuclear 
leukocytes (Jacob et aL 1994). Therefore the improved mononuclear leukocyte procedure has 
improved the white cell ascorbic acid values found in the Main study compared with 
unexpectedly high values found in the Pilot study (60-154 ýtg per 108 mononuclear 
leukocytes and 12.8-84.6 ýtg per 108 polymorphonuclear leukocytes). 
4.3.3 Subject PC and missing values (plasma, white cell, urines and diaries) 
The largest problem of the whole study was the behaviour of subject PC. His dietary 
record for the first period was the poorest in that he only succeeded in having a daily ascorbic 
acid intake of less than the target 10 mg on three days out of four, 75% success (table 3.2.4d). 
He failed to produce dietary records for the second and third periods and when challenged 
failed to produce them. Also, he did not provide the last three white cell samples while 
supplemented with water, and was suspected of having a breakfast meal when he should have 
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been fasting. He also failed to provide a urine sample for the period when supplemented with 
water. He was not recompensed for his involvement in the study, but his data were still used 
in statistical analysis, as they did not vary significantly from the other subjects. 
Subject RW endured a close personal bereavement and so although he still completed 
all three plasma sampling days, white cell data for his period while receiving the ascorbic acid 
in water were not collected. He was therefore asked only to undergo the dietary regime for 4 
days rather than 21 days before he received the ascorbic acid in water and the plasma samples 
were taken (see table 6.9a, appendix). He was recompensed for his involvement in the study 
pro rata. 
Stewart Edmed was ill for one of the sampling days. This meant that during the period 
in which the orange juice was given some scheduled blood samples were not taken. These 
were on day 31 (subjects DN, JF, PC and SD) and day 8 (subjects DP, NP and PY). Other 
scheduled samples (PY, blackcurrant, day 21; PY, water, day 8; HD, water, day I and NH, 
water, day 1) could not be taken due to faulty heparin blood tubes that failed to prevent the 
blood sample clotting. Once clotted, the cells could not be isolated with the current procedure. 
In total, 92% of white cell samples were taken. 
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4.3.4 White cell ascorbic acid levels 
As stated in section 2.4, statisticians of the Statistics Department of the University of Surrey carried out statistical analyses of the data. In discussions with Mr Peter Williams, 
Statistical Consultancy Officer and Professor of Statistics Martin Crowder, the following 
analyses were carried out. Upon their advice, Area under curve values (AUC), popular (in 
mathematical terms) in previous studies, were not used since the plasma and white cell curves 
were incomplete and there were not enough data points to provide reliable statistical analysis (Williams, personal communication). Therefore AUC comparisons were not used. 
4.3.4.1 Effect of vehicle on ascorbic acid repletion rate of white cells 
The question posed was "does the vehicle in which the ascorbic acid was presented (blackcurrant drink, orange juice or water) influence the rate at which either the 
polymorphonuclear or mononuclear leukocytes regain their ascorbic acid contentT 
For each type of white cell, each pair of vehicles was compared. In each case the null hypothesis was that there would be no difference and the statistical analysis sought to prove 
otherwise. This was done using the Student's two-tailed Mest. The Mest determines whether 
two samples' means are distinct. (If there are outlying data points the Student's Mest has a 
general tendency to find a significant difference when there is not in fact any true difference. ) 
Table 4.3.4.1a Effect of vehicle on ascorbic acid repletion of white cells after ten days of 
supplementation 
Polymorphonuclear 
B'currant 
drink n= 12 
Orange 
juice n=12 
Mononuclear leuko 
Water B'currant Orange Water 
n=ll 
I 
drink n=12 juice n=12 n--l 1 
B'currant drink 
Orange juice p=0.894 p=O. 105 
Water p=O. 128 p=O. 168 p=0.054 p=0.613 
Table 4-33.4.1a shows that after ten days of treatment, there were no significant differences between any 
vehicle for either cell type (all p values were >0.05), although blackcurrant was associated with an almost 
(p=0.054) significantly greater rate of repletion of mononuclear leukocytes than water after ten days. 
Table 4.3.4.1b Effect of vehicle on ascorbic acid repletion of white cells after seven days 
of supplementation 
Polymorphonuclear leukocytes 
B'currant Orange Water 
drink n-- 12 _juice n--12 n=l 
I 
Mononuclear 
B'currant Orange Water 
drink n= 12 juice n= 12 n-- 11 
B'currant drink 
Orange juice p=0.436 p=0.062 
Water p=O. 149 p7O. 443 p=O. 127 p=0.490 
Table 4.3.4.1b shows that after seven days of treatment, there were no significant 
differences between any vehicle for either cell type (an p values were >0.05) 
The analyses at I and 4 days were carried out and also showed no significant 
differences. However, the statistician again felt having so few data points would reduce the 
efficacy of the test results (Williams, personal communication) and so the analyses after I and 
4 days are not included here. 
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4.3.4.2 Relationship between ascorbic acid con cen tration on entry to study and ascorbic 
acid concentration achieved at end of supplementation 
In all cases, ascorbic acid concentrations rose as a result of supplementation regardless 
of the vehicle used. However, as illustrated in tables 3-2.2a, b and c, some volunteers had 
lower white cell levels of ascorbic acid when the supplementation began, and it seemed 
appropriate to ascertain whether a constant ascorbic acid dose produced a near constant increase in white cell ascorbic acid levels. Simply put, if the individual began with a higher 
leukocyte ascorbic acid baseline did he finish with a higher final leukocyte ascorbic acid level. 
Investigation of this relationship was carried out using Pearson's Correlation of 
Coefficients test, a robust test of correlation of normally distributed data. The Pearson test 
returns the Pearson product-moment correlation coefficient, r, a dimensionless index that 
ranges from -1.0 to 1.0 inclusively and reflects the extent of a linear relationship between two 
data sets. A value at or near zero shows no correlation, while a value at or near 1.0 or -1.0, 
shows a near perfect correlation). The square of the r value gives an estimate of how much of 
the total variation is due to the relationship between the dependent and independent variables. 
So for example, if the r value is 0.99, then (0.99)2=0 . 9801, or 98% of the variation can be 
explained by the relationship, leaving only 2% to other factors including chance. The p value 
then shows whether the correlation is significant. 
The test was carried out for all treatments together for both mononuclear and 
polymorphonuclear leukocytes and for each treatment individually. Table 4.3.4.2a shows the 
significance (p value) and the Pearson product-moment (r value) for each baseline and final 
level relationship. Figures 4.3.4.2a and b visually show the relationships of all mononuclear 
leukocytes and all polymorphonuclear leukocytes respectively. 
Table 4.3.4.2a The relationship between baseline and final levels of ascorbic acid in 
white cells. 
Significance, p and r value 
Polymorphonuclear leukocytes Mononuclear leukocytes 
All vehicles n=29 p=: O. 703, r--0.074 p==0.886, r--0.028 
B'currant drink n-- 11 p=0.511, r--0.222 p=0.035, r--0.636 
Orange juice n=8 p=0.815, r--0.100 p=0.243, r--0.467 
Water n= 10 p=0.630, r--0.175 p=0.915, r---0.039 
As table 4.3.4.2a shows, only when the dose of ascorbic acid was in the blackcurrant 
drink was a consistent increase in mononuclear leukocyte ascorbic acid levels produced for 
each volunteer. It is hardly surprising to find that the baseline level and final level would be 
related in some way, but it is a little surprising that the relationship is not always evident and 
then weak at best (since only 40%--ý0-636)2=0 . 404--of the variation is explained). Factors that may confound a simple relationship include a saturation of transport 
mechanisms into the cells and/or possibly even a saturation of stores, both of which would 
result in lower than expected final levels. 
The proposed mechanism for the uptake of ascorbic acid into cells such as 
mononuclear leukocytes is one of extracellular oxidation to dehydroascorbic acid and then 
preferential translocation across the membrane where it is quickly reduced back to ascorbic 
acid. It is of interest to note that blackcurrant juice contains substances such as anthocyanins 
that have been shown to have very strong antioxidant activity in vitro. However, any possible 
involvement of these in the uptake of ascorbic acid by the mononuclear cell cannot be 
supported or refuted by the data in this study. 
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Figure 4.3.4.2a. The relationship between baseline ascorbic acid and final ascorbic acid 
level in mononuclear leukocytes 
WBC plot : fned slope (over days 21-3ý vs. baseline (at day 21) 
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Figure 4.3.4.2b. The relationship between baseline ascorbic acid and final 
ascorbic acid level in polymorphonuclear leukocyte 
WBC plot : fitted slope (over days 21-31) vs. baseline (at day 21) 
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4.3.4.3 Effect of vehicle on ascorbate depletion 
It was considered useful to enquire whether the vehicle in which the ascorbic acid was 
presented had any influence on the post-supplementation decline in ascorbic acid content in 
white cells. This question was posed only after the study had been designed, and it may be 
that the design was not ideal for this purpose. However, the design was considered adequately 
robust for this purpose. This relationship was investigated by using the last data point of one 
supplementation period and the first data point of the next to estimate the mean daily decline 
in ascorbate for both mononuclear and polymorphonuclear leukocytes. Statistical evaluation 
was made by Students two-tailed Mest. The mean daily drop in polymorphonuclear leukocyte 
and mononuclear leukocyte ascorbic acid levels after the end of supplementation was 
calculated and compared between treatments and the results are shown in table 4.3.4.3a. 
Table 4.3.4.3a. The effect of vehicle on the post-supplementation rate of depletion of 
white cell ascorbic acid stores. 
Polymorl 
B'cuffant 
ýdrink n=8 
lear Mononuclear leuko 
Orange Water 
iuice n=8 n--7 
Orange Water B'currant 
iuice n=8 n=7 
I 
drink n=8 
B'currant drink 
Orange juice p=0.851 p=0.646 
Water P=o. 059 p=O. 173 p=0.582 p=0.949 
Therefore, as table 4.3.4.3a shows, the levels maintained after each supplementation 
period were independent of vehicle. However, during these periods between supplementation 
the volunteer 'relaxed' and reverted to a 'free-living' status. Diets were neither controlled nor 
monitored and may have varied substantially in many respects including, crucially, ascorbic 
acid content. This may account for the lack of a significant and consistent relationship. Had 
the question been thought of earlier, then in principle the protocol could have been altered. It 
might, however, have been less acceptable to the volunteers and then have prejudiced 
compliance. 
4.3.5 Plasma ascorbic acid levels 
4.3.5.1 Effect of vehicle on the rate of increase in the concentration of plasma ascorbic 
acid 
The question posed was, "Does the vehicle in which the ascorbic acid is presented 
influence the rate of increase in plasma ascorbic acid concentration over the initial 65,90 and 
105 minutes? " The question was addressed by fitting a linear regression to the data points at 
0,40 and 65 minutes (plus 90 and 105 minutes as appropriate) to estimate the gradient for 
each subject for each drink. The mean of the gradients were then compared by Student's two- 
tailed t-test. The greater the gradient the faster the increase in plasma ascorbic acid. (All 
comparisons had n=: 12). The results are shown in tables 4.3.5.1 a, b and c. 
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Table 4.3.5.1a. The effect of vehicle on the rate of increase in plasma ascorbic acid 
concentration over 65 minutes 
Drink mean gradient (mg/100ml/min) 
(and standard error) 
B'currant drink 
P<0.001 
P<0.001 
Orange juice 
B'currant drink 
Orange juice 
Water 
0.0011(-+0.0001) 
0.0018(-+0.0002) 
0.0021(-+0.0006) p=0.239 
Table 4.3.5.1b. The effect of vehicle on the rate of increase in plasma ascorbic acid 
concentration over 90 minutes 
Drink mean gradient (mg/100ml/min) B'currant drink Orange juice 
(and standard error) 
B'currant drink 0.0011(+-0.0001) 
Orange juice 0.0017(+-0.0003) p=0.042 
Water 0.0016(±0.0001) p=0.008 p=0.687 
Table 4.3.5.1c. The effect of vehicle on the rate of increase in plasma ascorbic acid 
concentration over 105 minutes 
Drink mean gradient (mg/100ml/min) B'currant drink Orange juice 
(and standard error) 
Blcurrant drink 
Orange juice 0.0015(-+0.0002) p=0.061 
Water 0.0014(+-0.0001 p=O. 108 p=0.458 
From tables 4.3.5.1 a, b and c, it is evident that for blackcurrant the rate of repletion of 
plasma ascorbic acid was significantly slower than for orange juice and water over the first 90 
minutes. However, by 105 minutes there was no longer a detectable difference. 
This is an interesting observation. The magnitude of the difference is clearly seen in 
figure 3.2.3a. It is difficult to assess whether this difference is only of statistical significance, 
or whether it occurs because of some distinctive chemical, physical or biological interaction 
manifest only in the case of the blackcurrant supplement. It is known that certain sugars, such 
as glucose, compete with ascorbic acid for transport systems that have an affinity for both 
molecules. It is also known that about half of the anthocyanins in blackcurrant are conjugated 
with glucose. There is then a possibility for competition between the glucoside residue and the 
ascorbic acid as has been observed (albeit not precisely quantified) for various flavonoid 
glucosides and glucose during active transport in the duodenum 
However, any theoretical effect of the glucosides must be tempered with the possible 
effect of the free sugars of the drinks that are present in a much greater concentration. As 
shown in table 2.2.4.6a, the blackcurrant drink contains more than twice as much glucose as 
the orange juice though comparatively only 23% more total sugars. Further evidence to refute 
the effect of glucose is that no significant difference is seen between the rates of increase of 
plasma ascorbic acid concentration after taking orange juice compared with water-the latter 
having no sugars whatsoever. 
One other possibility to explain the slower rates with the blackcurrant drink is that 
pectin and zinc may impair absorption (Sauberlich 1990), though this thesis contains no 
evidence for the concentrations of either in the vehicles in this study. It should be noted that 
orange juice also would have appreciable pectin content. 
OveralL the impact of these differences in rate of repletion is small and it appears to be 
of a transitory nature. It is unlikely to be of nutritional significance to those members of the 
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population that are borderline scorbutic, such as the old, the institutionalised and smokers that 
may have a poor ascorbic acid status through poor diet, increased requirement and/or a 
decreased capability for water-soluble vitamin absorption. 
4.3.5.2 Effect of vehicle on the final plasma ascorbic acid level 
The question posed was, "Does the vehicle in which ascorbic acid was presented 
influence the plasma ascorbic acid level attained at the end of the plasma sampling periodT' 
To address this question it was assumed that the plasma concentration had stabilised and 
could be estimated by averaging the later data points. Since it was not possible to precisely 
define the start of their plateau, statistical analyses were performed using the final five data 
points and final six data points (41/2-7 and 5-7 hours after taking the supplement). 
Comparisons were made with the baseline value by means of an analysis of variance. The 
analysis of variance (ANOVA) tests the hypothesis that means from two or more samples are 
equal (drawn from populations with the same mean). It is an expansion on the test for two 
means such as the Mest. All comparisons had n=12. Test results are shown in table 4.3.5.2a 
for the last five data points and table 4.3.5.2b for the last six data points. 
Table 4.3.5.2a The effect of vehicle on the final plasma ascorbic acid level--last five 
points 
Drink B'currant drink Orange juice Water 
BI currant drink 
Orange juice 0.225 
Water 0.952 0.239 
Table 4.3.5.2b The effect of vehicle on the final plasma ascorbic acid level--last six points 
Drink B'currant drink Orange juice Water 
BI currant drink 
Orange juice 0.239 
Water 0.727 0.546 
As seen from Tables 4.3.5.2a and b there were no significant differences attributable 
to the nature of the vehicle whichever time period was considered. It may thus be concluded 
that the nature of the vehicle does not influence the steady-state plasma concentration. 
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4.3.5.3 Relationship of baseline plasma ascorbic acid level and final steady-state level 
In all cases, plasma ascorbic acid concentrations rose at a rate and to a level that was 
independent of the vehicle used. However, as illustrated in tables 6.8.1--6.8.12, the baseline 
plasma ascorbic acid levels were variable, and it seemed appropriate to ascertain whether a 
constant ascorbic acid dose produced a near constant increase in plasma ascorbic acid levels. 
Simply put, if the individual began with a higher plasma ascorbic acid baseline did he fmish 
with a higher final plasma level. 
Investigation of this relationship was carried out using Pearson's Correlation of 
Coefficients test, as in section 4.3.4.2. The results are shown in table 4.3.5.3. 
Table 4.3.5.3. The relationship of baseline plasma ascorbic acid with the last two data 
points of the plasma-sampling period. 
r value and sig i icance 
All vehicles n--36 t--0.9525p<0.001 
B'currant drink n=12 --0.938, p<0.001 
Orange juice n-- 12 r--0.969, p<0.001 
Water n--12 r--0.952, p<0.001 
From table 4.3.5.3, it is evident that there was a highly significant, positive correlation 
between the baseline plasma ascorbic acid concentration and the concentration reached at the 
end of the plasma-sampling period for all treatments (n=36) and for each individual treatment. 
Therefore, if an individual began with a higher baseline plasma ascorbic acid level his plasma 
levels could be expected to be higher after treatment than if he began at a lower baseline level 
independent of treatment. 
These data suggest that there are no impediments in uptake from gut to plasma. 
However, since for leukocytes there was a weak and inconsistent relationship between 
baseline and final ascorbic acid concentrations, then something must exert a variable effect on 
uptake from plasma to leukocyte. It could not be pectin since this would not reach the plasma. 
It may be zinc as proposed by Sauberlich (1990), but the most likely cause is sugars. The 
glucose transporters GLUT I and GLUT3 have been shown to compete with dehydroascorbic 
acid (Vera et al. 1993). Glucose has also been found to compete with ascorbic acid for the 
ascorbic acid transporters in white cells (Washko et al. 1991). This competition would be 
largely controlled by the plasma glucose level, which in turn would be tightly controlled by 
insulin secretion. Since a relationship between baseline and final ascorbic acid concentrations 
was seen only in niononuclear leukocytes with the blackcurrant drink, and since the 
blackcurrant drink has the highest glucose (and total sugar) levels which would cause the 
higher insulin secretion, the levels of plasma glucose would be transitorily lower after taking 
the blackcurrant drink and so may not be so competitive with the ascorbic acid for transport 
into the mononuclear leukocyte. However, this does not explain why the relationship is not 
seen for the polymorphonuclear leukocytes. 
4.3.5.4 Relationship between baseline plasma ascorbic acid concentration and the rate of 
repletion over 105 minutes 
In all cases, plasma ascorbic acid concentrations were increasing at the 105-minute 
time point. The question posed was, "Does the rate at which the plasma ascorbic acid 
concentration is increasing have any relationship with the baseline plasma ascorbic acid 
concentrationT' To address this,, the Pearson's Correlation test, as described earlier, was used. 
The results are shown in table 4.3.5.4. 
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Table 4.3.5.4. The relationship between baseline plasma ascorbic acid concentration and 
the rate of repletion over 105 minutes. 
r value and significance 
All vehicles n=36 r--O. 163, p<0.341 
B'currant drink n= 12 r--0.408, p<O. 188 
Orange juice n-- 12 r---0.083, p<0.797 
Water n=12 r--0.153, p<0.635 
Therefore, the rate of increase in plasma ascorbic acid over 105 minutes is 
independent of the baseline plasma ascorbic acid concentration and is also independent of 
treatment. 
Tables 4.3.5.3 and 4.3.5.4 together then demonstrate that while the baseline plasma ascorbic 
acid level does significantly affect the final plasma ascorbic acid concentration it does not 
significantly affect the rate of plasma ascorbic acid increase (over 105 minutes). 
4.3.5.5 Was the treatment order significant 
With the twelve subjects split into pairs, all six possible sequences of drink order were 
used (see section 2.2.3). Whether the order had any significance to the results was 
investigated using an analysis of variance of the plasma levels each individual reached after 
each treatment. It was found that the treatment order was not significant (p=0.6652). 
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4.3.6 Urine analysis 
4.3.6.1 Hippuric acid in the urine 
As described in section 2.3.3, studies in the laboratory (Clifford et aL, unpublished) 
have observed that the amount of hippuric acid excreted over 24 hours by volunteers rises 
significantly when black tea is consumed. Nine volunteers on a low-phenol diet excreted 153- 
512 mg whereas when the same diet was supplemented with black tea the 24 hour excretion 
of hippuric acid rose to 742-1374 mg. It is thought that this occurs because the gut micro 
flora convert the polyphenols, of black tea to benzoic acid which is then conjugated 
endogenously with glycine. 
Since both orange juice and the blackcurrant drink have significant contents of 
flavonoids, which might similarly be metabolised by the gut microflora, it seemed appropriate 
to examine the 24 hour urine samples for their hippuric acid content. 
The values recorded in this study in table 3.2.5.1 a ranged from 18 to 438 mg per 24 
hours, considerably less than was observed with black tea. This difference may in part be due 
to the larger quantities of tea consumed (6-10 cups, 2.1-3.6 litres containing approximately 
2.4-4 g of polyphenols) compared with 500 ml fruit juice containing approximately 42 mg 
polyphenols in the blackcurrant drink and a little more than 42 mg in the orange juice 
(Clifford and Tomas-Barberan, in press). However, it is more difficult to explain why in the 
current study there was no significant difference in the quantity of hippuric: acid excreted 
whatever vehicle was used. Failure to establish a difference when water was used is 
particularly surprising, but a possible explanation may be that the volunteers were not 
restricted in their tea and coffee consumption, which would certainly make the orange juice 
supplement an insignificant additional source of polyphenols. 
4.3.6.2 NMR analysis of urines 
As described in section 2.3.4.0, Copeland (PhD thesis, 1996) has shown that the NMR 
profiling of 24 hour urine samples provide a measure of the aromatic and phenolic protons 
excreted, and this is related to the ingestion of dietary phenols. The particular advantage of 
this approach is that it can be utilised to monitor output when the extent of absorption is 
uncertain. It was thus particularly well suited for the analysis of the urine after the 
anthocyanin-containing blackcurrant drink had been consumed since the bioavailability of 
anthocyanins remains controversial-see section 1.6.1 and 1.6.2 and references therein. All 
data were normalised against an internal standard (sodium formate) and corrected for urine 
volumes and are presented in tables 3.5.2a, b and c. The size of the aromatic signal areas were 
compared using t-tests and the results shown in table 4.3.6.2. 
Table 4.3.6.2 Comparison of the size of urine aromatic proton signal area with 
supplement. 
Drink B'currant drink Orange juice Water 
B'currant drink 
Orange juice 0.530 
Water 0.241 0.908 
As the p values in table 4.3.6.2 show, there was no statistically significant difference 
found that could be attributed either to the vehicle used or to the individual. When put 
together with the analysis of hippuric acid as discussed above, it is not easy to explain the 
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failure to discriminate between water and the fruit juices. However, the most likely 
explanation is that as the subjects were not restricted in their drinking of tea and coffee, the intake of these may have obscured any differences caused by the fruit juice aromatic protons 
and hippuric acid precursors thus no differences were seen in the urines. 
4.3.6.3 HPLC analysis of urines 
As discussed in section 1.6.1, there have been controversial and unconfirmed reports 
of the absorption of anthocyanins. As discussed in section 1.6, anthocyanins and similar flavylium. salts present the analyst with unique difficulties, which are a reflection of their 
unusual chemistry. In particular, at typical plasma and urine pH values, the reddish flavylium 
cations will normally be present at such small proportions of the total anthocyanin content as 
to be virtually impossible to detect. In this study all samples were analysed both with and 
without acidification to regenerate the coloured flavylium cation. In addition, all samples 
were treated with glucuronidase and sulphatase to selectively hydrolyse conjugated 
anthocyanins. This was in part to ascertain whether or not these were present, but also to 
maximise the likelihood of detecting the aglycones if they were present in multiple forms- 
some of which might have been below the limit of detection or otherwise obscured on the 
chromatograms. 
The results of the analysis of urines at 530 nm by the six different methods given in 
section 2.3.2.3 are shown in Tables 3.2.5.3a-1. Conditions A, C and D were designed to detect 
compounds retaining a chrornophore absorbing at 530 rim even at high pH values. No such 
compounds were revealed with condition A but a range of peaks were observed us' 
conditions C and D, at least for some volunteers. Although this might indicate that some pH- 
stable anthocyanin transformation products are present in the urine as glucuronides or 
sulphate conjugates, it must be noted that these peaks were not restricted to urines collected 
after consumption of the blackcurrant drink. Since the diet followed would have been low in 
fruits and vegetables that might have provided anthocyanins or their transformation products 
when orange juice or water vehicles were used, this factor must put into question such a 
simple interpretation. 
Procedures B, E and F would have detected native anthocyanins and their conjugates 
as well as the transformation products referred to above. Once again a series of 530 m-n- 
absorbing peaks were seen, but these also were not restricted to urines associated with 
blackcurrant drink consumption, and again there was considerable person-to-person variation. 
Procedures E and F revealed considerably fewer peaks than treatment B. 
These observations may have been easier to explain had mass spectral data been 
available. However, it is possible to conclude that there is no evidence from this study for the 
excretion of anthocyanins after the consumption of a blackcurrant juice drink, and an 
unequivocal answer to the bioavailability of anthocyanins must await finther study. 
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4.4 Overview 
The greatest problem in comparing this study with previous ones in the literature is that they are all different in design, duration and dose, the tissues that were examined and the 
methods used to assay ascorbic acid. Studies have shown greater (Elmby and Warburg 1937, Vinson and Bose 1987,1988), equal (Todhunter and Fatzer 1940, Nelson et al. 1975, Mangels 
et aL 1993, Johnston and Luo 1994) and smaller (Pelletier and Keith 1974) bioavailability of 
ascorbic acid in its natural source or associated with flavonoids than 'synthetic' or 'crystalline' ascorbic acid. The studies that report the differences in urine ascorbic acid levels 
apparently caused by taking ascorbic acid in different vehicles are discounted as urine 
ascorbic acid cannot be accurately and reliably correlated with dietary ascorbic acid and has 
never been linked with the amount of ascorbic acid reaching tissue stores. Ehnby and Warburg (1937) and Todhunter and Fatzer (1940) both used poorly 
specific methodologies (dichlorophenolindophenol titration). However the latter was a well- designed study, and looked at the prevention of depletion of ascorbic acid stores using either 
red raspberries or ascorbic acid in water. Vinson and Bose (1987) gave no detail of study design, dose or duration, tissue examined, assay used and it will be ignored for these reasons 
alone. Their other study (Vinson and Bose 1988), published in a reputable journaL has 
obvious faults. Firstly, their plasma sampling intervals are 1 hour apart, and our study shows 
that this creates large gaps of knowledge about the precise time course of the plasma ascorbic 
acid level. Secondly, they also use area under curve comparispns, which have questionable 
robustness for these kind of data, as discussed in section 4.3. * Thirdly, the plasma ascorbic 
acid concentration that is reached at 8 hours after ingestion is not statistically compared, and 
from the values given the difference is insignificant. Therefore the effect of vehicle on the 
steady-state concentration of plasma ascorbic acid appears to have been insignificant, as was 
reported in the study in this thesis. Further, the general quality of science carried out by Dr 
Vinson has also been put in some doubt (Clifford, personal communication), as it is tempered 
by commercial activity. 
Pelletier and Keith (1974) studied the bioavailability of ascorbic acid alone, with rutin, 
and in orange juice and found that serum ascorbic acid levels were higher after taking 
ascorbic acid alone than with rutin, and both were higher than after taking ascorbic acid in 
orange juice. They found no difference in leukocyte or urine ascorbic acid levels. Probably 
the best designed studies are those of Mangels et aL (1993) and Johnston and Luo (1994) 
which were repletion and depletion studies respectively. Both looked at only plasma levels 
and found similar to this thesis that ascorbic acid is not more or less bioavailable when alone 
or when in its natural source. 
To date, this thesis is the first to look at the white cell levels of ascorbic acid as two 
discrete fractions rather than a mixed population. It is also believed that the plasma time- 
course data reported here are invaluable in assessing the final plateau reached and the initial 
rates of absorption rather than the crudy non-robust ý area under curve values used by many 
other workers. 
From the analysis of the data, vehicle type does affect the initial rate of increase of 
plasma ascorbic acid over 65 and 90 minutes. However the rate difference disappears at 105 
minutes and there is no difference in the final concentrations reached. The initial differences 
in rates may disappear through homeostatic control of plasma ascorbic acid, which would 
cause the ascorbic acid to be either 1) taken up by the body's cells (the depleted white cells) 
or 2) taken up by the kidney for excretion. A third reason for the disappearance of the rate 
difference is that the ascorbic acid in the blackcurrant drink does not arrive in the plasma as 
quickly as the other two vehicles, i. e. the blackcurrant drink causes the ascorbic acid to be 
absorbed at an initially slower rate than the water or the orange juice, though this rate is the 
same by 105 minutes after ingestion. 
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Taking these hypotheses in turn, the study was designed to look at the effect of uptake by cells by looking at the (depleted) white cells, which are considered to be a site where 
ascorbic acid is stored by the body. (There are other sites but these are not easily taken from a human). From the data in this thesis, it was found that the extra ascorbic acid seen in the 
plasma soon after supplementing with the water and orange juice vehicles did not appear in 
either white cell type. Therefore the data strongly suggest that sites of ascorbic acid storage in 
the body do not take up the ascorbic acid. 
Secondly, this thesis did not collect urine for ascorbic acid analysis and so it cannot be 
experimentally ascertained whether this extra ascorbic acid went to the kidney. (Urine 
ascorbic acid is a poor and misleading measure of ascorbic acid metabolism, excretion and 
status as discussed in section 1.11.5. ). However, it is known that there is a conservation effect 
at low plasma ascorbic acid levels that reduces the amount of ascorbic acid excreted (Kallner 
et aL 1979). It is therefore thought unlikely that the ascorbic acid goes to and is excreted by 
the kidneys. 
By deduction this leaves only the possibility that the blackcurrant drink impairs the 
absorption of ascorbic acid at the site of absorption in the gut lumen (the small intestine). 
While this thesis has no data to prove or disprove this hypothesis, there is evidence that some 
flavonol glycosides compete for the sugar transport mechanisms in the gut (Clifford, personal 
communication) and it is also known that ascorbic acid competes with sugars such as glucose 
for transport into cells. It is therefore possible that the initial rate differences are due to 
blackeurrant juice components impairing or slowing ascorbic acid absorption. Of course, there 
are other differences between the vehicles (table 2.2.4.6a) such as sugar type and content that 
may effect the stomach emptying time, which would then affect the absorption of ascorbic 
acid. However, the data show there was no significant difference between the rates of the 
water and orange juice vehicles at 65,90 and 105 minutes and therefore the sugars at the 
levels in the orange juice do not have any significant effect. It is thought unlikely that the 
slightly higher levels of sugars in the blackcurrant drink or the small levels Of S02 in the 
blackcurrant drink would have a significant effect on stomach emptying time relative to the 
orange juice. 
It logically follows that the hypothesis that the blackcurrant drink impairs only the 
initial absorption of ascorbic acid is, from these data, the most probable explanation of the 
three discussed here. Also, since 1) the ascorbic acid is unlikely to go to the kidney, 2) the 
final concentrations of ascorbic acid in the plasma after 7 hours do not significantly differ 
with vehicle and 3) as the white cells--considered to be long-term ascorbic acid store"o 
not differ in their ascorbic acid level, it also logically follows that the orange juice and water 
vehicles do not appear to supply more ascorbic acid per ingested dose. 
Therefore overall, the only significant difference between the vehicles appears to be 
the initial rates of ascorbic acid repletion in the plasma, which are not considered to be 
nutritionally significant. 
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5. Concluding Statements. 
5.1 The effect of vehicle (blackcurrant drink, orange juice or water) on the absorption of 
vitamin C 
Under the conditions in the studies reported in this thesis, it is possible to conclude that the initial rate of ascorbic acid absorption appears to be slower when the ascorbic acid is 
provided in a blackcurrant drink compared with when ascorbic acid is provided in orange juice or in water. 
Studies in this thesis also lead to the conclusion that the ascorbic acid vehicle, whether blackcurrant drink, orange juice or water, has no significant effect on the final ascorbic acid level attained in the plasma, nor that of the mononuclear and polymorphonuclear leukocytes. 
These conclusions concur with the most recent and the best-executed studies, in that the 
vehicle of ascorbic acid has no influence on the ascorbic acid status of human plasma and 
white cells. 
Through the experimental data in this thesis and existing knowledge, it is thought the 
most likely explanation for these observations of a slower uptake into plasma is that a 
component or characteristic of the blackcurrant drink causes an impairment in the rate of 
absorption of the ascorbic acid in the small intestine, but does not, however, significantly 
affect the final plasma ascorbic acid levels achieved. 
The studies in this thesis also show that the urines of subjects supplemented with a 
blackcurrant drink, orange juice or water show no significant differences in their content of 
aromatic protons (polyphenolic excretion products) nor hippuric acid. Neither do these urines 
show any visually significant or consistent differences in their content of substances that 
absorb light at 530 nmý notably anthocyanins. 
5.2 Suggestions for further work 
Following directly from the conclusions of this thesis, it would be scientifically 
prudent to investigate the nature of the transitory slower rates of plasma ascorbic acid 
concentration increase caused by the blackcurrant drink vehicle. 
From a commercial point of view, it may be useful to investigate whether, under the 
same conditions and the same study design, significant differences in ascorbic acid absorption 
can be seen by using a smaller (or larger) dose df ascorbic acid in the drink. It may also be of 
use to standardise the sugar levels of the vehicles to ascertain their significance in ascorbic 
acid absorption. 
From the writing of this thesis it has Jr,, come, apparent that there are deficits of 
knowledge and understanding of anthocyanins; 44d a'scorbic acid. Firstly there should be 
W ascorbic acid 'in the bottle'; do they investigations iftt6 the interactions of anthocyai4 
interact, wW-,; OtO&sses occur and what signifýig jFpJs this to the final drink. Also, how do 
. #. ý if , other sAV? els in a drink like blackcurrant jvjce, inieract with anthocyanins, ascorbic acid 
and with both molecules together. A better understanding of the drink and its chemistry would 
be useful both scientifically and for better commercial exploitation. 
Research is also needed for the long-term understanding of whether anthocyanins are 
absorbed from the diet, in what form, to what extent and to what significance to health. 
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Chairman: Dr. J. W. Wright Secretary: Mrs. G. A. Russell 
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Our Ref EC129/97 
Dr. M. Clifford 
Investigation Unit 
University of Surrey 
Dear Michael, 
Re: Investigation of the p harm aco kinetics of Vitamin C 
Thank you for submitting the above study for consideration by the Ethics Committee. I do 
not think that it raises any major ethical issues and I am happy to take Chairman's Action in 
approving it. This should be ratified at the next full meeting of the Committee on 9 
th 
December. 
Yours sincerely, 
Dr. I W. Wright 
Chairman, Ethics Committee 
ý31 
21 January 1998 
Dr M Clifford 
School of Biological Sciences 
University of Surrey 
Dear Dr Clifford 
Appendix 6-lob 
Investigation of the effect of fruit flavanoids-on the pharmacokinetics of 
Vitamin C. (ACE/97/40/SBS) 
University 
of Surrey 
I am writing to inform you that the Advisory Committee on Ethics has considered the 
above protocol, and has approved it on the understanding that the Ethics Guidelines 
are observed. 
The-ýCpmrnittee made one observation regarding the protocol i. e. the 'Volunteer 
'E6hs-eritTorm' still uses the phrase 'I understand also that my GP will be informed of 
my participation in this study' rather than using the phrase 'I understand that it is 
necessary for you to contact my GP and seek his consent for my participation in this 
study' as outlined in the 'Information for Volunteers' document. Please amend the 
'Volunteer Consent Form' to maintain continuity and forward a copy for our records, 
preferably no later than Friday 30 January 1998. 
'The Committee requires that the handling of blood must be carried out in accordance 
with the University Policy on the Donation and Use of Human Specimens in Teaching 
and Research (December 1995) and I enclose a copy of that Policy for your 
information. The Committee also requires that the Consent Form for the Donation of 
Blood conforms with that produced by the University and included in the attached 
policy document. 
This letter of approval relates only to the study specified in your research protocol 
(ACE/97/40/SBS). The Committee should be notified of any changes to the proposal, 
any adverse reactions and if the study is terminated earlier than expected (with 
reasons). I enclose a copy of the Ethics Guidelines for your information. 
Yours sincerely 
Helen Schuyleman (Mrs) 
Secretary, University Advisory Committee on Ethics 
cc Mr S Edmed, School of Biological Sciences 
Professor LJ King, Chairman, ACE 
4-. 
University of Surrey 
Guildford 
Surrey GU2 5XH 
England 
Telephone: (01483) 300800 
Fax: (01483) 300803 
Telex: 859331 
1: ý29 
SOUTH WEST SURREY LOCAL RESEARCH ETHICS COMMITTEE 
Postgraduate Medical Centre, 
The Royal Surrey County Hospital, Egerton Road, 
Guildford, Surrey. GU2 5XX 
Tel: 01483 571122 ext. 4381 Fax: 01483 303691 
Chairman: Dr. J. W. Wright Secretary: Mrs. G. A. Russell 
15"' December 1997 
Our Ref EC129/97 
Dr. M. Clifford 
School of Biological Sciences 
Universit of Surrey 
C, 
Dear Dr. or 
0, urr 
Re: Investigation of the effects of fruit flavonoids on the pharmaco kinetics of Vitamin C. 
Volunteer Information Sheet and Consent Form dated 02.12.97 
I am pleased to confirm that, at its meeting held on 9hDecember, the Ethics Committee 
ratified Chairman's Action taken to approve the above study. 
I have attached a signed copy of the application form. 
Should the start of the study be delayed by more than one year from the date of approval you 
should resubmit the protocol to the Committee. 
Please inform the Committee of any adverse effects to the subjects which may be related to 
taking part in the study. 
Finally, the Committee requests that you provide a report every six months as well as a final 
report of your study or a copy of any published paper, 
Yours s)hcerely, 
D-F/J. W Wright 
Chairman, Ethics Committee 
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Appendix 6.2 
Date: 
Subject name: Drink: 
Clinical Assistant: CIU, Royal Surrey County Hospital 
Time of '40 minute' sample 
Time V sample 
Time of Vitamin C Drink 
SCHEDULED TEME ACTUAL TIME 
+40 
+65 
+00 
+105 
+120 
+135 
+150 
+165 
+180 
+195 
+210 
+225 
+240 
+255 
+270 
+300 
+330 
+360 
+390 
+420 
12 ml White cell sample +420 
Comments 
Signed 
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Appendix 6.3 
Volunteer Instruction sheet for 24-hour urine collection. 
1. You are provided with. 
Measuring cylinder 
Large plastic bottle 
Plastic bag 
50 ml sample tube 
2. On the morning of day 30, when you wake up, go to the toilet and empty your bladder 
completely. DO NOT KEEP ANY OF TFUS URINE. 
3. Collect all urine produced for the rest of day 30 in the plastic bottle. 
4. On the morning of day 3 1, go to the toilet and empty your bladder completely into the 
plastic bottle. TFUS URM YOU WILL KEEP. 
5. Pour the contents of the plastic bottle (now containing 24 hours' worth of urine) into the 
measuring cylinder and read off the volume at eye level. Record this volume. 
6. Now pour 50 ml of this into the sample tube and put this into the labelled bag. Write on 
the bag the volume of your urine. 
7. Once you have filled the sample tube, discard the urine down the toilet and finse out the 
measuring cylinder and bottle. Return the bottle, cylinder and sample in the bag to me on 
day 31 (or later to 12 AY 20) 
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Appendix 6.4 
Orange juices tested for use in the Main study. 
Target: 200 mg/500 nil juice 
Brand Code Ascorbic acid content mg/ 
500 MI 
Sainsbury's Economy W7328 209.5 
Sainsbury's Economy W8005 216.5 
Sainsbury's Pure Jaffa 5H7290 188.4 
Somerfield Pure Unsweetened 723 1 HH02 205.8 
Somerfield Pure Florida 2V7203 162.9 
Princes Pure Unsweetened AN2 267.8 
Kwik Save No Frills Pure 7230 201.5 
Kwik Save Pure 7234 204.9 
Del Monte Pure Original 07/98 178.2 
Appendix 6.5 
Tesco's vitamin B complex-contents. 
Each tablet provides- 
Amount % RDA 
Thiamin 1.4 mg 100 
Riboflavin 1.6 mg 100 
Niacin 18 mg 100 
Vitamin B6 2 mg 100 
Vitamin B12 I Itg 100 
Folacin 200 gg 100 
Choline bitartate 10 mg 100 
Pantothenic acid 6 mg 100 
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Appendix 6.6 White cell data and calculation from the Pilot study 
The cell counting procedure is detailed in section 2.1.7.2.3. The calculation is as follows: 
ýtg ascorbic acid /10' cells IX 10, x mg ascorbic acid /100 ml 
White cell count /100 ml 
For example: 
Table 6.6a, first line, 
(I X 108 - 4.23 x 108) x 0.083 = 0.0196 mg/ 108 Cell S or 19.6 Lip. / 108 cells. 
Table 6.6a. Day One 
Subject Sample Mean of triplicate analyses White cells x 8 
jig ascorbic acid 
' mg ascorbic acid/100 ml 10 / 100 ml /10 cells 
PMN 0.083 4.23 19.6 
IM MN 0.649 9.85 65.9 
PN4N 0.045 4.48 10.0 
NB MN 1.110 8.90 124.9 
PMN 0.076 5.19 14.7 
RW MN 0.792 4.77 166.0 
PMN 0.062 4.48 13.8 
DP MN 0.570 5.90 96.7 
Table 6.6 b. Day Two 
Subject Sample Mean of triplicate analyses White cells x ýLg ascorbic acid 
mg ascorbic acid/100 ml to, / 100 mi /10" cells 
PMN 0.128 9.09 15.9 
Im 
MN 0.414 7.26 57.0 
PX1N 0.014 4.59 3.0 
NB 
MN 0.088 2.14 41.2 
PMN 0.073 3.28 22.4 
RW 
MN 0.469 9.44 49.6 
PA4N 0.070 6.03 11.6 
DP 
MN 0.752 6.60 114.1 
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Table 6.6c. Day Three 
Subject Sample Mean of triplicate analyses White cells x I-tg ascorbic acid 
mg ascorbic acid/100 ml 108/ 100 M, /10' cells 
PNIN 0.067 4.93 13.6 
Im 
MN 0.539 1.65 32.8 
PNW 0.041 1.73 23.8 
NB 
MN 0.524 7.01 74.8 
PMN 0.071 5.07 14.0 
RW 
MN 0.875 1.13 77.7 
PMN 0.032 1.41 22.5 
DP 
MN 0.339 4.83 70.2 
Table 6.6d. Day Four 
Subject Sample Mean of triplicate analyses White cells x [Lg ascorbic acid 
mg ascorbic acid/100 ml 108/ 100 mi /108cells 
PMN 0.066 5.94 11.0 
Im 
MN 0.497 1.74 28.5 
PMN 0.045 5.63 8.0 
N113 
NIN 0.784 7.46 105.1 
PN4N 0.111 1.19 9.3 
RW 
NIN 1.090 9.60 113.7 
PMN 0.019 3.08 6.1 
DP 
MN 0.357 3.58 99.5 
Table 6.6e. Day Five 
Subject Sample Mean of triplicate analyses White cells x ýtg ascorbic acid 
mg ascorbic acid/100 ml 108/ 100 ml 
/108 cells 
PNIN 0.075 1.15 6.5 
IM 
MN 0.601 1.35 44.5 
PMN 0.137 2.13 64.0 
NB 
MN 1.080 1.45 74.8 
PMN 0.016 1.50 10.7 
RW 
MN 0.449 6.67 66.4 
PMN 0.035 3.92 9.0 
DP 
MN 0.597 7.60 78.5 
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Table 6.6E Day Six 
Subject Sample Mean of triplicate analyses White cells x [tg ascorbic acid 
mg ascorbic aci&100 ml 108/ 100 M, /108 cells 
PMN 0.098 4.19 23.5 
IM 
MN 0.333 3.28 101.6 
PN1N 0.080 1.40 57.3 
NB 
MN 0.942 1.29 73.2 
PMN 0.255 3.62 70.4 
RW 
MN 0.907 6.59 137.6 
PMN 0.079 3.67 21 5 
DP . 
MN 0.462 5.15 89.7 
Table 6.6g. Day Seven 
Subject Sample Mean of triplicate analyses White cells x ýtg ascorbic acid 
mg ascorbic acid/100 ml 108/ 100 M, /10" cells 
PMN 0.125 9.76 12.8 
IM 
MN 0.649 1.08 60.0 
PN1N 0.025 1.71 14.6 
NB 
MN 0.375 3.07 122.1 
PNM 0.049 5.76 84.6 
RW 
MN 0.345 2.24 153.9 
PMN 0.015 3.24 45.0 
DP 
NIN 0.221 1.48 149.8 
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Appendix 6.7 White cell data and calculation from the Main study. 
The data are given in 24 tables. These tables are in sets of three. The first three show 
the white cell ascorbic acid levels on day one for the three treatments: table 6.7.1 a for the 
blackcurrant drink, table 6.7.1 b for the orange juice and table 6.7.1 c for water. Then tables 
6.7.2a-c gives the data for day two and so on. The calculation for ýtg ascorbic acid per 10' 
cells is as follows: 
ýtg ascorbic acid per 108 cells =Ix 10, 
-x mg ascorbic acid per 
100 ml. 
White cell count per 100 ml 
For example: 
Table 6.7.1 a, first line, 
(I x 108-- (3 042000 x50 ml)) x 0.0 13 27 = 0.00 8 72 mg/ 108 cel Is or 8.72 LLgj 108 cells. 
Table 6.7.1a. Day One, blackeurrant diink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
Gount/2 ml 
ýLg ascorbic acid 
per 108 cells 
DIP PMN 0.013 0.014 0.013 0.013 3042000 8.7 
MN 0.021 0.021 0.022 0.021 768000 55.9 
NB PMN 0.015 0.015 0.015 0.015 2412000 12.5 
MN 0.030 0.030 0.029 0.030 1248000 47.3 
NP PMN 0.027 0.024 0.026 0.026 6120000 8.4 
MN 0.031 0.031 nd 0.031 1568000 39.6 
PY PMN 0.011 0.011 0.010 0.011 936000 23.1 
MN 0.063 0.060 0.059 0.061 2592000 46.7 
HID PMN 0.029 0.029 0.022 0.027 3006546 17.7 
MN 0.086 0.087 0.084 0.086 4575542 37.5 
JT PMN 0.011 0.011 nd 0.011 1584000 14.0 
MN 0.082 0.077 0.077 0.078 4216498 37.1 
NH PMN 0.085 0.089 0.081 0.085 10176000 16.7 
MN 0.126 0.128 0.125 0.126 4576000 55.3 
RW PMN 0.074 0.073 0.070 0.072 6144000 23.6 
MN 0.130 0.129 0.126 0.128 5786000 44.4 
DN PMN 0.017 0.016 0.015 0.016 3108000 10.5 
MN 0.049 0.048 0.047 0.048 2860000 33.6 
JR PMN 0.030 0.029 0.027 0.029 7539698 7.6 
MN 0.053 0.052 0.049 0.051 2970000 34.5 
PC PMN 0.026 0.025 0.021 0.024 3348000 14.4 
MN 0.056 0.053 0.053 0.054 3828000 28.4 
SD PMN 0.012 0.011 0.011 0.011 2499900 9.1 
MN 0.040 0.041 0.036 0.039 2706000 29.0 
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Table 6.7. Ib Day One, orange juice 
Subject Sample mg ascorbic acid/1 00 ml mean ascorbic white cell gg ascorbic acid (tripli cate injections) acid mg/1 00 ml count/2 ml per 108 cells DP PMN 0.025 0.025 0.026 0.025 2832000 17.8 
MN nd 0.073 0.076 0.074 2310000 64.4 
NB PMN 0.018 0.020 0.020 0.019 4559817 8.4 
MN 0.083 0.090 0.086 0.086 2823220 61.0 
NP PMN 0.048 0.047 0.047 0.047 8520000 11.1 
MN 0.114 0.105 0.120 0.113 5434000 41.5 
PY PMN 0.036 0.033 0.033 0.034 4159833 16.4 
MN 0.108 0.117 0.119 0.114 5764000 39.7 
HD PMN 0.035 0.034 0.034 0.034 4128000 16.5 
MN 0.072 0.077 0.074 0.074 3410000 43.6 
JT PMN 0.042 0.043 0.042 0.042 5744000 14.7 
MN 0.069 0.069 0.072 0.070 3278000 42.7 
NH PMN nd nd nd 
MN 0.121 0.129 0.115 0.122 5243123 46.4 
RW PMN 0.059 0.057 0.057 0.058 7040000 16.5 
MN 0.105 0.106 0.104 0.105 3776515 55.6 
DN PMN 0.016 0.016 0.015 0.016 1746000 18.1 
MN 0.060 0.062 0.059 0.061 2688000 45.1 
JR PMN 0.011 0.011 0.009 0.011 1260000 16.7 
MN 0.016 0.016 0.014 0.015 1012000 30.3 
PC PMN 0.029 0.028 0.028 0.028 3708000 15.1 
MN 0.051 0.051 0.049 0.050 5192000 19.4 
SD PMN 0.012 0.012 0.011 0.012 1548000 15.3 
MN 0.024 0.022 0.022 0.023 896000 50.3 
Table 6.7.1c Day One, water 
Subject 
- -- 
Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean aSGorbic 
acid mg/1 00 ml 
white Gell 
count/2 ml 
ýtg ascorbic acid 
per 108 cells 
DP PMN 0.016 0.018 0.017 0.017 4764000 7.0 
MN 0.089 0.088 0.092 0.090 2816000 63.6 
NB PMN 0.020 0.019 0.019 0.019 2160000 17.7 
MN 0.143 0.136 0.129 0.136 4026000 67.5 
NP RMN 0.030 0.029 0.030 0.030 5299788 11.3 
MN 0.087 0.085 0.085 0.086 3849846 44.4 
PY PMN 0.029 0.032 0.028 0.030 2640000 22.4 
MN 0.146 0.146 0.153 0.148 8316000 35.6 
HD PMN nd nd nd 
MN nd nd nd 
JT PMN 0.010 0.011 0.010 0.010 1782000 11.7 
MN 0.018 0.019 0.017 0.018 976000 37.0 
NH PMN nd nd nd 
MN nd nd nd 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.025 0.024 0,022 0.024 5039798 9.5 
MN 0.050 0.047 0.041 0.046 3564000 25.8 
JR PMN 0.019 0.016 0.016 0.017 3576000 9.5 
MN 0.080 0.075 0.077 0.077 3740000 41.3 
PC PMN 0,024 0.023 0.022 0.023 3300000 14.0 
MN 0.093 0.093 0.097 0.094 8206000 22.9 
SD PMN 0.027 0.025 0.024 0.025 3564000 14.2 
MN 0-057 0.055 0.054 0.055 2134000 51.8 
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Table 6.7.2a Day Two, blackeurrant drink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
w, hite cell 
count/2 ml 
ýtg ascorbic acid 
per 108 cells DP PMN nd nd nd 
MN 0.005 0.009 0.005 0.006 380000 31.3 
NB PMN 0.017 0.018 0.017 0.017 3264000 10.6 
MN 0.076 0.074 0.074 0.075 6512000 22.9 
NP PMN 0.022 nd 0.022 0.022 6656000 6.5 
MN 0.093 0.091 0.091 0.092 5984000 30.7 
PY PMN 0.017 0.017 0.017 0.017 2208000 15.5 
MN 0.099 0.095 nd 0.097 8704000 22.3 
HD PMN 0.034 0.036 0.030 0.033 6816000 9.8 
MN 0.054 0.061 0.061 0.059 3776515 31.2 
JT RMN 0.013 0.013 0.013 0.013 1884000 14.1 
MN 0.042 0.042 0.041 0.042 3189872 26.0 
NH PMN 0.046 0.047 0.047 0.047 7344000 12.7 
iMN 0.134 0.133 0.134 0.134 5896000 45.4 
RW PMN 0.028 0.029 0.027 0.028 2376000 23.5 
MN 0.158 0.154 0.155 0.156 10648000 29.3 
DN PIVIN 0.031 0.029 0.028 0.030 6804000 8.7 
MN 0.093 0.092 0.093 0.093 6138000 30.2 
JR PMN 0.015 0.013 0.010 0.013 7599696 3.4 
MN 0.069 0.067 0.067 0.068 6086423 22.3 
PC PMN 0.032 0.032 0.030 0.031 4584000 13.6 
MN 0.086 0.082 0.083 0.084 9020000 18.6 
SD PMN 0.020 0.020 0.018 0.019 4939802 7.8 
MN 0.068 0.066 0.061 0.065 5573110 23.3 
Table 6.7.2b Day Two, orange juice 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white Gel[ 
Gount/2 ml 
ýtg ascorbic acid 
per 10 8 cells 
DP PMN nd nd nd 
MN nd nd nd 
NB PMN 0.027 0.027 0.025 0.027 8039678 6.6 
MN 0.076 0.075 0.073 0.075 5866432 25.4 
NP PMN nd nd nd 
MN nd nd nd 
Py PMN nd nd nd 
MN nd nd nd 
HID PMN 0.037 0.038 0.035 0.037 5916000 12.5 
MN 0.084 0.089 0.091 0.088 3960000 44.5 
JT PMN 0.033 0.034 0.034 0.034 5712000 11.8 
MN 0.107 0.119 0.105 0.110 9108000 24.3 
NH PMN 0.037 0.038 0.037 0.037 6799728 10.9 
MN 0.076 0.075 0.071 0.074 4216498 35.0 
RW PMN nd nd nd 
MN 0.117 0.115 0.111 0.115 5316454 43.1 
DN PMN 0.009 0.006 0.005 0.007 888000 14.8 
MN 0.053 0.049 0.048 0.050 2530000 39.2 
JR PMN 0.021 0.019 0.019 0.020 3228000 12.1 
MN 0.035 0.034 0.032 0.034 2486000 27.1 
PC PMN 0.030 0.030 0.027 0.029 5280000 111.0 
MN 0.077 0.074 0.072 0.074 7524000 19.7 
SD PMN 0.016 0.016 0.016 0.016 3264000 9.9 
MN 0039 0.041 0.038 0.039 2046000 3 8.6 
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Table 6.7.2c Day Two, water 
Subject Sample Mg ascorbic acid/1 00 ml mean ascorbic white cell ýLg ascorbic acid (triplicate injections) acid mg/100 ml count/2 ml per 10 8 cells DP PMN 0.021 0.020 0.016 0.019 6199752 6.1 
MN 0.063 0.064 0.061 0.063 2346572 53.4 
NB PMN 0.037 0.037 0.037 0.037 6216000 11.9 
MN 0.122 0.114 0.116 0.118 5060000 46.5 
NP PMN 0.044 0.041 0.041 0.042 19319807 4.4 
MN 0.077 0.073 0.069 0.073 3593189 40.6 
Py PMN nd nd nd 
MN nd nd nd 
HID PMN 0.016 0.015 0.014 0.015 2244000 13.3 
MN 0.131 0.131 0.133 0.132 9680000 27.2 
JT PMN 0.016 0.015 0.014 0.015 3060000 9.7 
MN 0.054 0.060 0.058 0.057 3608000 31.8 
NH PMN 0.060 0.063 0.055 0.059 9960000 11.9 
MN 0.086 0.091 0.090 0.089 3894000 45.7 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.010 0.010 0.008 0.009 2439902 7.6 
MN 0.057 0.056 0.049 0.054 5976427 18.2 
JR PMN 0.022 0.022 0.021 0.022 10020000 4.3 
MN 0.055 0.054 0.055 0.055 3080000 35.5 
PC PMN 0.023 0.022 0.021 0.022 3444000 12.9 
MN 0.011 0.095 0.091 0.065 17232644 7.6 
SID PMN 0.064 0.061 0.059 0.062 10272000 12.0 
MN 0.083 0.078 0.080 0.081 5280000 30.5 
Table 6.7.3a Day Three, blackeurrant drink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
Gount/2 ml 
l. Lg ascorbic acid 
per 108 cells 
DP PMN 0.006 0.013 0.013 0.011 2508000 8.6 
MN 0.056 0.026 0.026 0.036 2684000 26.9 
NB PMN 0.007 0.006 nd 0.006 1116000 11.3 
MN 0.045 0.041 0.042 0.043 3784000 22.7 
NP PMN 0.015 0.014 0.015 5748000 5.1 
MN 0.112 0.107 0.113 0.111 6534000 33.9 
PY PMN 0.043 0.039 0.040 0.041 8784000 9.3 
MN 0.109 0.103 0.106 0.106 10164000 21.0 
HID PMN 0.032 0.032 nd 0.032 7076383 9.1 
MN 0.062 0.058 nd 0.060 5023132 23.9 
JT PMN 0.014 0.013 nd 0.013 2640000 9.9 
MN 0.044 0.041 nd 0.043 5976427 14.3 
NH PMN 0.053 0.053 0.045 0.050 10476000 9.6 
MN 0.109 0.112 0.107 0.109 5060000 43.2 
RW PMN 0.030 0.030 0.029 0.029 3900000 15.1 
MN 0.105 0.103 0.102 0.103 9174000 22.5 
DN PMN 0.039 0.038 0.037 0.038 12159514 6.2 
MN 0,053 0.053 0.052 0.053 4656480 22.6 
JR PMN 0.014 0.013 0.013 0.013 8959641 3.0 
MN 0.078 0.077 0.072 0.076 9459621 16.0 
PC PMN 0.024 0.020 0.020 0.021 5859765 7.2 
MN 0.068 0.065 0.065 0.066 9422956 14.0 
SID PMN 0.009 0.008 0.006 0.008 3339866 4.5 
UN 0099 0.086 0,079 0.085 11182886 15.2 
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Table 6.7.3b Day Three, orange juice 
Subject Sample mg ascorbic acid/1 00 ml 
(triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
count/2 ml 
ýtg ascorbic acid 
per 10 8 cells 
DP PMN 0.014 0.013 0.013 0.013 2736000 9.6 
MN 0.072 0.067 0.068 0.069 2772000 49.7 
NB PMN 0.013 0.015 0.014 0.014 7369705 3.7 
MN 0.071 0.075 0.068 0.071 6446000 22.2 
NP PMN 0.036 0.036 0.036 0.036 14160000 5.0 
MN 0.098 0.095 0.090 0.094 5104000 37.0 
PY PMN 0.022 0.200 0.019 0.080 12399504 12.9 
MN 0.069 0.072 0.071 0.071 11256216 12.6 
HD PMN 0,028 0.028 0.028 0.028 5256000 10.6 
MN 0.060 0.056 0.052 0.056 3520000 31.7 
JT PMN 0.014 0.015 0.014 0.014 2904000 9.8 
MN 0.055 0.054 0.047 0.052 4994000 20.9 
NH PMN 0.047 0.044 nd 0.045 10192926 8.9 
MN 0.008 0.065 nd 0.036 2156000 33.9 
RW PMN 0.033 0.028 nd 0.031 7039718 8.7 
MN 0.073 nd nd 0.073 3776515 38.9 
DN PMN nd nd nd 
MN 0.020 0.019 0.017 0.019 2134000 17.5 
JR PMN 0.020 0.018 0.018 0.019 4752000 7.8 
MN 0.043 0.042 0.041 0.042 4510000 18.7 
PC PMN 0.037 0.036 0.036 0.036 9432000 7.7 
MN 0.087 0.087 0.084 0.086 12980000 13.2 
SID PMN 0.002 0.002 0.002 0.002 636000 5.5 
MN 0.055 0.055 0.055 0.055 3366000 32.7 
Table 6.7.3c Day Three, water 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
count/2 ml 
l. Lg ascorbic acid 
per 10 8 cells 
DP PMN 0.042 0.039 0.038 0.040 11604000 6.8 
MN 0.069 0.068 0.065 0.067 9606282 14.0 
NB PMN 0.026 0.026 0.024 0.025 3576000 14.2 
MN 0.106 0.094 0.094 0.098 5214000 37.6 
NP PMN 0.045 0.046 0.037 0.042 19659214 4.31 
MN 0.085 0.085 0.082 0.084 8066344 20.8 
PY PMN 0.023 0.023 0.023 0.023 6588000 7.0 
MN 0.093 0.090 0.084 0.089 5390000 32.9 
HID PMN 0.006 0.006 0.006 0,015 2376000 12.9 
MN 0.072 0.066 0.069 0.057 6864000 16.7 
JT PMN 0.017 0.017 0.016 0.001 372000 5.1 
MN 0.062 0.063 0.060 0.045 3498000 25.8 
NH PMN 0.028 0.027 0.024 0,018 3504000 10.5 
MN 0.093 0.087 0.090 0.137 6490000 42.3 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.015 0.015 0.014 0.014 4959801 5.8 
MN 0.075 0.069 0.068 0.071 8316000 17.0 
JR PMN 0.032 0.028 0.026 0.029 18699252 3.2 
MINI 0.053 0.050 0.049 0.051 3850000 26.3 
PC PMN 0.028 0.026 0.023 0.026 5639774 9.1 
MN 0.085 0.069 0.046 0.067 10816234 12.3 
SID PMN 0.017 0.015 0.016 0.016 5639774 5.7 
MN 0.053 0.047 0.042 0.048 6340796 15.0 
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Table 6.7.4a Day Four, blackeurrant drink 
Subject Sample mg ascorbic acid/l 00 ml (triplicate injections) 
mean ascorbic 
acid mg/l 00 ml 
white Gell 
count/2 ml 
ýtg ascorbic acid 
per 108 cells 
DP PMN 0.019 0.016 0.017 0.017 3888000 8.8 
MN 0.055 0.056 0.059 0,057 4048000 28.0 
NB PMN 0.015 0.012 0.012 0.013 2148000 12.3 
MN 0.094 0.088 0.086 0.089 6402000 28.0 
NP PMN 0.029 0.033 0.024 0.029 9840000 5.9 
MN 0.153 nd 0.131 0.142 8778000 32.4 
Py PMN nd nd nd 
MN nd nd nd 
HD PMN 0.023 0.023 0.022 0.023 5939762 7.7 
MN 0.023 0.019 0.016 0.019 6966388 5.5 
JT PMN 0.014 0.010 0.010 0.011 2859885 8.0 
MN 0.071 0.067 0.059 0.066 7149714 18.4 
NH PMN 0.032 0.031 0.028 0.030 7999680 7.6 
MN 0.088 0.087 0.082 0.086 6159753 27.8 
RW PMN 0.037 0.033 0.033 0.034 6239750 10.9 
MN 0.080 0.076 0.083 0.079 6599736 24.0 
DN PMN 0.014 0.015 0.011 0.014 5088000 5.3 
MN 0.059 0.056 0.056 0.057 9746000 11.7 
JR PMN 0.010 0.010 0.010 0.010 8239670 2.4 
MN 0.036 0.037 0.033 0.035 6123088 11.5 
PC PMN 0.029 0.029 0.027 0.028 9339626 6.1 
MN 0.075 0.073 0.070 0.073 12576164 11.6 
SD PMN 0.013 0.012 0.012 0.012 9559617 2.6 
MN 0.077 0.076 0.067 0.073 10706238 13.7 
Table 6.7.4b Day Four, orange juice 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
count/2 ml 
ýLg ascorbic acid 
per 108 cells 
DP PMN 0.012 0.011 0.011 0.011 2628000 8.6 
MN 0.043 0.044 0.041 0.043 1892000 45.3 
NB PMN 0.011 0.009 0.009 0.009 4899804 3.9 
MN 0.082 0.076 0.075 0.078 6856392 22.7 
NP PMN 0.043 0.044 0.042 0.043 14520000 6.0 
MN 0.086 0.081 0.076 0.081 3740000 43.3 
PY PMN 0.013 0.012 0.011 0.012 2599896 9.5 
MN 0.081 0.076 0.074 0.077 10522912 14.6 
HID PMN 0.028 0.028 0.025 0.027 8739650 6.3 
MN 0.088 0.087 0.080 0.085 6599736 25.7 
JT PMN 0.012 0.011 0.010 0.011 2519899 8.5 
MN 0.055 0.051 0.051 0.052 7039718 14.9 
NH PMN 0.046 0.040 0.036 0.040 17159314 4.7 
MN 0.079 0.071 0.063 0.071 3996506 35.6 
RW PMN 0.041 0.039 0.035 0.038 17599296 4.3 
MN 0.096 0.083 0.079 0.086 7626361 22.6 
DN PMN 0.009 0.008 0.009 0.008 2568000 6.6 
MN 0.044 0.043 0.041 0.043 4378000 19.6 
JR PMN 0.013 0.013 0.012 0.012 4776000 5.2 
MN 0.036 0.035 0.036 0.035 4136000 17.1 
PC PMN 0.025 0.026 0.024 0.025 7008000 7.2 
MN 0.064 0.063 0.063 0.063 10560000 12.0 
SD PMN 0.009 0.009 0.009 0.009 4140000 4.4 
MN 0.051 0.052 0.053 0.052 3960000 26.2 
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Table 6.7.4c Day Four, water 
Subject Sample mg ascorbic acid/1 00 ml 
(triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
count/2 ml 
ýtg ascorbic acid 
per 108 cells 
DP PMN 0.026 0.023 0.021 0.024 7639694 6.2 
MN 0.024 0.018 0.012 0.018 3849846 9.4 
NB PMN 0.015 0.015 0.015 0.015 2559898 11.9 
MN 0.092 0.081 0.082 0.085 3629855 46.9 
NP PMN 0.032 0.026 0.025 0.028 12839486 4.3 
MN 0.092 0.087 0.087 0.089 7296375 24.3 
PY PMN 0.031 0.031 0.031 0.031 7944000 7.9 
MN 0.091 0.088 0.065 0.081 6974000 23.3 
HD PMN 0.018 0.019 0.019 0.019 4524000 8.3 
MN 0.067 0.064 0.065 0.065 7018000 18.6 
JT PMN 0.006 0.006 0.006 0.006 2124000 5.8 
MN 0.064 0.061 0.063 0.063 5808000 21.8 
NH PMN 0.024 0.023 0.025 0.024 5976000 8.0 
MN 0.089 0.087 0.089 0.088 4312000 40.9 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.010 0.009 0.009 0.009 5479945 3.4 
MN 0.049 0.046 0.045 0.047 5609776 16.6 
JR PMN 0.024 0.024 0.022 0.023 19980000 2.3 
MN 0.042 0.039 0.037 0.039 4400000 17.9 
PC PNIN 0.020 0.018 0.018 0.019 6259750 6.0 
MN 0.063 0.059 0.054 0.058 10266256 11.4 
SID PMN 0.022 0.020 0.018 0.020 9239630 4.4 
MN 0.081 0.078 0.072 0.077 8799648 17.5 
Table 6.7.5a Day Five, blackcurrant drink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white GeH 
Gount/2 ml 
ýLg ascorbic acid 
per 10 8 cel'Is 
DP PMN 0.011 0.010 0.009 0.010 2172000 9.0 
MN 0.055 0.044 0.042 0.047 2662000 35.5 
NB PMN 0.012 0.011 0.010 0.011 1740000 12.8 
MN 0.033 0.032 0.031 0.032 1782000 35.9 
NP PMN 0.023 0.021 0.021 0.022 5880000 7.4 
MN 0.089 0.082 0.080 0.084 4708000 35.5 
PY PMN 0.062 0.058 0.061 0.060 11760000 10.3 
MN 0.063 0.059 0.056 0.059 6292000 18.9 
HID PMN 0.000 nd 0.000 0.000 92000 7.9 
MN 0.085 0.087 0.013 0.062 5573110 22.1 
JT PMN 0.000 0.000 0.000 0.000 20000 10.7 
MN 0.089 0.105 0.101 0.098 8066344 24.4 
NH PMN 0.011 0.011 0.010 0.011 1860000 11.7 
MN 0.049 0.043 0.043 0.045 3226538 27.9 
RW PMN 0.008 0.008 0.008 0.008 1488000 11.0 
MN 0.088 0.086 0.087 0.087 6673066 26.0 
DN PMN 0.021 0.020 0.020 0.020 8159674 5.0 
MN 0.050 0.048 0.047 0.048 4509820 21.4 
JR PMN 0.006 0.005 0.005 0.005 5539778 1.9 
MN 0.044 0.044 0.039 0.042 5133128 16.5 
PC PMN 0.021 0.021 0.021 0.021 6300000 6.6 
MN 0.070 0.071 0.068 0.070 10926230 12.8 
SD PMN 0.011 0.010 0.009 0.010 5659774 3.5 
MN 0.038 0.037 0.033 0.036 4399824 16.3 
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Table 6.7.5b Day Five, orange juice 
Subject Sample mg ascorbic acid/1 00 ml 
(triplicate injections) 
mean ascorbic 
acid mg/1 00 rInl 
white cell 
Gount/2 ml 
ýtg ascorbic acid 
per 108 cells 
DP PMN 0.013 0.013 0.109 0.045 8844000 10.2 
MN 0.072 0.073 0.073 0.073 2398000 60.6 
NB PMN 0.011 0.014 0.013 0.012 3899844 6.4 
MN 0.076 0.080 0,078 0.078 4070000 38.4 
NP PMN 0.043 0.036 0.036 0.038 13080000 5.9 
MN 0.097 0,107 0.101 0.102 5346000 38.1 
PY PMN 0.035 0.034 0.036 0.035 6324000 11.1 
MN 0.094 0.095 nd 0.094 7883018 23.9 
HD PMN 0.043 0.044 nd 0.044 12156000 7.2 
MN 0.059 0.057 0.048 0.055 3080000 35.6 
JT PMN 0.014 0.012 0.009 0.012 2844000 8.1 
MN 0.053 0.055 0.047 0.052 6856392 15.0 
NH PMN 0.020 0.022 0.019 0.020 7939682 5.1 
MN 0.146 0.167 0.169 0.161 5756436 55.8 
RW PMN 0.000 0.000 0.000 0.000 70000 4.8 
MN 0.121 0.135 0.132 0.129 9129635 28.3 
DN PMN 0.016 0.017 0.017 0.017 4116000 8.1 
MN 0.041 0.039 0.037 0.039 2266000 34.1 
JR PMN 0.024 0.023 0.021 0.023 5844000 7.9 
MN 0.065 0.065 0.063 0.064 5434000 23.6 
PC PMN 0.013 0.013 0.013 0.013 3408000 7.6 
NIN 0.047 0.045 0.047 0.046 6116000 15.0 
SD PMN 0.014 0.013 0.014 0.014 5328000 5.1 
MN 0.060 0.054 0.053 0.056 4224000 26.4 
Table 6.7.5c Day Five, water 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white cell 
count/2 ml 
l. Lg ascorbic acid 
per 108 cells 
DP PMN 0.006 0.007 nd 0.006 1119955 11.1 
MN 0.004 0.090 0.085 0.060 3849846 31.1 
NB PMN 0.025 0.023 0.022 0.023 3624000 12.9 
MN 0.079 0.075 0.073 0.076 2823220 53.6 
NP PMN 0.024 0.026 0.026 0.025 7699692 6.6 
MN 0.103 0.108 0,101 0.104 8359666 24.9 
PY PMN 0.076 0.068 0.062 0.069 14796000 9.3 
MN 0.067 0.067 0,063 0.066 4840000 27.2 
HID PMN 0.015 0.016 0.015 0.015 3432000 8.9 
MN 0.054 0.057 0,061 0.057 2838000 40.3 
JT PMN 0.001 0.001 0.001 0.001 296000 6.4 
MN 0.045 0.045 0.046 0.045 2376000 37.9 
NH PMN 0.019 0.019 0.018 0.018 3840000 9.6 
MN 0.114 0.153 0.145 0.137 4598000 59.8 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.011 0.010 0.008 0.010 5899764 3.2 
MN 0.071 0.075 0.065 0.070 7223044 19.5 
JR PMN 0.005 0.003 0.004 0.004 3139874 2.5 
MN 0.024 0.023 0.021 0.022 1943256 23.1 
PC PMN 0.009 0.009 0.008 0.009 2256000 7.6 
MN 0.069 0.069 0.060 0.066 9826274 13.4 
SD PMN 0.002 0.009 0.009 0.007 2376000 5.6 
MN 0.038 0.038 0.032 0.036 3373198 21.2 
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Table 6.7.6a Day Six, blackcurrant drink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white Gell 
Gount/2 ml 
ýLg ascorbic acid 
per 10 8 cells 
DP PMN 0.013 0.015 0.012 0.013 2928000 9.2 
MN 0.086 0.071 0,079 0.079 2288000 69.0 
NB PMN 0.009 0.008 0.008 0.008 1320000 12.8 
MN 0.107 0,101 0.097 0.101 3828000 53.0 
NP PMN 0.023 0.025 0.022 0.023 5760000 8.1 
MN 0.102 0.093 0.097 0.097 3696000 52.7 
PY PMN 0.018 0.017 0.014 0.016 2208000 14.8 
MN 0.100 0.105 0.107 0.104 6182000 33.7 
HD PMN 0.001 0.001 nd 0.001 120000 11.1 
MN 0.015 0.155 0.132 0.101 9899604 20.4 
JT PMN 0.000 0.000 0.000 0.000 42000 12.6 
MN 0.108 0.905 0.092 0.368 16316014 45.1 
NH PMN 0.050 0.051 0.046 0.049 7199928 13.7 
MN 0.136 0.136 0.123 0.132 4033172 65.3 
RW PMN 0.034 0.032 0.032 0.033 4979801 13.1 
MN 0.069 0.072 0.067 0.070 3409864 40.8 
DN PMN 0.021 0.020 0.019 0.020 5739770 7.0 
MN 0.055 0.053 0.054 0.054 4399824 24.4 
JR PMN 0.016 0.016 0.015 0.016 13159474 2.4 
MN 0.060 0.062 0.059 0.061 7443036 16.3 
PC PMN 0.010 0.009 0.008 0.009 1836000 9.6 
MN 0.038 0.038 0.035 0.037 3739850 19.7 
SID PMN 0.012 0.011 0.011 0.011 4560000 4.9 
MN 0.057 0.055 0.053 0.055 5389784 20.4 
Table 6.7.6b Day Six, orange juice 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white cell 
count/2 ml 
l. Lg ascorbic acid 
per 10 8 cells 
DP PMN 0.021 0.020 0.020 0.020 3396000 11.9 
MN 0.078 0.076 0.077 0.077 2310000 66.8 
NB PMN 0.009 0.008 0.010 0.009 2794000 6.6 
MN 0.070 0.007 0.071 0.049 2749890 36.8 
NP PMN 0.033 0.032 0.034 0.033 6456000 10.1 
MN 0.102 0.111 0.102 0.105 4334000 48.4 
PY PMN 0.016 0.016 0.018 0.017 2288000 14.5 
MN 0.063 0.064 0.066 0.064 4693146 27.5 
HID PMN 0.059 0.053 0.048 0.053 91596346 11.6 
MN 0.088 0.081 0.084 0.084 3299868 61.2 
JT PMN 0.014 0.013 0.012 0.013 1719931 15.4 
MN 0.084 0.083 0.078 0.082 4693146 34.8 
NH PMN 0.049 0.041 0.038 0.043 8499660 10.0 
MN 0.235 0.181 0.188 0,201 6966388 57.8 
RW PMN nd 0.038 0.041 0.039 9759610 8.1 
MN 0.157 0.131 0.124 0.137 7259710 37.9 
DN PMN 0.009 0.008 0.092 0.037 7284000 10.1 
MN 0.049 0.050 0.048 0.049 2596000 37.8 
JR PMN 0.027 0.027 0.026 0.026 5676000 9.3 
MN 0.050 0.074 0.076 0.067 4950000 N. 9 
PC PMN 0.020 0.019 0.002 0.014 2880000 9.5 
MN 0.052 0.047 0.045 0.048 6116000 15.7 
SID PMN 0.016 0.015 0,014 0.015 3660000 8.1 
MN 0.039 0.040 0.038 0.039 1958000 40.1 
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Table 6.7.6c Day Six, water 
Subject Sample mg ascorbic acid/100 ml 
(triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white Gell 
count/2 ml 
ýLg ascorbic acid 
per 108 cells 
DP PMN 0.021 0.021 0.021 0.021 4004000 10.3 
MN 0.069 0.075 0.069 0.071 4509820 31.4 
NB PMN 0.018 0.017 0.015 0.017 2538000 13.0 
MN 0.102 0.096 0.096 0.098 3124000 62.7 
NP PMN 0.036 0.036 0.037 0.036 8756000 8.3 
MN nd 0.061 0.063 0.062 3739850 33.0 
PY PMN 0.017 0.016 0.018 0.017 2460000 13.9 
MN 0.097 0.083 0.077 0.086 4136000 41.4 
Hb PMN 0.030 0.029 0.029 0.029 3540000 16.6 
MN 0.070 0.069 0.066 0.069 3036000 45.2 
JT PMN 0.202 0.020 0.020 0.081 11880000 13.6 
MN 0.042 0.039 0.039 0.040 1650000 48.8 
NH PMN 0.057 0.053 0.050 0.053 11088000 9.6 
MN 0.084 0.081 0.080 0.082 2838000 57.6 
RW PMN nd nd nd 
MN nd nd nd 
bN PMN 0.011 0.012 0.011 0.011 3899844 6.8 
MN 0.067 0.069 0.065 0.067 5500000 24.3 
JR PMN 0.016 0.014 0.013 0.014 5399784 5.3 
MN 0.048 0.048 0.047 0.048 3923176 24.3 
PC PMN nd nd nd 
MN nd nd nd 
SD PMN 0.011 0.011 0.010 0.011 2959882 7.4 
MN 0.054 0.053 0.053 0.053 3124000 34.3 
Table 6.7.7a Day Seven, blackcurrant dzink 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white cell 
Gount/2 ml 
pg ascorbic acid 
per 108 cells 
DP PMN 0.010 0.010 0.010 0.010 1704000 11.6 
MN 0.045 0.044 0.045 0.045 1232000 72.3 
NEI PMN 0.010 0.010 0.010 0.010 1248000 Il 6.3 
MN 0.085 0.081 0.083 0.083 2508000 66.4 
NP PMN 0.028 0.029 0.026 0.028 5136000 10.9 
MN 0.096 0.094 0.100 0.097 3520000 55.0 
PY PMN 0.013 0.013 0.013 0.013 1488000 17.4 
MN 0.093 0.094 0.110 0.099 5390000 36.8 
HD PMN 0.017 0.019 0.018 0.018 3324000 11.0 
MN 0.053 0.054 0.048 0.052 4950000 20.9 
JT PMN 0.000 0.000 0.000 0.000 16000 17.9 
MN 0.138 0.146 0.129 0.138 5676000 48.6 
NH PMN 0.031 0.026 0.021 0.026 3559857 14.4 
MN 0.228 0.219 0.220 0.222 6966388 63.8 
RW PMN 0.026 0.025 0.023 0.025 2580000 19.2 
MN 0.104 0.105 0.100 0.103 3849846 53.6 
DN PMN 0.019 0.018 0.016 0.018 4899804 7.3 
MN 0.058 0.055 0.055 0.056 4473154 25.1 
A PMN 0.018 0.019 0.017 0.018 6099756 6.0 
MN 0.078 0.081 0.080 0.079 7084000 22.4 
PC PMN 0.021 0.021 0.021 0.021 4620000 9.2 
MN 0.077 0.077 0.073 0.076 6116000 24.8 
Sb PMN 0.022 0.020 0.020 0.021 7039718 6.9 
MN 0.074 0.069 0.068 0.070 5280000 26.7 
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Table 6.7.7b Day Seven, orange juice 
Subject Sample mg ascorbic acid/1 00 ml 
(triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white Gell 
count/2 ml 
pg ascorbic acid 
per 108 cells 
DP PMN 0.018 0.020 0.0 Fg - 0.0 19 2904000 13.0 
MN 0.052 0.049 0.046 0.049 1576604 62.4 
NB PMN 0.038 0.034 0.035 0.036 10399584 6.9 
MN 0.119 0.101 0.097 0.105 5206458 40.5 
NP PMN 0.033 0.042 0.039 0.038 6660000 11.4 
MN 0.105 0.093 0.091 0.096 3739850 51.3 
PY PMN 0.022 0.017 0.016 0.018 2016000 18.2 
MN 0.110 0.100 0.098 0.103 8396331 24.4 
HID PMN 0.024 0.024 0.022 0.023 3859846 12.1 
MN 0.080 0.081 0.078 0.080 3116542 51.2 
JT PMN 0.021 0.019 0.020 0.020 2520000 15.7 
MN 0.093 0.092 0.086 0.090 5206458 34.1 
NH PMN 0.001 0.000 0.000 0.000 56000 12.2 
MN 0.109 0.098 0.096 0.101 3189872 63.5 
RW PMN 0.030 0.031 0.026 0.029 4284000 13.4 
MN 0.088 0.097 0.075 0.086 4289828 40.3 
DN PMN 0.019 0.018 0.016 0.018 351,6000 10.0 
MN 0.052 0.048 0.049 0.049 2398000 41.3 
JR PMN 0.027 0.026 0.025 0.026 5028000 10.3 
MN 0.062 0.062 0.063 0.062 4048000 30.8 
PC PMN 0.021 0.021 0.021 0.021 4272000 9.7 
MN 0.057 0.055 0.052 0.055 4884000 22.5 
SID PMN 0.034 0.030 0.031 0.032 7092000 9.0 
MN 0.080 0.081 0.077 0.079 3630000 43.7 
Table 6.7.7c Day Seven, water 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/100 ml 
white cell 
count/2 ml 
pg ascorbic acid 
per 108 cells 
DP PMN 0.017 0.015 0.013 0.015 2699892 11.1 
MN 0.085 0.073 0.069 0.076 4399824 34.6 
NB PMN 0.010 0.011 0.011 0.010 1319947 15.9 
MN 0.135 0.127 0.117 0.127 3960000 63.9 
NP PMN 0.039 0.034 0.033 0.035 8316000 8.5 
MN 0.124 0.115 0.100 0.113 5830000 38.8 
PY PMN 0.027 0.025 0.024 0.026 2939882 17.4 
MN 0.083 0.072 0.072 0.076 3300000 46.0 
HD PMN 0.027 0.025 0.025 0.026 3180000 16.3 
MN 0.043 0.040 nd 0.041 1914000 43.1 
JT PMN 0.006 nd nd 0.006 864000 13.1 
MN 0.052 0.056 0.058 0.056 2288000 48.7 
NH PMN 0.026 0.026 0.027 0.026 3132000 16.9 
MN 0.084 0.092 0.090 0.089 2728000 65.1 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.014 0.013 0.014 0.014 3259870 8.6 
MN 0.106 0.105 0.099 0.104 6380000 32.6 
JR PMN 0.008 0.009 0.008 0.008 2640000 6.2 
MN 0.049 0.045 0.048 0.047 4033172 23.4 
PC PMN nd nd nd 
MN nd nd nd 
SID PMN 0.016 0.015 0.014 0.015 3276000 9.2 
MN 0.048 0.047 0.046 0.047 2310000 40.4 
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Table 6.7.8a Day Eight, blackcurrant dtink 
Subject Sample m ascorbic acid/l 00 ml 
(triplicate injections) 
mean ascorbic 
acid mg/l 00 ml 
white Gell 
count/2 ml 
ýLg ascorbic acid 
per 10 8 cells 
DP PMN 0.011 0.011 0.011 0.011 1728000 12.9 
MN 0.079 0.081 0.082 0.081 2200000 73.2 
NB PMN 0.018 0.016 0.016 0.017 2052000 16.1 
MN 0.099 0.095 0.080 0.091 2904000 62.8 
NP PMN 0.059 0.061 0.059 0.060 10640000 11.2 
MN 0.112 0.112 0.108 0.111 4620000 48.0 
PY PMN 0.025 0.026 0.024 0.025 2616000 19.0 
MN 0.093 0.098 0.111 0.100 5522000 36.3 
HD PMN 0.027 0.026 0,025 0.026 4236000 12.2 
MN 0.064 0.062 0.064 0.063 5389784 23.5 
JT PMN 0.000 0.000 0.000 0.000 32000 15.8 
MN 0.063 0.065 0.068 0.065 3006546 43.4 
NH PMN 0.068 0.062 0.060 0.063 8639654 14.6 
MN 0.150 0.144 0.141 0.145 4509810 64.4 
RW PMN 0.060 0.055 0.050 0.055 5964000 18.5 
MN 0.093 0.094 0.092 0.093 3299868 56.3 
DN PMN 0.021 0.019 0.020 0.020 4659814 8.6 
MN 0.052 0.053 0.047 0.050 3542000 28.5 
JR PMN 0.020 0.021 0.019 0.020 6336000 6.3 
MN 0.077 0.078 0.073 0.076 5236000 29.1 
PC PMN 0.031 0.032 0.031 0.031 5400000 11.6 
MN 0.090 0.103 0.096 0.096 7348000 26.2 
SD PMN 0.011 0.012 nd 0.012 2916000 7.9 
MN 0.057 0.057 0.051 0.055 3593190 30.5 
Table 6.7.8b Day Eightý orange juice 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
Gount/2 ml 
ýLg ascorbic acid 
per 108 cells 
DP PMN 0.025 0.025 0.023 0.024 4224000 11.5 
MN 0.087 0.079 0.078 0.081 2662000 61.0 
NB PMN 0.036 0.033 0.033 0.034 10559578 6.4 
MN 0.132 0.121 0.113 0.122 5214000 46.8 
NP PMN 0.061 0.059 0.058 0.059 11256000 10.5 
MN 0.121 0.119 0.122 0.121 4913137 49.1 
PY PMN 0.026 0.028 0.027 0.027 5236000 10.3 
MN 0.126 0.130 0.120 0.126 8726318 28.8 
HD PMN 0.029 0.026 0.027 0.027 4459822 12.2 
MN 0.056 0.056 0.050 0.054 2053251 52.6 
JT PMN 0.027 0.026 0.023 0.026 3336000 15.3 
MN 0.094 0.092 0.090 0.092 4876472 37.8 
NH PMN 0.056 0.054 0.053 0.054 9359626 11.6 
MN 0.142 0.144 0.151 0.146 4972000 58.5 
RW PMN 0.028 0.029 0.027 0.028 4080000 13.6 
MN 0.097 0.108 0.098 0.101 4686000 43.2 
DN PMN nd nd nd 
MN nd nd nd 
JR PMN nd nd nd 
MN nd nd nd 
PC PMN nd nd nd 
MN nd nd nd 
SD PMN nd nd nd 
MN nd nd nd 
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Table 6.7.8c Day Eight, water 
Subject Sample mg ascorbic acid/1 00 ml (triplicate injections) 
mean ascorbic 
acid mg/1 00 ml 
white cell 
count/2 ml 
[tg ascorbic acid 
per 108 cells 
DP PMN 0.037 0.038 0.034 0.037 6160000 11.9 
MN 0.110 0.101 0.103 0.105 7406370 28.3 
NB PMN 0.018 0.020 0.020 0.019 2496000 15.4 
MN 0.083 0.090 0.086 0.086 2823220 61.0 
NP PMN 0.013 0.012 0.012 0.013 2699892 9.3 
MN 0.125 0.120 0.124 0.123 5793102 42.4 
PY PMN 0.040 0.040 0.040 0.040 4644000 17.3 
NIN 0.114 0.106 0.112 0.110 5412000 40.8 
HID PMN 0.034 0.037 0.032 0.034 3492000 19.6 
MINI 0.069 0.069 0.069 0.069 3234000 42.7 
JT PMN 0.011 0.012 0.011 0.011 1548000 14.7 
MN 0.074 0.076 0.075 0.075 3146000 47.8 
NH PMN 0.053 0.052 0.051 0.052 6036000 17.2 
MN 0.113 0.112 0.103 0.109 3476000 62.8 
RW PMN nd nd nd 
MN nd nd nd 
DN PMN 0.013 0.014 0.012 0.013 2940000 8.8 
MN 0.083 0.084 0.074 0.080 5939762 27.0 
JR PMN 0.015 0.014 0.013 0.014 3319967 8.4 
MN 0.047 0.046 0.046 0.046 3102000 29.7 
PC PMN nd nd nd 
MN nd nd nd 
SID PMN 0.016 0.019 0.017 0.017 3599856 9.7 
MN 0.042 0.051 0.050 0.048 2376000 40.1 
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6.8 Main study plasma data 
These data are tabulated by subject. Therefore in tables 6.8.1 a, b and c the data for 
subject DP is shown for blackcurrant drink, orange juice and water respectively. Tables 
6.8.2a, b and c show the data for subject NB, and so on. 
Two baseline readings were taken (at ' -10' and '0' minutes). These were combined to 
form the baseline value of mg ascorbic acid/100 ml plasma. This is the true plasma ascorbic 
acid concentration. However for better comparison with different drinks this baseline was 
subtracted from all subsequent values. These are in the right-hand column of each table and 
are the values used in the results section and in all statistical analyses. 
Table 6.8.1a Subject DP-blackcurrant 
Time 
(min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-15 0.139 0.135 0.132 0.143 0.143 0.000 0 0.156 0.150 0.146 
40 0.194 0.190 0.184 0.189 0.189 0.046 
65 0.262 0.252 0.209 0.241 0.241 0.098 
90 0.290 0.279 0.271 0.280 0.280 0.137 
105 0.286 0.281 0.277 0.281 0.281 0.138 
120 0.317 0.307 0.303 0.309 0.309 0.166 
135 0.328 0.322 0.315 0.322 0.322 0.179 
150 0.340 0.307 0.300 0.316 0.316 0.172 
165 0.317 0.302 0.292 0.304 0.304 0.161 
180 0.311 0.304 0.296 0.303 0.303 0.160 
195 0.316 0.306 0.302 0.308 0.308 0.165 
210 0.312 0.305 0.300 0.306 0.306 0.163 
225 0.301 0.288 0.276 0.289 0.289 0.146 
240 0.306 0.294 0.284 0.294 0.294 0.151 
255 0.291 0.279 0.268 0.279 0.279 0.136 
270 0.277 0.266 0.255 0.266 0.266 0.123 
302 0.282 0.271 0.263 0.272 0.272 0.129 
332 0.288 0.279 0.270 0.279 0.279 0.136 
360 0.282 0.274 0.269 0.275 0.275 0.132 
390 0.268 0.259 0.249 0.259 0.259 0.116 
420 0.257 0.251 0.244 0.251 0.250 0.107 
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Table 6.8. lb Subject DP-orange juice 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
iniection-" mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-6 0.155 0.155 0 155 0.171 
0 0.189 0.187 . 0.184 0.171 0.000 
43 0.284 0.277 0.273 0.278 0.278 0.107 
67 0.407 0.406 0.402 0.405 0.405 0.234 
92 0.614 0.601 0.602 0.606 0.606 0.435 
107 0.493 0.481 0.474 0.483 0.483 0.312 
121 0.453 0.447 0.438 0.446 0.446 0.275 
136 0.391 0.383 0.380 0.385 0.385 0.214 
150 0.368 0.361 0.353 0.361 0.361 0.190 
167 0.385 0.378 0.370 0.378 0.378 0.207 
182 0.376 0.366 0.360 0.367 0.367 0.196 
197 0.358 0.350 0.346 0.352 0.351 0.181 
212 0.430 0.427 0.415 0.424 0.424 0.253 
227 0.399 0.394 0.383 0.392 0.392 0.221 
242 0.384 0.376 0.370 0.377 0.377 0.206 
257 0.358 0.356 0.350 0.355 0.355 0.184 
272 0.332 0.322 0.309 0.321 0.321 0.150 
305 0.348 0.345 0.329 0.341 0.341 0.170 
330 0.342 0.340 0.334 0.339 0.339 0.168 
362 0.341 0.336 0.334 0.337 0.337 0.166 
391 0.322 0.317 0.308 0.316 0.316 0.145 
424 0.315 0.311 0.302 0.310 0.310 0.139 
Table 6.8.1c Subject DP-water. 
Time 
(min) 
mg asGorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/I 00 
ml plasma 
value minus 
baseline 
-2 0.138 0.137 0.134 0.145 0.145 0.000 0 0.162 nd 0.156 
40 0.258 nd 0.244 0.251 0.251 0.105 
65 0.353 0.351 0.345 0.350 0.350 0.204 
90 0.360 0.357 0.352 0.357 0.356 0.211 
105 0.359 0.354 0.349 0.354 0.354 0.209 
120 0.351 0.347 0.338 0.345 0.345 0.200 
135 0.335 0.324 0.321 0.327 0.327 0.181 
150 0.324 0.317 0.309 0.317 0.317 0.172 
165 0.335 0.328 0.318 0.327 0.327 0.182 
180 0.312 0.306 0.302 0.306 0.306 0.161 
195 0.317 0.309 0.311 0.313 0.312 0.167 
210 0.307 0.306 0.297 0.303 0.303 0.158 
225 0.306 0.299 0.295 0.300 0.300 0.155 
240 0.304 0.299 0.291 0.298 0.298 0.153 
255 0.293 0.288 0.286 0.289 0.289 0.144 
270 0.286 0.282 0.278 0.282 0.282 0.137 
300 0.277 0.268 0.260 0.268 0.268 0.123 
330 0.282 0.275 0.271 0.276 0.276 0.131 
360 0.272 0.267 0.265 0.268 0.268 0.123 
390 0.271 0.263 0.264 0.266 0.266 0.121 
420 0.281 0.267 0.263 0.270 0.270 0.125 
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Table 6.8.2a Subject NB-blackcurrant 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml, Plasma 
value minus 
baseline 
-14 0.161 0.156 0.158 0.159 
0 0.162 0.158 0.160 0.159 0.000 
40 0.197 0.191 0.192 0.193 0.193 0.034 
65 0.236 0.231 0.225 0.231 0.231 0.072 
90 0.258 0.253 0.248 0.253 0.253 0.094 
105 0.302 0.295 0.291 0.296 0.296 0.137 
120 0.313 0.310 0.308 0.311 0.311 0.152 
135 0.307 0.300 0.298 0.302 0.301 0.143 
150 0.307 0.308 0.304 0.307 0.307 0.148 
165 0.290 0.285 0.281 0.285 0.285 0.126 
180 0.306 0.307 0.307 0.306 0.306 0.148 
195 0.294 0.289 0.285 0.289 0.289 0.130 
210 0.242 0.243 0.243 0.243 0.243 0.084 
225 0.238 0.238 0.235 0.237 0.237 0.078 
240 0.247 0.248 0.246 0.247 0.247 0.088 
255 0.252 0.249 0.249 0.250 0.250 0.091 
270 nd nd nd 
300 0.262 0.258 0.258 0.259 0.259 0.101 
330 0.250 0.242 0.236 0.243 0.243 0.084 
362 0.258 0.257 0.255 0.257 0.257 0.098 
390 0.273 0.269 0.266 0.269 0.269 0.111 
422 0.271 0.265 0.266 0.267 0.267 0.108 
Table 6.8.2b Subject NB-orange juice 
Time 
(min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
mg ascorbic acid/I 00 
ml plasma 
value minus 
baseline 
0 0.182 0.183 0 178 0 178 
0 0.179 0.175 . 0.173 . 0.178 0.000 
40 0.239 0.235 0.234 0.236 0.236 0.058 
65 0.289 0.276 0.273 0.280 0.280 0.101 
90 0.277 0.296 0.292 0.289 0.289 0.110 
105 0.267 0.289 0.285 0.280 0.280 0.102 
120 0.261 0.282 0.276 0.273 0.273 0.095 
135 0.258 0.279 0.274 0.270 0.270 0.092 
150 0.260 0.281 0.282 0.274 0.274 0.096 
165 0.250 0.267 0.265 0.261 0.261 0.082 
180 0.257 0.268 0.273 0.266 0.266 0.087 
195 0.229 0.247 0.244 0.240 0.240 0.062 
210 0.250 0.270 0.267 0.262 0.262 0.084 
225 0.254 0.278 0.274 0.268 0.268 0.090 
240 0.268 0.268 0.259 0.265 0.265 0.086 
255 0.272 0.273 0.272 0.272 0.272 0.094 
270 0.263 0.260 0.257 0.260 0.260 0.082 
300 0.260 0.260 0.252 0.257 0.257 0.079 
330 0.249 0.247 0.243 0.247 0.246 0.068 
360 0.251 0.253 0.247 0.251 0.251 0.072 
390 0.250 0.244 0.238 0.244 0.244 0.066 
420 0.253 0.246 0.243 0.247 0.247 0.069 
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Table 6.8.2c Subject NB-water. 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-11 0.127 0.122 0.120 0.122 0.122 0 000 0 0.126 0.120 0.118 . 
41 0.209 0.201 0.195 0.202 0.202 0.079 
65 0.248 0.238 0.231 0.239 0.239 0.117 
91 0.208 0.203 0.199 0.203 0.203 0.081 
105 0.241 0.235 0.229 0.235 0.235 0.113 
120 0.229 0.220 0.216 0.222 0.222 0.100 
135 0.228 0.223 0.217 0.223 0.223 0.101 
150 0.216 0.207 0.203 0.209 0.209 0.086 
165 0.240 0.231 0.223 0.231 0.231 0.109 
180 0.208 0.199 0.193 0.200 0.200 0.078 
201 0.218 0.208 0.200 0.209 0.209 0.086 
210 0.225 0.218 0.213 0.219 0.219 0.096 
226 0.205 0.197 0.189 0.197 0.197 0.075 
241 0.184 0.177 0.171 0.177 0.177 0.055 
255 0.214 0.204 0.197 0.205 0.205 0.083 
270 0.198 0.192 0.187 0.192 0.192 0.070 
300 0.195 0.189 0.184 0.189 0.189 0.067 
330 0.178 0.173 0.169 0.173 0.173 0.051 
362 0.179 0.172 0.166 0.173 0.172 0.050 
391 0.190 0.181 0.173 0.182 0.182 0.059 
420 0.204 0.194 0.186 0.195 0.195 0.073 
Table 6.8.3a Subject NP-blackeurrant 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-15 0.171 0.166 0.163 0.183 0.183 0.000 
0 0.205 0.201 0.195 
40 0.202 0.198 0.196 0.199 0.199 0.015 
65 0.203 0.200 0.195 0.199 0.199 0.016 
90 0.234 0.227 0.216 0.226 0.226 0.042 
105 0.234 0.230 0.218 0.227 0.227 0.044 
120 0.238 0.234 0.228 0.233 0.233 0.050 
135 0.245 0.235 0.253 0.244 0.244 0.061 
151 0.247 0.247 0.241 0.245 0.245 0.061 
165 0.266 0.261 0.256 0.261 0.261 0.077 
180 0.235 0.233 0.226 0.231 0.231 0.048 
195 0.275 0.268 0.262 0.268 0.268 0.085 
211 0.259 0.256 0.252 0.256 0.256 0.072 
225 0.272 0.262 0.258 0.264 0.264 0.080 
240 0.256 0.253 0.248 0.253 0.253 0.069 
256 0.260 0.257 0.252 0.257 0.256 0.073 
273 0.259 0.260 0.255 0.258 0.258 0.074 
300 0.257 0.243 0.228 0.243 0.243 0.060 
331 0.266 0.262 0.258 0.262 0.262 0.078 
358 0.255 0.251 0.246 0.251 0.251 0.067 
395 0.239 0.240 0.234 0.238 0.238 0.054 
420 0.249 0.230 0.235 0.238 0.238 0.054 
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Table 6.8.3b Subject NP-orange juice 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
- 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-8 0.200 0.198 0.191 0.202 
0 0.213 0.205 0.203 0.202 0.000 
43 0.289 0.287 0.276 0.284 0.284 0.082 
68 0.319 0.325 0.317 0.320 0.320 0.118 
93 0.337 0.339 0.322 0.333 0.333 0.131 
108 0,339 0.335 0.327 0.334 0.334 0.132 
122 0.346 0.340 0.328 0.338 0.338 0.136 
138 0340 0.339 0.322 0.334 0.334 0.132 
152 0.347 0.346 0.329 0.341 0.340 '0.139 
168 0.337 0.341 0.327 0.335 0.335 0.133 
183 0.316 0.319 0.301 0.312 0.312 0.110 
198 0.318 0.312 0.301 0.310 0.310 0.109 
213 0.324 0,319 0.309 0.317 0.317 0.115 
227 0.335 0.331 0.314 0.327 0.327 0.125 
242 0.329 0.324 0.313 0.322 0.322 0.120 
257 0.315 0.311 0.298 0.308 0.308 0.106 
272 0.307 0.310 0.303 0.307 0.307 0.105 
308 0.316 0.316 0.320 0.317 0.317 0.11-6 
333 0.321 0.318 0.329 0.323 0.322 0.121 
361 0.307 0.301 0.293 0.301 0.300 0.099 
390 0.335 0.335 0.328 0.332 0.332 0.131 
425 0.301 0.300 0.298 0.299 0.299 0.098 
Table 6.8.3c Subject NP-water. 
Time 
(min) 
mg asGorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-10 0.291 0.288 0.283 0.277 0.277 0.000 0 0.274 0.264 0.263 
40 0.358 0.355 0.345 0.352 0.352 0.075 
65 0.427 0.419 0.409 0.418 0.418 0.141 
90 0.448 0.437 0.434 0.439 0.439 0.162 
105 0.478 0.467 0.457 0.467 0.467 0.190 
120 0.500 0.488 0.476 0.488 0.488 0.211 
135 0.509 0.496 0.487 0.497 0.497 0.220 
150 0.475 0.464 0.451 0.464 0.464 0.186 
165 0.490 0.476 0.463 0.476 0.476 0.199 
180 0.480 0.468 0.459 0.469 0.469 0.192 
195 0.475 0.465 0.460 0.467 0.467 0.190 
210 0.485 0.475 0.466 0.476 0.475 0.198 
225 0.451 0.439 0.433 0.441 0.441 0.164 
240 0.466 0.455 0.446 0.456 0.456 0.179 
255 0.472 0.458 0.450 0.460 0.460 0.183 
270 0.490 0.477 0.467 0.478 0.478 0.201 
300 0.487 0.472 0.462 0.474 0.474 0.197 
330 0.463 0.446 0.435 0.448 0.448 0.171 
360 nd nd nd 
390 0.460 0.446 0.436 0.447 0.447 0.170 
420 0.472 0.455 0.449 0.459 0.459 0.181 
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Table 6.8.4a Subject PY-blackcurrant 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/I 00 value minus 
(min) injections) mean ml plasma baseline 
-15 0.163 0.162 0.160 0.158 0.158 0 000 0 0.154 0.154 0.153 . 
40 0.193 0.192 0.190 0.192 0.192 0.034 
65 0.267 0.264 0.260 0.264 0.263 0.106 
90 0.286 0.282 0.277 0.282 0.282 0.124 
105 0.311 0.306 0.302 0.307 0.307 0.149 
120 0.312 0.308 0.303 0.308 0.308 0.150 
137 0.289 0.285 0.281 0.285 0.285 0.128 
150 0.303 0.300 0.296 0.300 0.300 0.142 
167 0.264 0.260 0.255 0.260 0.260 0.102 
180 0.281 0.275 0.271 0.276 0.275 0.118 
195 0.283 0.280 0.276 0.280 0.280 0.122 
212 0.266 0.262 0.258 0.262 0.262 0.105 
228 0.253 0.250 0.246 0.250 0.250 0.092 
245 0.242 0.237 0.235 0.238 0.238 0.080 
261 0.232 0.227 0.223 0.227 0.227 0.070 
270 0.272 0.266 0.263 0.267 0.267 0.109 
300 0.261 0.258 0.254 0.258 0.258 0.100 
330 0.242 0.240 0.237 0.240 0.240 0.082 
360 0.241 0.238 0.232 0.237 0.237 0.080 
390 0.229 0.227 0.224 0.227 0.227 0.069 
420 0.252 0.249 0.247 0.249 0.249 0.092 
Table 6.8.4b Subject PY-orange juice 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-1 0.143 0.146 0.145 0.146 0.146 0.000 
0 0.147 0.149 0.145 
40 0.247 0.246 0.241 0.245 0.245 0.099 
65 0.275 0.272 0.267 0.271 0.271 0.126 
90 0.300 0.298 0.296 0.298 0.298 0.152 
105 0.318 0.314 0.308 0.314 0.313 0.168 
120 0.321 0.314 0.309 0.315 0.315 0.169 
135 0.320 0.315 0.311 0.315 0.315 0.170 
150 0.293 0.289 0.284 0.289 0.289 0.143 
165 0.290 0.287 0.282 0.287 0.287 0.141 
180 0.269 0.263 0.259 0.263 0.263 0.118 
195 0.261 0.254 0.249 0.255 0.254 0.109 
210 0.254 0.248 0.246 0.249 0.249 0.103 
225 0.250 0.246 0.243 0.246 0.246 0.101 
240 0.250 0.247 0.243 0.247 0.247 0.101 
255 0.240 0.237 0.234 0.237 0.237 0.091 
270 0 233 0.230 0.226 0.230 0.230 0.084 
300 . 0.231 0.229 0.226 0.229 0.229 0.083 
330 0.223 0.221 0.215 0.220 0.220 0.074 
360 0 219 0.221 0.229 0.223 0.223 0.077 
390 . 227 0 0.223 0.219 0.223 0.223 0.077 
420 . 0.224 0.222 0.219 0-222 0.222 0.076 
158 
Table 6.8.4c Subject PY-water. 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/I 00 
ml plasma 
value minus 
baseline 
-15 0.125 0 125 0 120 0.133 
0 0.143 . 0.142 . 0.142 0.133 0.000 
40 0.256 0.249 0.244 0.250 0.250 0.117 
66 0.278 0.271 0.260 0.270 0.270 0.137 
90 0.299 0.290 0.283 0.291 0.291 0.158 
105 0.299 0.300 0.284 0.294 0.294 0.161 
120 0.353 0.342 0.326 0.340 0.340 0.208 
135 0.395 0.399 0.399 0.398 0.398 0.265 
150 0.378 0.371 0.365 0.371 0.371 0.239 
165 0.340 0.344 0.348 0.344 0.344 0.211 
180 0.299 0.298 0.293 0.297 0.297 0.164 
195 0.287 0.279 0.274 0.280 0.280 0.147 
210 0.261 0.247 0.242 0.250 0.250 0.118 
225 0.244 0.241 0.234 0.240 0.240 0.107 
240 0.230 0.230 0.232 0.231 0.231 0.098 
255 0.248 0.240 0.235 0.241 0.241 0.108 
270 0.237 0.232 0.228 0.233 0.233 0.100 
300 0.267 0.259 0.252 0.259 0.259 0.127 
330 0.217 0.209 0.207 0.211 0.211 0.078 
359 0.189 0.180 0.176 0.182 0.182 0.049 
389 0.188 0.169 0.184 0.181 0.181 0.048 
420 0.190 0.181 0.179 0.183 0.183 0.050 
Table 6.8.5a. Subject HD-blackcurrant 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
0 0.145 0.145 0.142 0.139 OA 39 0.000 
0 0.152 0.152 0.097 
40 0.205 0.205 0.199 0.203 0.203 0.064 
65 0.234 0.229 0.224 0.229 0.229 0.090 
90 0.251 0.246 0.246 0.248 0.248 0.109 
105 0.249 0.250 0.246 0.248 0.248 0.109 
120 0.249 0.248 0.239 0.245 0.245 0.107 
135 0.241 0.239 0.232 0.238 0.238 0.099 
150 0.240 0.238 0.236 0.238 0.238 0.099 
165 0.286 0.254 0.251 0.264 0.264 0.125 
180 0.251 0.247 0.242 0.247 0.247 0.108 
195 0.241 0.237 0.235 0.238 0.238 0.099 
210 0.225 0.228 0.218 0.224 0.224 0.085 
225 0.243 0.243 0.232 0.239 0.239 0.100 
240 0.233 0.229 0.225 0.229 0.229 0.090 
255 0.232 0.229 0.224 0.229 0.229 0.090 
270 0.231 0.227 0.220 0.226 0.226 0.087 
300 0.242 0.238 0.237 0.239 0.239 0.100 
330 nd nd nd 
360 0.232 0.226 0.224 0.227 0.227 0.089 
390 0 222 0.217 0.216 0.218 0.218 0.080 
420 . 0.227 0.220 0.222 0.223 0.223 0.084 
159 
Table 6.8.5b Subject RD-orange juice 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-10 0.147 0.147 0.142 0.153 0.153 0.000 0 0.162 0.160 0.158 
41 0.218 0.214 0.212 0.215 0.215 0.062 
63 0.256 0.252 0.248 0.252 0.252 0.099 
91 0.310 0.304 0.294 0.303 0.303 0.150 
105 0.320 0.314 0.306 0.313 0.313 0.161 
120 0.321 0.319 0.313 0.318 0.318 0.165 
137 0.307 0.305 0.303 0.305 0.305 0.153 
150 0.339 0.335 0.330 0.335 0.335 0.182 
165 0.310 0.308 0.303 0.307 0.307 0.154 
181 0.313 0.309 0.304 0.309 0.309 0.156 
195 0.314 0.310 0.304 0.309 0.309 0.157 
210 0.269 0.268 0.262 0.266 0.266 0.114 
226 0.274 0.269 0.262 0.269 0.268 0.116 
240 0.300 0.298 0.289 0.296 0.296 0.143 
255 0.263 0.260 0.255 0.260 0.260 0.107 
270 0.273 0.270 0.263 0.269 0.269 0.117 
300 0.270 0.267 0.259 0.265 0.265 0.113 
330 nd nd nd 
358 0.308 0.301 0.292 0.300 0.300 0.148 
390 0.289 0.282 0.278 0.283 0.283 0.130 
420 0.261 0.255 0.253 0.257 0.257 0.104 
Table 6.8.5c Subject RD-water. 
Time 
(min) 
mg asGorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-10 0.150 0.133 0.129 0.132 0.132 0.000 
0 nd 0.127 0.122 
40 0.188 0.172 0.167 0.176 0.176 0.043 
65 0.249 0.231 0.226 0.235 0.235 0.103 
90 0.247 0.232 0.226 0.235 0.235 0.103 
105 0.212 0.198 0.195 0.202 0.202 0.069 
120 0.230 0.219 0.215 0.221 0.221 0.089 
135 0.212 0.202 0.200 0.205 0.205 0.072 
150 0.220 0.211 0.206 0.212 0.212 0.080 
165 0.211 0.202 0.196 0.203 0.203 0.070 
180 0.213 0.207 0.203 0.208 0.208 0.075 
195 0.212 0.208 0.205 0.208 0.208 0.076 
210 0.205 0.198 0.195 0.199 0.199 0.067 
225 0.208 0.200 0.199 0.203 0.203 0.070 
240 0.188 0.183 0.179 0.183 0.183 0.051 
255 0.192 0.189 0.186 0.189 0.189 0.057 
270 198 0 0.196 0.193 0.196 0.196 0.063 
300 . 184 0 0.178 0.176 0.179 0.179 0.047 
330 . 186 0 0.175 0.169 0.177 0.177 0.044 
360 . 177 0 0.172 0.172 0.174 0.174 0.041 
390 . 170 0 0.166 0.166 0.167 0.167 0.035 
A'AA . n 'mr, n gni 0199 0.202 0.202 0.069 
160 
Table 6.8.6a Subject JT-blackeurrant 
Time 
(min) 
mg ascorbic acid/1 00 ml (Mplicate 
iniertion-" mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-10 0.112 0.111 0.112 0.109 
0 0.106 0.106 0.108 0.109 0.000 
40 0.154 0.154 0.154 0.154 0.154 0.045 
65 0.180 0.180 0.181 0.180 0.180 0.071 
90 0.190 0.190 0.192 0.191 0.191 0.081 
105 0.188 0.188 0.187 0.188 0.188 0.079 
120 0.177 0.180 0.176 0.178 0.178 0.069 
135 0.197 0.198 0.199 0.198 0.198 0.089 
150 0.195 0.196 0.197 0.196 0.196 0.087 
165 0.192 0.190 0.189 0.191 0.191 0.081 
180 0.186 0.184 0.185 0.185 0.185 0.076 
195 0.185 0.180 0.183 0.183 0.183 0.073 
210 0.188 0.187 0.186 0.187 0.187 0.078 
225 0.186 0.182 0.182 0.183 0.183 0.074 
240 0.187 0.184 0.184 0.185 0.185 0.076 
255 0.173 0.175 0.175 0.174 0.174 0.065 
270 0.172 0.171 0.171 0.171 0.171 0.062 
300 0.172 0.171 0.169 0.171 0.171 0.062 
330 0.162 0.160 0.160 0.161 0.1,61 0.052 
360 0.161 0.159 0.159 0.160 0.159 0.050 
390 0.157 0.156 0.156 0.156 0.156 0.047 
420 0.156 0.156 0.157 0.157 0.156 0.047 
Table 6.8.6b Subject JT-orange juice 
Time 
(min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
img ascorbic acid/100 
ml plasma 
value minus 
baseline 
-14 0.089 0.088 0.086 0.089 0.089 0.000 0 0.092 0.091 0.090 
41 0.173 0.167 0.163 0.168 0.168 0.078 
65 0.194 0.187 0.181 0.187 0.187 0.098 
91 0.207 0.199 0.192 0.199 0.199 0.110 
106 0.186 0.179 0.174 0.180 0.180 0.090 
120 0.203 0.193 0.187 0.194 0.194 0.105 
136 0.172 0.165 0.161 0.166 0.166 0.077 
150 0.186 0.179 0.175 0.180 0.180 0.090 
165 0.197 0.190 0.186 0.191 0.191 0.101 
180 0.208 0.199 0.191 0.200 0.200 0.1110 
1,95 0.163 0.156 0.152 0.157 0.157 0.068 
210 0.193 0.173 0.166 0.178 0.177 0.088 
226 0.179 0.172 0.167 0.173 0.173 0.083 
240 0.171 0.162 0.156 0.163 0.163 0.074 
255 0.164 0.156 0.151 0.157 0,167 0.068 
270 0.171 0.165 0.161 0.166 0.166 0.076 
300 0.154 0.146 0.142 0.147 0.147 0.058 
330 0.173 0.165 0.161 0.166 0.166 0.077 
363 0.151 0.145 0.140 0.145 0.145 0.056 
390 0.146 0.141 0.138 0.142 0.142 0.052 
419 0.164 0.154 0.147 0.155 0.155 0.066 
161 
Table 6.8.6c Subject JT-water 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-15 0.099 0.096 0.094 0.104 
0 0.114 0.110 0.109 0.104 0.000 
40 0.191 0.186 0.184 0.187 0.187 0.083 
67 0.202 0.200 0.195 0.199 0.199 0.095 
90 0.195 0.189 0.185 0.190 0.190 0.086 
105 0.206 0.201 0.196 0.201 0.201 0.097 
120 0.228 0.220 0.216 0.221 0.221 0.117 
135 0.207 0.201 0.197 0.202 0.202 0.098 
150 0.204 0.201 0.197 0.201 0.201 0.097 
165 0.198 0.194 0.190 0.194 0.194 0.091 
180 0.196 0.193 0.186 0.192 0.191 0.088 
195 0.198 0.196 0.188 0.194 0.194 0.091 
210 0.200 0.195 0.189 0.195 0.195 0.091 
225 0.191 0.187 0.184 0.187 0.187 0.084 
240 0.172 0.168 0.167 0.169 0.169 0.065 
255 0.182 0.178 0.175 0.179 0.179 0.075 
270 0.182 0.178 0.176 0.179 0.179 0.075 
300 0.155 0.151 0.148 0.151 0.151 0.048 
330 0.178 0.172 0.167 0.173 0.173 0.069 
360 0.170 0.166 0.162 0.166 0.166 0.062 
390 0.173 0.171 0.167 0.171 0.170 0.067 
420 0.170 0.167 0.165 0.167 0.167 0.064 
Table 6.8.7a Subject NH-blackcurrant 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-9 0.094 0.091 0.089 0.101 0.101 0.000 0 0.117 0.109 0.103 
42 0.147 0.142 0.137 0.142 0.142 0.041 
65 0.183 0.171 0.161 0.172 0.172 0.071 
91 0.215 0.203 0.195 0.204 0.204 0.104 
105 0.222 0.209 0.196 0.209 0.209 0.108 
120 0.221 0.207 0.196 0.208 0.208 0.108 
135 0.224 0.214 0.203 0.214 0.214 0.113 
150 0.207 0.194 0.185 0.195 0.195 0.094 
165 0.183 0.171 0.163 0.173 0.173 0.072 
180 0.179 0.168 0.159 0.169 0.169 0.068 
195 0.170 0.158 0.149 0.159 0.159 0.058 
210 0.174 0.166 0.160 0.167 0.167 0.066 
225 0.173 0.162 0.154 0.163 0.163 0.062 
240 0.171 0.160 0.152 0.161 0.161 0.060 
255 0.200 0.186 0.174 0.187 0.187 0.086 
270 0.159 0.150 0.194 0.168 0.168 0.067 
300 0.186 0.176 0.167 0.176 0.176 0.076 
330 0.163 0.151 0.142 0.152 0.152 0.051 
360 0.169 0.160 0.155 0.162 0.162 0.061 
390 0.165 0.153 0.146 0.155 0.155 0.054 
420 0.175 0.161 0.155 0.164 0.164 0.063 
162 
Table 6-8.7b Subject NH-orange juice 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus (min) injections) mean ml plasma baseline 
-10 0.108 0.102 nd 0.098 
0 0.097 0.094 0.091 0.098 0.000 
40 0.189 0.185 0.180 0.185 0.185 0.087 
65 0.188 0.184 0.181 0.184 0.184 0.087 
90 0.202 0.197 0.194 0.198 0.198 0.100 
105 0.227 0.217 0.214 0.219 0.219 0.122 
120 0.215 0.207 0.203 0.208 0.208 0.111 
135 0.213 0.209 0.206 0.209 0.209 0.111 
150 0.192 0.182 0.179 0.184 0.184 0.087 
165 0.189 0.183 0.179 0.184 0.184 0.086 
180 0.181 0.177 0.171 0.176 0.176 0.079 
195 0.190 0.184 0.177 0.184 0.184 0.086 
210 0.184 0.180 0.173 0.179 0.179 0.082 
225 0.170 0.164 0.161 0.165 0.165 0.067 
240 0.166 0.160 0.188 0.171 0.171 0.074 
255 0.178 0.171 0.168 0.173 0.172 0.076 
270 0.168 0.160 0.156 0.161 0.161 0.064 
300 0.167 0.161 0.158 0.162 0.162 0.064 
330 0.158 0.154 0.150 0.154 0.154 0.056 
360 0.172 0.169 0.167 0.170 0.170 0.072 
390 0.160 0.157 0.155 0.157 0.157 0.060 
420 0.165 0.161 0.160 0.162 0.162 0.065 
Table 6.8.7c Subject NH-water. 
Time mg ascorbic acid/1 00 m l (triplicate mg ascorbic acid/I 00 value minus 
(min) injections) mean ml plasma baseline 
-10 0.157 0.155 0.151 0.157 0 157 0.000 0 0.161 0.161 0.159 . 
40 0.264 0.261 0.255 0.260 0.260 0.103 
65 0.303 0.296 0.294 0.298 0.298 0.140 
90 0.294 0.290 0.287 0.290 0.290 0.133 
105 0.290 0.278 0.270 0.279 0.279 0.122 
120 0.268 0.259 0.252 0.260 0.259 0.102 
135 0.282 0.273 0.265 0.273 0.273 0.116 
150 0.238 0.233 0.228 0.233 0.233 0.076 
165 0.258 0.254 0.249 0.254 0.254 0.097 
180 0.259 0.253 0.245 0.252 0.252 0.095 
195 0.235 0.225 0.222 0.227 0.227 0.070 
210 0.244 0.235 0.227 0.236 0.236 0.078 
225 0.239 0.233 0.228 0.233 0.233 0.076 
240 0.238 0.228 0.222 0.230 0.230 0.072 
255 0.208 0.201 0.197 0.202 0.202 0.045 
270 0.231 0.222 0.218 0.224 0.224 0.067 
300 0.231 0.225 0.218 0.225 0.225 0.068 
330 0.213 0.205 0.199 0.206 ý0.206 0.048 
360 0.214 0.206 0.201 0.207 0.207 0.050 
390 0.200 0.196 0.192 0.196 0.196 0.038 
420 0.206 0.198 0.189 0.198 0.198 0.041 
163 
Table 6.8.8a Subject RW-blackcurrant 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-13 0.161 0.152 0.149 0.151 
0 0.153 0.148 0.143 0.161 0.000 
42 0.203 0.195 0.187 0.195 0.195 0.044 
65 0.203 0.197 0.186 0.195 0.195 0.044 
90 0.235 0.227 0.218 0.226 0.226 0.075 
106 0.242 0.234 0.228 0.234 0.234 0.083 
120 0.236 0.229 0.220 0.229 0.229 0.078 
136 0.242 0.236 0.226 0.235 0.235 0.084 
150 0.262 0.253 0.244 0.253 0.253 0.102 
165 0.264 0.252 0.245 0.254 0.254 0.103 
180 0.249 0.238 0.232 0.240 0.240 0.089 
195 0.248 0.235 0.233 0.239 0.239 0.088 
210 0.242 0.227 0.222 0.230 0.230 0.079 
227 0.247 0.234 0.230 0.237 0.237 0.086 
240 0.236 0.224 0.221 0.227 0.227 0.076 
255 0.244 0.231 0.231 0.235 0.235 0.084 
270 0.236 0.221 0.218 0.225 0.225 0.074 
300 0.235 0.221 0.218 0.225 0.225 0.074 
330 0.226 0.211 0.208 0.215 0.215 0.064 
364 0.242 0.230 0.225 0.233 0.232 0.081 
390 0.214 0.204 0.202 0.207 0.207 0.056 
420 0.222 0.208 0.204 0.211 0.211 0.060 
Table 6.8.8b Subject RW-orange juice 
Time 
(min) 
mg ascorbic acid/1 00 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-5 0.183 0.179 0.178 0.181 0.181 0.000 
0 0.184 0.182 0.180 
40 0.254 0.251 0.249 0.251 0.251 0.070 
65 0.293 0.288 0.282 0.287 0.287 0.106 
90 0.303 0.299 0.296 0.300 0.300 0.119 
105 0.334 0.332 0.326 0.331 0.331 0.150 
120 0.329 0.325 0.321 0.325 0.325 0.144 
135 0.311 0.300 0.290 0.301 0.300 0.120 
150 0.306 0.303 0.298 0.302 0.302 0.121 
165 0.301 0.296 0.291 0.296 0.296 0.115 
180 0.291 0.287 0.283 0.287 0.287 0.106 
195 0.281 0.275 0.268 0.275 0.275 0.094 
210 0.271 0.264 0.259 0.265 0.265 0.084 
225 0.275 0.271 0.267 0.271 0.271 0.090 
240 0.289 0.288 0.281 0.286 0.286 0.105 
255 0.287 0.284 0.276 0.282 0.282 0.101 
270 0.279 0.275 0.272 0.275 0.275 0.094 
300 0.281 0.273 0.263 0.272 0.272 0.091 
330 0.289 0.285 0.281 0.285 0.285 0.104 
360 0.261 0.257 0.252 0.257 0.257 0.076 
390 0 253 0.255 0.251 0.253 0.253 0.072 
Agn . n 97n 0966 0.260 0.265 0.265 0.084 
164 
Table 6.8.8c Subject RW-water. 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus (min) iniprlinn-" mean ml plasma baseline 
-13 0.334 0.331 0.326 0.324 
0 0.323 0.318 0.312 0.324 0.000 
40 0.441 0.432 0.427 0.434 0.434 0.110 67 0.473 0.462 0.454 0.463 0.463 0.139 
90 0.433 0.427 0.416 0.425 0.425 0.101 105 0.451 0.443 0.437 0.444 0.444 0.120 
120 0.498 0.489 0.494 0.493 0.493 0.169 
135 0.485 0.474 0.465 0.474 0.474 0.150 
150 0.452 0.437 0.434 0.441 0.441 0.117 
165 0.443 0.432 0.426 0.434 0.434 0.110 
180 0.465 0.449 0.440 0.452 0.451 0.127 
195 0.464 0.448 0.442 0.451 0.451 0.127 
210 0.458 0.449 0.442 0.450 0.450 0.126 
225 0.435 0.425 0.417 0.426 0.425 0.101 
240 0.468 0.452 0.443 0.454 0.454 0.130 
255 0.439 0.428 0.419 0.429 0.429 0.105 
270 0.453 0.440 0.431 0.441 0.441 0.117 
300 0.431 0.421 0.408 0.420 0.420 0.096 
330 0.418 0.405 0.395 0.406 0.406 0.082 
360 0.450 0.440 0.432 0.441 0.441 0.117 
390 0.456 0.444 0.435 0.445 0.445 0.121 
420 0.431 0.417 0.410 0.419 0.419 0.095 
Table 6.8.9a Subject DN-blackcurrant 
Time 
(min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
mg ascorbic acid/I 00 
ml plasma 
value minus 
baseline 
-4 0.206 0.206 0.205 0.195 0.195 0.000 0 0.188 0.183 0.185 
40 0.222 0.219 0.221 0.221 0.221 0.025 
65 0.263 0.260 0.257 0.260 0.260 0.065 
90 0.278 0.273 0.275 0.275 0.275 0.080 
105 0.296 0.286 0.279 0.287 0.287 0.092 
120 0.315 0.314 0.305 0.311 0.311 0.116 
135 0.330 0.323 0.313 0.322 0.322 0.126 
150 0.324 0.321 0.315 0.320 0.320 0.124 
165 0.323 0.319 0.314 0.318 0.318 0.123 
180 0.312 0.305 0.299 0.305 0.305 0.110 
195 0.281 0.278 0.275 0.278 0.278 0.083 
210 0.296 0.290 0.290 0.292 0.292 0.097 
225 0.285 0.275 0.271 0.277 0.277 0.082 
240 0.286 0.283 0.283 0.284 0.284 0.089 
255 0.320 0.314 0.308 0.314 0.314 0.118 
270 0.315 0.314 0.316 0.315 0.315 0.119 
300 0.282 0.278 0.277 0.279 0.279 0.084 
330 0.294 0.292 0.288 0.292 0.291 0.096 
360 0.290 0.289 0.286 0.288 0.288 0.093 
390 0.256 0.251 0.254 0.254 0.254 0.058 
420 0.286 0.283 0.280 0.283 0.283 0.088 
165 
Table 6.8.9b Subject DN-orange juice 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus (min) injections) mean ml plasma baseline 
-10 0.185 0.182 0.181 0.188 
0 0.197 0.194 0.191 0.188 0.000 
40 0.267 0.262 0.261 0.263 0.263 0.075 
65 0.292 0.294 0.282 0.289 0.289 0.101 
90 0.331 0.331 0.330 0.331 0.331 0.143 
105 0.366 0.364 0.360 0.363 0.363 0.175 
120 0.320 0.313 0.301 0.311 0.311 0.123 
135 0.345 0.344 0.328 0.339 0.339 0.151 
150 0.343 0.344 0.341 0.343 0.342 0.154 
165 0.323 0.322 0.314 0.320 0.320 0.132 
180 0.340 0.343 0.338 0.340 0.340 0.152 
195 0.323 0.319 0.314 0.319 0.319 0.131 
210 0.303 0.301 0.301 0.302 0.302 0.114 
225 0.295 0.292 0.287 0.291 0.291 0.103 
240 0.305 0.300 0.297 0.301 0.301 0.113 
255 0.307 0.302 0.297 0.302 0.302 0.114 
270 0.293 0.286 0.280 0.286 0.286 0.098 
302 0.281 0.275 0.271 0.276 0.276 0.088 
343 0.300 0.293 0.290 0.294 0.294 0.106 
360 0.280 0.274 0.269 0.274 0.274 0.086 
390 0.280 0.273 0.267 0.273 0.273 0.085 
420 0.299 0.296 0.287 0.294 0.294 0.106 
Table 6.8.9c Subject DN-water. 
Time 
(min) 
mg asGorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-14 0.226 0.224 0.222 0.229 0.229 0.000 
0 0.234 0.232 0.233 
40 0.330 0.329 0.323 0.327 0.327 0.099 
65 0.374 0.380 0.367 0.374 0.374 0.145 
90 0.369 0.371 0.366 0.369 0.369 0.141 
105 0.377 0.371 0.368 0.372 0.372 0.144 
122 0.352 0.350 0.347 0.349 0.349 0.121 
135 0.367 0.365 0.358 0.363 0.363 0.135 
150 0.355 0.350 0.347 0.351 0.351 0.122 
165 0.368 0.364 0.362 0.365 0.365 0.136 
180 0.365 0.361 0.356 0.361 0.361 0.132 
195 0.339 0.338 0.337 0.338 0.338 0.110 
210 0.360 0.358 0.353 0.357 0.357 0.128 
225 0.339 0.333 0.330 0.334 0.334 0.105 
240 0.359 0.356 0.353 0.356 0.356 0.127 
255 0.366 0.360 0.356 0.360 0.360 0.132 
270 0.365 0.364 0.360 0.363 0.363 0.134 
300 0.350 0.347 0.339 0.345 0.345 0.117 
330 0.347 0.343 0.336 0.342 0.342 0.114 
360 0.342 0.342 0.340 0.341 0.341 0.113 
390 0.345 0.339 0.334 0.339 0.339 0.111 
420 0.332 0.328 0.322 0.328 0.328 0.099 
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Table 6.8.10a Subject JR-blackeurrant 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-10 0.166 0.173 0.169 0.164 
0 0.157 0.159 0.157 0.164 0.000 
40 0.193 0.194 0.190 0.193 0.193 0.029 
65 0.214 0.211 0.211 0.212 0.212 0.048 
90 0.237 0.237 0.237 0.237 0.237 0.073 
105 0.236 0.234 0.235 0.235 0.235 0.071 
120 0.252 0.251 0.252 0.252 0.252 0.088 
135 0.236 0.234 0.233 0.234 0.234 0.070 
150 0.283 0.284 0.279 0.282 0.282 0.118 
165 0.242 0.241 0.238 0.240 0.240 0.077 
180 0.240 0.240 0.238 0.240 0.239 0.076 
195 0.234 0.212 0.215 0.220 0.220 0.057 
210 0.227 0.225 0.221 0.224 0.224 0.060 
225 0.240 0.234 0.232 0.235 0.235 0.072 
240 0.232 0.223 0.229 0.228 0.228 0.064 
255 0.236 0.227 0.230 0.231 0.231 0.067 
270 0.214 0.217 0.219 0.217 0.216 0.053 
300 0.228 0.227 0.229 0.228 0.228 0.065 
330 0.223 0.218 0.218 0.220 0.220 0.056 
360 0.256 0.249 0.251 0.252 0.252 0.089 
390 0.239 0.232 0.234 0.235 0.235 0.072 
420 0.213 0.210 0.211 0.211 0.211 0.048 
Table 6.8. 10b Subject JR-orange juice 
Time mg ascorbic acid/100 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-11 0.146 0.145 0.139 0.151 0.161 0.000 
0 0.162 0.159 0.157 
42 0.224 0.223 0.217 0.221 0.221 0.070 
67 0.266 0.260 0.256 0.261 0.261 0.109 
91 0.314 0.304 0.249 0.289 0.289 0.138 
106 0.303 0.297 0.288 0.296 0.296 0.145 
121 0.301 0.295 0.289 0.295 0.295 0.144 
137 0.295 0.286 0.274 0.285 0.285 0.134 
152 0.312 0.300 0.293 0.302 0.302 0.150 
165 0.292 0.284 0.277 0.284 0.284 0.133 
181 0.311 0.301 0.293 0.302 0.302 0.150 
195 0.293 0.284 0.278 0.285 0.285 0.134 
211 0.279 0.270 0.266 0.271 0.271 0.120 
226 0.286 0.276 0.273 0.278 0.278 0.127 
241 0.285 0.277 0.272 0.278 0.278 0.126 
256 0.275 0.266 0.261 0.267 0.267 0.116 
270 0.260 0.253 0.246 0.253 0.253 0.101 
303 0.266 0.260 0.254 0.260 0.260 0.108 
334 0 225 0.220 0.215 0.220 0.220 0.068 
360 . 247 0 0.244 0.241 0.244 0.244 0.093 
392 . 227 0 0.220 0.218 0.222 0.222 0.071 
424 . 0.230 0.223 0.219 0.224 0.224 0.073 
167 
Table 6.8.10c Subject JR-water. 
Time mg ascorbic acid/1 00 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections)__ mean ml plasma baseline 
-4 0.129 0.128 0.128 0.134 
0 0.140 0.137 0.140 0.134 0.000 
40 0.182 0.178 0.174 0.178 0.178 0.044 
65 0.227 0.218 0.210 0.218 0.218 0.084 
90 0.258 0.251 0.249 0.252 0.252 0.119 
105 0.260 0.249 0.247 0.252 0.252 0.118 
120 0.250 0.240 0.233 0.241 0.241 0.107 
135 0.239 0.231 0.228 0.233 0.233 0.099 
150 0.256 0.250 0.248 0.251 0.251 0.117 
165 0.247 0.244 0.238 0.243 0.243 0.109 
180 0.242 0.232 0.220 0.231 0.231 0.097 
195 0.239 0.233 0.227 0.233 0.233 0.099 
210 0.236 0.230 0.223 0.230 0.230 0.096 
225 0.258 0.257 0.255 0.257 0.257 0.123 
240 0.268 0.264 0.257 0.263 0.263 0.129 
255 0.270 0.269 0.262 0.267 0.267 0.134 
270 0.238 0.237 0.232 0.236 0.236 0.102 
300 0.233 0.230 0.225 0.229 0.229 0.095 
330 0.239 0.237 0.232 0.236 0.236 0.102 
360 0.234 0.228 0.224 0.229 0.229 0.095 
390 0.225 0.220 0.218 0.221 0.221 0.087 
420 0.239 0.235 0.235 0.236 0.236 0.102 
Table 6.8. 11a Subject PC-blackeurrant 
Time mg ascorbic acid/100 ml (triplicate mg ascorbic acid/100 value minus 
(min) injections) mean ml plasma baseline 
-10 0.213 0.207 0.207 0.209 0.209 0.000 
0 0.218 0.207 0.203 
40 0.271 0.164 0.255 0.230 0.230 0.021 
65 0.288 0.177 0.272 0.246 0.246 0.037 
90 0.409 0.302 0.296 0.336 0.336 0.127 
105 0.342 0.330 0.319 0.330 0.330 0.121 
120 0.396 0.388 0.373 0.386 0.386 0.177 
135 0.390 0.367 0.350 0.369 0.369 0.160 
150 0.394 0.386 0.371 0.384 0.384 0.176 
165 0.425 0.404 0.380 0.403 0.403 0.194 
180 0.411 0.409 0.396 0.405 0.405 0.196 
195 0.410 0.399 0.387 0.399 0.398 0.189 
210 0.367 0.358 0.347 0.358 0.358 0.148 
225 0.360 0.359 0.367 0.362 0.362 0.153 
240 0.377 0.367 0.363 0.369 0.369 0.160 
255 0.393 0.386 0.383 0.387 0.387 0.178 
270 0.393 0.389 0.387 0.390 0.390 0.181 
300 0.395 0.388 0.387 0.390 0.390 0.181 
330 0.377 0.375 0.372 0.375 0.375 0.166 
360 0.379 0.370 0.371 0.374 0.373 0.164 
390 388 0 0.377 0.367 0.378 0.378 0.168 
420 . 0.391 0.356 0.323 0.357 0.357 0.148 
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Table 6.8.1 lb Subject PC-orange juice 
Time 
(min) 
-10 
0 
mg ascorbic acid/1 00 ml (triplicate 
injections) 
0.315 0.305 0.299 
0.339 0.336 0.331 
mean 
0.321 
mg ascorbic acid/100 
ml plasma 
0.321 
value minus 
baseline 
0.000 
40 0.469 0.459 0.451 0.459 0.459 0.138 
65 0.452 0.448 0.442 0.447 0.447 0.126 
90 0.485 0.471 0.461 0.472 0.472 0.151 
105 0.477 0.470 0.464 0.471 0.470 0.150 
120 0.513 0.502 0.491 0.502 0.502 0.181 
135 0.474 0.463 0.456 0.464 0.464 0.144 
150 0.484 0.474 0.465 0.474 0.474 0.153 
165 0.445 0.437 0.431 0.438 0.438 0.117 
180 0.480 0.475 0.471 0.476 0.475 0.155 
195 0.486 0.473 0.462 0.474 0.474 0.153 
210 0.484 0.477 0.471 0.477 0.477 0.156 
225 0.444 0.437 0.431 0.437 0.437 0.116 
240 0.485 0.472 0.469 0.476 0.475 0.155 
255 0.447 0.437 0.430 0.438 0.438 0.117 
270 0.457 0.451 0.444 0.451 0.451 0.130 
300 0.454 0.445 0,441 0.447 0.447 0.126 
330 0.448 0.441 0.435 0.441 0.441 0.120 
360 0.449 0.439 0.428 0.439 0.439 0.118 
390 0.497 0.488 0.480 0.488 0.488 0.167 
420 0.473 0.464 0.458 0.465 0.465 0.144 
Table 6.8.11c Subject PC-water. 
Time 
(min) 
mg ascorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/I 00 
ml plasma 
value minus 
baseline 
-10 0.165 0.160 0.159 0.168 0.168 0.000 0 0.179 0.175 nd 
40 0.316 0.312 0.308 0.312 0.312 0.144 
65 0.297 0.293 0.292 0.294 0.294 0.126 
90 0.351 0.347 0.347 0.348 0.348 0.180 
105 0.333 0.331 0.327 0.330 0.330 0.162 
120 0.306 0.304 0.305 0.305 0.305 0.137 
135 0.295 0.293 0.293 0.294 0.293 0.125 
150 0.290 0.291 0.286 0.289 0.289 0.120 
165 0.333 0.330 0.330 0.331 0.331 0.163 
180 0.316 0.313 0.311 0.313 0.313 0.145 
195 0.321 0.320 0.318 0.320 0.320 0.151 
210 0.300 0.300 0.298 0.299 0.299 0.131 
225 0.283 0.279 0.279 0.281 0.281 0.112 
240 0.282 0.280 0.279 0.280 0.280 0.112 
255 0.287 0.284 0.285 0.285 0.285 0.117 
270 0.402 0.294 0.296 0.331 0.331 0.162 
300 0.270 0.269 0.268 0.269 0.269 0.101 
330 0.304 0.298 0.299 0.300 0.300 0.132 
360 0.272 0.268 0.267 0.269 0.269 0.101 
390 0.270 0.267 0.267 0.268 0.268 0.100 
42n n269 0.269 0.265 0.268 0.268 0.100 
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Table 6.8.12a Subject SD-blackeurrant 
Time 
(min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-14 0.294 0.283 0.277 0.287 
0 0.296 0.291 0.278 0.287 0.000 
40 0.378 0.369 0.356 0.368 0.368 0.081 
65 0.418 0.406 0.401 0.408 0.408 0.122 
90 0.445 0.430 0.431 0.435 0.435 0.149 
105 0.486 0.475 0.470 0.477 0.477 0.191 
120 0.493 0.476 0.476 0.482 0.482 0.195 
135 0.483 0.465 0.456 0.468 0.468 0.181 
150 0.493 0.478 0.474 0.482 0.482 0.195 
165 0.493 0.481 0.477 0.484 0.484 0.197 
180 0.467 0.456 0.450 0.458 0.458 0.171 
195 0.455 0.442 0.436 0.444 0.444 0.158 
210 0.474 0.461 0.456 0.464 0.464 0.177 
225 0.470 0.457 0.455 0.461 0.460 0.174 
240 0.483 0.471 0.470 0.475 0.475 0.188 
255 0.465 0.444 0.441 0.450 0.450 0.163 
271 0.452 0.439 0.438 0.443 0.443 0.157 
300 0.469 0.455 0.452 0.459 0.459 0.172 
330 0.463 0.442 0.437 0.448 0.448 0.161 
360 0.463 0.448 0.442 0.451 0.451 0.164 
390 0.447 0.437 0.427 0.437 0.437 0.150 
421 0.443 0.430 0.425 0.433 0.433 0.146 
Table 6.8.12b Subject SD-orange juice 
Time 
(min) 
mg ascorbic acid/1 00 ml (tripliGate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
-10 0.165 0.162 0.163 0.166 0.166 0.000 0 0.170 0.167 0.168 
40 0.320 0.316 0.316 0.317 0.317 0.151 
65 0.373 0.367 0.369 0.370 0.370 0.204 
90 0.384 0.375 0.379 0.379 0.379 0.213 
105 0.384 0.383 0.384 0.384 0.384 0.218 
120 0.362 0.351 0.352 0.355 0.355 0.189 
135 0.347 0.338 0.343 0.343 0.343 0.177 
150 0.345 0.343 0.345 0.344 0.344 0.179 
165 0.335 0.328 0.327 0.330 ý0.330 0.164 
180 0.334 0.324 0.322 0.327 0.327 0.161 
195 0.333 0.324 0.322 0.326 0.326 0.160 
210 0.304 0.298 0.301 0.301 0.301 0.135 
225 0.347 0,344 0.339 0.343 0.343 0.177 
240 0.301 0.297 0.297 0.298 0.298 0.132 
255 0.298 0.294 0.291 0.294 0.294 0.128 
270 0.276 0.273 0.269 0.273 0.273 0.107 
300 0.280 0.275 0.268 0.274 0.274 0.108 
330 0.276 0.268 0.259 0.268 0.268 0.102 
360 0.280 0.267 0.245 0.264 0.264 0.098 
390 0.278 0.277 0.273 0.276 0.276 0.110 
420 0.271 0.268 0.260 0.266 0.266 0.101 
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Table 6.8.12c Subject SD-water. 
Time 
, min) 
mg ascorbic acid/100 ml (triplicate 
injections) mean 
mg ascorbic acid/100 
ml plasma 
value minus 
baseline 
11 0.155 0.152 0.142 0.154 0.154 0.000 0 0.163 0.161 0.152 
41 0.274 0.264 0.253 0.264 0.264 0.110 
66 0.283 0.276 0.268 0.275 0.275 0.121 
90 0.348 0.338 0.329 0.338 0.338 0.184 
105 0.359 0.350 0.333 0.348 0.348 0.194 
121 0.339 0.329 0.315 0.327 0.327 0.173 
136 0.307 0.304 0.291 0.300 0.300 0.146 
151 0.325 0.322 0.309 0.318 0.318 0.164 
165 0.293 0.288 0.279 0.287 0.287 0.133 
180 0.296 0.289 0.275 0.286 0.286 0.132 
195 0.283 0.277 0.266 0.275 0.275 0.121 
210 0.271 0.265 0.250 0.262 0.262 0.108 
226 0.277 0.271 0.260 0.269 0.269 0.115 
240 0.290 0.283 0.275 0.283 0.283 0.129 
255 0.243 0.237 0.232 0.237 0.237 0.083 
270 0.271 0.265 0.258 0.265 0.265 0.111 
303 0.269 0.264 0.265 0.266 0.266 0.112 
340 0.268 0.261 0.261 0.264 0.264 0.110 
360 0.267 0.260 0.260 0.262 0.262 0.108 
391 0.258 0.247 0.250 0.252 0.252 0.098 
420 0.234 0.225 0.228 0.229 0.229 0.075 
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Appendix 6.10.1 Hippuric acid concentration calculation 
The calculation is as follows, using the urine from DP after he was supplemented with the 
blackcurrant drink. (Multiply the data in table 3.2.5.1 a by 100,000 for use in this equation. ) 
Hippuric acid calibration curve equation (from Copeland, personal communication): 
y=6x 109x 
All samples were diluted 250 ýtl: 250 gl with water (i. e. x 2) 
Injection volume: 100 gl 
Average peak area (from DP-blackcurrant): 13 5 82011 
Using calibration curve, y=6x 109x 
13582011 =6x 109x 
*=2.26 x 10-3 mg hippuric acid in the 100 ýtl injection 
*2 for the dilution with water = 4.53 x 
10-3 mg 
Urine volume: 1680 ml 
Therefore 4.53 x 10-3 x (1680000 ýd -- 100 ýtl) = 76.1 mg /24 hours of urine excreted. 
Appendix 6.10.2 NMR aromatic to formate signal ratio calculation 
The values are given in table 3.2.5.2a, b and C. Multiply the values by 100,000 
for use in this 
equation. 
Using DP-blackcurrant as the example: 
Area of formate signal = 63352000 
Area of aromatic region = 45540000 
Aromatic area - formate area = 0.72 
Muhiply this by the 24 hour urine volume = 1.68 x 0.72 = 1.208 
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